



ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)

Sidney C. Smith, Jr, Ted E. Feldman, John W. Hirshfeld, Jr, Alice K. Jacobs, Morton J. Kern, Spencer B. King, III, Douglass A. Morrison, William W. O'Neill, Hartzell V. Schaff, Patrick L. Whitlow, David O. Williams, Elliott M. Antman, Sidney C. Smith, Jr, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page and Barbara Riegel

J. Am. Coll. Cardiol. 2006;47;1-121

doi:10.1016/j.jacc.2005.12.001

This information is current as of March 19, 2006



The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://content.onlinejacc.org/cgi/content/full/47/1/e1>



ACC/AHA/SCAI PRACTICE GUIDELINES—FULL TEXT

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)

WRITING COMMITTEE MEMBERS

Sidney C. Smith, Jr, MD, FACC, FAHA, *Chair*

Ted E. Feldman, MD, FACC, FSCAI*
John W. Hirshfeld, Jr, MD, FACC, FSCAI*
Alice K. Jacobs, MD, FACC, FAHA, FSCAI
Morton J. Kern, MD, FACC, FAHA, FSCAI*
Spencer B. King, III, MD, MACC, FSCAI

Douglass A. Morrison, MD, PhD, FACC, FSCAI*
William W. O'Neill, MD, FACC, FSCAI
Hartzell V. Schaff, MD, FACC, FAHA
Patrick L. Whitlow, MD, FACC, FAHA
David O. Williams, MD, FACC, FAHA, FSCAI

TASK FORCE MEMBERS

Elliott M. Antman, MD, FACC, FAHA, *Chair*
Sidney C. Smith, Jr., MD, FACC, FAHA, *Vice Chair*

Cynthia D. Adams, MSN, APRN-BC, FAHA
Jeffrey L. Anderson, MD, FACC, FAHA
David P. Faxon, MD, FACC, FAHA†
Valentin Fuster, MD, PhD, FACC, FAHA, FESC†
Jonathan L. Halperin, MD, FACC, FAHA
Loren F. Hiratzka, MD, FACC, FAHA†

Sharon Ann Hunt, MD, FACC, FAHA
Alice K. Jacobs, MD, FACC, FAHA
Rick Nishimura, MD, FACC, FAHA
Joseph P. Ornato, MD, FACC, FAHA
Richard L. Page, MD, FACC, FAHA
Barbara Riegel, DNSc, RN, FAHA

*SCAI Official Representative

†Former Task Force Member during this writing effort

Acknowledgement: The ACC and AHA recognize Dr J. Ward Kennedy for his dedicated service on developing ACC/AHA guidelines for PTCA and PCI since their inception in 1986 and for his counsel and advice in the preparation of this guideline.

This document was approved by the American College of Cardiology Foundation Board of Trustees in August 2005, by the American Heart Association Science Advisory and Coordinating Committee in August 2005, and by the Society for Cardiovascular Angiography and Interventions Board of Trustees in August 2005.

When citing this document, the American College of Cardiology Foundation requests that the following citation format be used: Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). American College of

Cardiology Web Site. Available at: <http://www.acc.org/clinical/guidelines/percutaneous/update/index.pdf>.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org), the American Heart Association (www.americanheart.org), and the Society for Cardiovascular Angiography and Interventions (www.scai.org). Single copies of this document are available by calling 1-800-253-4636 or writing the American College of Cardiology Foundation, Resource Center, at 9111 Old Georgetown Road, Bethesda, MD 20814-1699. Ask for reprint number 71-0347. To obtain a copy of the Summary Article published in the January 3, 2006 issue of the *Journal of the American College of Cardiology*, the January 3, 2006 issue of *Circulation*, and the January 2006 issue of *Catheterization and Cardiovascular Interventions*, ask for reprint number 71-0346. To purchase bulk reprints (specify version and reprint number): Up to 999 copies, call 1-800-611-6083 US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1789, fax 214-691-6342, or e-mail pubauth@heart.org.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please direct requests to copyright_permissions@acc.org.

TABLE OF CONTENTS

PREAMBLE.....	e3
1. INTRODUCTION.....	e3
2. GENERAL CONSIDERATIONS AND BACKGROUND.....	e5
3. OUTCOMES.....	e6
3.1. Definitions of PCI Success.....	e6
3.1.1. Angiographic Success.....	e6
3.1.2. Procedural Success.....	e7
3.1.3. Clinical Success.....	e7
3.2. Acute Outcome: Procedural Complications.....	e7
3.3. Acute Outcome: Success Rates.....	e11
3.4. Long-Term Outcome and Restenosis.....	e11
3.5. Predictors of Success/Complications.....	e12
3.5.1. Lesion Morphology and Classification.....	e12
3.5.1.1. Clinical Factors.....	e13
3.5.1.2. Left Main CAD.....	e15
3.5.2. Risk of Death.....	e18
3.5.3. Women.....	e18
3.5.4. The Elderly Patient.....	e20
3.5.5. Diabetes Mellitus.....	e20
3.5.6. PCI After Coronary Artery Bypass Surgery.....	e21
3.5.7. Specific Technical Considerations.....	e21
3.5.8. Issues of Hemodynamic Support in High-Risk PCI.....	e22
3.6. Comparison With Bypass Surgery.....	e22
3.7. Comparison With Medicine.....	e24
4. INSTITUTIONAL AND OPERATOR COMPETENCY....	e29
4.1. Quality Assurance.....	e29
4.2. Operator and Institutional Volume.....	e31
4.3. Role of On-Site Cardiac Surgical Back-up.....	e35
4.4. Primary PCI for STEMI Without Onsite Cardiac Surgery.....	e37
4.5. Elective PCI Without Onsite Surgery.....	e38
5. CLINICAL PRESENTATIONS.....	e39
5.1. Patients With Asymptomatic Ischemia or CCS Class I or II Angina.....	e40
5.2. Patients With CCS Class III Angina.....	e41
5.3. Patients With UA/NSTEMI.....	e41
5.4. Patients With STEMI.....	e43
5.4.1. General and Specific Considerations.....	e43
5.4.2. PCI in Fibrinolytic-Ineligible Patients.....	e49
5.4.3. Facilitated PCI.....	e51
5.4.4. PCI After Failed Fibrinolysis (Rescue PCI).....	e51
5.4.5. PCI After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion.....	e53
5.4.6. PCI for Cardiogenic Shock.....	e54
5.4.7. PCI in Selected Patient Subgroups.....	e54
5.4.7.1. Young and Elderly Postinfarct Patients.....	e54
5.4.7.2. Patients With Prior MI.....	e56
5.5. Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery.....	e56
5.5.1. Early Ischemia After CABG.....	e56
5.5.2. Late Ischemia After CABG.....	e57
5.5.3. Early and Late Outcomes of Percutaneous Intervention.....	e57
5.5.4. General Considerations.....	e58
5.6. Use of Adjunctive Technology (Intracoronary Ultrasound Imaging, Flow Velocity, and Pressure).....	e58
5.6.1. Intravascular Ultrasound Imaging.....	e58
5.6.2. Coronary Artery Pressure and Flow: Use of Fractional Flow Reserve and Coronary Vasodilatory Reserve.....	e59
6. MANAGEMENT OF PATIENTS UNDERGOING PCI... e61	
6.1. Evolution of Technologies.....	e61
6.1.1. Acute Results.....	e61
6.1.2. Late-Term Results.....	e61
6.2. Antiplatelet and Antithrombotic Adjunctive Therapies For PCI.....	e62
6.2.1. Oral Antiplatelet Therapy.....	e62
6.2.2. Glycoprotein IIb/IIIa Inhibitors.....	e64
6.2.2.1. Abciximab.....	e65
6.2.2.2. Eptifibatide.....	e67
6.2.2.3. Tirofiban.....	e68
6.2.3. Antithrombotic Therapy.....	e69
6.2.3.1. Unfractionated Heparin, Low-Molecular-Weight Heparin, and Bivalirudin.....	e69
6.2.3.2. Heparin Dosing Guidelines.....	e70
6.3. Post-PCI Management.....	e70
6.3.1. Postprocedure Evaluation of Ischemia.....	e71
6.3.2. Risk Factor Modifications.....	e72
6.3.3. Exercise Testing After PCI.....	e72
6.3.4. Left Main CAD.....	e76
7. SPECIAL CONSIDERATIONS.....	e76
7.1. Ad Hoc Angioplasty—PCI at the Time of Initial Cardiac Catheterization.....	e76
7.2. PCI in Cardiac Transplant Patients.....	e77
7.3. Clinical Restenosis: Background and Management....	e78
7.3.1. Background on Restenosis After PTCA.....	e78
7.3.2. Clinical and Angiographic Factors for Restenosis After PTCA.....	e78
7.3.3. Management Strategies for Restenosis After PTCA.....	e78
7.3.4. Background on Restenosis After BMS Implantation.....	e78
7.3.5. Drug-Eluting Stents.....	e80
7.3.6. Management Strategies for ISR.....	e85
7.3.6.1. PTCA.....	e85
7.3.6.2. Drug-Eluting Stents.....	e85
7.3.6.3. Radiation.....	e86
7.3.6.4. Medical Therapy.....	e88
7.3.7. Subacute Stent Thrombosis.....	e88
7.3.8. Drug-Eluting Stents: Areas Requiring Further Investigation.....	e88
7.4. Cost-Effectiveness Analysis for PCI.....	e88
8. FUTURE DIRECTIONS.....	e89

Appendix 1. Relationships With Industry: Writing Committee.....e91
Appendix 2. Relationships With Industry: Peer Reviewers.....e92
References.....e93

PREAMBLE

It is important that the medical profession play a significant role in critically evaluating the use of diagnostic procedures and therapies as they are introduced and tested in the detection, management, or prevention of disease states. Rigorous and expert analysis of the available data documenting relative benefits and risks of those procedures and therapies can produce helpful guidelines that improve the effectiveness of care, optimize patient outcomes, and favorably affect the overall cost of care by focusing resources on the most effective strategies.

The American College of Cardiology (ACC) and the American Heart Association (AHA) have jointly engaged in the production of such guidelines in the area of cardiovascular disease since 1980. This effort is directed by the ACC/AHA Task Force on Practice Guidelines, whose charge is to develop and revise practice guidelines for important cardiovascular diseases and procedures. The Task Force is pleased to have this guideline cosponsored by the Society for Cardiovascular Angiography and Interventions (SCAI). Experts in the subject under consideration have been selected from all three organizations to examine subject-specific data and write guidelines. The process includes additional representatives from other medical practitioner and specialty groups where appropriate. Writing groups are specifically charged to perform a formal literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes where data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered, as well as frequency of follow-up and cost-effectiveness. When available, information from studies on cost will be considered; however, review of data on efficacy and clinical outcomes will be the primary basis for preparing recommendations in these guidelines.

The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual, potential, or perceived conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at each meeting, and updated and reviewed by the writing committee as changes occur.

The practice guidelines produced are intended to assist healthcare providers in clinical decision making by describing a range of generally acceptable approaches for the diag-

nosis, management, or prevention of specific diseases or conditions. These guidelines attempt to define practices that meet the needs of most patients in most circumstances. These guideline recommendations reflect a consensus of expert opinion after a thorough review of the available, current scientific evidence and are intended to improve patient care. If these guidelines are used as the basis for regulatory/payer decisions, the ultimate goal is quality of care and serving the patient's best interests. The ultimate judgment regarding care of a particular patient must be made by the healthcare provider and patient in light of all of the circumstances presented by that patient.

These guidelines were approved for publication by the governing bodies of the ACCF, AHA, and SCAI. The guidelines will be reviewed annually by the ACC/AHA Task Force on Practice Guidelines and will be considered current unless they are revised or withdrawn from distribution. The summary article and recommendations are published in the January 3, 2006 issue of the *Journal of the American College of Cardiology*, the January 3, 2006 issue of *Circulation*, and the January 2006 issue of *Catheterization and Cardiovascular Interventions*. The full-text guideline is posted on the World Wide Web sites of the ACC (www.acc.org), the AHA (www.americanheart.org), and the SCAI (www.scai.org). Copies of the full text and the executive summary are available from the ACC, AHA, and the SCAI.

Elliott M. Antman, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines

1. INTRODUCTION

The ACC/AHA Task Force on Practice Guidelines was formed to gather information and make recommendations about appropriate use of technology for the diagnosis and treatment of patients with cardiovascular disease. Percutaneous coronary interventions (PCIs) are an important group of technologies in this regard. Although initially limited to balloon angioplasty and termed percutaneous transluminal coronary angioplasty (PTCA), PCI now includes other new techniques capable of relieving coronary narrowing. Accordingly, in this document, implantation of intracoronary stents and other catheter-based interventions for treating coronary atherosclerosis are considered components of PCI. In this context, PTCA will be used to refer to those studies using only balloon angioplasty, whereas PCI will refer to the broader group of percutaneous techniques. These new technologies have impacted the effectiveness and safety profile initially established for balloon angioplasty. Moreover, additional experience has been gained in the use of adjunctive pharmacological treatment with glycoprotein (GP) IIb/IIIa receptor antagonists and the use of bivalirudin, thienopyridines, and drug-eluting stents (DES). In addition, since publication of the guidelines in 2001, greater experience in the performance of PCI in patients with acute coronary syndromes and in community hospital settings has been gained.

In view of these developments, an update of these guidelines

is warranted. This document reflects the opinion of the ACC/AHA/SCAI writing committee charged with updating the 2001 guidelines for PCI (1).

Several issues relevant to the Writing Committee's process and the interpretation of the guidelines have been noted previously and are worthy of restatement. First, PCI is a technique that has been continually refined and modified; hence, continued, periodic guideline revision is anticipated. Second, these guidelines are to be viewed as broad recommendations to aid in the appropriate application of PCI. Under unique circumstances, exceptions may exist. These guidelines are intended to complement, not replace, sound medical judgment and knowledge. They are intended for operators who possess the cognitive and technical skills for performing PCI and assume that facilities and resources required to properly perform PCI are available. As in the past, the indications are categorized as class I, II, or III on the basis of a multifactorial assessment of risk and expected efficacy viewed in the context of current knowledge and the relative strength of this knowledge.

These classes summarize the recommendations for procedures or treatments as follows:

Class I: Conditions for which there is evidence for and/or general agreement that a given procedure or treatment is beneficial, useful, and effective.

Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.

Class IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.

Class IIb: Usefulness/efficacy is less well established by evidence/opinion.

Class III: Conditions for which there is evidence and/or general agreement that a procedure/treatment is not useful/effective and in some cases may be harmful.

In addition, the weight of evidence in support of the recommendation is listed as follows:

- Level of Evidence A: Data derived from multiple randomized clinical trials or meta-analyses.
- Level of Evidence B: Data derived from a single randomized trial or nonrandomized studies.
- Level of Evidence C: Only consensus opinion of experts, case studies, or standard-of-care.

A recommendation with level of evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials

are not available, there may be a very clear clinical consensus that a particular test or therapy is useful and effective.

In instances where recommendations of class III, level of evidence C, occur, it is recognized that the bases of these recommendations are opinion and the consensus of the writing group. In this setting, it is not unreasonable for clinical trials to be conducted to further investigate the validity of this consensus opinion. The schema for classification of recommendations and level of evidence is summarized in Table 1, which also illustrates how the grading system provides an estimate of the size of the treatment effect and an estimate of the certainty of the treatment effect.

The committee conducted comprehensive searching of the scientific and medical literature on PCI, with special emphasis on randomized controlled trials and meta-analyses published since 2001. In addition to broad-based searching on PCI, specific targeted searches were performed on the following subtopics: catheter-based intervention, stents (drug-eluting and bare-metal), cardiac biomarkers (e.g., creatine kinase and troponins), pharmacological therapy (aspirin, thienopyridines, GP IIb/IIIa inhibitors, heparin, and direct thrombin inhibitors), special populations (women, patients with diabetes, elderly), coronary artery bypass grafting (CABG), high-risk PCI, quality, outcomes, volume, left main PCI (protected and unprotected), distal embolic protection, intravascular ultrasound (IVUS), fractional flow reserve (FFR), vascular closure, and secondary prevention/risk factor modification. The complete list of keywords is beyond the scope of this section. The committee reviewed all compiled reports from computerized searches and conducted additional searching by hand. Literature citations were generally restricted to published manuscripts appearing in journals listed in Index Medicus. Because of the scope and importance of certain ongoing clinical trials and other emerging information, published abstracts were cited when they were the only published information available. Additionally, the Committee reviewed and incorporated recommendations and/or text from published ACC/AHA or SCAI documents to maintain consistency, as appropriate.

Initially, this document describes the background information that forms the foundation for specific recommendations. Topics fundamental to coronary intervention are reviewed, followed by separate discussions relating to unique technical and operational issues. This format is designed to enhance the usefulness of this document for the assessment and care of patients with coronary artery disease (CAD). Formal recommendations for the use of PCI according to clinical presentation are included in Section 5. A clear distinction is drawn between the emergency use of PCI for patients with ST-segment elevation myocardial infarction (STEMI), termed "primary PCI," and all other procedures, which are included under the term "elective PCI" (see Section 4.2 for further discussion).

This committee includes cardiologists with and without involvement in interventional procedures, and a cardiac surgeon. This document was reviewed by 2 official reviewers nominated by ACC; 2 official reviewers nominated by AHA;

Table 1. Applying Classification of Recommendations and Level of Evidence

“Size of Treatment Effect”

	Class I <i>Benefit >>> Risk</i>	Class IIa <i>Benefit >> Risk</i> <i>Additional studies with focused objectives needed</i>	Class IIb <i>Benefit ≥ Risk</i> <i>Additional studies with broad objectives needed; Additional registry data would be helpful</i>	Class III <i>Risk ≥ Benefit</i> <i>No additional studies needed</i>
Level A <i>Multiple (3-5) population risk strata evaluated*</i> <i>General consistency of direction and magnitude of effect</i>	<p>Procedure/Treatment SHOULD be performed/administered</p> <ul style="list-style-type: none"> • Recommendation that procedure or treatment is useful/effective • Sufficient evidence from multiple randomized trials or meta-analyses 	<p>IT IS REASONABLE to perform procedure/administer treatment</p> <ul style="list-style-type: none"> • Recommendation in favor of treatment or procedure being useful/effective • Some conflicting evidence from multiple randomized trials or meta-analyses 	<p>Procedure/Treatment MAY BE CONSIDERED</p> <ul style="list-style-type: none"> • Recommendation’s usefulness/efficacy less well established • Greater conflicting evidence from multiple randomized trials or meta-analyses 	<p>Procedure/Treatment should NOT be performed/administered SINCE IT IS NOT HELPFUL AND MAY BE HARMFUL</p> <ul style="list-style-type: none"> • Recommendation that procedure or treatment not useful/effective and may be harmful • Sufficient evidence from multiple randomized trials or meta-analyses
Level B <i>Limited (2-3) population risk strata evaluated*</i>	<ul style="list-style-type: none"> • Recommendation that procedure or treatment is useful/effective • Limited evidence from single randomized trial or non-randomized studies 	<ul style="list-style-type: none"> • Recommendation in favor of treatment or procedure being useful/effective • Some conflicting evidence from single randomized trial or non-randomized studies 	<ul style="list-style-type: none"> • Recommendation’s usefulness/efficacy less well established • Greater conflicting evidence from single randomized trial or non-randomized studies 	<ul style="list-style-type: none"> • Recommendation that procedure or treatment not useful/effective and may be harmful • Limited evidence from single randomized trial or non-randomized studies
Level C <i>Very limited (1-2) population risk strata evaluated*</i>	<ul style="list-style-type: none"> • Recommendation that procedure or treatment is useful/effective • Only expert opinion, case studies, or standard-of-care 	<ul style="list-style-type: none"> • Recommendation in favor of treatment or procedure being useful/effective • Only diverging expert opinion, case studies, or standard-of-care 	<ul style="list-style-type: none"> • Recommendation’s usefulness/efficacy less well established • Only diverging expert opinion, case studies, or standard-of-care 	<ul style="list-style-type: none"> • Recommendation that procedure or treatment not useful/effective and may be harmful • Only expert opinion, case studies, or standard-of-care

Suggested phrases for writing recommendations †

should	is reasonable	is not recommended
is recommended	can be useful/effective/ beneficial	is not indicated
is indicated	is probably recommended or indicated	should not
is useful/effective/beneficial		is not useful/effective/beneficial
		may be harmful
		may/might be considered
		may/might be reasonable
		usefulness/effectiveness is unknown/unclear/uncertain or not well established

*Data available from clinical trials or registries about the usefulness/efficacy in different sub-populations, such as gender, age, history of diabetes, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All recommendations in this guideline have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.

2 official reviewers nominated by SCAI; 1 official reviewer from the ACC/AHA Task Force on Practice Guidelines; and 8 content reviewers, including members from the AHA Committee on Diagnostic and Interventional Cardiac Catheterization and the ACCF Cardiac Catheterization and Intervention Committee.

2. GENERAL CONSIDERATIONS AND BACKGROUND

Coronary angioplasty was first introduced by Andreas Gruentzig in 1977 (2) as a nonsurgical method for coronary arterial revascularization. Fundamentally, the technique involved advancing a balloon-tipped catheter to an area of coronary narrowing, inflating the balloon, and then removing the catheter after deflation. Early reports demonstrated that balloon angioplasty could reduce the severity of coronary stenosis and diminish or eliminate objective and subjective manifestations of ischemia (3-5). Although angioplasty was clearly feasible and effective, the scope of coronary disease to be treated was quite narrow. Also, because angioplasty could result in sudden arterial occlusion and subsequent myocardial infarction (MI), immediate access to coronary bypass surgery was essential (6). With experience and time, however, the cognitive and technical aspects as much as the equipment used to perform angioplasty became more refined. Observational reports of large numbers of patients confirmed that coronary angioplasty could be applied to broad groups of coronary patients with higher rates of success and lower rates of complications than seen in initial experiences (7,8). More than 1 000 000 PCI procedures are performed yearly in the United States (9), and it has been estimated that nearly 2 000 000 procedures are performed annually worldwide.

The value of coronary angioplasty was further defined by comparing its results to those of alternative methods of treatment. Randomized clinical trials have assessed the outcomes of patients treated by a strategy of initial angioplasty to one of medical therapy alone or to coronary artery bypass surgery (10-14). The results of these trials have clarified the utility of angioplasty in terms of effectiveness, complications, and patient selection. The technique of coronary angioplasty has also been expanded by the development of devices that replace or serve as adjuncts to the balloon catheter. These “new devices” have been evaluated and have had a variable impact in enhancing the immediate- and long-term efficacy and safety of coronary angioplasty. The following section of this report expands on this background and describes the practice of PCI as it is applied today.

Advances in coronary-based interventions, especially the use of bare-metal stents (BMS) and drug-eluting stents (DES), have improved the efficacy and safety profile of percutaneous revascularization observed for patients undergoing PTCA. For example, stents reduce both the acute risk of major complications and late-term restenosis. The success of new coronary devices in meeting these goals is reflected in part by the rapid transition from the use of PTCA alone (less than 30%) to the high use of PCI with stenting, which was greater than 70% by the late 1990s (Figure 1) (15). Atherectomy devices and stenting, associated with improved acute angiographic and clinical outcomes compared with PTCA alone in specific subsets, continue to be applied to a wider patient domain that includes multivessel disease and complex coronary anatomy. However, strong evidence (level A data from multiple randomized clinical trials) is primarily available for stenting over PTCA in selected patients undergoing single-vessel PCI.




Figure 1. Frequency of device use in the SCAI registry. Source data from Laskey *et al.* *Catheter Cardiovasc Interv* 2000;49:19-22 (15).

The range of non-balloon revascularization technology approved by the Food and Drug Administration (FDA) for use in native and/or graft coronary arteries includes balloon expandable stents, DES, extraction atherectomy, directional coronary atherectomy, rotational atherectomy, rheolytic thrombectomy catheter, proximal and distal embolic protection devices, excimer laser coronary atherectomy, and local radiation devices to reduce in-stent restenosis (ISR) (16,17). A variety of devices are under investigation, including new designs of balloon or self-expanding stents and mechanical thrombectomy devices. This guideline update will focus on the FDA-approved balloon-related and non-balloon coronary revascularization devices.

3. OUTCOMES

The outcomes of PCI are measured in terms of success and complications and are related to the mechanisms of the employed devices, as well as the clinical and anatomic patient-related factors. Complications can be divided into 2 categories: (a) those common to all arterial catheterization procedures and (b) those related to the specific technology used for the coronary procedure. Specific definitions of success and complications exist, and where appropriate, the definitions used herein are consistent with the ACC-National Cardiovascular Data Registry (NCDR[®]) Catheterization Laboratory Module version 3.0 (18). The committee recommends such standards whenever feasible in order to accommodate the common database for the assessment of outcomes. With increased operator experience, new technology, and adjunctive pharmacotherapy, the overall success and complication rates of angioplasty have improved.

3.1. Definitions of PCI Success

The success of a PCI procedure may be defined by angiographic, procedural, and clinical criteria.

3.1.1. Angiographic Success

A successful PCI produces substantial enlargement of the lumen at the target site. The consensus definition before the widespread use of stents was the achievement of a minimum stenosis diameter reduction to less than 50% in the presence of grade 3 Thrombolysis In Myocardial Infarction (TIMI) flow (assessed by angiography) (1). However, with the advent of advanced adjunct technology, including coronary stents, a minimum stenosis diameter reduction to less than 20% has been the clinical benchmark of an optimal angiographic result. Frequently, there is a disparity between the visual assessment and computer-aided quantitative stenosis measurement (19,20), and, thus, the determination of success may be problematic when success rates are self-reported.

3.1.2. Procedural Success

A successful PCI should achieve angiographic success without major clinical complications (e.g., death, MI, emergency coronary artery bypass surgery) during hospitalization (1,3).

Although the occurrence of emergency coronary artery bypass surgery and death are easily identified end points, the definition of procedure-related MI has been debated. The development of Q waves in addition to a threshold value of creatine kinase (CK) elevation has been commonly used. Most agree that the definition of MI as put forth by the ACC/European Society of Cardiology document on the redefinition of MI (21) should be the accepted standard. However, the clinical significance and definition of cardiac biomarker elevations in the absence of Q waves remains the subject of investigation and debate (21a). Several reports have identified non-Q-wave MIs with CK-MB elevations 3 to 5 times the upper limit of normal as having clinical significance (22,23). One report suggests that a greater than 5 times increase in CK-MB is associated with worsened outcome (24). Thus, this degree of increase in CK-MB without Q waves is considered by most to qualify as an associated complication of PCI. Troponin T or I elevation occurs frequently after PCI. The timing of the peak elevation after PCI is unclear (25). Minor elevations do not appear to have prognostic value, whereas marked (greater than 5 times) elevations are associated with worsened 1-year outcome (Table 2) (26-40). Troponin T or I elevation occurs more frequently than CK-MB increase after PCI (34).

3.1.3. Clinical Success

In the short term, a clinically successful PCI includes anatomic and procedural success with relief of signs and/or symptoms of myocardial ischemia after the patient recovers from the procedure. The long-term clinical success requires that the short-term clinical success remain durable and that the patient have persistent relief of signs and symptoms of myocardial ischemia for more than 6 months after the procedure. Restenosis is the principal cause of lack of long-term clinical success when a short-term clinical success has been achieved. Restenosis is not considered a complication but rather an associated response to vascular injury. The incidence of clinically important restenosis may be judged by the frequency with which subsequent revascularization procedures are performed on target vessels after the index procedure.

3.2. Acute Outcome: Procedural Complications

Class I

All patients who have signs or symptoms suggestive of MI during or after PCI and those with complicated procedures should have CK-MB and troponin I or T measured after the procedure. (Level of Evidence: B)

Class IIa

Routine measurement of cardiac biomarkers (CK-MB and/or troponin I or T) in all patients undergoing PCI is reasonable 8 to 12 hours after the procedure. (Level of Evidence: C)

Table 2. Incidence of Troponin Elevations After Percutaneous Coronary Intervention in the Published Literature

First Author of Study (Reference)	n	Marker	% Positive	Positive Definition	Prognostic Information
Hunt (29)	22	Troponin I	0	Greater than 6 ng per mL	N/A
Ravkilde (30)	23	Troponin T	13	Greater than 0.12 ng per mL	N/A
Karim (31)	25	Troponin T	44	Greater than 0.2 ng per mL	N/A
La Vecchia (32)	19 (Stent) 25 (balloon PCI)	Troponin T and troponin I	37 cTnI; 21 cTnT 14 cTnI; 0 cTnT	N/A	N/A
Johansen (33)	75	Troponin T	28	Greater than 0.1 ng per mL	N/A
Shyu (34)	59 (Stent) 61 (balloon PCI)	Troponin T	29 13	Greater than 0.1 ng per mL	Significantly higher incidence of elevated cTnT in patients undergoing stenting than angioplasty alone.
Bertinchant (35)	105	Troponin I	22	Greater than 0.1 ng per mL	No difference in incidence of recurrent angina, MI, cardiac death, or RR after 12 months between patients positive or negative for cTnI. Stenting not associated with more minor myocardial damage than angioplasty.
Garbarz (36)	109	Troponin I	27	Greater than 0.3 ng per mL	No association between post-PCI cTnI and adverse ischemic events.
Fuchs (37)	1129	Troponin I	31	Greater than 0.15 ng per mL	cTnT levels greater than 3× normal limit associated with increased risk of major in-hospital complications, but no association with adverse intermediate-term (8 months) clinical outcomes.
Cantor (26)	481	Troponin I	48 overall; 26 after excluding positive or unknown pre-PCI cTnI	Greater than 1.5 ng per mL	Significantly higher 90-day rates of MI and the composite of MI or death in patients with positive cTnI.
Wu (38)	98	Troponin T	26	Greater than 0.1 ng per mL	At a mean of 77 months follow-up, no increase in risk of major adverse events detected in relation to post-PCI cTnT elevation.
Kizer (27)	212	Troponin T	40 positive prior to PCI; 18 of baseline negative were positive post-PCI	Greater than or equal to 0.1 ng per mL	Pre-PCI cTnT elevation was significantly related to event-free survival during 6-year follow-up; in baseline negative patients, positive cTnT was the only independent predictor of major adverse events at 1 year; post-PCI elevations of cTnT greater than or equal to 5× normal was the strongest long-term predictor of major adverse events at 6 years.
Ricciardi (39)	286	Troponin I	13.6	Greater than 2.3 ng per mL	cTnI elevations greater than 3-fold care predictive of future major adverse cardiac events (MACE). Increased incidence of MACE is accounted for by higher rate of early RR and not late cardiac events.
Kini (40)	2873	Troponin I	38.9	Greater than 2 ng per mL	Neither cTnI peak elevations nor any subgroup predicted mid-term mortality in low- to medium-risk patients.

cTnI indicates cardiac troponin I; cTnT, cardiac troponin T; N/A, not applicable; PCI, percutaneous coronary intervention; and RR, repeat revascularization.

Complications associated with PCI are similar to those resulting from diagnostic cardiac catheterization, but their prevalence is more frequent. Complications have been categorized as major (death, MI, and stroke) or minor (transient ischemic attack, access site complications, renal insufficiency, or adverse reactions to radiographic contrast). Additional specific complications include intracoronary thrombosis, coronary perforation, tamponade, and arrhythmias.

Reported rates for death after diagnostic catheterization range from 0.08% to 0.14%, whereas analyses of large registries indicate overall unadjusted in-hospital rates for PCI of 0.4% to 1.9% (Table 3) (41-52). This range is greatly influenced by the clinical indication for which PCI is performed, with the highest mortality rates occurring among patients with STEMI and cardiogenic shock. Death in such patients may not be a direct result of the PCI procedure but rather a consequence of the patient's underlying illness. For example, in a combined analysis of PCI as primary reperfusion therapy for STEMI, the short-term mortality rate was 7% (53). Even after exclusion of patients with cardiogenic shock, in-hospital mortality was 5%.

Myocardial infarction can be a direct result of PCI, most commonly due to abrupt coronary occlusion or intracoronary embolization of obstructive debris. Determining and comparing the incidence of MI after PCI is difficult because the definition of MI as a result of PCI is controversial. The conventional definition requires 2 of the following: a) prolonged chest discomfort or its equivalent; b) development of pathologic Q waves; and c) rise in serum cardiac biomarkers above a critical level. Rates of periprocedural MI using this definition have ranged from 0.4% to 4.9%. Using a consistent definition for MI, the incidence of this complication has declined approximately 50% with the routine use of intracoronary stents (21,21a,50).

More recently, an isolated rise and fall in either CK-MB or troponin is considered to be a marker of myocardial necrosis (21). The relationship between cardiac biomarker elevation and myocardial cell death and evidence of subendocardial infarction on magnetic resonance imaging (MRI) support this position (54,55). Furthermore, large rises in cardiac biomarkers are associated with an increased risk for late death (26,56,57). Whether death in such patients is a consequence of the myonecrosis or a marker of patients who are at increased risk for death because of more advanced coronary disease is unclear. Complicating our understanding of the implications of this definition is the very frequently observed mild to modest elevation of serum CK-MB among patients with apparently uncomplicated PCI. When troponin is measured after PCI, more than 70% of patients exhibit elevated values after an otherwise successful intervention (58). Such patients may have no symptoms or electrocardiographic (ECG) abnormalities to suggest ischemia yet are "enzyme positive." One study has suggested a postprocedural increase in troponin T of 5 times normal is predictive for adverse events at 6 years. The long-term prognostic significance of smaller postprocedural troponin T elevations awaits further investigation (27) (Table 2) (26-40).

Another study indicated that more extensive stent expansion resulted in CK release but did not increase adverse cardiac events (59). Accordingly, it is important to acknowledge that the significance of mild biomarker rises after clinically successful PCI should be distinguished from situations wherein patients experience an unequivocal "clinical" infarction manifested by chest pain and diagnostic ECG findings (60).

Routine measurement of CK-MB is advocated by some (21) and actually mandated by certain healthcare systems. In this regard, the current Committee supports the recommendations of the 2001 Guidelines and recommends that all patients who have signs or symptoms suggestive of MI during or after PCI and those with complicated procedures should have CK-MB and troponin I or T measured after the procedure. In addition, the Committee recommends that routine measurement of cardiac biomarkers (CK-MB and/or troponin I or T) in every patient undergoing PCI is reasonable 8 to 12 h after the procedure. In such patients, a new CK-MB or troponin I or T rise greater than 5 times the upper limit of normal would constitute a clinically significant periprocedural MI.

The need to perform emergency coronary artery bypass surgery (CABG) has been considered as a potential complication of PCI. Typically, CABG is performed as a rescue revascularization procedure to treat acute ischemia or infarction resulting from PCI-induced acute coronary occlusion. In the era of balloon angioplasty, the rate of emergency CABG was 3.7% (49). In a more contemporary time period, with the availability of stents, the reported rate was 0.4% among a similar cohort of patients.

Various definitions have been proposed for stroke. A common feature to definitions has been a loss of neurologic function of vascular cause that lasts more than 24 h. More recently, attention has been directed to refining the definition of transient ischemic attack (TIA), which indirectly broadens that of stroke (61). The time-based definition of a TIA is a sudden, focal neurologic deficit that lasts less than 24 h that is of presumed vascular origin and confined to an area of the brain or eye perfused by a specific artery. The new definition of TIA is a brief episode of neurologic dysfunction caused by brain or retinal ischemia, with clinical symptoms typically lasting less than 1 hour and without evidence of infarction. Presence of cerebral infarction by imaging techniques constitutes evidence of stroke regardless of the duration of symptoms.

Bleeding is a complication of increasing concern with the more frequent use of potent antithrombin and antiplatelet agents. A frequently used definition for bleeding developed by the TIMI group includes classification as major, moderate, or minor. Major bleeding is defined as intracranial, intraocular, or retroperitoneal hemorrhage or any hemorrhage requiring a transfusion or surgical intervention or that results in a hematocrit decrease of greater than 15% or hemoglobin decrease of greater than 5 g per dL (62). Episodes of hemorrhage of lesser magnitude would fall into the moder-

Table 3. Unadjusted In-Hospital Outcome Trends After Percutaneous Coronary Interventions

Registry	Years	Reference	n	Clinical Success, %	In-Hospital Mortality, %	Q-Wave MI, %	Emergency CABG, %
NHLBI (I)‡	1977-1981	(41)	3079*	61	1.2	NR	5.8
NHLBI (II)§	1985-1986	(41)	2311*	78	1.0	4.8	5.8
BARI Registry	1988-1991	(42)	1189*	NR	0.7	2.8	4.1
Northern New England¶	1990-1993	(43)	13 014†	88.8	1.0	2.4	2.2
SCAI#	1990-1994	(44)	4366†	91.5	2.5	NR	3.4
NACI**	1990-1994	(45)	4079*	NR	1.6	1.6	1.9
NY State Database	1991-1994	(46,47)	62 670*	NR	0.9	NR	3.4
Northern New England¶	1994-1995	(43)	7248†	89.2	1.1	2.1	2.3
NCN	1994-1997	(48)	76 904†	NR	1.3	NR	1.7
Northern New England¶	1995-1997	(43)	14 490†	91.5	1.2	2.0	1.3
NHLBI Dynamic Registry‡‡	1997-1998	(49)	1559*	92	1.9	2.8	0.4
NHLBI Dynamic	1997-1999	(50)	857	91	0.9	0.8	1.9
ACC-NCDR	1998-2000	(51)	100 292	96.5	1.4	0.4	1.9
NY State Database	1997-2000	(52)	22 102	NR	0.68	NR	NR

CABG indicates coronary artery bypass graft surgery; MI, myocardial infarction; NACI, New Approaches in Coronary Interventions; NCN, National Cardiovascular Network; and NR, not reported.

*N indicates number of patients.

†N indicates number of procedures.

‡In NHLBI (I), emergency CABG was defined as in-hospital CABG.

§In NHLBI (II), MI was defined as the presence of at least 2 of the 3 criteria: clinical symptoms, Q waves on ECG (Minnesota code), or elevated cardiac enzyme level (double the normal levels for CK or its MB fraction without Q waves). Emergency CABG was defined as in-hospital CABG.

||In BARI, MI was defined as the appearance of ECG changes (new pathologic Q waves) supported by abnormal CK-MB elevations.

¶In Northern New England, a new MI was defined as a clinical event, ECG changes, and a creatinine phosphokinase rise at least 2 times normal levels with positive isozymes. Emergency CABG was defined as surgery performed to treat acute closure, unstable angina, or congestive heart failure requiring intravenous nitroglycerin or ABB, or tamponade resulting from the intervention.

#In SCAI, a new MI was defined as any significant infarction (greater than 3 times normal rise in MB fraction).

**In NACI, MI was defined as a Q-wave MI.

‡‡MI was defined as 2 or more of the following: 1) typical chest pain greater than 20 min not relieved by nitroglycerin; 2) serial ECG recordings showing changes from baseline or serially in ST-T and/or Q waves in at least 2 contiguous leads; or 3) serum enzyme elevation of CK-MB greater than 5% of total CK (total CK more than 2 times normal; lactate dehydrogenase subtype 1 greater than lactate dehydrogenase subtype 2).

ate/minor categories. A listing of other bleeding classifications has been developed for use by the ACC-NCDR[®] (18).

3.3. Acute Outcome: Success Rates

Success has been described on both a lesion and patient basis. In early studies of PTCA, lesion success is defined as an absolute 20% reduction in lesion severity with final stenosis less than 50%. When describing the results of multiple attempted lesions, success is classified as either partial (some but not all attempted lesions successfully treated) or total (each attempted lesion successfully treated). Procedural success is defined as the achievement of either partial or total angiographic success without death, MI, or emergency CABG (49).

Reported rates of angiographic success now range between 82% and 98% depending on the device used and the types of lesions attempted. Formal comparisons demonstrate that success rates are now higher (91% to 92%) in the era of new technology, which includes stents and contemporary drug therapies, than in the era of conventional balloon angioplasty (72% to 74%) (49). The types of lesions attempted strongly influence success rates. The chance of dilating a chronic total occlusion averages 65%, and specific clinical and anatomic factors have been identified that affect this rate (63). Quite different are the success rates for total occlusions associated with STEMI. Success rates over 90% can be expected in this subgroup (64).

With an increase in angiographic success rates and a decline in periprocedural MI and the need for emergency CABG, procedural success rates have risen from a range of 80% to 85% to a range of 90% to 95% (Table 3) (41-52).

3.4. Long-Term Outcome and Restenosis

Although improvements in technology, such as stents, have resulted in an improved acute outcome of the procedure, the impact of these changes on long-term (5 to 10 years) outcome may be less dramatic because factors such as advanced age, reduced left ventricular (LV) function, and progression of complex multivessel disease in patients currently undergoing PCI may have a more important influence. In addition, available data on long-term outcome are mostly limited to patients undergoing PTCA. Ten-year follow-up of the initial cohort of patients treated with PTCA revealed an 89.5% survival rate (95% in patients with single-vessel disease, 81% in patients with multivessel disease) (65). In patients undergoing PTCA within the 1985-1986 National Heart, Lung, and Blood Institute (NHLBI) PTCA Registry (66), 5-year survival was 92.9% for patients with single-vessel disease, 88.5% for those with 2-vessel disease, and 86.5% for those with 3-vessel disease. In patients with multivessel disease undergoing PTCA in the Bypass Angioplasty Revascularization Investigation (BARI) (10), 5-year survival was 86.3%, and infarct-free survival was 78.7%. Specifically, 5-year survival was 84.7% in patients with 3-vessel disease and 87.6% in patients with 2-vessel disease.

In addition to multivessel disease, other clinical factors adversely impact late mortality. In randomized patients with treated diabetes undergoing PTCA in BARI, the 5-year survival was 65.5%, and the cardiac mortality rate was 20.6% compared with 5.8% in patients without treated diabetes (67), although among eligible but not randomized diabetic patients treated with PTCA, the 5-year cardiac mortality rate was 7.5% (68). In the 1985-1986 NHLBI PTCA Registry, 4-year survival was significantly lower in women (89.2%) than in men (93.4%) (69). In addition, although LV dysfunction was not associated with an increase in in-hospital mortality or nonfatal MI in patients undergoing PTCA in the same registry, it was an independent predictor of a higher long-term mortality (70).

A major determinant of event-free survival after coronary intervention is the incidence of restenosis, which had, until the development of stents, remained fairly constant despite multiple pharmacologic and mechanical approaches to limit this process (Table 4) (71-95). The incidence of restenosis after coronary intervention varies depending on the definition, i.e., whether clinical or angiographic restenosis or target-vessel revascularization is measured (96). Data from multiple randomized clinical trials and prospective registries suggest that DES incorporating either rapamycin or paclitaxel with a timed-release polymer are associated with a reduction in restenosis rates to less than 10% across a wide spectrum of clinical and angiographic subsets.

The pathogenesis of the response to mechanical coronary injury is thought to relate to a combination of growth factor stimulation, smooth muscle cell migration and proliferation, organization of thrombus, platelet deposition, and elastic recoil (97,98). In addition, change in vessel size (or lack of compensatory enlargement) has been implicated (99). It has been suggested that attempts to reduce restenosis have failed in part because of lack of recognition of the importance of this factor (100). Although numerous definitions of restenosis have been proposed, greater than 50% diameter stenosis at follow-up angiography has been most frequently used because it was thought to correlate best with maximal flow and therefore ischemia. However, it is now recognized that the response to arterial injury is a continuous rather than a dichotomous process, occurring to some degree in all patients (101). Therefore, cumulative frequency distributions of the continuous variables of minimal lumen diameter or percent diameter stenosis are frequently used to evaluate restenosis in large patient populations (102) (Figure 2) (80).

Although multiple clinical factors (diabetes, unstable angina [UA]/NSTEMI, STEMI, and prior restenosis) (103,104), angiographic factors (proximal left anterior descending artery [LAD], small vessel diameters, total occlusion, long lesion length, and saphenous vein grafts [SVGs]) (105), and procedural factors (higher postprocedure percent diameter stenosis, smaller minimal lumen diameter, and smaller acute gain) (102) have been associated with an increased incidence of restenosis, the ability to integrate these factors and predict the risk of restenosis in individual patients after the procedure remains difficult. The most promising potential

Table 4. Selected Trials of Pharmacological and Mechanical Approaches to Limit Restenosis

Study	Year	Reference	n	Agent	Restenosis Rate, %	
					Placebo or Control	Agent
Schwartz	1988	(71)	376	Aspirin and dipyridamole	39	38
Ellis	1989	(72)	416	Heparin	37	41
Pepine	1990	(73)	915	Methylprednisolone	39	40
CARPORT	1991	(74)	649	Vapiprost	19	21
O'Keefe	1992	(75)	197	Colchicine	22	22
MERCATOR	1992	(76)	735	Cilazapril	28	28
CAVEAT*	1993	(77)	500	DCA versus PTCA	57	50
CCAT	1993	(78)	136	DCA versus PTCA	43	46
Serruys	1993	(79)	658	Ketanserin	32	32
BENESTENT*	1994	(80)	520	Stent versus PTCA	32	22
ERA	1994	(81)	458	Enoxaparin	51	52
Leaf	1994	(82)	551	Fish oil	46	52
STRESS*	1994	(83)	410	Stent versus PTCA	42	32
Weintraub	1994	(84)	404	Lovastatin	42	39
BOAT*	1998	(85)	492	DCA versus PTCA	40	31
Wantanabe*	1996	(86)	118	Probuco	40	20
Tardif*	1997	(87)	317	Probuco	39	21
BENESTENT II*	1998	(88)	823	Stent versus PTCA	31	17
TREAT*	1999	(89)	255	Tranilast	39	18
PRESTO*	2000	(90)	192	DCA and Tranilast	26	11
ARTIST*	2002	(91)	298	Rotablation (in-stent) versus PTCA	51	65
START*	2002	(92)	476	Radiation (in-stent)	45	29
SIRIUS*	2003	(93)	1058	Sirolimus-coated stent versus bare stent	36	9
TAXUS-IV*	2004	(94)	1314	Paclitaxel-coated stent versus bare stent	27	8
RESCUT	2004	(95)	428	Cutting balloon (in-stent) versus PTCA	31	30

DCA indicates directional coronary atherectomy; n, number of patients; and PTCA, percutaneous transluminal coronary angioplasty.
 *P less than 0.05.

approaches to favorably impact the restenosis process are stents and, more recently, DES and catheter-based radiation. More than 6300 patients have been studied in 12 randomized clinical trials to assess the efficacy of PTCA versus stents to reduce restenosis (Table 5) (80,83,88,106-114).

The pivotal BENESTENT (BELgian NETHERlands STENT study) (80) and STRESS (STent REStenosis Study) trials (83) documented that stents significantly reduce angiographic restenosis compared with balloon angioplasty (BENESTENT: 22% vs 32%; STRESS: 32% vs 42%, respectively). These results were further corroborated in the BENESTENT II trial, in which the angiographic restenosis rate was reduced by almost half (from 31% to 16% in patients treated with balloon angioplasty versus heparin-coated stents, respectively) (88).

In addition, randomized studies in patients with ISR have shown that both intracoronary gamma and beta radiation significantly reduced the rate of subsequent angiographic and clinical restenosis by 30% to 50% (92,115-117). Late subacute thrombosis was observed in some of these series (117), but this syndrome has resolved with judicious use of stents and extended adjunct antiplatelet therapy with ticlopidine or

clopidogrel. The development of DES has significantly reduced the rate of ISR (see Section 7.3.6 for full discussion).

3.5. Predictors of Success/Complications

3.5.1. Lesion Morphology and Classification

Target lesion anatomic factors related to adverse outcomes have been widely examined. Lesion morphology and absolute stenosis severity were identified as the prominent predictors of immediate outcome during PTCA in the pre-stent era (118,119). Abrupt vessel closure, due primarily to thrombus or dissection, was reported in 3% to 8% of patients and was associated with certain lesion characteristics (120-122). The risk of PTCA in the pre-stent era relative to anatomic subsets has been identified in previous NHLBI PTCA Registry data (7) and by the ACC/AHA Task Force on Practice Guidelines (1,123). The lesion classification based on severity of characteristics proposed in the past (123-125) has been principally altered using the present PCI techniques, which capitalize on the ability of stents to manage initial and subsequent complications of coronary interven-

BALLOON STENT VERSUS BALLOON ANGIOPLASTY IN CORONARY ARTERY DISEASE




Figure 2. Balloon stent vs balloon angioplasty in coronary artery disease. Cumulative frequency distribution curves for the 2 study groups, showing minimum lumen diameters measured before and after intervention and follow-up (B), the percentage of stenosis at follow-up, and the percentage of patients with clinical end points. Significant differences were apparent that consistently favored the stent group over the angioplasty group with respect to the increased minimal lumen diameter at intervention (A) and follow-up (B), the percentage of stenosis at follow-up (C), and the incidence of major clinical events (D). The vertical dashed line in D indicated the end of the study. Reprinted with permission from Serruys *et al.* *N Engl J Med* 1994;331:489-95 (80). Copyright 2004 Massachusetts Medical Society. All rights reserved.

tions (126). As a result, the Committee has revised the previous ACC/AHA lesion classification system to reflect high-risk (at least 1 type C lesion characteristic) and non-high-risk (no type C lesion characteristic) lesions (Table 6) in accordance with the PCI Clinical Data Standards from the ACC-NCDR[®] (18). Studies (127-130) have confirmed that complex coronary lesions remain predictive of adverse events after PCI. However, although the risk of restenosis and technical failure remains high for chronic total occlusions, the risk of acute complications is not increased.

The SCAI proposed a new lesion classification using 7 lesion characteristics (131). This system dichotomizes lesions by the presence or absence of a type C characteristic and vessel patency versus total occlusion, yielding 4 lesion classes (Table 7) (132). Utilizing data from the voluntary ACC-NCDR[®], the SCAI group presented analyses that showed that the more simplified SCAI lesion classification provided better discrimination for success and complications than the ACC/AHA lesion classification system (132,133).

The SCAI lesion classification system was validated from a voluntary registry, which imposes a potential bias because

the operator classified the lesion after finishing the case and knowing whether the case was successful or had complications. No prospective studies using core laboratory analysis have validated this system. Nonetheless, the SCAI classification system utilizing vessel patency in addition to C and non-C class appears promising to categorize the risk of success and complications with PCI.

3.5.1.1. Clinical Factors

Coexistent clinical conditions can increase the complication rates for any given anatomic risk factor. For example, complications occurred in 15.4% of patients with diabetes versus 5.8% of patients without diabetes undergoing balloon angioplasty in a multicenter experience (119,122). Several studies have reported specific factors associated with increased risk of adverse outcome after PTCA. These factors include advanced age, female gender, UA, congestive heart failure (HF), diabetes, and multivessel CAD (10,118,119,127-130,134,135). Elevated baseline C-reactive protein (CRP) has recently also been shown to be predictive of 30-day death and MI (128,136). Other markers of inflammation, such as

Table 5. Studies Comparing Balloon Angioplasty with Stents for Native Coronary Artery Lesions

Study (Ref)	Year	Follow-Up, mo	n, Stent/Angioplasty	Angiographic Restenosis, %		TVR, %		Death, %				
				Stent	Angioplasty	P value	Stent	Angioplasty	P value	Stent	Angioplasty	P value
STRESS (83)	1994	6	205/202	31.6	42.1	0.046	10.2	15.4	0.06	1.5	1.5	NS
BENESTENT (80,107)	1996	7/12*	259/257	22	32	0.02	10	21	0.001	1.2	0.8	NS
Versaci et al. (108)	1997	12	60/60	19	40	0.02	6.6	22	NA	NA	NA	NA
STRESS II (109)	1998	12	100/89	NA	NA	NA	10	20	NA	17II	34II	NA
BENESTENT II (88)	1998	6	413/410	16	31	Less than 0.001	8†	13.7	0.02	0.2%	0.5%	NS
OCBAS (110)	1998	7	57/59	18.8	16.6	NA	17.5	9.2	NA	0	1.6	NS
EPISTENT (111,112)‡	1998	6	794/796	NA	NA	NA	8.7	15.4	Less than 0.001	0.5	1.8	0.02
START (113)	1999	6/48§	229/223	22	37	Less than 0.002	12	24.6	Less than 0.002	2.7	2.4	NS
OPUS (114)	2000	6	479 (Overall)	NA	NA	NA	3.0	10.1	0.003	0.4	1.2	NS

mo indicates months; NA, data not reported for that category; NS, not significant; and TVR, target vessel revascularization. Data are for lesions in coronary arteries with vessel diameter greater than or equal to 3.0 mm. *6-7 months angiographic follow-up and 12 months clinical follow-up.

†Any repeat procedure.

‡Stent plus abciximab versus percutaneous transluminal angioplasty plus abciximab.

§6 months angiographic follow-up and 48 months clinical follow-up.

||End point of death/any MI/CABG/target lesion percutaneous transluminal angioplasty.

Modified with permission from Al Si et al. JAMA 2000;284:1828-36 (106).

Table 6. Lesion Classification System

Descriptions of a High-Risk Lesion (Type C Lesion)

- Diffuse (length greater than 2 cm)
- Excessive tortuosity of proximal segment
- Extremely angulated segments, greater than 90°
- Total occlusions more than 3 months old and/or bridging collaterals*
- Inability to protect major side branches
- Degenerated vein grafts with friable lesions*

*The high risk with these criteria is for technical failure and increased restenosis, not for acute complications.

interleukin-6 and other cytokines, have also been shown to be predictive of outcome (137). The BARI trial found that patients with diabetes and multivessel CAD had an increased periprocedural risk of ischemic complications and increased 5-year mortality compared with patients without diabetes or patients with diabetes undergoing bypass surgery using internal mammary artery (IMA) grafts (10,42). Patients with impaired renal function, especially those with diabetes, are at increased risk for contrast nephropathy (138) and increased 30-day and 1-year mortality (139,140). Renal insufficiency is a strong predictor of outcome in both primary and elective PCI (141-143). Increased risk for death or severe compromise in LV function may occur in association with a complication involving a vessel that also supplies collateral flow to viable myocardium. Certain variables were used to prospectively identify patients at risk for significant cardiovascular compromise during PTCA (144,145). These resulted in a

Table 7. SCAI Lesion Classification System: Characteristics of Class I-IV Lesions

Type I lesions (highest success expected, lowest risk)

- (1) Does not meet criteria for C lesion
- (2) Patent

Type II lesions

- (1) Meets any of these criteria for ACC/AHA C lesion
 - Diffuse (greater than 2 cm length)
 - Excessive tortuosity of proximal segment
 - Extremely angulated segments, greater than 90°
 - Inability to protect major side branches
 - Degenerated vein grafts with friable lesions
- (2) Patent

Type III lesions

- (1) Does not meet criteria for C lesion
- (2) Occluded

Type IV lesions

- (1) Meets any of the criteria for ACC/AHA C lesion
 - Diffuse (greater than 2 cm length)
 - Excessive tortuosity of proximal segment
 - Extremely angulated segments, greater than 90°
 - Inability to protect major side branches
 - Degenerated vein grafts with friable lesions
 - Occluded for more than 3 months
- (2) Occluded

composite 4-variable scoring system, prospectively validated to be both sensitive and specific in predicting cardiovascular collapse for failed PTCA, which includes: 1) percentage of myocardium at risk (e.g., greater than 50% viable myocardium at risk and LV ejection fraction of less than 25%), 2) pre-angioplasty percent diameter stenosis, 3) multivessel CAD, and 4) diffuse disease in the dilated segment (124) or a high myocardial jeopardy score (125). Patients with higher pre-procedural jeopardy scores were shown to have a greater likelihood of cardiovascular collapse when abrupt vessel closure occurred during PTCA (144).

3.5.1.2. Left Main CAD

CABG has long been considered the “gold standard” for revascularization of lesions in the unprotected left main (ULM) coronary artery (146). With the advent of newer technology utilizing BMS and DES, experience has been gained in performing PCI in ULM coronary artery lesions. Some studies have demonstrated that stenting of the ULM is feasible and appears to be a promising strategy in selected patients (147-152). Patients treated for ULM disease have varied from those presenting with stable angina to those with MI and shock. However, despite the feasibility and high procedural success rate of ULM PCI in the pre-DES era, there are reports of an unacceptably high incidence of long-term adverse events (153-155). This may be attributed to the inclusion of high-risk patients, such as those not considered good surgical candidates. The experience with BMS for ULM PCI in the multicenter ULTIMA (Unprotected Left Main Trunk Intervention Multicenter Assessment) registry suggested a high early mortality (2% per month among hospital survivors over the first 6 months after hospital discharge), and careful surveillance with coronary angiography was recommended (153) (see Section 6.3.4). Patients presenting with MI, ULM occlusion, and cardiogenic shock have lower successful PCI rates (69.7% vs 100%, *P* equals 0.040), higher in-hospital mortality (71.4% vs 10%, *P* equals 0.0008), and higher 1-year mortality rates (*P* equals 0.0064) than stable MI patients regardless of performance of primary PCI with stents (155).

More recently, published studies of left main PCI using DES have reported 6-month or 1-year death rates ranging from 0% to 14% (Table 8) (147-150,152-161). Furthermore, ISR appears to be improved with the use of DES versus BMS. One of the larger studies performed to date showed that the 6-month angiographic restenosis rate was signifi-

Reprinted from Krone *et al.* Evaluation of the American College of Cardiology/American Heart Association and the Society for Coronary Angiography and Interventions lesion classification system in the current “stent era” of coronary interventions (from the ACC-National Cardiovascular Data Registry[®]). *Am J Cardiol* 2003;92:394 (Appendix B) (132).

Table 8. Published Trials and Selected Registry Experiences of PCI for Unprotected Left Main Coronary Artery Stenosis

First Author, Year (Reference)	Device Used	n	In-Hospital Mortality, %	Mortality, % (Follow-Up Period)	Restenosis, %	TVR, %	Comments
Ellis 1994-1996 (147)	50% BMS	107	20.6	66.0 plus or minus 4.7 (9 mo)	20.8	N/A	Survival to hospital discharge 31% in acute MI patients; in elective patients, in-hospital mortality 5.9% in good candidates for CABG, 30.4% in poor CABG candidates; in-hospital survival strongly correlated with LVEF
Silverstri 1993-1998 (148)	100% BMS	140	9% high CABG risk; 0% low CABG risk	2% high CABG risk; 2.6% low CABG risk (6 mo)	23	17.4	Good immediate results of PCI in ULM stenosis, especially in good CABG candidates
Black 1994-1998 (149)	100% BMS	92	4.3	10.8 (7.3 plus or minus 5.8 mo)	N/A	7.3	PCI to ULM appears better in candidates for CABG than in patients in whom CABG is contraindicated; trend toward cardiac mortality with 3-vessel disease and low LVEF; low final stent lumen diameter only significant predictor of cardiac mortality
ELTIMA 1993-1998 (153)	68.8% BMS	279	13.7	24.2 (1 y)	N/A	33.6*	46% of patients were deemed inoperable or at high risk for CABG; in patients less than 65 y old with LVEF greater than 30% and no shock, 0% periprocedural deaths and 1-year mortality 3.4%; 2% per month death rate among hospital survivors over 6 months after discharge; careful surveillance with coronary angiography recommended
Park 1995-2000 (150)	100% BMS	127	0	3.1 (25.5 plus or minus 16.7 mo)	19	11.8	Elective stenting in patients with normal LVEF; IVUS may optimize immediate results; significantly lower restenosis rate with debulking before stenting
Fukagi 1993-2001 (154)	96% BMS	67	0	16.4 (31 plus or minus 23 mo)	31.4	23.9	High rate of restenosis and RR; 11.9% cardiac mortality; significantly higher cardiac mortality in patients with Parsonnet score greater than 15 at 3 years
Park 1995-2000 (152)	100% BMS	270	0	7.4 (32.3 plus or minus 18.5 mo)	21.1	16.7†	Good overall long-term (3-year) survival in selected patients with normal LVEF; combined CAD and post-procedural lumen diameter significant predictors of MACE
Sakai 1992-2000 (155)	65% to 74% BMS	38	71.4% with shock; 10% without shock	71.4% with shock; 20% without shock (1 y)	N/A	N/A	Patients with acute MI due to ULM stenosis and shock have poor survival regardless of performance of PCI with stents

Continued on next page

Table 8. Continued

First Author, Year (Reference)	n	Device Used	In-Hospital Mortality, %	Mortality, % (Follow-Up Period)	Restenosis, %	TVR, %	Comments
de Lezo 2002-2004 (156)	52	100% SES	0	0 (12 plus or minus 4 mo)	3.8	1.9	Treatment with SES appears feasible and safe; promising midterm results
Agostoni 2002-2003 (158)	58	100% DES	2	5 (1 y)	N/A	7	Rate of events did not differ significantly between IVUS and angiographically guided procedures; Anatomic location of atherosclerotic disease in ULM artery only independent predictor of events at follow-up
Chieffo 2002-2004 (159)	85	100% DES	0	3.5 (6 mo)	19	19	Despite higher risk profile, patients receiving DES had significant advantage in the incidence of MACE compared with historical control group receiving BMS
Park 2003-2004 (160)	102	100% SES	0	0 (1 y)	7	2	SES implantation in ULM and normal LVEF associated with low in-hospital and 1-year mortality; SES more effective in preventing in-stent restenosis than historical BMS control
RESEARCH/ 2003 T-SEARCH 2002- (161)	95 (15 protected LM)	100% DES	11	14 (1 y)	N/A	6	More than 50% of study population at high surgical risk by Parsonnet classification; 47% relative risk reduction in MACE in DES group compared with BMS control, driven by significantly lower incidence of MI and TVR

*1-Year estimate; †32.3 plus or minus 18.5 mo.

n indicates number of patients; LVEF, LV ejection fraction; MACE, major adverse cardiac events; RR, repeat revascularization; SES, sirolimus-eluting stent; TVR, target-vessel revascularization; and ULM, unprotected left main.

cantly lower in the ULM group receiving DES than in those who received BMS (7.0% vs 30.3%, *P* less than 0.001) (160). The lower rate of restenosis of DES compared with BMS has been confirmed in other studies of ULM PCI (159).

There have been some attempts to predict success of ULM PCI using customary risk factors such as age, renal failure, coronary calcification, and location of the lesion in the left main coronary artery. In general, younger patients with preserved LV function, noncalcified coronary arteries, and complete delivery of stent, fare better. Maintenance of antiplatelet therapy after the procedure is critical, as is the implementation of secondary prevention therapies. Careful postprocedure surveillance with coronary angiography is needed to prevent fatal MI or sudden death that may be associated with ISR with a large area of myocardium in jeopardy; however, the frequency and best method of follow-up are unknown (162). One study's authors from the BMS era suggested routine surveillance angiography at 2 and 4 months after PCI (153). Others advocate routine stress testing or cardiac catheterization at 3 and 6 months even in asymptomatic patients (148,150). Studies from the DES era have reported performing routine angiography 4 to 8 months after PCI or earlier if clinically indicated by symptoms or documented myocardial ischemia (159,160). Other issues that remain to be resolved are technical issues (e.g., optimal bifurcation stenting technique, stent size), degree of revascularization necessary, cost-effectiveness, and the selection of patients best suited for DES.

In conclusion, CABG using IMA grafting is the "gold standard" for treatment of ULM disease and has proven benefit on long-term outcomes. The use of DES has shown encouraging short-term outcomes, but long-term follow-up is needed. Nevertheless, the use of PCI for patients with significant ULM stenosis who are candidates for revascularization but not suitable for CABG can improve cardiovascular outcomes and is a reasonable revascularization strategy in carefully selected patients. Recommendations for ULM PCI in specific angina subsets can be found in Sections 5.1, 5.2, 5.3, and 5.4 and in Section 6.3.4 for post-PCI follow-up.

3.5.2. Risk of Death

In the majority of patients undergoing elective PCI, death as a result of PCI is directly related to the occurrence of coronary artery occlusion and is most frequently associated with pronounced LV failure (144,145). The clinical and angiographic variables associated with increased mortality include advanced age, female gender, diabetes, prior MI, multivessel disease, left main or equivalent coronary disease, a large area of myocardium at risk, pre-existing impairment of LV or renal function, post-PCI worsening of renal function, and collateral vessels supplying significant areas of myocardium that originate distal to the segment to be dilated (10,118,120,122,134,135,138,139,140,144,163-167). Periprocedural stroke also increases in-hospital and 1-year mortality (168). PCI in the setting of STEMI is associated with a significantly higher death rate than is seen in elective PCI.

3.5.3. Women

An estimated 33% of the more than 1 million PCIs performed in the United States annually are in women. The need for more data concerning outcomes from PCI in women has led the AHA to issue a scientific statement summarizing available studies (169). Compared with men, women undergoing PCI are older and have a higher incidence of hypertension, diabetes mellitus, hypercholesterolemia, and comorbid disease (69,170-174). Women also have more UA and a higher functional class of stable angina (Canadian Cardiovascular Society [CCS] class III and IV) for a given extent of disease (175). Yet, despite the higher-risk profile in women, the extent of epicardial coronary disease is similar to (or less than) that in men. In addition, although women presenting for revascularization have less multivessel disease and better LV systolic function, the incidence of HF is higher in women than in men. The reason for this gender paradox is unclear, but it has been postulated that women have more diastolic dysfunction than men (176).

Early reports of patients undergoing PTCA revealed a lower procedural success rate in women (172); however, subsequent studies have noted similar angiographic outcome and incidence of MI and emergency CABG in women and men (69). Although reports have been inconsistent, in several large-scale registries, in-hospital mortality is significantly higher in women (177), and an independent effect of gender on acute mortality after PTCA persists after adjustments for the baseline higher-risk profile in women (69,178). The reason for the increase in mortality is unknown, but small vessel size (179) and hypertensive heart disease in women have been thought to play a role. Although a few studies have noted that gender is not an independent predictor of mortality when body surface area (a surrogate for vessel size) is accounted for (171), the impact of body size on outcome has not been thoroughly evaluated. The higher incidence of vascular complications, coronary dissection, and perforation in women undergoing coronary intervention has been attributed to the smaller vasculature in women than in men. In addition, diagnostic IVUS studies have not detected any gender-specific differences in plaque morphology or luminal dimensions once differences in body surface area were corrected, which suggests that differences in vessel size account for some of the apparent early and late outcome differences previously noted in women (180). It has also been postulated that the volume shifts and periods of transient ischemia during PTCA are less well tolerated by the hypertrophied ventricle in women, and HF has shown to be an independent predictor of mortality in both women and men undergoing PTCA (181).

Women continue to have increased bleeding and vascular complications compared with men, but these rates have decreased with the use of smaller sheath sizes and early sheath removal, weight-adjusted heparin dosing, and less aggressive anticoagulation regimens (169). Use of IIb/IIIa platelet receptor antagonists during PCI is not associated with an increased risk of major bleeding in women

(182,183), and the direct thrombin inhibitor bivalirudin during elective PCI appears to reduce the risk of bleeding (combined major and moderate bleeding) in both women and men compared with unfractionated heparin (184).

Improved outcomes have been reported in more recently treated women undergoing both PTCA and PCI, despite the fact that the women are older and have more complex disease than women treated previously (Table 9) (69,170,185-189). In fact, in the 1993-1994 NHLBI PTCA Registry (open to women only), procedural success was higher and major complications lower than in women treated in the 1985-1986 registry (190). Additionally, in patients undergoing PTCA in BARI, in-hospital mortality, MI, emergency coronary artery bypass surgery rates, and 5-year mortality were similar in women and men, although women had a higher incidence of periprocedural HF and pulmonary edema (188).

The widespread use of stents and adjunctive pharmacologic therapy has improved outcomes in patients undergoing contemporary PCI (80,83,112,191-202). Early studies of drug-eluting stents in small vessels (less than or equal to 2.75 mm), of particular importance in women, report favorable long-term results in both women and men (203). The hope that stents would eliminate the difference in outcomes between women and men has not been realized. Gender differences in mortality have persisted for patients treated with stents both in the setting of acute and nonacute MI (204). In a meta-analysis of invasive versus conservative therapy of patients with UA/NSTEMI, men demonstrated a clear survival advantage using routine invasive therapy with GP IIb/IIIa inhibitors and intracoronary stents; however, using similar therapy, the results for women were not significantly improved (205), although it has been shown that the benefits of an invasive strategy have been limited to high-risk women (206).

In women with STEMI, the relative benefit of primary PCI compared with fibrinolytic therapy is similar to that in men, but there is a larger absolute benefit in women owing to their higher event rate (207). In patients with shock complicating acute MI, the benefit of revascularization is similar in women and men (208).

In general, the risks and benefits of adjunctive pharmacotherapy in women are similar to those in men, although an increased rate of minor bleeding has been reported in women treated with abciximab (183). When IIb/IIIa platelet receptor antagonists are used with unfractionated heparin, a lower dose of the latter should be considered to decrease the risk of bleeding in women (Table 9) (69,170,185-189).

Few gender-specific data are available on the outcomes of other percutaneous coronary devices. Although directional coronary atherectomy has been associated with lower procedural success and higher bleeding complications in women (209), similar benefit to that in men has been reported from embolic protection devices used in saphenous vein PCI (210) and from vascular brachytherapy (169).

Table 9. Gender-Specific Mortality Risk

Study	Years	Reference	Women Versus Men (n)	Follow-Up (years)	Device	Mortality, Men Versus Women (%)	P	Adjusted OR (95% CI)
Mayo Clinic	1979-1990	(186)	3027 (824 vs 2203)	5.5	PTCA	27 versus 22	0.06	0.94 (0.76 to 1.15)
Emory University	1980-1991	(187)	10785 (2845 vs 7940)	5	PTCA	8 versus 5	0.0002	1.08 (0.84 to 1.39)
NHLBI PTCA Registry	1985-1986	(69)	2136 (546 vs 1590)	4	PTCA	6.6 versus 10.8	0.001	1.20 (0.84 to 1.73)
BARI	1988-1994	(188)	1829 (489 vs 1340)	5	PTCA	12.8 versus 12.0	NS	0.60 (0.43 to 0.84)
NACI	1990-1994	(189)	2855 (975 vs 1880)	1	PCI	5.7 versus 5.9	NS	NS
Northern New England	1994-1999	(170)	33666 (10997 vs 22689)	In-hospital	PCI	1.21 versus 1.06	0.096	1.24 (0.96 to 1.60)
NHLBI Dynamic Registry	1997-1998	(185)	2524 (895 vs 1629)	1	PCI	4.3 versus 6.5	0.022	1.26* (0.85 to 1.87)

CI indicates confidence interval; NS, not significant; n, number of patients; OR, odds ratio; PCI, percutaneous coronary intervention; and PTCA, percutaneous transluminal coronary angioplasty. For expansion of study names, see corresponding reference.
 *Expressed as relative risk (RR).

3.5.4. The Elderly Patient

Age greater than 75 years is one of the major clinical variables associated with increased risk of complications (211-214). In the elderly population, the morphologic and clinical variables are compounded by advanced years, with the very elderly having the highest risk of adverse outcomes (215). In octogenarians, although feasibility has been established for most interventional procedures, the risks associated with both percutaneous and nonpercutaneous revascularization are increased (216-218). Octogenarians undergoing PCI have a higher incidence of prior MI, lower LV ejection fraction, and more frequent HF (219,220). In the stent era, procedural success and restenosis rates are comparable to those for nonoctogenarians, albeit with higher incidences being reported for in-hospital and long-term mortality and for vascular and bleeding complications (221). A multicenter study compared an early invasive strategy versus an early conservative strategy in 2220 patients hospitalized for UA/NSTEMI. Among patients 65 years or older, the early invasive strategy conferred a 4.8% absolute risk reduction (39% Relative Risk Reduction [RRR]) in death or MI at 6 months. In a post hoc analysis, patients aged 75 years or older experienced a 10.8% reduction (56% RRR) in 6-month death or MI with an early invasive strategy. However, there was a significant major bleeding rate in patients aged 75 years or older assigned to an invasive versus a conservative strategy (16.6% vs 6.5%, P equals 0.009) (222). For patients enrolled in the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial of PCI for STEMI using routine stenting versus balloon angioplasty, with or without abciximab administration in both revascularization strategies, 1-year mortality increased exponentially for each decile of age after 65 years (1.6% for patients less than 55 years, 2.1% for 55 to 65 years, 7.1% for 65 to 75 years, 11% for greater than 75 years; P less than 0.0001). The incidence of stroke and major bleeding was also increased in the elderly at 1 year. Abciximab administration did not confer a benefit in elderly patients but was deemed safe. In contrast, routine stent implantation in elderly patients reduced 1-year rates of ischemic target-vessel revascularization (7.0% vs 17.6%, P less than 0.0001) and subacute or late thrombosis (0% vs 2.2%, P equals 0.005) compared with balloon angioplasty. The authors acknowledged that additional risks/benefits of stent or IIB/IIIa inhibitor use in elderly patients with STEMI might have become evident had more patients been enrolled in this study (223). Thus, with rare exception (primary PCI for cardiogenic shock in patients greater than 75 years of age), a separate category has not been created in these guidelines for the elderly (224). However, their higher incidence of comorbidities and risk for bleeding complications should be taken into account when considering the need for PCI (218,225).

3.5.5. Diabetes Mellitus

In the TIMI-IIIB study of MI, patients with diabetes mellitus had significantly higher 6-week (11.6% vs 4.7%), 1-year

(18.0% vs 6.7%), and 3-year (21.6% vs 9.6%) mortality rates than nondiabetic patients (226). Patients with diabetes with a first MI who were randomly assigned to the early invasive strategy fared worse than those managed conservatively (42-day mortality: death or MI, or death alone, 14.8% vs 4.2%; P less than 0.001) (227). An early catheterization and intervention strategy after fibrinolysis was of little benefit in these patients with diabetes. Although adjusted in-hospital mortality was not different in diabetic and nondiabetic patients, data from the NHLBI registry showed that at 1 year, adjusted mortality and repeat revascularization were significantly higher in diabetics (228). Thus, routine catheterization and PCI in this patient subgroup should be based on clinical need and ischemic risk stratification.

Stenting decreases the need for target-vessel revascularization procedures in diabetic patients compared with PTCA (229). The efficacy of stenting with GP IIB/IIIa inhibitors was assessed in the diabetic population compared with those without diabetes in a substudy of the EPISTENT (Evaluation of IIB/IIIa Platelet Inhibitor for Stenting) trial (230). One hundred seventy-three diabetic patients were randomized to stent/placebo combination, 162 patients to stent/abciximab combination, and 156 patients to PTCA/abciximab combination. For the composite end point of death, MI, or target-vessel revascularization, the rates were as follows: 25%, 23%, and 13% for the stent/placebo, PTCA/abciximab, and stent/abciximab groups (P equals 0.005). Irrespective of revascularization strategy, abciximab significantly reduced 6-month death and MI rate in patients with diabetes for all strategies. Likewise, 6-month target-vessel revascularization was reduced in the stent/abciximab group approach. One-year mortality for diabetics was 4.1% for the stent/placebo group and 1.2% for the stent/abciximab group. Although this difference was not significant, the combination of stenting and abciximab among diabetics resulted in a significant reduction in 6-month rates of death and target-vessel revascularization compared with stent/placebo or PTCA/abciximab therapy (230). Similar results in 1-year target-vessel revascularization and mortality have been reported with abciximab and the small-molecule GP IIB/IIIa inhibitor tirofiban (231). (See Section 6.2.2 Glycoprotein IIB/IIIa Inhibitors.) The BARI trial, in which stents and abciximab were not used, showed that survival was better for patients with treated diabetes undergoing CABG with an arterial conduit than for those undergoing PTCA (232). The benefit of CABG in patients with diabetes may be related to lessened mortality after subsequent Q-wave MI among patients with diabetes. In the BARI trial, the benefit of bypass surgery in diabetic patients was greater in those patients with more extensive disease (e.g., more than 4 lesions). This advantage was largely due to a lower mortality for subsequent MI (233).

Since the BARI trial was completed, several studies have assessed the use of PCI with stenting versus CABG in patients with multivessel disease. Patients with diabetes were assessed specifically in studies from the ARTS (Arterial Revascularization Therapies Study) and AWESOME (Angina

With Extremely Serious Operative Mortality Evaluation) groups. Glycoprotein IIb/IIIa inhibitors were used in approximately 11% of AWESOME PCI patients and were not incorporated into the ARTS protocol. At 3 years of follow-up, the survival rates of the diabetic subsets treated with CABG and PCI were not significantly different in either ARTS or AWE-SOME. Repeat revascularization was higher with PCI in the subsets of patients with diabetes in both trials.

Randomized trials, meta-analysis of trials, and epidemiological studies have shown the superiority of DES over BMS in terms of reducing late repeat revascularization (234-236). There are, as yet, inadequate data from which to infer impact on long-term survival after PCI for patients with diabetes. The sum effect of DES and GP IIb/IIIa inhibitors will be assessed against contemporary CABG in multivessel-disease patients with diabetes in the upcoming National Institutes of Health (NIH)-sponsored Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM trial) (237). A discussion about the selection of patients with diabetes for surgical revascularization or PCI may be found in Section 3.6, Comparison With Bypass Surgery. Preliminary data suggest late outcomes in diabetic patients after PCI are similar to nondiabetics if the hemoglobin A1C can be maintained less than 7.0% (238). Management of other risk factors, particularly lipid abnormalities, in patients with diabetes has also been shown to have a very significant effect on long-term outcome (239-242). These observations emphasize the importance of diabetes management and secondary prevention therapies after PCI.

3.5.6. PCI After Coronary Artery Bypass Surgery

Although speculated to be at higher risk, patients having PCI of native vessels after prior coronary bypass surgery have, in recent years, nearly equivalent interventional outcomes and complication rates compared with patients having similar interventions without prior surgery. For PCI of SVG, studies indicate that the rate of successful angioplasty exceeds 90%, the death rate is less than 1.2%, and the rate of Q-wave MI is less than 2.5% (Table 10) (243-248). The incidence of non-Q-wave MI may be higher than that associated with native coronary arteries (249-251).

In consideration of PCI for SVG, the age of the SVG and duration and severity of myocardial ischemia should be taken into consideration. Use of GP IIb/IIIa blockers has not been shown to improve results of angioplasty in vein grafts (252). However, preliminary studies of 2 different distal

embolic protection devices (Percusurge and GuideWire) (253-255) are associated with promising results (254,255) (see Section 5.5.2, Late Ischemia After CABG). The native vessels should be treated with PCI if feasible. Patients with older and/or severely diseased SVGs may benefit from elective repeat CABG surgery rather than PCI (256,257).

In some circumstances, PCI of a protected left main coronary artery stenosis with a patent and functional LAD or left circumflex coronary conduit can be considered. PCI should be recognized as a palliative procedure with the potential to delay the ultimate application of repeat CABG surgery.

3.5.7. Specific Technical Considerations

Certain outcomes of PCI may be specifically related to the technology utilized for coronary recanalization. Periprocedural CK-MB elevation appears to occur more frequently after use of ablative technology such as rotational or directional atherectomy (23,77,85,243,258). Antecedent UA appears to be a clinical predictor of slow flow and periprocedural infarction after ablative technologies (259), and direct platelet activation has been demonstrated to occur with both directional and rotational atherectomy (260). In support of the premise that platelets play a pathophysiologic role in periprocedural MI are observations that the presence and magnitude of CK-MB elevation after ablative technologies can be reduced to levels observed after PTCA by the administration of prophylactic platelet GP IIb/IIIa receptor blockade (261,262).

Coronary perforation may occur more commonly after the use of atheroablative devices, including rotational, directional, or extraction atherectomy, and excimer laser coronary angioplasty. However, the incidence of perforation has been reported variably to be 0.10% to 1.14% with balloon angioplasty, 0.25% to 0.70% with directional coronary atherectomy, 0.0% to 1.3% with rotational atherectomy, 1.3% to 2.1% with extraction atherectomy, and 1.9% to 2.0% after excimer laser coronary angioplasty (263,264). Coronary perforation complicates PCI more frequently in the elderly and in women. Although 20% of perforations may be secondary to the coronary guidewire, most are related to the specific technology used. Perforation is usually (80% to 90%) evident at the time of the interventional procedure and should be a primary consideration in the differential diagnosis for cardiac tamponade manifest within 24 h of the procedure. Perforations may be classified on the basis of angiographic appearance as type I (extraluminal crater without extravasation), type II (pericardial and myocardial blush without contrast jet

Table 10. Probability of Success, Complications, and Restenosis After Balloon Angioplasty or Stenting in Patients After Coronary Bypass Surgery

Conduit Site	Reference	Success Rate	Death Rate	MI Rate*	Restenosis Rate†
Saphenous vein graft	(243-246)	Greater than 92%	Less than 2%	15%	20% to 35%
Internal mammary artery	(247)	97%	Less than 1%	12.5%	7% anastomotic, 25% ostial site
Left main	(248)	95%	Less than 2%	10%	25%

MI indicates myocardial infarction.

*Greater than 3 times normal CK-MB on 2 consecutive days. Downloaded from <http://onlineacc.org> by Ted Feldman on March 19, 2006

†Restenosis measured as target-vessel revascularization.

extravasation), and type III (extravasation through a frank [1 mm] perforation) (263). In the absence of extravasation (type III), the majority of perforations may be effectively managed without urgent surgical intervention. Type III perforations have been successfully managed nonoperatively with pericardiocentesis, reversal of anticoagulation, and either prolonged perfusion balloon inflation at the site of perforation or deployment of a covered stent. Perforations caused by atheroablative devices usually require surgical repair.

3.5.8. Issues of Hemodynamic Support in High-Risk PCI

Controversy exists about the ability to predict hemodynamic compromise during PCI. Hemodynamic compromise, defined as a decrease in systolic blood pressure to an absolute level less than 90 mm Hg during balloon inflation, was often associated with LV ejection fraction less than 35%, greater than 50% of myocardium at risk, and PTCA performed on the last remaining vessel (120,163).

Early feasibility studies of high-risk PTCA using percutaneous cardiopulmonary support (CPS) indicated that although initial likelihood of success was high, vascular morbidity was also high, with an incidence of 43% (265,266). However, no study has published data to validate commonly used high-risk categorizations.

Elective high-risk PCI can be performed safely without intra-aortic balloon pump (IABP) or CPS in most circumstances. Emergency high-risk PCI such as primary PCI for STEMI can usually be performed without IABP or CPS. CPS for high-risk PCI should be reserved only for patients at the extreme end of the spectrum of hemodynamic compromise, such as those patients with extremely depressed LV function and patients in cardiogenic shock. However, in patients with borderline hemodynamics, ongoing ischemia, or cardiogenic shock, insertion of an intra-aortic balloon just before coronary instrumentation has been associated with improved outcomes (267,268). Furthermore, it is reasonable to obtain vascular access in the contralateral femoral artery before the procedure in patients in whom the risk of hemodynamic compromise is high, thereby facilitating intra-aortic balloon insertion, if necessary.

For high-risk patients, clinical and anatomic variables influencing complications and outcome should be assessed before the performance of PCI to determine procedural risk, the risk of abrupt vessel closure, and potential for cardiovascular collapse. In patients having a higher-risk profile (such as those with LV dysfunction, single patent vessel or ULM, degenerated SVG, or high thrombus burden in the obstructed vessel), consideration of alternative therapies, particularly coronary bypass surgery, formalized surgical standby, or periprocedural hemodynamic support should be addressed before proceeding with PCI. Several small retrospective studies have evaluated the use of elective balloon pump support before high-risk PCI. These studies generally reveal successful reperfusion by PCI, with improved procedural or in-hospital morbidity and mortality (267,269,270). An alterna-

tive approach is to use standby IABP, which results in slightly greater complications for patients undergoing standby IABP than for those in whom the IABP was in place before the procedure (271). Available data for the use of IABP in high-risk patients involve retrospective analyses of relatively small numbers of patients; therefore, no formal recommendations are suggested. The decision to proceed with IABP before PCI remains a clinical judgment made by the physician based on the high-risk characteristics of coronary anatomy and overall status of the patient.

3.6. Comparison With Bypass Surgery

The major advantage of PCI is its relative ease of use and avoidance of general anesthesia, thoracotomy, extracorporeal circulation, central nervous system complications, and prolonged convalescence. Repeat PCI can be performed more easily than repeat bypass surgery, and revascularization can be achieved more quickly in emergency situations. The disadvantages of PCI are early restenosis and the inability to relieve many totally occluded arteries and/or those vessels with extensive atherosclerotic disease.

Coronary artery bypass surgery has the advantages of greater durability (graft patency rates exceeding 90% at 10 years with arterial conduits) (272) and more complete revascularization regardless of the morphology of the obstructing atherosclerotic lesion. Generally speaking, the greater the extent of coronary atherosclerosis and its diffuseness, the more compelling the choice of coronary artery bypass surgery, particularly if LV function is depressed. Patients with a lesser extent of disease and localized lesions are good candidates for endovascular approaches.

PTCA and coronary artery bypass surgery have been compared in many nonrandomized and randomized studies. Whereas randomized controlled trials are the only way to completely eliminate bias between comparative therapies, large prospective registries can best extend observations to broad segments of the population who might be excluded from randomized trials. Through risk-adjustment methodologies, large groups of patients can be evaluated between therapies to attempt to eliminate the impact of baseline differences. A number of registries have compared coronary bypass graft surgery with PCI (52). New York State mandates a registry of all patients undergoing PCI and CABG that is monitored by audit and provides survival data on all New York State residents. Patients with multivessel disease treated between January 1, 1997, and December 31, 2000, were followed up for 3 years (52). During this period when stent utilization was common, the adjusted hazard ratio favored surgery for all subsets of multivessel disease patients. The surgical advantage was greatest for patients with 3-vessel disease with involvement of the proximal LAD and least for patients with 2-vessel disease without anterior descending involvement. One important factor differentiating the techniques was significantly more complete revascularization in the surgery group. By identifying trends such as

these, registries can provide important insight for clinical improvement.

The most accurate comparisons of outcomes are best made from prospective randomized trials of patients suitable for either treatment. Although results of these trials provide useful information for selection of therapy in several patient subgroups, prior studies of PTCA may not reflect outcome of current PCI practice, which includes frequent use of stents and antiplatelet drugs. Similarly, many previous studies of CABG may not reflect outcome of current surgical practice, in which arterial conduits are used whenever practicable. Beating heart bypass operations are also employed for selected patients with single-vessel disease with reduced morbidity (273). In addition, patients are selected for PCI (with or without stenting) because of certain lesion characteristics, and these anatomic criteria are not required for CABG.

Randomized trials also must be interpreted carefully. It is unethical to withhold subsequent PCI or CABG from patients solely because they fail an earlier treatment; thus, comparative prospective studies can only compare initial strategies of revascularization. This critically important point is frequently overlooked by those who claim that a randomized study proves equally good outcome of one method of revascularization over the other.

Despite these limitations, some generalizations can be made from comparative trials of PTCA and CABG. First, for most patients with single-vessel disease, late survival is similar with either revascularization strategy, and this might be expected given the generally good prognosis of most patients with single-vessel disease managed medically (274-276).

Two prospective clinical trials have evaluated PTCA and CABG for revascularization of isolated disease of the LAD. Investigators in the Medicine, Angioplasty or Surgery Study (MASS) used a combined end point of cardiac death, MI, or refractory angina requiring repeat revascularization by surgery; at 3 years of follow-up, this combined end point occurred in 24% of PTCA patients, 17% of medical patients, and 3% of surgical patients (277). Importantly, there was no difference in overall survival in the 3 groups. In the Lausanne trial of 134 patients with isolated LAD disease treated by either PTCA (68 patients) or bypass with an IMA, survival was similar in the 2 groups, and 94% of PTCA patients and 95% of CABG patients were free of limiting symptoms (278). However, patients in the PTCA group took more antianginal drugs than surgical patients, and at median follow-up of 2.5 years, 86% of CABG-treated versus 43% of PTCA-treated patients were free from late events (P less than 0.01); this difference was primarily due to restenosis (32%) requiring subsequent CABG (16%) or PTCA (15%). Neither of the 2 aforementioned trials included stenting, a technique that would be expected to reduce rates of early restenosis by as much as 50% in appropriately selected lesions (108,279,280).

In a similar manner, the 3-year follow-up of the Argentine randomized trial of PTCA versus CABG multivessel disease (ERACI study) (279) demonstrated that in patients randomized to PTCA or bypass surgery, the 1-, 3-, and 5-year fol-

low-up results indicated that freedom from combined cardiac events was significantly greater for bypass surgery than for the PTCA group (77% vs 47%; P less than 0.001). However, there were no differences in overall and cardiac mortality or in the frequency of MI between the 2 groups. Patients who had bypass surgery were more frequently free of angina (79% vs 57%) and had fewer additional reinterventions (6.3% vs 37%) than patients who had PTCA. This study indicated that freedom from combined cardiac events at 3-year follow-up was greater in bypass patients than in those who had PTCA and that the PTCA group had a higher incidence of recurrence of angina and need for repeat procedures. Cumulative cost at 3 years was greater for surgery than for the PTCA group.

In the ARTS trial, the first trial to compare stenting with surgery, there was no significant difference in mortality between PCI and surgical groups at 1 and 3 years (281,282). The main difference compared with previous PTCA and CABG trials was an approximate 50% reduction in the need for repeat revascularization in a group randomized to PCI with stent placement (281).

Similar results were reported by the Stent or Surgery (SoS) trial. In this trial, 988 patients with multivessel disease were randomized to PCI (78% received stents) or CABG. At a median follow-up of 2 years, 21% of the PCI group required repeat revascularization compared with 6% of the CABG group (hazard ratio 3.85, 95% confidence interval [CI] 2.56-5.79, P less than 0.0001). The incidence of death or Q-wave MI was similar in both groups (hazard ratio 0.95, 95% CI 0.63-1.42, P equals 0.80). Mortality was higher in the PCI group, but this was influenced by a particularly low surgical mortality and a high rate of noncardiovascular deaths in the PCI group (283).

The ERACI II study randomized 450 patients with multivessel disease (91% UA) to PCI or CABG. At a mean follow-up of 18.5 months, survival was 96.9% in PCI group versus 92.5% in the CABG group (P less than 0.017). Freedom from MI was also better in the PCI group than in the CABG group (97.7% vs 93.4%, P less than 0.017). Similar to other studies, the need for repeat revascularization was higher in the PCI group (16.8% vs 4.8%, P less than 0.002) (284).

In the AWESOME study, 454 patients with medically refractory myocardial ischemia and high-risk features for adverse outcomes with surgery were randomized to either PCI (54% received stents) or CABG. High-risk features included: prior open heart surgery, age greater than 70 years, LV ejection fraction less than 0.35, MI within 7 days, or IABP required. Comparable survival was observed between the PCI and CABG groups at 3 years (80% vs 79%), with more frequent repeat revascularization in the PCI group. Additionally, survival free of UA in the PCI group was within 90% of that in the CABG group (285).

Direct comparison of initial strategies of PCI or CABG in patients with multivessel coronary disease is possible only by randomized trials because of selection criteria of patients for PCI. There have been 5 large (more than 300 patients) randomized trials of PTCA versus CABG and 2 smaller stud-

ies and 5 large trials of PCI using stents versus CABG (10-12,279,281,283-289). Characteristics of the studies are summarized in Table 11 (11,12,279,282-290). These trials demonstrate that in appropriately selected patients with multivessel coronary disease, an initial strategy of standard PCI with BMS yields similar overall outcomes (e.g., death, MI) to initial revascularization with coronary artery bypass.

An important exception to the conclusion of the relative safety of PCI in multivessel disease is the subgroup of patients with treated diabetes mellitus. In BARI, the only trial with a sufficiently large patient enrollment to examine survival alone, the data showed that among treated diabetic patients assigned to PTCA, 7-year survival was 55.7% compared with 76.4% for patients having CABG (P equals 0.0011); the improved outcome with CABG was due to reduced cardiac mortality (5.8% vs 20.6%, P equals 0.0003), which was confined to those receiving at least 1 IMA graft (10,67,290). There was no mortality difference at 7 years in the remainder of the patients, those without diabetes and patients with diabetes not undergoing medical treatment (290). Better survival of diabetic patients with multivessel disease treated initially with CABG has also been observed in a large retrospective study from Emory (291) and in the 8-year results of Emory Angioplasty Surgery Trial (EAST) (292). In the BARI trial, the benefit of bypass surgery in diabetic patients was greater in those patients with more extensive disease (e.g., more than 4 lesions). This advantage was largely due to a lower mortality for subsequent MI (233,293). As compelling as these reports may be, it is of interest that treated diabetic patients enrolled in the BARI registry did not show a similar advantage for CABG over PCI, which suggests that physician judgment in the selection of diabetic patients for PCI may be an important factor (42,68).

Patients with diabetes have been evaluated specifically in studies from the ARTS and AWESOME groups, which included the use of stents (294,295). GP IIb/IIIa inhibitors were used in approximately 11% of AWESOME PCI patients and were not incorporated into the ARTS protocol. After 3 years of follow-up, the survival rates of the diabetic subsets treated with CABG and PCI were not significantly different in either ARTS or AWESOME. Repeat revascularization was higher with PCI in the subsets of patients with diabetes in both trials. The sum effect of DES and GP IIb/IIIa inhibitors will be assessed against contemporary CABG in multivessel disease patients with diabetes in the upcoming NIH-sponsored FREEDOM trial.

Overall, 6 trials have been published comparing PCI using stents with CABG in single-vessel or multivessel disease. Both revascularization techniques relieve angina. In aggregate, these trials have not shown a difference between CABG and PCI in terms of mortality or procedural MI among the populations studied, which have mostly included low-risk patients. Stents appear to have narrowed the late repeat revascularization difference that favored CABG in the balloon era. Randomized trials, meta-analysis of trials, and epidemiological studies have shown the superiority of DES over BMS in terms of reducing late repeat revascularization (234-

236) (see also Section 7.3.5 on DES). At this writing, no published studies are available comparing PCI with DES to CABG; thus, the impact of contemporary therapy with DES compared with CABG requires further evaluation. The ARTS II study compared outcomes for 600 surgically treated patients in ARTS II with 600 similar patients prospectively treated with multistent, sirolimus-eluting stent (SES) implantation [P.W. Serruys, oral presentation, American College of Cardiology Scientific Session, Orlando, Fla, March 2005]. Preliminary data from that study showed a lower rate of perioperative MI for the stent group. The surgery group still had fewer repeat revascularization procedures; however, the difference was markedly attenuated compared with the ARTS I BMS group. Furthermore, medical management of atherosclerosis, both before and after revascularization, has continued to evolve with the increased use of beta-blockers, inhibitors of the renin-angiotensin-aldosterone system, and lipid-lowering agents. Other changes in patient management that may influence these conclusions are the use of GP IIb/IIIa inhibitors, as mentioned above, and the use of direct thrombin inhibitors during PCI, the more frequent use of IMA grafts, and the emergence of less invasive surgical approaches. It is likely that during the progress of their disease, many patients will benefit from a combined application of percutaneous and surgical techniques, taking advantage of the low morbidity of percutaneous methods and the established long-term benefit of surgical revascularization with arterial conduits. Recommendations for revascularization in various patient subsets are presented in Section 5.

3.7. Comparison With Medicine

There has been a considerable effort made to evaluate the relative effectiveness of bypass surgery compared with PCI for coronary artery revascularization. In contrast to this, very little effort has been directed toward comparing medical therapy with PCI for the management of stable and UA. Several randomized trials are currently available comparing PCI with the medical management of angina (Table 12) (289,296-302). Most trials comparing PCI with medical therapy have utilized PTCA, not stents, in comparison with medical therapy, and no major trials are available comparing DES with medical therapy. The ACME (Angioplasty Compared to Medicine) investigators randomized 212 patients with single-vessel disease, stable angina pectoris, and ischemia on treadmill testing to PTCA or medical therapy. This trial demonstrated superior control of symptoms and better exercise capacity in patients managed with PTCA than in those given medical therapy. Death and MI were infrequent occurrences, and their incidence was similar in both groups. The Veterans Administration ACME trial investigators provided long-term results in an additional 101 randomized patients with double-vessel disease not previously reported (300) that indicated that patients randomized to medical therapy or PTCA had similar improvement in exercise duration, freedom from angina, and improvement in quality of life at the

Table 11. Summary of Randomized Trials of PTCA and Stents Versus CABG for Multivessel Disease

Trial	Years	Ref	Location	n	Follow-Up, y	End Point	Comments
PTCA Trials							
RITA	1989-1991	(11)	U.K. multicenter	1011	2.5	Death or MI	45% of patients had SVD
EAST	1987-1990	(286)	Emory University	392	3	Death, Q-wave MI, or large ischemic defect on thallium	Repeat revascularization in 5.4% of PTCA group compared with 13% of patients having CABG
GABI	1986-1991	(12)	Germany multicenter	359	1	Freedom from angina	IMA used in only 37% of CABG patients; more than 80% of patients had 2-vessel disease
CABRI	1988-1993	(287)	Europe multicenter	1054	1	Mortality, symptom status	Complete revascularization with PTCA was not required
ERACI	1988-1990	(279)	Argentina	127	3.8	Event-free survival (MI, angina, and RR)	Similar in-hospital and 1-year survival and freedom from MI; less angina and fewer repeat procedures after CABG
BARI	1988-1991	(290)	North American multicenter	1829	7	Death	Overall survival similar with PTCA and CABG, but late survival of treated diabetic patients better with CABG when IMA grafts were used
Toulouse	1989-1993	(288)	France	152	2.8	Freedom from angina 1 year after revascularization	Similar survival with PTCA and CABG at 5 years, but better event-free survival with CABG (fewer repeat procedures)
Stent Trials							
ARTS	1997-1998	(282)	Europe multicenter	1205	3	Freedom from major adverse cardiac and CV events	No significant difference between PCI and CABG in terms of death, stroke, or MI; PCI was associated with greater need for RR
AWESOME	1995-2000	(285)	Veterans Affairs multicenter	454	3	Death	Comparable survival between PCI and CABG in patients with medically refractory myocardial ischemia, with higher RR in PCI group
ERACI II	1996-98	(284)	Argentina	450	1.5	MACE (death, Q-wave MI, stroke, RR)	Better survival and freedom from MI with PCI than with CABG; RR higher in PCI group
SoS	1996-99	(283)	Europe, Canada multicenter	988	1	RR	Significantly higher number of RRs with PCI; no difference in composite measure of death and Q-wave MI; fewer deaths in the CABG group
MASS II	1995-2000	(289)	Brazil single center	611	1	Cardiac death, nonfatal acute MI, and unstable angina	Included medical therapy arm; no difference in cardiac death or MI among patients in the CABG, PCI, or medical therapy groups; significantly greater need for RR procedures in patients who underwent PCI

CABG indicates coronary artery bypass graft surgery; CV, cerebrovascular; IMA, internal mammary artery; MACE, major adverse cardiac events; MI, myocardial infarction; n, number of patients; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; Ref, reference; RR, repeat revascularization; SVD, single-vessel disease; and y, year.

Table 12. PCI Comparison With Medical Therapy

Study	Year	Ref	n	Patient Population	Treatment	Follow-Up	Results		Comments
							PCI	Medical Therapy	
ACME	1992	(296)	212	Patients with single-vessel disease	Medical therapy vs balloon angioplasty	6 mo	64% less angina	46% less angina	The PTCA group had less angina, better exercise performance, and more improvement in quality-of-life scores but had more complications (emergency bypass 2 patients, MI in 5, and repeat PTCA in 16)
VA CME	1997	(300)	328	Patients with documented chronic stable angina	Medical therapy vs balloon angioplasty	3 y	63% less angina	48% less angina	Among patients with single-vessel disease, the PTCA group had less angina, better exercise performance, and more improvement in quality-of-life scores
ACI	1997	(301)	558	Patients with documented CAD and asymptomatic ischemia	Angina-guided drug therapy vs angina-guided drug therapy vs revascularization	2 y	4.7% death or MI	8.8% death or MI for ischemia-guided drug therapy	40% of patients had previous MI, 23% had prior PTCA or CABG, and 38% had triple-vessel disease
AVERT	1999	(298)	341	183 angina-guided drug therapy 183 angina-plus ischemia-guided drug therapy 192 revascularization by PTCA or CABG	Medical therapy with atorvastatin vs PTCA	18 mo	21% ischemic events	13% ischemic events	Only 2 deaths among 341 patients in 18 months; significant improvement in angina in patients treated with PTCA compared with medical therapy

Continued on next page

Table 2. Continued

Study	Year	Ref	n	Patient Population	Treatment	Follow-Up	Results			
							PCI	Medical Therapy	Significance (P)	Comments
RITA-3	2003	(299)	1018	53% with Class II angina 47% with prior angina 7% with triple-vessel disease	Medical therapy vs balloon angioplasty	7 y	14.5% death or MI	12.3% death or MI	0.21	PTCA group had increased rates of death and MI but had 6.4% less class II angina or worse at 5 years and longer exercise treadmill time at 3 years
RITA-2	2002	(302)	1810	Suspected cardiac chest pain at rest with documented CAD (at least 1 of the following: ECG changes, pathological Q waves, previous arteriogram)	Medical therapy and either early invasive or conservative (selectively invasive) treatment strategy; both groups received enoxaparin in addition to standard medical therapy	1 y	7.6% death or MI	8.3% death or MI	NS	Similar results for death or MI between treatment groups; significant difference in primary end point (death, MI, refractory angina) due to halving of refractory angina in intervention group
MASCC II	2004	(289)	611	Stable angina, multivessel disease, preserved LV function	Medical therapy, CABG, or PCI	1 y	4.5% death	1.5% death	NS	Aggressive medical management for multivessel disease has low incidence of early events, including death and Q-wave MI, but is inferior to PCI (and CABG) for control of angina

n indicates number of patients; CABG, coronary artery bypass graft; CAD, coronary artery disease; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; and PCI, percutaneous coronary intervention.

time of 6-month follow-up. Thus, these patients with double-vessel PTCA did not demonstrate superior control of their symptoms as compared with medical therapy, as was experienced by the ACME patients with single-vessel disease. This small study suggests that PTCA is less effective in controlling symptoms in patients with double-vessel disease and stable angina than in those with single-vessel disease.

The Randomized Intervention Treatment of Angina (RITA)-2 investigators randomized 1018 patients with stable angina to PTCA or conservative (medical) therapy (297,299). Patients who had inadequate control of their symptoms with optimal medical therapy were allowed to cross over to myocardial revascularization. The combined end point of the trial was all-cause mortality and nonfatal MI. The 504 PTCA and 514 medically treated patients were followed up for a mean of 7 years. Death due to all causes occurred in 43 (8.5%) of the PTCA patients and 43 (8.4%) of the medical patients. Of the 86 deaths, only 8 were due to heart disease. Angina improved in both groups, but there was a 16.5% absolute excess of grade 2 or worse angina in the medical group at 3 months after randomization (P less than 0.001). These differences in angina narrowed over time, with the PTCA group always having less angina than the medically treated patients. Thus, RITA-2 demonstrated that PTCA results in better control of symptoms of ischemia and improves exercise capacity compared with medical therapy but is associated with a higher combined end point of death and periprocedural MI. It is important to remember that although the patients in this trial were asymptomatic or had only mild angina, 62% of them had multivessel CAD, and 34% had significant disease in the proximal segment of the LAD (301). Thus, most of these patients had severe anatomic CAD.

The Asymptomatic Cardiac Ischemia Pilot (ACIP) study provides additional information comparing medical therapy with PTCA or CABG revascularization in patients with documented CAD and asymptomatic ischemia by both stress testing and ambulatory ECG monitoring (301). This trial randomized 558 patients suitable for revascularization by PTCA or CABG to 3 treatment strategies: angina-guided drug therapy (n equals 183), angina- plus ischemia-guided drug therapy (n equals 183), and revascularization by PTCA or CABG surgery (n equals 192). Of the 192 patients who were randomized to revascularization, 102 were selected for PTCA and 90 for CABG. At 2 years of follow-up, death or MI had occurred in 4.7% of the revascularization patients compared with 8.8% of the ischemia-guided group and 12.1% of the angina-guided group (P less than 0.01). Because a large portion of the patients underwent CABG surgery instead of PTCA to achieve complete revascularization, it is not appropriate to directly compare these results with RITA-2. Nonetheless, the ACIP study suggests that outcomes of revascularization with CABG surgery and PTCA are very favorable compared with medical therapy in patients with asymptomatic ischemia with or without mild angina. It should be emphasized that aggressive lipid-lowering therapy was not widely employed in either treatment arm of ACIP.

The Atorvastatin Versus Revascularization Treatment (AVERT) trial (298) randomly assigned 341 patients with stable CAD, normal LV function, and class I and/or II angina to PTCA or medical therapy with 80 mg of atorvastatin daily (mean low-density lipoprotein cholesterol equals 77 mg per dL). At 18 months of follow-up, 13% of the medically treated group had ischemic events compared with 21% of the PTCA group (P equals 0.048). Angina relief was greater in those treated with PTCA. Although not statistically different when adjusted for interim analysis, these data suggest that in low-risk patients with stable CAD, aggressive lipid-lowering therapy can be as effective as PTCA in reducing ischemic events.

During the MASS-II trial (289), 611 patients with stable angina, multivessel disease, and preserved LV function were randomized to 3 treatment groups: medical therapy, CABG, or PCI (medical therapy n equals 203, CABG n equals 203, and PCI n equals 205). One-year survival was similar in the 3 groups at 98.5%, 96.0%, and 95.6%, respectively. At 1 year of follow-up, a Q-wave MI had occurred in 2% of CABG patients, 8% of the PCI patients, and 3% of the medical therapy patients. By 1 year, additional revascularization procedures were performed in 8.3% of medical therapy patients, 13.3% of PCI patients, and only 0.5% of CABG patients. More patients were free of angina at 1 year in the CABG and PCI groups (88% and 79%, respectively) than in the medical therapy groups, in which only 46% were free of angina. This small contemporary trial utilizing aggressive medical management demonstrated that medical therapy for multivessel disease has a low incidence of early events including death and Q-wave MI but is inferior to PCI and CABG for the control of angina.

Given the limited data available from randomized trials comparing medical therapy with PCI, it seems prudent to consider medical therapy for the initial management of most patients with CCS classification class I and II stable angina and to reserve PCI and CABG for those patients with more severe symptoms and ischemia. The symptomatic patient who wishes to remain physically active, regardless of age, will usually require PCI or CABG to accomplish this.

The Clinical Outcomes Utilization Revascularization and Aggressive Drug Evaluation (COURAGE) trial was designed to compare intensive medical therapy with PCI plus intensive medical therapy. Enrollment has been completed, and results are expected to be available in the next few years. This trial will provide further valuable information about the relative merits of medical treatment plus PCI versus medical treatment alone and will also give us a detailed assessment of outcomes relative to quality of life and economic cost (303). The Bypass Angioplasty Revascularization trial in patients with diabetes (BARI 2d) was designed to compare revascularization in addition to aggressive medical therapy in patients with diabetes compared with aggressive medical therapy alone. Enrollment was completed in the first quarter of 2005.

Patients with UA and NSTEMI have been randomized to medical therapy or PCI in the FRagmin and Fast

Revascularisation during InStability in Coronary artery disease (FRISC) II and Treat Angina with Aggrastat and determine the Cost of Therapy with an Invasive or Conservative Strategy (TACTICS) TIMI 18 trials, as well as in RITA-3. These trials utilizing stenting as the primary therapy have favored the invasive approach (206,302,304). They are discussed in Section 5.3.

4. INSTITUTIONAL AND OPERATOR COMPETENCY

4.1. Quality Assurance

Class I

1. **An institution that performs PCI should establish an ongoing mechanism for valid peer review of its quality and outcomes. Review should be conducted both at the level of the entire program and at the level of the individual practitioner. Quality-assessment reviews should take risk adjustment, statistical power, and national benchmark statistics into consideration. Quality-assessment reviews should include both tabulation of adverse event rates for comparison with benchmark values and case review of complicated procedures and some uncomplicated procedures. (Level of Evidence: C)**
2. **An institution that performs PCI should participate in a recognized PCI data registry for the purpose of benchmarking its outcomes against current national norms. (Level of Evidence: C)**

Definition of Quality in PCI

Satisfactory quality in PCI may be defined as the appropriate selection of patients for the procedure and the achievement of risk-adjusted outcomes that are comparable to national benchmark standards in terms of procedure success and adverse event rates. To achieve optimal quality and outcomes in PCI, it is necessary that both the physician operator and the supporting institution be appropriately skilled and experienced.

Institutional Quality-Assurance Requirement

PCI is a demanding, technically complex procedure. The potential exists for substantial quality variation among both operators and institutions.

In the United States, responsibility for quality assurance is vested in the healthcare institution, which is responsible to the public to ensure that patient care conducted under its jurisdiction is of acceptable quality. Thus, the institution has the responsibility to monitor its PCI program's quality with respect to process, appropriateness, and outcomes in order to identify and correct any circumstances in which quality falls below accepted norms. Quality-assessment review should be conducted both at the level of the entire program and at the level of the individual practitioner.

Each institution that performs PCI must establish an ongoing mechanism for valid peer review of its quality and outcomes. The program should provide an opportunity for inter-

ventionalists, as well as for physicians who do not perform angioplasty but are knowledgeable about it, to review its overall results on a regular basis. The review process should tabulate the results achieved both by individual physician operators and by the overall program and compare them with national benchmark standards with appropriate risk adjustment. Valid quality assessment requires that the institution maintain meticulous records that include the patient demographic and clinical characteristics necessary to assess appropriateness and to conduct risk adjustment.

Role of Risk Adjustment in Assessing Quality

A raw adverse event rate that is not appropriately risk adjusted has little meaning. Data compiled from large registries of procedures performed in recent years have generated multivariate risk-adjustment models for adverse event rates for PCI in the current era. Six multivariate models of the risk of mortality after PCI have been published (43,47,305-308).

Although these models differ somewhat, they are consistent in identifying acute MI, shock, and age as important risk-stratification variables for mortality. The ACC-NCDR reported a univariate mortality rate of 0.5% for patients undergoing elective PCI, a mortality rate of 5.1% for patients undergoing primary PCI within 6 h of the onset of STEMI, and a mortality rate of 28% for patients undergoing PCI for cardiogenic shock (305). Thus, it is clear that to assess PCI mortality rates, patients should be stratified by whether they are undergoing elective PCI, primary PCI for acute STEMI without shock, or primary PCI for STEMI with shock.

Challenges in Determining Quality

As discussed above, given the complexity of case selection and procedure conduct, quality is difficult to measure in PCI and is not determined solely by adverse event rates even when properly adjusted for risk. Accurate assessment of quality becomes more problematic for low-volume operators and institutions, because absolute event rates are expected to be small. Thus, particularly in low-volume circumstances, quality may be better assessed by an intensive case review process conducted by recognized experts who can properly judge all of the facets of the conduct of a case. Case review also has merit in high-volume situations, because it can identify subtleties of case selection and procedure conduct that may not be reflected in pooled statistical data.

Requirement for Institutional Resources and Support

A high-quality PCI program requires appropriately trained and experienced skilled physician operators. However, the operator does not work in a vacuum. An operator needs a well-maintained, high-quality cardiac catheterization facility to practice effectively. In addition, the operator depends on a multidisciplinary institutional infrastructure for support and response to emergencies. Thus, to provide quality PCI services, the institution must ensure that its catheterization facility is properly equipped and managed and that all of its necessary support services are of high quality and are readily available.

The Quality-Assessment Process

Quality assessment is a complex process that includes more than mere tabulation of success and complication rates. Components of quality in coronary interventional procedures include appropriateness of case selection, quality of procedure execution, proper response to intraprocedural problems, accurate assessment of procedure outcome, and appropriateness of postprocedure management. It is important to consider each of these parameters when conducting a quality-assessment review. A quality program performs appropriately selected procedures that achieve risk-adjusted outcomes, in terms of procedure success and complication rates, that are comparable to national benchmark standards. Patient characteristics that determine appropriateness are discussed elsewhere in this document. Multivariate models that predict risk have been published previously (43,47,305-308).

It is accepted that quality-assurance monitoring is best conducted through the peer review process despite the political challenges associated with colleagues evaluating each other. There has been a considerable controversy surrounding efforts to define standards, criteria, and methodologies for conducting quality assessment. There are many challenges to conducting this process in a fair and valid manner.

The cornerstone of quality-assurance monitoring is the assessment of procedural outcomes in terms of success and adverse event rates. Other components of quality-assurance monitoring include establishment of criteria for assessing procedure appropriateness and application of proper risk adjustment to interpret adverse event rates. Because adverse events should be rare, a valid estimate of a properly risk-adjusted adverse event rate generally requires tabulation of the results of a large number of procedures. This adds an additional challenge to the valid assessment of low-volume operators and institutions. The responsible supervising authority should monitor the issues outlined in Table 13 (309).

Initial Physician Operator Credentialing Criteria

The institutional credentialing committee should document that an interventionalist wishing to initiate practice meets the established training criteria, including those of the ACC Task Force on Training in Cardiac Catheterization and Interventional Cardiology (310-312). The ACC Training Statement (312) for coronary invasive training requires a 3-year comprehensive cardiac program with 12 months of training in diagnostic catheterization, during which the trainee performs 300 diagnostic catheterizations, with at least 200 of those as the primary operator. Interventional training requires a fourth year of fellowship, during which the trainee should perform more than 250 but not more than 600 interventional procedures (312). The physician's training program director should certify that the candidate has completed the program and has achieved the necessary competence to perform coronary interventional procedures independently. The certification should also include whether the candidate has achieved requisite competence in related interven-

tional techniques such as rotational atherectomy, balloon valvuloplasty, and closure of patent foramen ovale and atrial septal defect.

It is recommended that an interventional cardiology operator be certified by the American Board of Internal Medicine in interventional cardiology. Ideally, board certification in interventional cardiology should be required for credentialing. The American Board of Internal Medicine certifying examination in interventional cardiology has been administered annually since 1999. As of the 2004 administration, a total of 4718 individuals have been certified.

Privilege Renewal

Criteria for practitioner privilege renewal should be based on both activity level and outcomes. The assessment process should ascertain whether a physician operator's activity level is sufficient to maintain competence. In addition, the assessment process should assess the appropriateness of the operator's case selection and compare the operator's risk-adjusted outcomes with established national benchmark standards (310). This is discussed in depth in Section 4.2. Current benchmark standards for mortality, complication rates, and risk adjustment will be subject to future revision as procedure technique is refined and newer data emerge. It is important that institutions assist with these efforts by participating in active database efforts to track clinical and procedural information for individual operators and their institutions.

Outcome Data Tabulation and Reporting

Institutions performing PCI should gather data needed to monitor their outcomes and should submit their data to a national registry for benchmarking purposes. Institutions should conduct meticulous record keeping that details the cases performed-patient demographics and comorbidities,

Table 13. Key Components of a Quality-Assurance Program

Clinical proficiency

- General indications/contraindications
- Institutional and individual operator complication rates, mortality and emergency CABG
- Institutional and operator procedure volumes
- Training and qualifications of support staff

Equipment maintenance and management

- Quality of laboratory facility [See ACC/SCAI Expert Consensus Document on Catheterization Laboratory Standards (309)]

Quality improvement process

- Establishment of an active concurrent database to track clinical and procedural information and patient outcomes for individual operators and the institution. The ACC-NCDR[®] or other databases are strongly recommended for this purpose

Radiation safety

- Educational program in the diagnostic use of X-ray
 - Patient and operator exposure
-

ACC indicates American College of Cardiology; CABG, coronary artery bypass graft surgery; NCDR[®], National Cardiovascular Data Registry; and SCAI, Society for Cardiovascular Angiography and Interventions.

cardiovascular characteristics including type of presentation, coronary anatomy, ventricular function, procedures performed, and periprocedural complications. These data are necessary to permit appropriate risk adjustment. Institutions should carefully monitor their risk-adjusted outcomes at the level of the institution and of the individual operators and should ascertain that their outcomes fall within national norms. One example is the ACCF CathKit[®], a tool that provides templates and guidance for the quality assessment process.

This Writing Committee agrees with the ACC Task Force recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures (310). Institutions and healthcare providers performing PCI should meet the standards outlined in Table 14 (309,310,312) and in Section 4.2.

4.2. Operator and Institutional Volume

Class I

- 1. Elective PCI should be performed by operators with acceptable annual volume (at least 75 procedures) at high-volume centers (more than 400 procedures) with onsite cardiac surgery (310,312). (Level of Evidence: B)**
- 2. Elective PCI should be performed by operators and institutions whose historical and current risk-adjusted outcomes statistics are comparable to those reported in contemporary national data registries. (Level of Evidence: C)**
- 3. Primary PCI for STEMI should be performed by experienced operators who perform more than 75 elective PCI procedures per year and, ideally, at least 11 PCI procedures for STEMI per year. Ideally, these procedures should be performed in institutions that perform more than 400 elective PCIs per year and more than 36 primary PCI procedures for STEMI per year. (Level of Evidence B)**

Class IIa

- 1. It is reasonable that operators with acceptable volume (at least 75 PCI procedures per year) perform PCI at low-volume centers (200 to 400 PCI procedures per year) with onsite cardiac surgery (310,312). (Level of Evidence: B)**
- 2. It is reasonable that low-volume operators (fewer than 75 PCI procedures per year) perform PCI at high-volume centers (more than 400 PCI procedures per year) with onsite cardiac surgery (310,312). Ideally, operators with an annual procedure volume less than 75 should only work at institutions with an activity level of more than 600 procedures per year. Operators who perform fewer than 75 procedures per year should develop a defined mentoring relationship with a highly experienced operator who has an annual procedural volume of at least 150 procedures per year. (Level of Evidence: B)**

Table 14. Considerations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures

Institutions

- Quality-assessment monitoring of privileges and risk-stratified outcomes
- Provide support for a quality-assurance staff person (e.g., nurse) to monitor complications
- Minimal institutional performance activity of 200 interventions per year, with ideal minimum of 400 interventions per year
- Interventional program director who has a career experience of more than 500 PCI procedures and who is board certified by the ABIM in interventional cardiology
- Facility and equipment requirements to provide high-resolution fluoroscopy and digital video processing
- Experienced support staff to respond to emergencies (see Section 4.3, Role of On-Site Cardiac Surgical Backup for discussion)
- Establishment of a mentoring program for operators who perform fewer than 75 procedures per year by individuals who perform at least 150 procedures per year

Physicians

- Procedural volume of 75 per year or more
- Continuation of privileges based on outcome benchmark rates, with consideration of not granting privileges to operators who exceed adjusted case mix benchmark complication rates for a 2-year period
- Ongoing quality assessment comparing results with current benchmarks, with risk stratification of complication rates
- Board certification by ABIM in interventional cardiology

ABIM indicates American Board of Internal Medicine; and PCI, percutaneous coronary intervention.

Class IIb

The benefit of primary PCI for STEMI patients eligible for fibrinolysis when performed by an operator who performs fewer than 75 procedures per year (or fewer than 11 PCIs for STEMI per year) is not well established. (Level of Evidence: C)

Class III

It is not recommended that elective PCI be performed by low-volume operators (fewer than 75 procedures per year) at low-volume centers (200 to 400) with or without onsite cardiac surgery (310,312). An institution with a volume of fewer than 200 procedures per year, unless in a region that is underserved because of geography, should carefully consider whether it should continue to offer this service. (Level of Evidence: B)

Operator and Institution Volume-Outcome Relationships

Threshold activity level standards for institutions and operators have been particularly controversial. Such standards are

derived from the principle that proper skill maintenance requires a requisite activity level. It is logical that both a threshold experience and an ongoing activity level are necessary to achieve and maintain requisite proficiency in PCI.

Standards originally formulated for the earliest versions of these guidelines were based on opinion (Level of Evidence: C) drawing on the well-documented existence of volume-outcome relationships for other complex surgical procedures. Initially, a panel of experts identified a threshold activity level of 75 procedures per year as necessary for maintenance of competence in PCI (313). Subsequent studies of PCI continue to identify annual procedural volume both at the program level and at the operator level as strongly correlated with complication rates. Most studies' findings are consistent with the operator threshold of 75 procedures per year (47, 306,309,314-320).

Most studies of the PCI volume-outcome relationship focus on mortality and emergent bypass surgery as quality-determining outcome variables. These variables, while important, encompass only a portion of the overall quality determinants for PCI.

McGrath *et al.* examined volume outcome relationships using procedures performed on 167 208 Medicare recipients in 1997 (321). Procedures performed by low-volume physicians (fewer than 30 Medicare procedures per year) had a greater emergency CABG rate (2.25%) than procedures performed by high-volume physicians (more than 60 Medicare procedures per year; 1.55%, *P* less than 0.001). An increased 30-day mortality rate was found for low-volume programs (fewer than 80 Medicare procedures per year) versus high-volume programs (more than 160 Medicare procedures per year; 4.29% vs 3.15%, *P* less than 0.001).

Kimmel *et al.*, using data from the SCAI, found that an inverse relationship existed between the number of angioplasty procedures performed at a hospital and the rate of major complications (315). These results were risk stratified and independent of the patient-risk profile. Significantly fewer complications occurred in laboratories that performed at least 400 angioplasty procedures per year.

Jollis *et al.* found that low-volume hospitals were associated with higher rates of emergency coronary artery bypass surgery and death (316). Improved outcomes were identified with a threshold volume of 75 Medicare angioplasties per physician and 200 Medicare angioplasty procedures per hospital. Using a 35% to 50% ratio of Medicare patients, the threshold value was 150 to 200 angioplasty procedures per cardiologist and 400 to 600 angioplasty procedures per institution (322).

Epstein *et al.*, using an administrative data set, analyzed risk-adjusted mortality in 362 748 admissions to 1000 United States hospitals between 1997 and 2000 during which a PCI was performed (323). They found a consistent trend of decreasing risk-adjusted mortality with increasing hospital volume. The differences between groups were small, and there was considerable heterogeneity within groups, which indicates that hospital volume is not the sole determinant of outcome.

Other studies have also supported the relationship of complication rate to procedural volume (47,306,314). Although some investigators have suggested that low procedure volume does not contribute to poor outcomes (44,309), these studies are small in number and underpowered for analysis (318).

Progress in technique and instrumentation has reduced absolute complication rates, which makes the procedure safer and more effective. This has fueled the opinion that the volume-outcome relationship has weakened, justifying advocacy that PCI be diffused to smaller-volume institutions and lower-volume operators. Although it is possible to consider earlier studies anachronistic because of the lack of availability of coronary stents and other adjunctive therapies, studies based on data sets accumulated in the stent era continue to show a volume-outcome relationship (albeit with lower absolute event rates).

Brown evaluated the outcomes of PCI at all hospitals in California in 1997 (324). Mortality for PCI in which a stent was used was 1.5% in hospitals performing fewer than 400 procedures per year compared with 1.1% in hospitals performing more than 400 procedures per year. The rate of emergent CABG was 1.2% in hospitals performing fewer than 400 procedures per year compared with 0.8% in hospitals that performed more than 400 procedures per year.

Moscucci *et al.* studied the outcomes of 18 504 consecutive PCIs performed at 14 hospitals in Michigan in 2002 (325). Operator volume was divided in quintiles (1-33, 34-89, 90-139, 140-206, and 207-582 procedures per year). The primary end point was a composite of MACE including death, CABG, stroke or TIA, MI, and repeat PCI at the same site during the index hospitalization. The unadjusted MACE rate was significantly higher in quintiles 1 and 2 of operator volume than in quintile 5 (7.38% and 6.13% vs 4.15%, *P* equals 0.002 and *P* equals 0.0001, respectively). A similar trend was observed for in-hospital death. After adjustment for comorbidities, patients treated by low-volume operators had a 63% increased odds of MACE (adjusted odds ratio [OR] 1.63, 95% CI 1.29-2.06, *P* less than 0.0001 for quintile 1; adjusted OR 1.63, 95% CI 1.34-1.90, *P* less than 0.0001 for quintile 2 vs quintile 5) but not of in-hospital death. Overall, high-volume operators had better outcomes than low-volume operators in both low-risk and high-risk patients (325).

Distinction Between Elective PCI and Primary PCI for STEMI

Elective PCI and primary PCI for STEMI are different, although related, disciplines. Experience in elective PCI translates only partially to experience with primary PCI for STEMI. Throughout this guideline, a distinction is drawn between primary PCI, which is performed under emergency circumstances, and all other PCI procedures, which are included under the term "elective." The volume-outcome relationship exists for both elective procedures and primary angioplasty for STEMI (326-328) but has important differences. Available data indicate that the best results are

obtained by operators who are highly experienced both in elective PCI and in primary PCI for STEMI who work in institutions that have established an active program for performing primary PCI for STEMI.

Operator experience in elective PCI is not sufficient to confer expertise in primary PCI for STEMI. This finding is not surprising, because there are aspects of procedure conduct that are unique to primary PCI for STEMI.

Vakili *et al.*, analyzing primary PCI procedures for STEMI performed in New York State, found no relationship between physician total angioplasty procedure volume and mortality after primary PCI for STEMI but did find an association between an operator's primary PCI activity level and the outcome of primary PCI for STEMI that was independent of the operator's experience in elective PCI (328,329). Low-volume physicians, who performed 1 to 10 primary PCI procedures per year, had an unadjusted mortality rate of 7.1% compared with 3.8% for physicians who performed 11 or more primary PCI procedures per year.

Magid *et al.* analyzed the National Registry of Myocardial Infarction (NRMI) database and grouped acute-care hospitals by volume tertiles of primary PCI for STEMI procedures (327). They found a reduction in risk-adjusted mortality with increasing hospital volume of PCI: low volume (fewer than 16 procedures), 6.2%; intermediate volume (17 to 48 procedures), 4.5%; and high volume (more than 49 procedures), 3.4% (327). Canon *et al.* analyzed or reviewed 20 080 consecutive patients with STEMI in the NRMI-2 database (330). A multivariate model was used to show that overall adjusted mortality was lower as volume increased, with the greatest reduction in mortality occurring at hospitals performing more than 3 angioplasties per month (330). Different studies identified different cutpoints. The relationship between the studies is graded, and the individual cutpoints are artifacts of analysis methodology.

Vakili *et al.* found a doubling of mortality in STEMI patients who underwent PCI in hospitals that performed fewer than 400 total PCI procedures per year compared with hospitals that performed more than 400 (8.1% vs 4.3%) (329). Furthermore, they found that high-volume hospitals that performed more than 56 primary PCI procedures per year had a nonsignificant trend toward a lower crude mortality rate (4.0% vs 5.8%), with a multivariate OR for mortality of 0.53 (0.29 to 1.1). The best outcomes were achieved by high-volume physicians working in high-volume hospitals (crude mortality rate 3.7% compared with 7.1% for low-volume physicians in low-volume hospitals; adjusted relative risk 0.51, 95% CI 0.26 to 0.99).

Canto *et al.* (331) also found a graded relationship between hospital volume and mortality after PCI for STEMI. The highest quartile of hospital volume performed more than 33 primary PCIs for STEMI per year and achieved a 28% reduction in mortality compared with the lowest-volume hospitals.

Appropriateness of Activity Levels as a Surrogate for Quality

The documented relationships between activity level and outcome are statistical associations, and activity level is not a surrogate for quality. The heterogeneity within hospital volume groups found by Epstein *et al.* (323) validates that activity level is an incomplete surrogate for quality. An activity level above a threshold value does not guarantee good quality, and an activity level below a threshold value may not necessarily indicate lower quality. Thus, high-volume operators and institutions are not necessarily of uniformly high quality, and low-volume operators and institutions are not, by definition, poor.

However, an activity level below a threshold necessarily raises the question of whether an operator or institution has sufficient ongoing experience to maintain expertise and skills. In particular, it is plausible that an operator or institution that is below a threshold activity level cannot accrue the necessary ongoing experience to perform complex procedures skillfully, to acquire experience with new techniques and devices, and to respond effectively to adverse and emergency situations. The emergency response consideration is particularly relevant, because the likelihood of a serious complication cannot be predicted from patient baseline characteristics.

Quality Assessed by Outcomes: Statistical Power Considerations and the Importance of Case Reviews

The quality of both institutions and operators should ultimately be judged through the quality-assessment process as outlined in Section 4.1. Because expected adverse event rates are low, a large number of procedures are required to achieve the requisite statistical power to assign an interpretable confidence interval to an operator's or a program's adverse event rate estimate. Furthermore, adverse event rates cannot be interpreted without appropriate risk adjustment.

The first approximation in assessing an operator's or a program's quality is to compare the actual adverse event rate to an expected rate as predicted by an accepted risk-prediction model (ACC-NCDR[®] model or Dynamic Registry model). Calculation of an expected adverse event rate can be conducted by entering the characteristics of the group of patients treated into the model. The model yields an expected adverse event rate with confidence intervals that can then be compared with the actual event rate. Interpretation of the expected adverse event rate is complex because of the precision of the estimate. An arbitrary criterion will need to be applied to determine whether a particular actual adverse event rate is an outlier when compared with the expected event rate. For example, 50% of operators may be expected to have an adverse event rate above the expected value purely by chance. Thus, merely being above the predicted mean value does not automatically identify an operator or a program as an outlier.

95% Confidence Interval - Actual Complication Rate = 0.02




Figure 3. Plot of an actual adverse event rate of 2% over a procedure number range from 25 to 400. The horizontal line at 0.02 represents the actual adverse event rate. The curved lines above and below the horizontal line represent the upper and lower bounds of the 95% confidence interval of the estimate of the adverse event rate. Note that as the number of procedures decreases, the range between the upper and lower bounds increases, which indicates lack of stability of any adverse event rate estimate at procedure numbers below 200.

Furthermore, valid assessment of an operator’s or an institution’s actual adverse event rate becomes problematic if the number of procedures available for analysis is small. The statistical basis for this issue is illustrated in Figures 3 and 4.

Figure 3 plots the upper and lower 95% CI bounds of an observed adverse event rate of 2% (1 adverse event per 50 procedures) as a function of the number of procedures available for analysis. It demonstrates that if only 50 cases are available, the upper bound of the confidence interval is

10.6%. Thus, if 50 cases are performed with 1 adverse event, it is possible that the true adverse event rate is as high as 10.6%. However, it is also possible that it is as low as 0.05%. The upper-bound value decreases as the number of cases increases such that if 400 cases are available, it is only 3.9%.

If only a small number of cases are available, even if no adverse events occur, it may be difficult to exclude that an increased risk of adverse events exists. Figure 4 plots the upper bound of the 95% CI for very low numbers of cases

95% Confidence Interval - Actual Complication Rate




Figure 4. Plot of an actual complication rate of 0% over a procedure number range from 10 to 100. The format is similar to Figure 3. The horizontal line at 0 represents the actual complication rate. The curved line above the horizontal line represents the upper bound of the 95% confidence interval of the estimate of the complication rate. Note that if 50 procedures are performed without a complication, the upper bound of the 95% confidence interval of the estimated rate is 6%.

performed with a zero adverse event rate. It demonstrates that if 10 consecutive cases are performed without a complication, the upper bound of the 95% CI is 25%. If 50 cases are performed without an adverse event, the upper bound is 5.8%.

Thus, although it is likely that certain low-volume operators and institutions perform procedures with acceptable quality, satisfactory quality is difficult to prove unless a sufficient number of procedures are compiled for analysis. The quality-assessment process must take the above issues into consideration. This means that it is essential that institution and operator outcomes be tracked over sufficiently long periods of time to assemble a sufficient number of procedures to permit a satisfactory analysis.

In addition, mere tabulation of adverse event rates, even with appropriate risk adjustment, is inadequate to judge operator or program quality. Such tabulations do not address numerous other quality issues, in particular, appropriateness. Thus, the quality-assessment process should also conduct detailed reviews both of cases that have adverse outcomes (to determine the cause(s) of the adverse event) and of uncomplicated cases (to judge case selection appropriateness and procedure execution quality). These reviews should be conducted by recognized experienced interventionalists drawn either from within the institution or externally if a requisite number of appropriately qualified, unconflicted individuals are not available.

Role of Low-Volume PCI Programs

There is an ongoing debate as to whether PCI services should be diffused widely to be available in most healthcare institutions or whether the service should be regionalized and concentrated in specialized high-volume centers. Given the widespread availability of sophisticated interventional/surgical programs in the United States, it is difficult to demonstrate a need for additional low-volume programs to perform elective angioplasty except in underserved areas that are geographically distant from major centers. At this writing, outcome data that link activity level to outcomes indicate that the development of small cardiovascular surgical programs to support angioplasty is a poor use of resources that will likely lead to suboptimal results (320). In general, the proliferation of small angioplasty or small surgical programs to support such angioplasty programs is not needed to improve patient access to PCI services and would appear not to be in the interest of fostering optimal quality; thus, it should be discouraged. An exception to this principle should be when geographic considerations become important determinants of patient access.

These data support the conclusion that not every cardiologist desiring to perform PCI should perform these procedures, and not every hospital that would like to have an interventional program should start one (322). This caveat is particularly true where high-volume programs and operators are already nearby.

The Writing Committee, therefore, recommends that elective PCI be performed by higher-volume operators (75 cases per year) with advanced technical skills (e.g., subspecialty certification) at institutions with fully equipped interventional laboratories and an experienced support staff. This setting is optimally a high-volume center (more than 400 cases per year) with an onsite cardiovascular surgical program (332).

It is recommended that primary PCI for STEMI be performed by higher-volume operators experienced in both elective PCI and primary PCI for STEMI with ongoing activity levels of more than 75 elective PCI procedures per year and, ideally, annual PCI for STEMI activity levels of at least 11 per year. It is clear that an effective PCI for STEMI program, irrespective of whether cardiac surgery is available onsite, requires appropriate physician operator expertise, appropriate institutional commitment, and the achievement of the requisite utilization levels. The nursing and technical catheterization laboratory staff must be experienced in handling acutely ill patients, must be skilled in all aspects of interventional equipment, and must participate in a 24-hours-per-day, 365-days-per-year call schedule. Ideally, these procedures should be performed in institutions that perform more than 400 elective PCIs per year and more than 36 primary PCIs for STEMI per year and that achieve risk-adjusted outcomes that are comparable to national benchmark standards.

The Writing Committee cannot recommend angioplasty by low-volume operators (fewer than 75 cases per year) working in low-volume institutions (200 to 400 cases per year) with or without onsite surgical coverage. As noted earlier, ongoing investigational experience and clinical data are mandatory if these recommendations are to be modified. Any change in this recommendation awaits further data assessing the safety and outcomes for patients treated in various settings.

4.3. Role of Onsite Cardiac Surgical Back-Up

Class I

- 1. Elective PCI should be performed by operators with acceptable annual volume (at least 75 procedures per year) at high-volume centers (more than 400 procedures annually) that provide immediately available onsite emergency cardiac surgical services. (Level of Evidence: B)**
- 2. Primary PCI for patients with STEMI should be performed in facilities with onsite cardiac surgery. (Level of Evidence: B)**

Class III

Elective PCI should not be performed at institutions that do not provide onsite cardiac surgery. (Level of Evidence: C)*

*Several centers have reported satisfactory results based on careful case selection with well-defined arrangements for immediate trans-

fer to a surgical program (333-337,348-353). A small, but real fraction of patients undergoing elective PCI will experience a life-threatening complication that could be managed with the immediate onsite availability of cardiac surgical support but cannot be managed effectively by urgent transfer. Wennberg, et al., found higher mortality in the Medicare database for patients undergoing elective PCI in institutions without onsite cardiac surgery (356). This recommendation may be subject to revision as clinical data and experience increase.

The purpose of cardiac surgical backup for PCI is to provide emergent hemodynamic support and revascularization to salvage complications that cannot be addressed by catheter-based techniques. PCI can be complicated by life-threatening hemodynamic and ischemic emergencies that can be addressed only by the availability of emergency cardiac surgery. The role of onsite cardiac surgical backup is 2-fold: onsite cardiac surgical backup provides prompt availability of cardiac surgical support in the event of a hemodynamic or ischemic emergency, and onsite cardiac surgical backup is a surrogate for an institution's overall capability to provide a highly experienced and promptly available team to respond to a catheterization laboratory emergency.

Cardiac surgical backup for PCI has evolved from a formal surgical standby in the 1980s to an informal arrangement of first-available operating room and, in some cases, off-site surgical backup (44,333-337). With the advent of intracoronary stenting, there has been a decrease in the need for emergency CABG ranging between 0.4% and 2% (49,305,338-342). Not surprisingly, emergency CABG surgery for a patient with an occluded or dissected coronary artery is associated with a higher mortality than elective surgery (146,343-347). Emergency procedures are also associated with high rates of perioperative infarction and less frequent use of arterial conduits. Complex CAD intervention, hemodynamic instability, and prolonged time to reperfusion are contributing factors to the increased risk of emergency bypass surgery.

Technical improvements in PCI instruments and technique have led to the concept that the requirement for emergency cardiac surgery is sufficiently rare that PCI can be performed safely without onsite surgery. This has led to the development of elective angioplasty programs without onsite surgical coverage. Several centers have reported satisfactory results based on careful case selection with well-defined arrangements for immediate transfer to a surgical program (333-337,348-352). These studies of angioplasty without onsite surgical coverage have not identified significant differences in the outcomes, which recalls the infrequent rate of complications (353). Despite many reported successful angioplasty series without onsite surgical backup and a very low percentage of need for off-site surgery in failed angioplasty, some clinicians have expressed concern (354,355) about the appropriateness of elective angioplasty in centers without onsite surgical coverage.

Even with current interventional techniques, life-threatening complications requiring surgical intervention still occur. Such complications include left main coronary dissection, spiral coronary trunk dissection, and coronary perforation.

Many emergency surgery patients did not receive a coronary stent, which indicates that either a stent delivery was not feasible or a stent would not solve the problem that required surgical intervention. Data from the ACC-NCDR[®] indicate that PCI programs staffed by highly experienced practitioners still experience a 0.4% likelihood of a patient requiring emergency cardiac surgery for a complication that developed during a procedure. Roughly half of patients who require emergency surgery are severely hemodynamically unstable at the time of transfer to the operating room. Furthermore, analyses of series of patients requiring emergency cardiac surgery indicate that patient baseline characteristics do not predict the risk of the need for emergency surgery (305,342).

It has been argued that a well-planned strategy to provide rapid transfer to a surgical center in the event of a complication is tantamount to providing onsite surgical backup support. Such strategies are unrealistic because they are logistically difficult to achieve and require that a critically ill patient be transported outside of a hospital environment, possibly without a physician in attendance. Furthermore, if an institution without cardiac surgery is sufficiently close to one that provides surgery to permit sufficiently timely transfer, there is little justification for not transferring the patient electively in the first place.

Although individual programs have reported successful results, the national experience with PCI programs at institutions that do not offer onsite cardiac surgery has been less satisfactory. Wennberg et al. (356) analyzed the Medicare database for a 2-year period from 1999 to 2001 (when stents and IIb/IIIa inhibitors were in widespread use). They identified 178 hospitals without onsite cardiac surgical facilities and 943 hospitals with onsite cardiac surgery that performed PCI during that period. After adjusting for baseline differences, they found similar mortality rates in patients who underwent primary PCI for STEMI. However, for the larger nonprimary/rescue PCI population, mortality was higher in hospitals without onsite cardiac surgery (adjusted OR 1.38; 95% CI 1.14 to 1.67; *P* equals 0.001). This increase in mortality was primarily confined to hospitals that performed 50 or fewer Medicare PCIs per year. This experience is consistent with the concept that expansion of PCI services outside of large, full-service centers creates small, low-volume programs with inadequate infrastructure that are not able to perform PCI at the same level of sophistication and quality that a larger institution can.

This Writing Committee concludes that performance of elective PCI in a setting without immediately available onsite cardiac surgery potentially compromises patient safety and is not recommended. Although the frequency of PCI complications for which the outcome is favorably affected by prompt surgery is small, it is nonetheless finite. Consequently, performance of PCI in such a setting exposes the patient to a small but very real additional and medically unnecessary risk. In addition, an institution without an established cardiac surgery program is likely to be a low-volume institution less able to offer as high quality PCI service as a larger, full-service institution. Therefore, at this time, the

Writing Committee continues to support the recommendation that elective PCI should not be performed in facilities without onsite cardiac surgery. Mere convenience should not replace safety and efficacy in establishing an elective PCI program without onsite surgery. As with many dynamic areas in interventional cardiology, these recommendations may be subject to revision as clinical data and experience increase.

4.4. Primary PCI for STEMI Without Onsite Cardiac Surgery

Class IIb

Primary PCI for patients with STEMI might be considered in hospitals without onsite cardiac surgery, provided that appropriate planning for program development has been accomplished, including appropriately experienced physician operators (more than 75 total PCIs and, ideally, at least 11 primary PCIs per year for STEMI), an experienced catheterization team on a 24 hours per day, 7 days per week call schedule, and a well-equipped catheterization laboratory with digital imaging equipment, a full array of interventional equipment, and intra-aortic balloon pump capability, and provided that there is a proven plan for rapid transport to a cardiac surgery operating room in a nearby hospital with appropriate hemodynamic support capability for transfer. The procedure should be limited to patients with STEMI or MI with new or presumably new left bundle-branch block on ECG and should be performed in a timely fashion (goal of balloon inflation within 90 minutes of presentation) by persons skilled in the procedure (at least 75 PCIs per year) and at hospitals performing a minimum of 36 primary PCI procedures per year. (Level of Evidence: B)

Class III

Primary PCI should not be performed in hospitals without onsite cardiac surgery and without a proven plan for rapid transport to a cardiac surgery operating room in a nearby hospital or without appropriate hemodynamic support capability for transfer. (Level of Evidence: C)

Fibrinolytic trials in STEMI have demonstrated that early reperfusion saves myocardium and reduces mortality (357-360). Randomized trials comparing primary PCI for STEMI have shown that primary PCI performed by a highly experienced team achieves superior results. Primary PCI, compared with fibrinolytic therapy, has achieved modest reductions in overall mortality, but its overall benefit is chiefly leveraged by a reduction in early recurrent ischemic events (361-364).

In patients who have a contraindication to fibrinolytic therapy, or when there are complications such as cardiogenic shock, catheter-based therapy may limit infarct size (365,366). Thus, the potential overall superiority and greater applicability of primary PCI for the treatment of STEMI has

raised the question of whether primary PCI should be performed at institutions with diagnostic cardiac catheterization laboratories that do not perform elective PCI or have onsite cardiac surgery. For this reason, the establishment of PCI programs at institutions without onsite cardiovascular surgery has been promoted as necessary to maintain quality of care (333-335,367-376).

PCI in the early phase of a STEMI requires a cognitive knowledge base and technical skill set that is somewhat different from that required to perform elective PCI. Primary PCI for STEMI can be technically difficult and requires even more skill and experience than routine PCI in the stable patient. The linkage between experience in performing elective PCI and primary PCI is incomplete (328). A successful primary PCI program requires an experienced operator and an experienced laboratory technical staff accustomed to managing critically ill patients (377). In addition, it is necessary to have available a broad range of catheters, guidewires, stents, and other devices (e.g., IABP) that are required to achieve results in an acutely ill patient (Table 15) (368).

Observational data from large, multi-institutional data sets have demonstrated that patients with STEMI who are treated with primary PCI performed by interventionalists with limited experience at institutions with low volume experience outcomes comparable to those achieved by fibrinolytic therapy (331). Thus, the benefits of primary PCI for STEMI require the infrastructure of a well-organized program with requisite experience and capabilities. In the absence of such capabilities, either onsite fibrinolytic therapy or transfer to a center that routinely performs complex PCI will often be a more effective and efficient course of action (123). The Danish Myocardial Infarction Study (DANAMI-2) demonstrated superior results in patients with STEMI who were urgently transferred to an experienced PCI center compared with those for whom fibrinolytic therapy was administered locally. In addition, the results in patients emergently transferred for primary PCI were comparable to those achieved in patients receiving primary PCI who initially presented to the PCI center institution (378). Nonetheless, fibrinolysis remains an acceptable form of therapy (379) and is likely preferable to acute PCI by an inexperienced team (62,379).

There are important institutional considerations in creating an effective program of primary PCI for STEMI. An institution must commit its catheterization facility to be capable of a 24-hours-per-day, 7-days-per-week rapid response to a patient presenting with STEMI. In addition, the institution's catheterization facility staff must be sufficiently trained and experienced in the management of the seriously ill patient with STEMI. In general, this means that the institution best positioned to provide effective PCI for STEMI is the institution with an active high-quality elective PCI program.

It has been demonstrated that institutions without an elective PCI program that care for a large number of patients with STEMI can create high-quality programs of PCI for STEMI. These programs require the 24-hours-per-day, 7-days-per-week availability of experienced interventionalists and an institutional commitment to invest in the physical and

Table 15. Criteria for the Performance of Primary PCI at Hospitals Without On-Site Cardiac Surgery

The operators must be experienced interventionalists who regularly perform elective PCI at a surgical center (greater than or equal to 75 cases per year). The catheterization laboratory must perform a minimum of 36 primary PCI procedures per year.

The nursing and technical catheterization laboratory staff must be experienced in handling acutely ill patients and must be comfortable with interventional equipment. They must have acquired experience in dedicated interventional laboratories at a surgical center. They participate in a 24-hours-per-day, 365-days-per-year call schedule.

The catheterization laboratory itself must be well-equipped, with optimal imaging systems, resuscitative equipment, and IABP support, and must be well-stocked with a broad array of interventional equipment.

The cardiac care unit nurses must be adept in hemodynamic monitoring and IABP management.

The hospital administration must fully support the program and enable the fulfillment of the above institutional requirements.

There must be formalized written protocols in place for immediate and efficient transfer of patients to the nearest cardiac surgical facility that are reviewed/tested on a regular (quarterly) basis.

Primary PCI must be performed routinely as the treatment of choice around the clock for a large proportion of patients with AMI, to ensure streamlined care paths and increased case volumes.

Case selection for the performance of primary PCI must be rigorous. Criteria for the types of lesions appropriate for primary PCI and for the selection for transfer for emergency aortocoronary bypass surgery are shown in Table 14.

There must be an ongoing program of outcomes analysis and formalized periodic case review.

Institutions should participate in a 3- to 6-month period of implementation, during which time development of a formalized primary PCI program is instituted that includes establishment of standards, training of staff, detailed logistic development, and creation of a quality-assessment and error-management system.

AMI indicates acute myocardial infarction; IABP, intra-aortic balloon pump; and PCI, percutaneous coronary intervention.
Adapted with permission from Wharton *et al.* *J Am Coll Cardiol* 1999;33:1257-65 (368).

cognitive resources needed to support a high-quality program. The feasibility of such an undertaking was first demonstrated by Wharton *et al.* in a 2-center study (368) and subsequently confirmed in multicenter studies by Aversano *et al.* (380) and Wharton *et al.* (375).

Before the use of stenting and GP receptor blockers, primary angioplasty in certain hospitals had been associated with acute mortality rates greater than those reported from centers with established primary angioplasty programs. Overall, in-hospital mortality rates have ranged from 1.4% to 13% (334,335,370).

Criteria have been suggested for the performance of primary PCI at hospitals without onsite cardiac surgery (Tables 15 and 16) (319,368,381). Of note, large-scale registries have shown an inverse relationship between the number of primary angioplasty procedures performed and in-hospital mortality (321,327,331). These data suggest that both door-to-balloon time and in-hospital mortality are significantly lower in institutions that perform more than 36 primary angioplasty procedures per year (330). It is important to point out that these data were achieved in hospitals with established elective PCI programs, and the numerical data may not extrapolate directly to hospitals that perform only primary PCI.

As an alternative to establishing numerous freestanding, modest-sized, primary PCI-only programs, a community

may choose to concentrate PCI in a subset of its healthcare institutions, identifying well-qualified and experienced centers to perform this procedure. Suboptimal results may relate to operator/staff inexperience and capabilities and delays in performing angioplasty for logistical reasons (382).

From clinical data and expert consensus, the Writing Committee recommends that primary PCI for STEMI performed at hospitals without established elective PCI programs be restricted to those institutions capable of performing a requisite minimum number of primary angioplasty procedures (36 per year) by highly experienced operators after careful program development according to the procedures used by the C-PORT (Cardiovascular Patient Outcomes Research Team trial) and PAMI-No SOS (PAMI with No Surgery On Site) studies, including a proven plan for rapid and effective PCI and rapid access to cardiac surgery in a nearby facility (383). Although some experience suggests that an institution can develop an effective stand-alone primary PCI program, currently available data also indicate that concentration rather than diffusion of this capability will provide the most effective patient care. Thus, a strategy of emergency transfer to an established center with a well-developed primary PCI program is preferred to the development of new freestanding primary PCI programs.

Table 16. Patient Selection for Primary PCI and Emergency Aortocoronary Bypass at Hospitals Without On-Site Cardiac Surgery

Avoid intervention in hemodynamically stable patients with:

Significant (greater than or equal to 60%) stenosis of an unprotected left main coronary artery upstream from an acute occlusion in the left coronary system that might be disrupted by the angioplasty catheter

Extremely long or angulated infarct-related lesions with TIMI grade 3 flow

Infarct-related lesions with TIMI grade 3 flow in stable patients with 3-vessel disease (319, 381)

Infarct-related lesions of small or secondary vessels

Hemodynamically significant lesions in other than the infarct artery

Transfer for emergency aortocoronary bypass surgery patients with:

High-grade residual left main or multivessel coronary disease and clinical or hemodynamic instability present after primary PCI of occluded vessels, preferably with IABP support.

IABP indicates intra-aortic balloon pump; PCI, percutaneous coronary intervention; and TIMI, Thrombolysis In Myocardial Infarction.

Adapted with permission from Wharton *et al.* *J Am Coll Cardiol* 1999;33:1257-65 (368).

4.5. Elective PCI Without Onsite Surgery

Class III

Elective PCI should not be performed at institutions that do not provide onsite cardiac surgery. (Level of Evidence: C)*

*Several centers have reported satisfactory results based on careful case selection with well-defined arrangements for immediate transfer to a surgical program (333-337,348-353). A small, but real fraction of patients undergoing elective PCI will experience a life-threatening complication that could be managed with the immediate onsite availability of cardiac surgical support but cannot be managed effectively by urgent transfer. Wennberg *et al.*, found higher mortality in the Medicare database for patients undergoing elective PCI in institutions without onsite cardiac surgery (356). This recommendation may be subject to revision as clinical data and experience increase.

Technical improvements in interventional cardiology have led to the development of elective angioplasty programs without onsite surgical coverage. Several centers have reported satisfactory results based on careful case selection with well-defined arrangements for immediate transfer to a surgical program (333-337,348-353). The studies of angioplasty without onsite surgical coverage have not identified significant differences in outcomes, which recalls the infrequent rate of complications (353). Despite many reported successful angioplasty series without onsite surgical backup and a very low percentage need for off-site surgery in failed angioplasty, some clinicians have expressed concern (354,355) about the appropriateness of elective angioplasty in centers without onsite surgical coverage. Life-threatening complications of elective PCI are, fortunately, rare but have

not been reduced to negligible levels. A small but valid fraction of patients undergoing elective PCI will experience a life-threatening complication that could be managed with the immediate onsite availability of cardiac surgical support but cannot be managed effectively by urgent transfer. Lotfi *et al.* reported the experience of a large, high-quality coronary interventional center (384). Of 6582 PCI procedures performed between 1996 and 2000, 45 (0.7%) required emergency cardiac surgery. Of the 45 patients, 11 (0.2%) required truly emergent surgery because they were too unstable to tolerate an interhospital transfer. Thus, under the best of circumstances 1 in 500 patients undergoing elective PCI will experience a life-threatening complication that can be salvaged by immediate access to onsite cardiac surgery. As previously noted, Section 4.4, Wennberg, *et al.*, found higher mortality in the Medicare database for patients undergoing elective PCI in institutions without onsite cardiac surgery (356). Furthermore, the availability of onsite cardiac surgery is a surrogate for overall program size and capability, as well as for the availability of many other experienced support services.

Caution is warranted before an unrestricted policy for PCI in hospitals without appropriate facilities is endorsed. Several outstanding and critically important clinical issues, such as timely management of ischemic complications, adequacy of specialized postinterventional care, logistics for managing cardiac surgical or vascular complications and operator/laboratory volumes, and accreditation, must be addressed. Mere convenience should not replace safety and efficacy in the establishment of an elective PCI program without onsite surgery.

At this time, the Writing Committee, therefore, continues to support the recommendation that elective PCI should not be performed in facilities without onsite cardiac surgery. As with many dynamic areas in interventional cardiology, these recommendations may be subject to revision as clinical data and experience increase.

5. CLINICAL PRESENTATIONS

A broad spectrum of clinical presentations exists wherein patients may be considered candidates for PCI, ranging from asymptomatic to severely symptomatic or unstable, with variable degrees of jeopardized myocardium. In this guideline, the CCS classification system for grading angina pectoris is used to summarize the severity of angina, as shown below (Table 17) (385).

Each time a patient is considered for revascularization, the potential risk and benefits of the particular procedure under consideration must be weighed against alternative therapies (Table 18). When PCI is considered, the benefits and risks of surgical revascularization and medical therapy always deserve thoughtful discussion with the patient and family. The initial simplicity and associated low morbidity of PCI compared with surgical therapy is always attractive, but the patient and family must understand the limitations inherent in current PCI procedures, including a realistic presentation

Table 17. Grading of Angina Pectoris According to CCS Classification

Class	Description of Stage
I	“Ordinary physical activity does not cause...angina,” such as walking or climbing stairs. Angina occurs with strenuous, rapid, or prolonged exertion at work or recreation.
II	“Slight limitation of ordinary activity.” Angina occurs on walking or climbing stairs rapidly; walking uphill; walking or stair climbing after meals; in cold, in wind, or under emotional stress; or only during the few hours after awaking. Angina occurs on walking more than 2 blocks on the level and climbing more than 1 flight of ordinary stairs at a normal pace and under normal conditions.
III	“Marked limitations of ordinary physical activity.” Angina occurs on walking 1 to 2 blocks on the level and climbing 1 flight of stairs under normal conditions and at a normal pace.
IV	“Inability to carry on any physical activity without discomfort—anginal symptoms may be present at rest.”

CCS indicates Canadian Cardiovascular Society.
Adapted with permission from Campeau. *Circulation* 1976;54:522-3 (385).

of the likelihood of restenosis and the potential for incomplete revascularization compared with CABG surgery. In patients with CAD who are asymptomatic or have only mild symptoms, the potential benefit of antianginal drug therapy along with an aggressive program of risk reduction must also be understood by the patient before a revascularization procedure is performed. In those clinical settings in which PCI is recommended without evidence that it will reduce cardiovascular mortality but in which it does hold a promise to reduce symptoms, a class IIa or IIb classification has been chosen, which indicates a role for patient preference.

5.1. Patients With Asymptomatic Ischemia or CCS Class I or II Angina

Class IIa

1. PCI is reasonable in patients with asymptomatic ischemia or CCS class I or II angina and with 1 or more significant lesions in 1 or 2 coronary arteries suitable for PCI with a high likelihood of success and a low risk of morbidity and mortality. The vessels to be dilated must subtend a moderate to large area of viable myocardium or be associated with a moderate to severe degree of ischemia on noninvasive testing. (*Level of Evidence: B*)
2. PCI is reasonable for patients with asymptomatic ischemia or CCS class I or II angina, and recurrent stenosis after PCI with a large area of viable myocardium or high-risk criteria on noninvasive testing. (*Level of Evidence: C*)
3. Use of PCI is reasonable in patients with asymptomatic ischemia or CCS class I or II angina with significant left main CAD (greater than 50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG. (*Level of Evidence: B*)

Table 18. Provider Checklist: Key Areas for Consideration

Patients at High Risk

- Assess key clinical and anatomic variables
- Consider alternative therapies such as CABG in consultation with the patient
- Ensure that formalized surgical standby is available
- Ensure periprocedural hemodynamic support is available

Patients at Low Risk

- Assess key clinical and anatomic variables
- Consider alternative therapies such as medical therapy in consultation with the patient

CABG indicates coronary artery bypass graft surgery.

Class IIb

1. The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2- or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established. (*Level of Evidence: B*)
2. PCI might be considered for patients with asymptomatic ischemia or CCS class I or II angina with nonproximal LAD CAD that subtends a moderate area of viable myocardium and demonstrates ischemia on noninvasive testing. (*Level of Evidence: C*)

Class III

- PCI is not recommended in patients with asymptomatic ischemia or CCS class I or II angina who do not meet the criteria as listed under the class II recommendations or who have 1 or more of the following:
- a. Only a small area of viable myocardium at risk (*Level of Evidence: C*)
 - b. No objective evidence of ischemia. (*Level of Evidence: C*)
 - c. Lesions that have a low likelihood of successful dilatation. (*Level of Evidence: C*)
 - d. Mild symptoms that are unlikely to be due to myocardial ischemia. (*Level of Evidence: C*)
 - e. Factors associated with increased risk of morbidity or mortality. (*Level of Evidence: C*)
 - f. Left main disease and eligibility for CABG. (*Level of Evidence: C*)
 - g. Insignificant disease (less than 50% coronary stenosis). (*Level of Evidence: C*)

In the previous ACC/AHA guidelines for PCI, specific recommendations were made separately for patients with single-vessel or multivessel disease (1,123). The current techniques of PCI have matured to the point at which, in patients with favorable anatomy, the competent practitioner can perform either single-vessel or multivessel PCI with low risk and with a high likelihood of initial success. For this reason, in this update of the guidelines, recommendations have been made largely based on the patient's clinical condition, spe-

cific coronary lesion morphology and anatomy, LV function, and associated medical conditions, and less emphasis has been placed on the number of lesions or vessels requiring PCI. The CCS classification of angina (I to IV) is used to define the severity of symptoms. The categories described in this section refer to an initial PCI procedure in a patient without prior CABG surgery. The randomized trials comparing PCI and medical therapy have been discussed (Table 12) (11,12,279,282-290).

The Writing Committee recognizes that the majority of patients with CCS class I or II angina should be treated medically. The published ACIP study (301) casts some doubt on the wisdom of medical management for those higher-risk patients who are asymptomatic or have mild angina but have objective evidence by both treadmill testing and ambulatory monitoring of significant myocardial ischemia and CAD. In addition, a substantial portion of the middle-aged and older-age populations in the United States remain physically active, participating in sports, such as tennis and skiing, or performing regular and vigorous physical exercise, such as jogging, have CAD. For such individuals with moderate or severe ischemia and few symptoms, revascularization with PCI or CABG surgery may reduce their risk of serious or fatal cardiac events (301). For this reason, patients in this category of higher-risk asymptomatic ischemia or mild symptoms and severe anatomic CAD are placed in class IIa or IIb recommendations. PCI may be considered if there is a high likelihood of success and a low risk of morbidity or mortality. The judgment of the experienced physician is deemed valuable in assessing the extent of ischemia.

5.2. Patients With CCS Class III Angina

Class IIa

1. It is reasonable that PCI be performed in patients with CCS class III angina and single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more significant lesions in 1 or more coronary arteries suitable for PCI with a high likelihood of success and low risk of morbidity or mortality. (*Level of Evidence: B*)
2. It is reasonable that PCI be performed in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy with focal saphenous vein graft lesions or multiple stenoses who are poor candidates for reoperative surgery. (*Level of Evidence: C*)
3. Use of PCI is reasonable in patients with CCS class III angina with significant left main CAD (greater than 50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG. (*Level of Evidence: B*)

Class IIb

1. PCI may be considered in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of suc-

cess. (*Level of Evidence: B*)

2. PCI may be considered in patients with CCS class III angina and no evidence of ischemia on noninvasive testing or who are undergoing medical therapy and have 2- or 3-vessel CAD with significant proximal LAD CAD and treated diabetes or abnormal LV function. (*Level of Evidence: B*)

Class III

PCI is not recommended for patients with CCS class III angina with single-vessel or multivessel CAD, no evidence of myocardial injury or ischemia on objective testing, and no trial of medical therapy, or who have 1 of the following:

- a. Only a small area of myocardium at risk. (*Level of Evidence: C*)
- b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. (*Level of Evidence: C*)
- c. A high risk of procedure-related morbidity or mortality. (*Level of Evidence: C*)
- d. Insignificant disease (less than 50% coronary stenosis). (*Level of Evidence: C*)
- e. Significant left main CAD and candidacy for CABG. (*Level of Evidence: C*)

The primary benefit of PCI among patients with CCS class III angina and single-vessel or multivessel CAD resides in the relief of symptoms, which may be accomplished with medical therapy. However, many patients with moderate or severe stable angina do not respond adequately to medical therapy and often have significant coronary artery stenoses that are suitable for revascularization with CABG surgery or PCI. In addition, a proportion of these patients have reduced LV systolic function, which places them in a group that is known to have improved survival with CABG surgery and possibly with revascularization by PCI (386-389). In patients without diabetes with 1- or 2-vessel disease in whom angioplasty of 1 or more lesions has a high likelihood of initial success, PCI is the preferred approach. In a minority of such patients, CABG surgery may be preferred, particularly for those in whom the LAD can be revascularized with the IMA or in those with left main coronary disease. (See Section 3.5.1.2 on left main CAD.)

5.3. Patients With UA/NSTEMI

Class I

An early invasive PCI strategy is indicated for patients with UA/NSTEMI who have no serious comorbidity and coronary lesions amenable to PCI. Patients must have any of the following high-risk features:

- a. Recurrent ischemia despite intensive anti-ischemic therapy. (*Level of Evidence: A*)
- b. Elevated troponin level. (*Level of Evidence: A*)
- c. New ST-segment depression. (*Level of Evidence: A*)
- d. HF symptoms or new or worsening MR. (*Level of*

Evidence: A)

- e. Depressed LV systolic function. (*Level of Evidence: A*)
- f. Hemodynamic instability. (*Level of Evidence: A*)
- g. Sustained ventricular tachycardia. (*Level of Evidence: A*)
- h. PCI within 6 months. (*Level of Evidence: A*)
- i. Prior CABG. (*Level of Evidence: A*)

Class IIa

- 1. It is reasonable that PCI be performed in patients with UA/NSTEMI and single-vessel or multivessel CAD who are undergoing medical therapy with focal saphenous vein graft lesions or multiple stenoses who are poor candidates for reoperative surgery. (*Level of Evidence: C*)
- 2. In the absence of high-risk features associated with UA/NSTEMI, it is reasonable to perform PCI in patients with amenable lesions and no contraindication for PCI with either an early invasive or early conservative strategy. (*Level of Evidence: B*)
- 3. Use of PCI is reasonable in patients with UA/NSTEMI with significant left main CAD (greater than 50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG. (*Level of Evidence: B*)

Class IIb

- 1. In the absence of high-risk features associated with UA/NSTEMI, PCI may be considered in patients with single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with reduced likelihood of success. (*Level of Evidence: B*)
- 2. PCI may be considered in patients with UA/NSTEMI who are undergoing medical therapy who have 2- or 3-vessel disease, significant proximal LAD CAD, and treated diabetes or abnormal LV function. (*Level of Evidence: B*)

Class III

In the absence of high-risk features associated with UA/NSTEMI, PCI is not recommended for patients with UA/NSTEMI who have single-vessel or multivessel CAD and no trial of medical therapy, or who have 1 or more of the following:

- a. Only a small area of myocardium at risk. (*Level of Evidence: C*)
- b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. (*Level of Evidence: C*)
- c. A high risk of procedure-related morbidity or mortality. (*Level of Evidence: C*)
- d. Insignificant disease (less than 50% coronary stenosis). (*Level of Evidence: C*)

e. Significant left main CAD and candidacy for CABG. (*Level of Evidence: B*)

Clinical investigations have evaluated the use of routine catheterization and PCI for patients with UA or NSTEMI and have yielded inconsistent results. TIMI-IIIb was the first trial to compare strategies of routine catheterization and revascularization in addition to medical therapy and selective use of aggressive treatment. In TIMI-IIIb, there was no difference in the incidence of death or recurrent MI at 1 year between the 2 strategies, but patients treated by the aggressive strategy experienced less angina and repeat hospitalizations for ischemia and required fewer medications (390). In the VANQWISH trial (Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital) performed by the US Veterans Administration, no difference in death or death and MI was observed between the 2 strategies at late follow-up, but the minority of patients in the aggressive strategy received revascularization, and the mortality rate for those having CABG was high (391). The FRISC II trial compared medical and revascularization approaches among patients after 6 days of low-molecular-weight heparin therapy before a decision regarding PCI (304). Those randomized to the conservative therapy only underwent PCI if they had at least 3 mm of ST-segment depression on stress testing. Compared with prior studies, patients assigned to the aggressive strategy in FRISC II experienced a 22% reduction (P equals 0.031) in the incidence of death or MI at 6 months (9.4%) compared with conservatively treated patients (12.1%). In addition, there was a significant decrease in the MI rate alone and a nonsignificantly lower mortality rate in the treated group (1.9% vs 2.9%; P equals 0.10). Symptoms of angina and hospital readmission were decreased 50% by the invasive strategy. These findings were supported by long-term follow-up from the FRISC II study that indicated that low-molecular-weight heparin and early intervention lowered the risk of death, MI, and revascularization in unstable coronary syndromes, at least during the first month of therapy. Early protective therapy could be used to reduce the risk of late events in patients waiting for definitive PCI (392). This treatment benefit was most pronounced for high-risk patients. The FRISC II trial (304) results support the use of catheterization and revascularization for selected patients with an acute coronary syndrome. The TACTICS trial randomized 2220 patients to an early invasive strategy in which cardiac catheterization and revascularization were performed 4 to 48 h after randomization or to a conservative strategy in which revascularization was reserved for those patients who developed recurrent ischemia after medical stabilization (393). All patients were treated with aspirin, heparin, beta-blockers, cholesterol-lowering therapy, and tirofiban. The primary end point, a composite of death, MI, and rehospitalization for worsening chest pain by 6 months, was lower in patients assigned to the invasive strategy (15.9% vs 19.4% in patients assigned to conservative therapy; P equals 0.0025). The rate of death or MI was also significantly reduced at 6 months in the invasive strategy arm (7.3% vs 9.5% in patients assigned

to conservative therapy; *P* less than 0.05) (393). The TIMI-TACTICS group (394) has proposed a new risk stratification. The early invasive strategy was particularly effective for patients at moderate to high risk. The greater benefits derived from PCI in the TACTICS and FRISC trials compared with the TIMI III and VANQWISH trials can be explained in part by the use of stents and GP-receptor blockers and lower periprocedural complications in the TACTICS and FRISC II trials. In several studies published to date, the use of routine invasive therapy in patients with UA/NSTEMI, accompanied by IIB/IIIa receptor antagonists, has been shown to improve survival (205,302,393,395-397). New trials such as RITA-3 (302) further demonstrate the safety and effectiveness of an early invasive strategy.

It is recognized by the Committee that the assessment of risk of unsuccessful PCI or serious morbidity or mortality must always be made with consideration of the alternative therapies available for the patient, including more intensive or prolonged medical therapy or surgical revascularization (Table 19) (302,304,390,391,393), especially in patients with UA/NSTEMI.

When CABG surgery is a poor option because of high risk due to special considerations or other organ system disease, patients otherwise in class IIB may be appropriately managed with PCI. Under these special circumstances, formal surgical consultation is recommended.

5.4. Patients With STEMI

5.4.1. General and Specific Considerations

Class I

General considerations:

1. If immediately available, primary PCI should be performed in patients with STEMI (including true posterior MI) or MI with new or presumably new left bundle-branch block who can undergo PCI of the infarct artery within 12 hours of symptom onset, if performed in a timely fashion (balloon inflation goal within 90 minutes of presentation) by persons skilled in the procedure (individuals who perform more than 75 PCI procedures per year, ideally at least 11 PCIs per year for STEMI). The procedure should be supported by experienced personnel in an appropriate laboratory environment (one that performs more than 200 PCI procedures per year, of which at least 36 are primary PCI for STEMI, and that has cardiac surgery capability). (*Level of Evidence: A*) Primary PCI should be performed as quickly as possible, with a goal of a medical contact-to-balloon or door-to-balloon time within 90 minutes. (*Level of Evidence: B*)

Specific Considerations:

2. Primary PCI should be performed for patients less than 75 years old with ST elevation or presumably new left bundle-branch block who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of

shock, unless further support is futile because of the patient's wishes or contraindications/unsuitability for further invasive care. (*Level of Evidence: A*)

3. Primary PCI should be performed in patients with severe congestive heart failure and/or pulmonary edema (Killip class 3) and onset of symptoms within 12 hours. The medical contact-to-balloon or door-to-balloon time should be as short as possible (i.e., goal within 90 minutes). (*Level of Evidence: B*)

Class IIa

1. Primary PCI is reasonable for selected patients 75 years or older with ST elevation or left bundle-branch block or who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock. Patients with good prior functional status who are suitable for revascularization and agree to invasive care may be selected for such an invasive strategy. (*Level of Evidence: B*)
2. It is reasonable to perform primary PCI for patients with onset of symptoms within the prior 12 to 24 hours and 1 or more of the following:
 - a. Severe congestive heart failure (*Level of Evidence: C*)
 - b. Hemodynamic or electrical instability (*Level of Evidence: C*)
 - c. Evidence of persistent ischemia (*Level of Evidence: C*)

Class IIb

The benefit of primary PCI for STEMI patients eligible for fibrinolysis when performed by an operator who performs fewer than 75 PCI procedures per year (or fewer than 11 PCIs for STEMI per year) is not well established. (*Level of Evidence: C*)

Class III

1. Elective PCI should not be performed in a non-infarct-related artery at the time of primary PCI of the infarct related artery in patients without hemodynamic compromise. (*Level of Evidence: C*)
2. Primary PCI should not be performed in asymptomatic patients more than 12 hours after onset of STEMI who are hemodynamically and electrically stable. (*Level of Evidence: C*)

Acute STEMI results from a severe and sudden cessation of myocardial blood flow, most commonly due to atherosclerotic-thrombotic occlusion of a major epicardial coronary artery. PCI is a very effective method for re-establishing coronary perfusion and is suitable for 90% of patients. Considerable data support the use of PCI for patients with STEMI (53,364,398). Reported rates of achieving TIMI 3 flow, the goal of reperfusion therapy, range from 70% to 90% (399). Late follow-up angiography demonstrates that 87% of infarct arteries remain patent (400). Although most studies of primary PCI have been in patients who are eligible to receive fibrinolytic therapy, considerable experience supports the

Table 19. Invasive Versus Conservative Strategies in Unstable Angina Patients

Study	Years	Ref	n	Patient Population	Treatment	Follow-Up	Results			Comments
							PCI	Medical Therapy	P	
TIMI-IIIb	1989-1992	(390)	1473	Patients 21 to 76 years of age presenting within 24 h of ischemic discomfort at rest consistent with unstable angina or non-Q-wave MI	Medical therapy (tPA vs placebo) and early invasive or conservative strategy	6 wk	16.2% combined primary end points	18.1% combined primary end points	NS	Although no difference was found in combined primary end points (death, MI, positive ETT), the early invasive strategy was associated with shorter hospital stay and lower incidence of rehospitalization
VAQWISH	1993-1996	(391)	920	Patients with an evolving MI	Invasive vs conservative	Average 23 mo	32.9% death and MI	30.3% death and MI	0.35	Fewer patients treated conservatively had death plus MI or death at hospital discharge at 1 month and at 1 year; the invasive group had a higher CABG mortality rate (11.6% vs 3.4%)
FRISC II	1996-1998	(304)	2457	Patient's ischemic symptoms in previous 48 hours accompanied by ECG changes or elevated markers	Early invasive therapy or noninvasive treatment strategy. Patients also received dalteparin or placebo for 3 months	6 mo	9.4% death or MI	12.1% death or MI	0.031	Invasive strategy was associated with 50% lower recurrent angina and hospital readmission rates
TACTICS-TIMI 18	1997-1999	(393)	2220	UA and NSTEMI with ECG changes, elevated levels of cardiac biomarkers, a history of CAD, or all 3 findings	Medical therapy (aspirin, heparin, tirofiban) and either early invasive or conservative (selectively invasive) treatment strategy	6 mo	7.3% death or MI	9.5% death or MI	Less than 0.05	Significant 22% relative risk reduction in composite end point of death, nonfatal MI, and rehospitalization
RITA-3	1997-2001	(302)	1810	Suspected cardiac chest pain at rest with documented evidence of CAD (at least 1 of the following: ECG changes, pathological Q waves, previous arteriogram)	Medical therapy and either early invasive or conservative (selectively invasive) treatment strategy; both groups received enoxaparin in addition to standard medical therapy	1 y	7.6% death or MI	8.3% death or MI	NS	Similar results for death or MI between treatment groups; significant difference in primary end point (death, MI, refractory angina) due to halving of refractory angina in the intervention group

CABG indicates coronary artery bypass graft surgery; CAD, coronary artery disease; ECG, electrocardiography; ETT, exercise treadmill test; MI, myocardial infarction; mo, month; n, number; NS, not significant; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; Ref, reference; tPA, alteplase; UA, unstable angina; wk, week; and y, year.

value of PCI for patients who may not be suitable for fibrinolytic therapy owing to an increased risk of bleeding (401).

Primary PCI has been compared with fibrinolytic therapy in 23 randomized clinical trials (361-363,378,380,381,402-415), including the SHOCK (SHould we emergently revascularize Occluded Coronaries in cardiogenic shock?) trial (366). The recommendations for primary PCI in patients with cardiogenic shock are discussed and summarized separately in Section 5.4.6. These investigations consistently demonstrate that PCI-treated patients experience lower short-term mortality rates (7.0% vs 9.0%, relative risk 0.73, 95% CI 0.62 to 0.86, *P* equals 0.0002, and 5.0% vs 7.0%, relative risk 0.70, 95% CI 0.58 to 0.85, *P* equals 0.003 excluding the SHOCK trial), fewer nonfatal reinfarctions (3.0% vs 7.0%, relative risk 0.35, 95% CI 0.27 to 0.45, *P* equals 0.0003), and fewer hemorrhagic strokes (0.05% vs 1.0%, relative risk 0.05, 95% CI 0.006 to 0.35, *P* equals 0.0001) than those treated by fibrinolysis (53), albeit with an increased risk of bleeding (7.0% vs 5.0%, RR 1.3, 95% CI 1.02 to 1.65, *P* equals 0.032). These results have been achieved in medical centers and by providers experienced in the performance of primary PCI and under circumstances in which angioplasty can be performed promptly after patient presentation. The magnitude of the treatment differences for death, nonfatal reinfarction, and stroke vary depending on whether PCI is compared with streptokinase or a fibrin-specific lytic. The short- and long-term outcomes of patients with STEMI treated by fibrinolysis versus PCI and the numbers of patients who need to be treated to prevent 1 event or to cause a harmful complication when PCI is selected instead of fibrinolysis as the reperfusion strategy are shown in Figure 5 (53,416,417).


Time from symptom onset to reperfusion is an important predictor of patient outcome. Two studies (330,418) have reported increasing mortality rates with increasing door-to-balloon times. Other studies have shown better LV function and fewer complications when reperfusion occurs before PCI (419,420). An analysis of the randomized controlled trials comparing fibrinolysis with primary PCI suggests that the mortality benefit with PCI exists when treatment is delayed by no more than 60 min (Figure 6) (421). Mortality increases significantly with each 15-minute delay in the time between arrival and restoration of TIMI-3 flow (door-to-TIMI-3 flow time), which further underscores the importance of timely reperfusion in patients who undergo primary PCI (422). Given that the door-to-needle time goal is 30 min, this Writing Committee joins the Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology (423) and the ACC/AHA STEMI Guidelines Writing Committee (332) in lowering the door-to-balloon time goal from 120 to 90 min in an attempt to maximize the benefits for reperfusion by PCI (Figure 7) (418). Importantly, after adjustment for baseline characteristics, time from symptom onset to balloon inflation is significantly correlated with 1-year mortality in patients undergoing primary PCI for STEMI (relative risk equals 1.08 for

each 30-minute delay from symptom onset to balloon inflation, *P* equals 0.04) (424).


The enthusiasm for primary PCI has led to the concept of emergency interhospital transfer for catheter-based reperfusion rather than fibrinolytic therapy in the initial hospital (425-427). Five randomized trials have enrolled 2466 patients with favorable results for PCI versus fibrinolytic therapy (378,381,407,412). Mortality was reduced with PCI (6.8% vs 9.6%, relative risk 0.69, 95% CI 0.51 to 0.92, *P* equals 0.01), as was the combined end point of death, nonfatal reinfarction, and stroke (8.5% vs 15.5%, relative risk 0.51, 95% CI 0.39 to 0.65, *P* less than 0.0001). Importantly, mean time to treatment was delayed only 44 min in these studies (Figure 8) (378,415). In contrast, first hospital door-to-balloon time, as recorded in 1346 patients undergoing hospital transfer before PCI in NRMI-4, was 185 min in the United States in 2002 (Figure 9) (428). Emergency transport in Europe is centrally organized and more efficient than in the United States (Table 20) (378,381,407,412,415). Delays in door-to-balloon time versus door-to-needle time of more than 60 min because of interhospital transfer might negate the potential mortality benefit of transfer for primary PCI over immediate intravenous fibrinolysis demonstrated in these trials (421). However, transfer of patients to PCI-capable centers should be accomplished when fibrinolytic therapy is contraindicated or unsuccessful, when cardiogenic shock ensues, when the anticipated delay is less than 60 min, or when symptoms have been present for more than 2 to 3 h (410,415). To achieve optimal results, a systems approach for rapid triage and transfer must be established. Time from first hospital door to balloon inflation in the second hospital should be as short as possible, with a goal within 90 min. Significant reductions in door-to-balloon times might be achieved by transporting patients directly to PCI centers, rather than transporting them to the nearest hospital, if interhospital transfer will subsequently be required to obtain primary PCI. Central to the success of all of the acute reperfusion strategies is a well-developed process of triage, as discussed in the STEMI guidelines (332,429).

Primary PCI with stenting has been compared with fibrinolytic therapy in 12 randomized clinical trials (366,378,380,381,407-412,415,430). These investigations demonstrate that PCI-treated patients experience lower mortality rates (5.9% vs 7.7%, OR 0.75, 95% CI 0.60 to 0.94, *P* equals 0.013), fewer reinfarctions (1.6% vs 5.1%, OR 0.31, 95% CI 0.21 to 0.44, *P* equals 0.0001), and fewer hemorrhagic strokes than those treated by fibrinolysis (53). Compared with PTCA, intracoronary stents achieve a better immediate angiographic result with a larger arterial lumen, less reclosure of the infarct-related artery, and fewer subsequent ischemic events (431-433). Primary stenting has been compared with primary angioplasty in 9 studies (64,106,433-440) (Table 21). There were no differences in mortality (3.0% vs 2.8%) or reinfarction (1.8% vs 2.1%) rates. However, subsequent target-vessel revascularization rates were lower with stenting (440).


**PCI versus Fibrinolysis:
Short Term Clinical Outcomes**



**PCI versus Fibrinolysis:
Long Term Clinical Outcomes**



**PCI versus Fibrinolysis: NNT (NNH)
Short Term Clinical Outcomes**



**PCI versus Fibrinolysis: NNT (NNH)
Long Term Clinical Outcomes**




Figure 5. Percutaneous coronary intervention vs fibrinolysis for STEMI. The short-term (4 to 6 weeks; top left) and long-term (top right) outcomes for the various end points shown are plotted for STEMI patients randomized to PCI or fibrinolysis for reperfusion in 23 trials (n=7739). Based on the frequency of events for each end point in the 2 treatment groups, the number needed to treat (NNT) or number needed to harm (NNH) is shown for the short-term (bottom left) and long-term (bottom right) outcomes. Modified with permission from Elsevier (Keeley *et al.* *The Lancet*, 2003, 361, 13-20). Note: The magnitude of the treatment differences for death, non-fatal reinfarction, and stroke vary depending on whether PCI is compared with streptokinase or a fibrin-specific lytic. For example, when primary PCI is compared with alteplase (tPA) and the SHOCK trial is excluded, the mortality rate is 5.5% vs 6.7% (OR 0.81, 95% CI 0.64 to 1.03, *P* equals 0.081). Source: Melandri. *Circulation* 2003;108:e162. CVA indicates cerebrovascular accident; Hem. Stroke, hemorrhagic stroke; MI, myocardial infarction; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; Rec. Isch, recurrent ischemia; ReMI, recurrent MI; and STEMI, ST-elevation myocardial infarction.

Preliminary reports suggest that compared with conventional BMS, DES are not associated with increased risk when used for primary PCI in patients with STEMI. Postprocedure vessel patency, biomarker release, and the incidence of short-term adverse events were similar in patients receiving SES or BMS. Thirty-day event rates of death, reinfarction, or revascularization were 7.5% versus 10.4%, respectively (*P* equals 0.4) (441).

Furthermore, the impact of IIb/IIIa platelet receptor antagonists in the setting of primary PCI has undergone considerable evaluation. In a randomized trial of stents plus abciximab compared with fibrinolysis plus abciximab in patients with STEMI, myocardial salvage and salvage index measured by technetium-99m sestamibi scintigraphy was significantly greater in the stent group (430). In a similar study

comparing primary PCI with stent plus abciximab to fibrinolysis with alteplase, infarct size was smaller and the cumulative incidence of death, reinfarction, or stroke at 6 months significantly lower in the primary PCI group (411).

However, results of studies comparing primary PCI with stents with or without IIb/IIIa platelet receptor antagonists have been less consistent. In the CADILLAC trial, a composite of death, reinfarction, disabling stroke, and ischemia-driven target-vessel revascularization was similar in patients treated with stents with or without abciximab (64). Yet, in a similar randomized comparison of stent plus abciximab versus stent alone in patients with STEMI (ADMIRAL trial; Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up), a composite of death, reinfarction, or urgent target-




Figure 6. PCI versus fibrinolysis with fibrin-specific agents: is timing (almost) everything? PCI indicates percutaneous coronary intervention. Modified with permission from Nallamothu and Bates. *Am J Cardiol* 2003;92:824-6 (421).

vessel revascularization at 30 days occurred significantly less often in the abciximab group than in the control group (6.0% vs 14.6%, P equals 0.01), a difference that was sustained at 6 months of follow-up (442). The less favorable comparable clinical outcomes in patients treated with abciximab in the CADILLAC trial compared with those in the ADMIRAL trial have been attributed to the earlier administration of abciximab in the latter trial. The results of a pooled analysis of these 2 trials plus 3 similar trials (RAPPORT,

ISAR-2, and ACE) (443-445) suggest that early (before coronary angiography) administration of abciximab will be associated with the most favorable clinical outcomes (446).

PCI appears to have its greatest mortality benefit in high-risk patients. In patients with cardiogenic shock, an absolute 9% reduction in 30-day mortality with mechanical revascularization instead of immediate medical stabilization was reported in the SHOCK trial (366) (see Section 5.4.6, PCI for Cardiogenic Shock). In NRMI-II, patients with HF had a




Figure 7. Relationship between 30-day mortality and time from study enrollment to first balloon inflation. Patients assigned to angioplasty in whom angioplasty was not performed are also shown. n indicates number of patients; and PTCA, percutaneous transluminal coronary angioplasty. Reprinted with permission from Berger *et al.* *Circulation* 1999;100:14-20 (418).




Figure 8. Comparison of elapsed time to fibrinolysis versus primary PCI. Time is presented as a continuous variable in minutes on the horizontal axis. For DANAMI-2, times reflect components of delay from symptom onset to randomization (vertical bar) and are further separated according to whether patients presented at community referral hospitals or those equipped for primary PCI. For those patients randomized to PCI at a referral hospital, the 3 components of delay after randomization are related to duration of stay at referral hospital, time for transport to PCI hospital, and delay from arrival at PCI hospital to balloon inflation. Lysis indicates fibrinolysis; PCI, percutaneous coronary intervention; Rand, randomization; SK, streptokinase; and Transp, transportation. Top graph reprinted with permission from Anderson *et al.* *N Engl J Med* 2003;349:733-42 (378). Copyright 2003 Massachusetts Medical Society. All rights reserved. Bottom graph reprinted from Widimsky *et al.* *Eur Heart J* 2003;24:94-104 (415) with permission from the European Society of Cardiology.

33% relative risk reduction with primary PCI compared with a 9% relative risk reduction with fibrinolytic therapy (447-449). Primary PCI in patients with anterior STEMI reduces mortality compared with fibrinolytic therapy, but there is no difference in patients with nonanterior STEMI (450,451).

Despite the evidence supporting primary PCI in the treatment of STEMI, there is serious concern that a routine policy of primary PCI for patients with STEMI will result in unacceptable delays in achieving reperfusion in a substantial number of patients and less than optimal outcomes if performed by less experienced operators. The mean time delay for PCI instead of fibrinolysis in the randomized trials was only 40 min (364). Strict performance criteria must be mandated for primary angioplasty programs so that excessive

delays in reperfusion and performance by low-volume or poor-outcome operators/centers do not occur. The physicians, nursing, and technical catheterization laboratory staff must be experienced in handling acutely ill patients, must be skilled in all aspects of interventional equipment and procedures, and must participate in a 24-hours-per-day, 365-days-per-year call schedule. Interventional cardiologists and centers should strive for 1) balloon dilation within 90 min of admission and diagnosis of STEMI (452); 2) TIMI 2 to 3 flow attained in more than 90% of patients; 3) emergency CABG rate less than 2% among all patients undergoing the procedure; 4) actual performance of PCI in 85% of patients brought to the laboratory; and 5) a risk-adjusted in-hospital mortality rate less than 7% in patients without cardiogenic

1st Door to Data:
9 min. (4-16 min.)

Data (Transport) to Cath Lab Arrival:
132 min. (88-219 min.)

Cath Lab to Balloon:
37 min. (28-50 min.)

9	132	37
---	-----	----

Total Door 1 to Balloon Time: 185 minutes (137-276 minutes)
Percent of Patients with Door to Balloon Time Less Than 90 Minutes: 3.0%

Sample Size: 1,346; Time Period: January 2002 – December 2002

Figure 9. Door-to-balloon times: patients transferred in NRM1 4. Data are expressed in minutes as median time (25th percentile to 75th percentile). Cath Lab indicates catheterization laboratory. Modified, with permission, from NRM1-4 Investigators: The National Registry of Myocardial Infarction-4 Quarterly Report. Genentech, South San Francisco, Calif; March, 2003;2 (428).

shock. Otherwise, the focus of treatment should be the early use of fibrinolytic therapy, with further referral to PCI when indicated.

Evidence: C)

c. Evidence of persistent ischemia. (Level of Evidence: C)

5.4.2. PCI in Fibrinolytic-Ineligible Patients

Class I

Primary PCI should be performed in fibrinolytic-ineligible patients who present with STEMI within 12 hours of symptom onset. (Level of Evidence: C)

Class IIa

It is reasonable to perform primary PCI for fibrinolytic-ineligible patients with onset of symptoms within the prior 12 to 24 hours and 1 or more of the following:

- a. Severe congestive heart failure. (Level of Evidence: C)**
- b. Hemodynamic or electrical instability. (Level of Evidence: C)**

Randomized, controlled clinical trials evaluating the outcome of PCI for patients who present with STEMI but who are ineligible for fibrinolytic therapy have not been performed. Nevertheless, these patients are at increased risk for mortality (453), and there is a general consensus that PCI is an appropriate means for achieving reperfusion in those who cannot receive fibrinolytic drugs because of an increased risk of bleeding (401,454-456). Other reasons also exclude STEMI patients from fibrinolytic therapy, and the outcome of PCI in these patients may differ from those eligible for fibrinolytic therapy. Few data are available to characterize the value of primary PCI for this subset of STEMI patients (Table 22) (332,401).

Table 20. Transport of Patients With STEMI for Primary PCI

Study (Reference)	Number Transported	Distance, km	Time Between Randomization and First Balloon Inflation, min
Vermeer et al. (412)	75	25 to 50	85*
PRAGUE-1 (407)	101	5 to 74	80*
AIR-PAMI (381)	71	52*	155†
PRAGUE-2 (415)	429	5 to 120	97*
DANAMI-2 (378)	567	3 to 150	90†
Total	1243	3 to 150	

min indicates minutes; km, kilometer; PCI, percutaneous coronary intervention; and STEMI, ST-elevation myocardial infarction.

*Mean.

†Median.

Table 21. Studies Comparing PTCA with Stents in Acute Myocardial Infarction

Study	Year	Follow-Up (mo)	n, Stent/PTCA	Success (%)	Early Events (0-30 days), %					Late Events (Cumulative) %				
					Crossover	Death	Reinfarction	TVR	Any Event	Restenosis	Death	Reinfarction	TVR	Any Event
FRISCO (434)	1998	6	75/75	99*	NA	0/0	1.3/2.6	1.3/1.2	3/15	17/43	1/0	1/3	7/25	13/32
GRAMI (438)	1998	12	52/52	98/94.2	25*	3.8/7.6	0/7.6	0/5.7	3.8/19.2	NA	NA	NA	14/21	17/35
Surapanata et al. (439)	2001	4	112/115	98/96	2/13	2/3	1/4	NA	NA	NA	3/3	1/9	13/34	16/38
PASA (436)	1999	12	67/69	99/97	1/10	3/7	3/4	6/13	6/19	17/37.5	5/9	NA	NA	22/49
Step-PAMI (433)	1999	6	452/448	89.4/92.7	1.5/15	3.5/1.8	0.4/1.1	1.8/3.8	4.6/5.8	20.3/33.5	4.2/2.7	2.4/2.2	7.7/1.7	12.6/20.1
STEP-TIMI-2 (435)	2000	12	101/110	95/94.5	3/36.4	1/0	4/3.6	5/5.4	5/5.4	25.3/39.6	3/1.9	4.0/5.5	17.8/28.2	12.9/20.0
PSAAMI (437)	2001	710 plus or minus 282 days	44/44	NA	1/27	2/5	0/2	0/9	5/11	24/61	9/18	2/9	16/34	23/43
CALLACA (64)	2002	6	512/518	94.5/94.7	16†	2.2/2.5	1.0/0.8	3.2/5.6	5.7/8.3	22.2/40.8§	3.0/4.5	1.6/1.8	8.3/15.7	11.5/20.0
CALLACb (64)	2002	6	524/528	96.9/96.1	14‡	2.7/1.1	0.8/0.8	1.6/3.4	4.4/4.8	NA	4.2/2.5	2.2/2.7	5.2/13.8	10.2/16.5

n indicates number of patients; NA, data not gathered for that category; and TVR, target-vessel revascularization. All data are presented as values for stent/PTCA groups.

CALLACA = Stent alone and PTCA alone arms.

CALLACb = Stent plus abciximab and PTCA plus abciximab arms.

*Success rate of 99% before randomization.

†Values for crossovers from PTCA to stent treatment.

‡Values for crossovers from PTCA or stenting alone to combination with abciximab treatment.

§7-month follow-up; n = 636; independent of abciximab use.

Modified from Al SJ et al. JAMA 2000;284:1828-36 (106).

Table 22. Contraindications and Cautions for Fibrinolysis in STEMI*

Absolute contraindications

- Any prior intracranial hemorrhage
- Known structural cerebral vascular lesion (e.g., AVM)
- Known malignant intracranial neoplasm (primary or metastatic)
- Ischemic stroke within 3 months, EXCEPT acute ischemic stroke within 3 hours
- Suspected aortic dissection
- Active bleeding or bleeding diathesis (excluding menses)
- Significant closed head or facial trauma within 3 months

Relative contraindications

- History of chronic severe, poorly controlled hypertension
- Severe uncontrolled hypertension on presentation (SBP greater than 180 mm Hg or DBP greater than 110 mm Hg)[†]
- History of prior ischemic stroke greater than 3 months, dementia, or known intracranial pathology not covered in contraindications
- Traumatic or prolonged (greater than 10 minutes) CPR or major surgery (less than 3 weeks)
- Recent (within 2 to 4 weeks) internal bleeding
- Noncompressible vascular punctures
- For streptokinase/anistreplase: prior exposure (more than 5 days ago) or prior allergic reaction to these agents
- Pregnancy
- Active peptic ulcer
- Current use of anticoagulants: the higher the INR, the higher the risk of bleeding

AVM indicates arteriovenous malformation; CPR, cardiopulmonary resuscitation; DBP, diastolic blood pressure; INR, international normalized ratio; SBP, systolic blood pressure; and STEMI, ST-elevation myocardial infarction.

*Viewed as advisory for clinical decision making and may not be all inclusive or definitive.

[†]Could be an absolute contraindication in low-risk patients with STEMI (see Section 6.3.1.6.3.2 in the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, available at: <http://www.acc.org/clinical/guidelines/stemi/index.pdf>).

Reprinted from Antman *et al.* J Am Coll Cardiol 2004;44:e1-e211 (332).

5.4.3. Facilitated PCI

Class IIb

Facilitated PCI might be performed as a reperfusion strategy in higher-risk patients when PCI is not immediately available and bleeding risk is low. (Level of Evidence: B)

Facilitated PCI refers to a strategy of planned immediate PCI after an initial pharmacological regimen such as a full-dose fibrinolytic, a half-dose fibrinolytic, a GP IIb/IIIa inhibitor, or a combination of reduced-dose fibrinolytic therapy and a platelet GP IIb/IIIa inhibitor. Facilitated PCI should be differentiated from primary PCI without fibrinolysis; from primary PCI with a GP IIb/IIIa inhibitor started at the time of PCI; from immediate, early, or delayed PCI after successful full-dose fibrinolysis; and from rescue PCI after unsuccessful fibrinolysis. Potential advantages include earlier time to reperfusion, improved patient stability, greater procedure success rates, higher TIMI flow rates, and improved survival rates (419,420,442,457-460). However, preliminary studies have not demonstrated any benefit in reducing infarct

size or improving outcomes. It is unlikely that this strategy would be beneficial in low-risk patients.

A strategy of facilitated PCI holds promise in higher-risk patients when PCI is not immediately available. Potential risks include increased bleeding complications, especially in older patients, and potential limitations include added cost. Several randomized trials of facilitated PCI with a variety of pharmacological regimens are in progress.

5.4.4. PCI After Failed Fibrinolysis (Rescue PCI)

Class I

- 1. Rescue PCI should be performed in patients less than 75 years old with ST elevation or left bundle-branch block who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock, unless further support is futile because of the patient's wishes or contraindications/unsuitability for further invasive care. (Level of Evidence: B)**
- 2. Rescue PCI should be performed in patients with severe congestive heart failure and/or pulmonary edema (Killip class 3) and onset of symptoms within 12 hours. (Level of Evidence: B)**

Class IIa

- 1. Rescue PCI is reasonable for selected patients 75 years or older with ST elevation or left bundle-branch block or who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock. Patients with good prior functional status who are suitable for revascularization and agree to invasive care may be selected for such an invasive strategy. (Level of Evidence: B)**
- 2. It is reasonable to perform rescue PCI for patients with 1 or more of the following:**
 - a. Hemodynamic or electrical instability. (Level of Evidence: C)**
 - b. Evidence of persistent ischemia. (Level of Evidence: C)**

Class III

Rescue PCI in the absence of 1 or more of the above class I or IIa indications is not recommended. (Level of Evidence: C)

PCI Immediately After Failed Fibrinolysis

Intravenous fibrinolytic therapy successfully restores antegrade coronary flow at 90 min in 50% to 80% of patients with acute STEMI (461). In those in whom it is unsuccessful, antegrade coronary flow can usually be restored with PCI. Several studies have demonstrated the marked beneficial effect of infarct-related artery patency (obtained via endogenous, pharmacological, or mechanical recanalization) on survival in patients with acute STEMI (462). Survivors of STEMI with a patent infarct-related artery demonstrated at 90 min after treatment have an improved long-term outcome

compared with those with an occluded infarct-related artery, even when LV systolic function is similar (463,464). The REACT trial (Rapid Early Action for Coronary Treatment) was a randomized trial comparing medical therapy, immediate PCI, or repeat fibrinolytic in patients previously treated with fibrinolytic therapy. Preliminary data at 30 days demonstrated a significant advantage to rescue PCI [A.H. Gershlick, oral presentation, American Heart Association Scientific Sessions, New Orleans, LA, November 2004.]

Rescue (also known as salvage) PCI is defined as PCI within 12 h after failed fibrinolysis for patients with continuing myocardial ischemia. Rescue PCI has resulted in higher rates of early infarct-artery patency, improved regional infarct-zone wall motion, and greater freedom from adverse in-hospital clinical events compared with a deferred PCI strategy or medical therapy (465). The Randomized Evaluation of Rescue PCI with Combined Utilization Endpoints (RESCUE) trial demonstrated a reduction in rates of in-hospital death and combined death and HF that was maintained up to 1 year after study entry for patients presenting with anterior wall STEMI who failed fibrinolytic therapy when performed a mean of 8 h after symptom onset (466,467). Improvement in TIMI grade flow from 2 to 3 may offer additional clinical benefit. Similar data are not available for patients with nonanterior STEMI.

A major problem in adopting a strategy of rescue PCI lies in the limitation of accurate identification of patients in whom fibrinolytic therapy has not restored antegrade coronary flow. Unless unsuccessful fibrinolysis is recognized and corrected quickly (within 3 to 6 h of onset of symptoms), salvage of ischemic myocardium is unlikely. Unfortunately, clinical markers of reperfusion, such as relief of ischemic-type chest discomfort, partial resolution of ST-segment elevation, and reperfusion arrhythmias, have limited predictive value in identifying failure of fibrinolysis (468). Immediate catheterization of all patients after fibrinolytic therapy to identify those with an occluded infarct-related artery in a prior era in which the practice of PCI was less mature failed to show a significant benefit and was associated with bleeding complications. However, there was no specific study using stents and current pharmacotherapy. This strategy is being re-evaluated in clinical trials testing facilitated PCI in the contemporary PCI setting.

Even in the patient with documented failure of fibrinolysis, rescue PCI has limitations. First, because extensive myocardial necrosis occurs when coronary occlusion has been present for more than 3 h (469), PCI may not salvage a substantial amount of myocardium, considering the time delay associated with presentation of the patient to the hospital after onset of symptoms, infusion of the fibrinolytic agent, recognition of failed fibrinolysis, and subsequent initiation of PCI. Second, rescue PCI fails to reestablish antegrade coronary flow in about 10% of patients, and reocclusion of the infarct-related artery occurs in as many as 20% of the remainder (470), although GP IIb/IIIa inhibitors and stent implantation may have improved these results. Third, unsuccessful rescue PCI is associated with a high mortality (471,472). Finally,

coronary reperfusion occurs over the subsequent h after fibrinolytic therapy in many patients. Although infarct-related artery patency is achieved in only 50% to 85% of patients 90 min after fibrinolytic therapy, it rises to 90% by 24 h (473). Such "late" reperfusion may improve survival without the risk of invasive procedures coupled with fibrinolytic therapy. Confounding the issue, both fibrinolysis and PCI may successfully restore flow in the epicardial artery but fail to improve microvascular perfusion.

Hours to Days After Failed Fibrinolysis

Patency of the infarct-related artery is an important predictor of mortality in survivors of STEMI (462,463,474). Compared with those with a patent infarct artery, survivors of STEMI with a persistently occluded artery after fibrinolysis, PCI, or no reperfusion therapy have 1) increased LV dilatation (475), 2) a greater incidence of spontaneous and inducible ventricular arrhythmias (476), and 3) a poorer prognosis (477). On the basis of observational and experimental data, it has been hypothesized that infarct artery patency may favorably influence LV remodeling and electrical stability, even if accomplished at a time when salvage of ischemic myocardium is unlikely (i.e., more than 12 h to days after coronary artery occlusion). Five small randomized trials, which enrolled a total of 562 patients, have directly tested the hypothesis that mechanical opening of persistent total occlusions late after MI will improve long-term LV remodeling and clinical outcomes (the late open artery hypothesis). Most studies enrolled a combination of patients, including those who had failed fibrinolysis and those who had not received reperfusion therapy (478-480), with a range from almost no fibrinolytic therapy (481) to fibrinolytic therapy in nearly all patients (482). There was wide variation in the effect of routine PCI compared with medical therapy only on LV size and function. Most studies showed no significant differences between the treatment groups (478,479). One single-center study of 83 patients with LAD occlusions reported improved LV volumes and clinical outcomes (composite of HF, MI, and death) at 6 months in the PCI group (481). In contrast, a multicenter study of 66 patients with LAD occlusions reported significantly worse LV remodeling, with progressive LV dilation at 1 year and more clinical events in the PCI group than in those assigned to optimal medical therapy alone (482). The latter included very high rates of beta-blocker and angiotensin converting enzyme inhibitor use. The largest multicenter study, DECOPI (DEobstruction COronaire en Post-Infarctus), enrolled 212 patients and reported no difference in the primary end point, the composite of death, ventricular tachycardia, and MI at 6 months (483). Stents were used in 80% of patients in the PCI group, and GP IIb/IIIa antagonists were used in 9%. The study reached less than one third of the target sample size and was severely underpowered, as were all the other studies, to assess clinical events.

Selection of patients for revascularization based on viability testing has gained a great deal of investigational support, i.e., delayed enhancement or low-dose dobutamine cardiac

MRI assessment. If viability is shown, outcomes are excellent, whereas if transmural MI is present, it is not, and revascularization is not recommended (484-486).

There are no convincing data to support the routine use of late adjuvant PCI days after failed fibrinolysis or for patients who do not receive reperfusion therapy. Nevertheless, this is being done in some STEMI patients as an extension of the invasive strategy for NSTEMI patients. The Occluded Artery Trial (OAT) is currently randomizing patients to test whether routine PCI days to weeks after MI improves long-term clinical outcomes in asymptomatic high-risk patients with an occluded infarct-related artery (487).

5.4.5. PCI After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion

Class I

1. **In patients whose anatomy is suitable, PCI should be performed when there is objective evidence of recurrent MI. (Level of Evidence: C)**
2. **In patients whose anatomy is suitable, PCI should be performed for moderate or severe spontaneous or provokable myocardial ischemia during recovery from STEMI. (Level of Evidence: B)**
3. **In patients whose anatomy is suitable, PCI should be performed for cardiogenic shock or hemodynamic instability. (Level of Evidence: B)**

Class IIa

1. **It is reasonable to perform routine PCI in patients with LV ejection fraction less than or equal to 0.40, HF, or serious ventricular arrhythmias. (Level of Evidence: C)**
2. **It is reasonable to perform PCI when there is documented clinical heart failure during the acute episode, even though subsequent evaluation shows preserved LV function (LV ejection fraction greater than 0.40). (Level of Evidence: C)**

Class IIb

PCI might be considered as part of an invasive strategy after fibrinolytic therapy. (Level of Evidence: C)

PCI Immediately After Successful Fibrinolysis

In early studies, asymptomatic patients undergoing routine PCI of the stenotic infarct-related artery immediately after successful fibrinolysis showed no benefit with regard to salvage of jeopardized myocardium or prevention of reinfarction or death. In addition, in some studies, this approach was associated with an increased incidence of adverse events, including bleeding, recurrent ischemia, emergency CABG surgery, and death (488-491). However, these studies have not been repeated in the modern interventional era with improved equipment, improved antiplatelet and anticoagulant therapy, and coronary stents. Notwithstanding this, rou-

tine PCI immediately after fibrinolysis may increase the chance for vascular complications at the catheterization access site and hemorrhage into the infarct-related vessel wall (491).

Hours to Days After Successful Fibrinolysis

It was initially suggested that elective PCI of the stenotic infarct-related artery hours to days after fibrinolysis might allow sufficient time for development of a more stable hemostatic milieu at the site of previous thrombotic occlusion. In this setting, PCI would be safer and more effective in reducing the incidence of reocclusion and improving survival. Two large randomized, prospective trials from an earlier PCI era tested this hypothesis, with both concluding that 1) there are fewer complications if PCI is delayed for several days after fibrinolytic therapy, and 2) routine PCI in the absence of spontaneous or provokable ischemia does not improve LV function or survival (226,489,490,492). Thus, in unselected patients receiving fibrinolytic therapy, PCI of the stenotic infarct-related artery in the absence of evidence of recurrent ischemia within 48 h did not appear to be beneficial.

Great improvements in equipment, operator experience, and adjunctive pharmacotherapy have increased PCI success rates and decreased complications. More recently, the invasive strategy for patients with NSTEMI has been given a class I recommendation by the ACC/AHA 2002 Guideline Update for the Management of Patients With UA/NSTEMI (493). Patients with STEMI are increasingly being treated similarly as an extension of this approach. Although 7 published reports (474,480,494-498) support this strategy, randomized studies similar to those in NSTEMI are needed.

One study supports the policy of performing catheterization and subsequent revascularization for patients who do have spontaneous or inducible angina after STEMI. The DANAMI trial (499) randomly assigned 1008 survivors of a first acute MI treated with fibrinolytic therapy within 12 h of onset of symptoms to catheterization and subsequent revascularization or standard medical therapy if they showed evidence of spontaneous or inducible angina. Those who underwent revascularization had less UA and fewer nonfatal MIs during a 2.5-year period of follow-up than those patients randomly assigned to medical treatment only (18% and 5.6% vs 30% and 10.5%, respectively). Among 500 patients undergoing fibrinolysis for STEMI, the GRACIA-1 (randomized trial comparing stenting within 24 hours of thrombolysis versus ischemia-guided approach to thrombolysed acute myocardial infarction with ST elevation) trial compared a strategy of angiography and intervention within 6 to 24 h of fibrinolysis to an ischemia-guided conservative approach for intervention. Eighty percent of patients assigned to angiography and intervention underwent stenting of the culprit artery compared with 20% in the ischemia-guided group. At 1 year, patients in the invasive group had a lower frequency of the primary end point (death, reinfarction, or revascularization; 9% vs 21%, P equals 0.008), and they tended to have a reduced rate of death or reinfarction (7% vs 12%, P equals

0.07). In the angiography and intervention group, 81% had TIMI-3 flow before PCI was performed (494).

Days to Weeks After Successful Fibrinolysis

Continued thrombus lysis and remodeling of the infarct artery stenosis occur over the days to weeks after successful fibrinolysis, which makes the underlying residual coronary stenosis more stable and less prone to rethrombosis and reocclusion. Thus, a delay in performing PCI for days to weeks after fibrinolysis might improve survival, even though earlier routine PCI does not. To date, there have not been adequately sized trials to evaluate this treatment strategy. Two older, small, randomized trials (488,500) demonstrated similar LV function, rates of reinfarction, and mortality in patients randomized to PCI or conservative therapy.

5.4.6. PCI for Cardiogenic Shock

Class I

Primary PCI is recommended for patients less than 75 years old with ST elevation or left bundle-branch block who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock, unless further support is futile because of the patient's wishes or contraindications/unsuitability for further invasive care. (Level of Evidence: A)

Class IIa

Primary PCI is reasonable for selected patients 75 years or older with ST elevation or left bundle-branch block who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock. Patients with good prior functional status who are suitable for revascularization and agree to invasive care may be selected for such an invasive strategy. (Level of Evidence: B)

Observational studies support the value of PCI for patients who develop cardiogenic shock in the early hours of MI. For patients who do not have mechanical causes of shock, such as acute mitral regurgitation or septal or free wall rupture, mortality among those having PCI is lower than among those treated by medical means (366). However, undergoing cardiac catheterization alone, with or without PCI, is associated with a lower mortality because of patient selection bias (501).

Two randomized clinical trials (366,502) have further clarified the role of emergency revascularization in STEMI complicated by cardiogenic shock. Both showed a statistically insignificant, but clinically important, absolute 9% reduction in 30-day mortality. In the SHOCK trial (366), the survival curves continued to progressively diverge such that at 6 months and 1 year, there was a significant mortality reduction with emergency revascularization (53% vs 66%, P less than 0.03) (503). The prespecified subgroup analysis of patients less than 75 years old showed an absolute 15%

reduction in 30-day mortality (P less than 0.02), whereas there was no apparent benefit for the small cohort (n equals 56) of patients more than 75 years old. These data strongly support the approach that patients younger than 75 years with STEMI complicated by cardiogenic shock should undergo emergency revascularization and support measures. Three registries (504-506) have demonstrated a marked survival benefit for elderly patients who are clinically selected for revascularization (approximately 1 of 5 patients), so age alone should not disqualify a patient for early revascularization (see Section 3.5.9).

Several additional discussions elsewhere in this guideline are important to consider in these patients. Intra-aortic balloon pump support or ventricular assist devices can stabilize hemodynamics so that revascularization procedures can be performed (see Section 3.5.8). Post hoc analyses (507-509) have suggested that GP IIb/IIIa inhibitors may reduce mortality, but the studies are limited by lower than expected mortality rates, larger than expected mortality reduction, and small sample sizes. Although PCI in a noninfarct artery is not recommended in stable patients, it can be beneficial in hemodynamically compromised patients if the stenotic artery perfuses a large area of myocardium and the procedure can be performed efficiently. In patients with significant left main disease or severe 3-vessel disease and without right ventricular infarction or major comorbidities such as renal insufficiency or severe pulmonary disease, CABG can be considered as the revascularization strategy (Figure 10) (510).

5.4.7. PCI in Selected Patient Subgroups

5.4.7.1. Young and Elderly Postinfarct Patients

Although not supported by randomized trials, routine cardiac catheterization after fibrinolytic therapy for STEMI has been a frequently performed strategy in all age groups. Young patients (less than 50 years old) often undergo cardiac catheterization after fibrinolytic therapy owing to a "perceived need" to define coronary anatomy and thus establish psychological as well as clinical outcomes. In contrast, older patients (greater than 75 years of age) have higher in-hospital and long-term mortality rates and enhanced clinical outcomes when treated with primary PCI (511-514). In addition, patients thought to be candidates for implantable cardioverter-defibrillator placement and those with small infarcts may undergo cardiac catheterization for further evaluation after STEMI.

In a secondary analysis of the TIMI-IIB study that compared angiographic findings and clinical outcomes among 841 young (aged less than 50 years) and 859 older (aged 65 to 70 years) patients randomly assigned to an invasive or conservative post-lytic management strategy (515), the younger patients assigned to the invasive strategy commonly had insignificant (i.e., less than 60% diameter stenosis) and single-vessel CAD. Severe 3-vessel or left main coronary disease findings were infrequent (3-vessel incidence, 4%; left main, 0%). Fatal and nonfatal MI and death through-




Figure 10. Recommendations for initial reperfusion therapy when cardiogenic shock complicates STEMI. Early mechanical revascularization with PCI/CABG is a Class I recommendation for candidates less than 75 years of age with ST elevation or left bundle-branch block who develop shock less than 36 hours from STEMI and in whom revascularization can be performed within 18 hours of shock, and it is a Class IIa recommendation for patients 75 years of age or older with the same criteria. Eighty-five percent of shock cases are diagnosed after initial therapy for STEMI, but most patients develop shock within 24 hours. IABP is recommended when shock is not quickly reversed with pharmacological therapy, as a stabilizing measure for patients who are candidates for further invasive care. Dashed lines indicate that the procedure should be performed in patients with specific indications only. Recommendations for staged CABG and PCI are discussed in the text, as are definitions of moderate and severe 3-vessel CAD. CABG indicates coronary artery bypass graft surgery; CAD, coronary artery disease; IABP, intra-aortic balloon pump; IRA, infarct-related artery; and STEMI, ST-elevation myocardial infarction. Modified with permission from Hochman. *Circulation* 2003;107:2998-3002 (510).

out the first year after study entry were also infrequent. There were no differences in the rates of in-hospital recurrent ischemia, reinfarction, or death among patients assigned to the conservative strategy of selective cardiac angiography and coronary revascularization compared with an invasive strategy, which consisted of routine post-lytic coronary angiography. Compared with younger patients, older patients had a higher prevalence of multivessel CAD (i.e., 44%) and higher 42-day rates of reinfarction and death.

In spite of these observations, there was no difference in the 42-day rates of reinfarction or death among the older patient subgroup, regardless of the post-lytic management strategy. The TIMI-II data of younger and older infarct patients are consistent with the overall results of other randomized trials of fibrinolysis/PTCA. More recent studies have examined PCI compared with fibrinolysis in young and elderly patients. The Primary Angioplasty in Myocardial Infarction (PAMI) investigators reviewed 3362 patients with ST-elevation MI enrolled in the various PAMI trials. All underwent primary angioplasty. Hospital mortality was higher for older patients, but the improvement in survival was also significant. Patients with high-risk infarction, including those with age greater than 70 years, had an improved out-

come when treated with primary PTCA compared with fibrinolysis (512). In a review of more than 37 000 patients with STEMI from a national cohort of the Medicare database, after age adjustment, fibrinolytic therapy was not associated with a better 30-day survival than no therapy, whereas primary angioplasty was (OR 0.79, 95% CI 0.66 to 0.94). The benefit of primary angioplasty was noted at 1 year as well (513). In the GUSTO-IIB (Global Use of Strategies to Open occluded coronary arteries in acute coronary syndromes) angioplasty study, 1138 patients were randomized to receive primary angioplasty or fibrinolytic therapy. Irrespective of treatment, the risk of hospital mortality increased with age. For each 10-year increment in patient age, outcome was improved with angioplasty compared with fibrinolytic therapy. After adjustment for baseline characteristics, each increment of 10 years of age increased the risk of death or MI by a factor of 1.3 (95% CI 1.04 to 1.76, *P* equals 0.022). Advancing age was found to be associated with worse outcomes, and the risks increased in proportion to age. Primary angioplasty improved outcome compared with fibrinolysis but was not incrementally better in older than in younger patient groups (514). Given the current data, with the exception of patients presenting with cardiogenic shock, use of

PCI should be determined by clinical need without special consideration of age.

5.4.7.2. Patients With Prior MI

A prior MI is an independent predictor of death, reinfarction, and need for urgent coronary bypass surgery (516). In fibrinolytic trials, 14% to 20% of enrolled patients had a history of prior MI (490,517,518), and patients with prior MI have higher rates of reinfarction after fibrinolytic therapy (519).

In the TIMI-II study, patients with a history of prior MI had a higher 42-day mortality (8.8% vs 4.3%; *P* less than 0.001), higher prevalence of multivessel CAD (60% vs 28%; *P* less than 0.001), and a lower LV ejection fraction (42% vs 48%; *P* less than 0.001) than patients with a first MI (520). Among patients assigned to the conservative post-lytic strategy, those with a prior MI had a significantly higher 42-day mortality than patients with a first MI (11.5% vs 3.5%; *P* less than 0.001), whereas in the invasive strategy, the mortality outcome was essentially the same in the 2 patient groups. Mortality tended to be lower among patients with a prior MI undergoing the invasive versus the conservative strategy, a benefit that persisted up to 1 year after study entry (492).

In a registry involving almost 12 000 patients with acute coronary syndromes, with and without ST-segment elevation, a history of prior MI was noted in almost one third of patients. There was no significant increase in relative risk for hospital mortality in this group (521). Some analyses of predictors of mortality for angioplasty after fibrinolytic therapy have found relatively little importance for prior infarction and emphasized the much greater importance of time delays in achieving reperfusion among patients with failed fibrinolysis (418).

Given the above findings and current practice, PCI should be based on clinical need. The presence of prior MI places the patient in a higher-risk subset and should be considered in the PCI decision.

5.5. Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery

Class I

1. **When technically feasible, PCI should be performed in patients with early ischemia (usually within 30 days) after CABG. (Level of Evidence: B)**
2. **It is recommended that distal embolic protection devices be used when technically feasible in patients undergoing PCI to saphenous vein grafts. (Level of Evidence: B)**

Class IIa

1. **PCI is reasonable in patients with ischemia that occurs 1 to 3 years after CABG and who have preserved LV function with discrete lesions in graft conduits. (Level of Evidence: B)**
2. **PCI is reasonable in patients with disabling angina secondary to new disease in a native coronary circulation after CABG. (If angina is not typical, objective**

evidence of ischemia should be obtained.) (Level of Evidence: B)

3. **PCI is reasonable in patients with diseased vein grafts more than 3 years after CABG. (Level of Evidence: B)**
4. **PCI is reasonable when technically feasible in patients with a patent left internal mammary artery graft who have clinically significant obstructions in other vessels. (Level of Evidence: C)**

Class III

1. **PCI is not recommended in patients with prior CABG for chronic total vein graft occlusions. (Level of Evidence: B)**
2. **PCI is not recommended in patients who have multiple target lesions with prior CABG and who have multivessel disease, failure of multiple SVGs, and impaired LV function unless repeat CABG poses excessive risk due to severe comorbid conditions. (Level of Evidence: B)**

5.5.1. Early Ischemia After CABG

Recurrent ischemia early (less than 30 days) postoperatively usually reflects graft failure, often secondary to thrombosis (522-524), and may occur in both saphenous vein and arterial graft conduits (525). Incomplete revascularization and unbypassed native vessel stenoses or stenoses distal to a bypass graft anastomosis may also precipitate recurrent ischemia. Urgent coronary angiography is indicated to define the anatomic cause of ischemia and to determine the best course of therapy. Emergency PCI of a focal graft stenosis (venous or arterial) or recanalization of an acute graft thrombosis may successfully relieve ischemia in the majority of patients. Balloon dilatation across suture lines has been accomplished safely within days of surgery (526-528). Intracoronary fibrinolytic therapy should be administered with caution during the first week postoperatively (529-532), and if required, residual thrombus may be "targeted" in low doses through a local drug delivery system. Conversely, mechanical thrombectomy with newer catheter technologies may be effective without the attendant risk of fibrinolysis (533). Adjunctive therapy with abciximab for percutaneous intervention during the first week after bypass surgery has been limited but intuitively may pose less risk for hemorrhage than fibrinolysis. Because flow in vein graft conduits is pressure dependent, IABP support should be considered in the context of systemic hypotension or severe LV dysfunction. If feasible, PCI of both bypass graft and native vessel offending stenoses should be attempted, particularly if intracoronary stents can be deployed successfully.

When ischemia occurs 1 to 12 months after surgery, the cause is usually perianastomotic graft stenosis. Distal anastomotic stenoses (both arterial and venous) respond well to balloon dilation alone and have a more favorable long-term prognosis than stenoses involving the midshaft or proximal vein graft anastomosis (250,251,534-537). Midshaft vein graft stenoses occurring during this time frame are usually

due to intimal hyperplasia. Restenosis may be less frequent and event-free survival may be enhanced after angioplasty of SVGs dilated within 6 months of surgery compared with grafts of older age. The immediate results of PCI in midshaft ostial or distal anastomotic vein graft stenoses may be enhanced by coronary stent deployment (537,538). Ablative technologies such as directional atherectomy or excimer laser coronary angioplasty may facilitate angioplasty and stent deployment in patients with aorto-ostial vein graft stenoses (539,540).

Stenoses in the midportion or origin of the IMA graft are uncommon but respond to balloon dilation (541,542) with stent deployment as feasible. Long-term follow-up of patients after IMA angioplasty has demonstrated sustained benefit and relief of ischemia in the majority of patients (543,544). Balloon angioplasty with or without stent deployment can be performed successfully in patients with distal anastomotic stenoses involving the gastroepiploic artery bypass graft and in patients with free radial artery bypass grafts (545). Percutaneous intervention has also been effective in relieving ischemia for patients with stenosis of the subclavian artery proximal to the origin of a patent left IMA bypass graft (546,547).

5.5.2. Late Ischemia After CABG

Ischemia occurring more than 1 year postoperatively usually reflects the development of new stenoses in graft conduits and/or native vessels that may be amenable to PCI (548). At 3 years or more after SVG implantation, atherosclerotic plaque is frequently evident and is often progressive. These lesions may be friable and often have associated thrombus formation, which may contribute to the occurrence of slow flow, distal embolization, and periprocedural MI after attempted percutaneous intervention (56). Slow flow occurs more frequently in grafts that have diffuse atherosclerotic involvement, angiographically demonstrable thrombus, and irregular or ulcerative lesion surfaces, and with long lesions that have large plaque volume (549,550). Although a reduced incidence of distal embolization has been reported after the use of the extraction atherectomy catheter to recanalize stenoses in older vein graft conduits (551-555), embolization may still complicate adjunctive balloon dilation. Distal embolic protection devices have significantly reduced the occurrence of complications of embolization in SVGs and should be used when possible (254,255). Slow flow with signs and symptoms of myocardial ischemia may be ameliorated by the intragraft administration of agents such as adenosine, diltiazem, nitroprusside, and verapamil (549,556-559). The adjunctive administration of abciximab during vein graft intervention was evaluated in a meta-analysis of 5 studies that demonstrated no improvement in outcomes after PCI and in the absence of distal protection and was associated with a high incidence of death and nonfatal ischemic events (252).

Although postprocedural minimum lumen diameter is larger after directional coronary atherectomy (243,560,561) or

stent deployment (244,245,562-569) than with balloon angioplasty of SVG stenoses, long-term prognosis remains guarded, and late recurrent ischemic events may be due to both restenosis of the target lesion and diffuse vein graft disease (570-572). Final patency after PCI is greater for distal SVG lesions than for ostial or mid-SVG lesions (535), and stenosis location appears to be a better determinant of final patency than graft age or the type of interventional device used.

Percutaneous intervention for chronic vein graft occlusion has been problematic. Balloon angioplasty alone has been associated with high complication rates and low rates of sustained patency (572). Although prolonged intragraft infusion of fibrinolytic therapy was reported to successfully recanalize 69% of a selected group of patients with chronic SVG occlusion of less than 6 months' duration, long-term patency rates with or without adjunctive stent deployment were low (573-575). In addition, prolonged fibrinolytic therapy has been associated with thromboembolic MI (576-579), intracranial hemorrhage (580), and intramyocardial hemorrhage (581), as well as vascular access-site complications. Favorable results have been obtained with both local "targeted" and more prolonged infusion of fibrinolytic agents for nonocclusive intragraft thrombus (582,583). Fibrinolytic catheter-based systems appear to successfully treat SVG thrombosis as well as or better than fibrinolytic agents (584).

5.5.3. Early and Late Outcomes of Percutaneous Intervention

Before the general availability of coronary stenting, overall angioplasty procedural success rates exceeded 90%, and adverse outcomes of emergency repeat coronary bypass surgery (2.3%) and death (0.8%) were infrequent as reported in combined series of over 2000 patients with prior bypass surgery undergoing percutaneous intervention (250,585-597). These results are comparable to those achieved in patients without prior bypass surgery, an observation confirmed by NHLBI registry data (7). The most common complications observed in this population are NSTEMI and atheroembolism, particularly after SVG intervention (538,598).

Patients with prior bypass surgery who undergo successful PCI have a long-term outcome that is dependent on patient age, the degree of LV dysfunction, and the presence of multivessel coronary atherosclerosis. The best long-term results are observed after recanalization of distal anastomotic stenoses occurring within 1 year of operation. Angioplasty of distal anastomotic stenoses involving IMA grafts has been associated with similar, favorable long-term patency rates (543,544). Conversely, event-free survival is less favorable after angioplasty of totally occluded SVGs, ostial vein graft stenoses, or grafts with diffuse or multicentric disease (570-572). Coexistent multisystem disease, the presence of which may have prompted the choice of a percutaneous revascularization strategy, may also influence long-term outcomes in this population.

5.5.4. General Considerations

Aged, diffuse, friable, and degenerative SVG disease in the absence of a patent arterial conduit to the LAD represents a prime consideration for repeat surgical revascularization. In contrast, the presence of a patent arterial conduit to the LAD favors a percutaneous interventional approach to other vessels (599). The overall risk of repeat operation, especially the presence of comorbidities such as concomitant cerebrovascular, renal, or pulmonary disease and the potential for jeopardizing patent, nondiseased bypass conduits, must be considered carefully. Isolated, friable stenoses in vein grafts may be approached with primary stenting or the combination of extraction atherectomy and stenting in an attempt to reduce the likelihood of distal embolization. Distal embolic protection devices have reduced the occurrence of complications of embolization significantly and should be used when possible (254,255) (see Sections 5.5.2 and 6.1.1).

Another therapeutic option for patients with prior coronary bypass surgery that has become available is grafting with the IMA through a “minimally invasive” surgical approach (273,600-604). This strategy, which avoids both the risk of cardiopulmonary bypass (stroke or coagulopathy) and repeat median sternotomy, may be particularly applicable to patients with chronic native-vessel LAD coronary occlusion and friable atherosclerotic disease that involves a prior SVG to this vessel. The role of combining a minimally invasive surgical approach with PCI requires further study (605,606).

In general, patients with multivessel disease, failure of multiple SVGs, and moderately impaired LV function derive the greatest benefit from the durability provided by surgical revascularization with arterial conduits. Regardless of repeat revascularization strategy, risk factor modification with cessation of smoking (607,608) and lipid-lowering therapy (609,610) should be implemented in patients with prior CABG surgery. An aggressive lipid-lowering strategy that targets a low-density lipoprotein cholesterol level substantially less than 100 mg per dL (optional therapeutic target for low-density lipoprotein cholesterol less than 70 mg per dL in very-high-risk patients) (611) can be effective in reducing recurrent ischemic events and the need for subsequent revascularization procedures (610).

5.6. Use of Adjunctive Technology (Intracoronary Ultrasound Imaging, Flow Velocity, and Pressure)

The limitations of coronary angiography for diagnostic and interventional procedures can be reduced by the use of adjunctive technology such as intracoronary ultrasound imaging, flow velocity, and pressure. Information obtained from the adjunctive modalities of intravascular imaging and physiology can improve PCI methods and outcomes.

5.6.1. Intravascular Ultrasound Imaging

Class IIa

IVUS is reasonable for the following:

- a. **Assessment of the adequacy of deployment of coronary stents, including the extent of stent apposition and determination of the minimum luminal diameter within the stent. (Level of Evidence: B)**
- b. **Determination of the mechanism of stent restenosis (inadequate expansion versus neointimal proliferation) and to enable selection of appropriate therapy (vascular brachytherapy versus repeat balloon expansion). (Level of Evidence: B)**
- c. **Evaluation of coronary obstruction at a location difficult to image by angiography in a patient with a suspected flow-limiting stenosis. (Level of Evidence: C)**
- d. **Assessment of a suboptimal angiographic result after PCI. (Level of Evidence: C)**
- e. **Establishment of the presence and distribution of coronary calcium in patients for whom adjunctive rotational atherectomy is contemplated. (Level of Evidence: C)**
- f. **Determination of plaque location and circumferential distribution for guidance of directional coronary atherectomy. (Level of Evidence: B)**

Class IIb

IVUS may be considered for the following:

- a. **Determination of the extent of atherosclerosis in patients with characteristic anginal symptoms and a positive functional study with no focal stenoses or mild CAD on angiography. (Level of Evidence: C)**
- b. **Preinterventional assessment of lesional characteristics and vessel dimensions as a means to select an optimal revascularization device. (Level of Evidence: C)**
- c. **Diagnosis of coronary disease after cardiac transplantation. (Level of Evidence: C)**

Class III

IVUS is not recommended when the angiographic diagnosis is clear and no interventional treatment is planned. (Level of Evidence: C)

IVUS imaging provides a tomographic 360-degree sagittal scan of the vessel from the lumen through the media to the vessel wall. IVUS measurements of arterial dimensions (minimal and maximal diameters, cross-sectional area, and plaque area) complement and enhance angiographic information. IVUS has been used to refine device selection through plaque characterization (e.g., calcified) and artery sizing. IVUS has contributed to the understanding of the mechanisms of coronary angioplasty in general and specifically to the advancement of coronary stenting without long-term anticoagulation (612-617). In a large observational study, IVUS-guided angioplasty resulted in a decreased final residual plaque area from 51% to 34%, despite a final angiographic percent stenosis of 0% (612). IVUS-facilitated stent deployment was associated with a subacute thrombosis rate of 0.3% without systemic anticoagulation, although

antiplatelet agents are still required for stenting (612). In the placement of coronary stents, because radiographic contrast material can be located between stent struts and the vascular wall, an angiographic appearance of a large lumen may exist when the stent has not been fully deployed. IVUS documents full apposition of stent struts to the vessel wall (612).

IVUS is not necessary for all stent procedures. The results of the French Stent Registry study of 2900 patients treated without warfarin and without IVUS reported a subacute closure rate of 1.8% (618). In the Stent Anticoagulation Regimen Study (STARS) (619), a subacute closure rate of 0.6% in patients having optimal stent implantation supports the approach that IVUS does not appear to be required routinely in all stent implantations. However, the use of IVUS to evaluate results in high-risk procedures (e.g., those patients with multiple stents, impaired TIMI grade flow or coronary flow reserve, and marginal angiographic appearance) appears warranted.

The long-term outcomes when adjunctive IVUS is used are currently under study. In the Multicenter Ultrasound Stent In Coronaries (MUSIC) trial of 161 patients (620), which evaluated optimal stent expansion (defined as complete apposition of the stent over its length) with symmetrical expansion (defined as a ratio of minimum to maximum luminal diameter greater than 0.7) and minimal luminal area (compared with greater than 80% of the reference area), the subacute closure rate was 1.3% with monotherapy of aspirin. The angiographic restenosis rate was less than 10% when stent cross-sectional areas were greater than 9.0 mm².

Fitzgerald *et al.* reported that the degree of stent expansion as measured by IVUS directly correlates to clinical outcomes in the CRUISE (Can Routine Ultrasound Influence Stent Expansion) study (621). This multicenter study compared 270 patients with IVUS-guided stent implantation with IVUS-documented, but not guided, stent implantation in 229 patients. At 9-month follow-up, there was no difference in rates of death or MI, but the target-lesion revascularization rate was substantially lower in the IVUS-guided group (8.5% vs 15.3%; *P* equals 0.019). These data suggest that ultrasound guidance of stent implantation may result in more effective stent expansion than angiographic guidance alone and subsequently reduce the need for late target-lesion revascularization.

In several instances, IVUS has been useful in determining the reason for reduced efficacy of new technology. In the RESCUT (REStenosis CUTting balloon evaluation) trial comparing cutting balloon with PTCA for ISR, IVUS examinations showed that there was stent underexpansion when a cutting balloon was used at low pressure compared with high-pressure balloons (91).

IVUS has also identified complications of PCI that require further therapy. Postprocedure hematomas that were not identifiable by angiography were identified by IVUS (622).

Stent underexpansion was also shown to be common in diabetic patients assessed with angiography. This can be revealed by IVUS so that further expansion of the stent can be accomplished (623). IVUS increasingly is also being used to measure the volume of intimal hyperplasia in experimen-

tal studies to evaluate the efficacy of systemic and locally delivered antirestenotic therapies (624-628) or in clinical research trials to assess the effect of therapies for dyslipidemia on vascular wall and plaque structure.

5.6.2. Coronary Artery Pressure and Flow: Use of Fractional Flow Reserve and Coronary Vasodilatory Reserve

Class IIa

It is reasonable to use intracoronary physiologic measurements (Doppler ultrasound, fractional flow reserve) in the assessment of the effects of intermediate coronary stenoses (30% to 70% luminal narrowing) in patients with anginal symptoms. Coronary pressure or Doppler velocimetry may also be useful as an alternative to performing noninvasive functional testing (e.g., when the functional study is absent or ambiguous) to determine whether an intervention is warranted. (Level of Evidence: B)

Class IIb

- 1. Intracoronary physiologic measurements may be considered for the evaluation of the success of PCI in restoring flow reserve and to predict the risk of restenosis. (Level of Evidence: C)**
- 2. Intracoronary physiologic measurements may be considered for the evaluation of patients with anginal symptoms without an apparent angiographic culprit lesion. (Level of Evidence: C)**

Class III

Routine assessment with intracoronary physiologic measurements such as Doppler ultrasound or fractional flow reserve to assess the severity of angiographic disease in patients with a positive, unequivocal noninvasive functional study is not recommended. (Level of Evidence: C)

Historically, translesional pressure gradients were used as end points for early interventional cardiology procedures. The use of a translesional pressure gradient measured at rest was abandoned because of difficult technique and improved angiographic imaging. Pijls *et al.* (545) introduced the concept of fractional flow reserve (FFR) of the myocardium, the ratio of distal coronary pressure to aortic pressure measured during maximal hyperemia, which correlates with the fraction of normal blood flow through the stenotic artery (629,630). The coronary pressure measuring technique is relatively simple, especially with pressure guidewires, a method superior to small catheters. The normal FFR value for all vessels under all hemodynamic conditions, regardless of the status of microcirculation, is 1.0. FFR values less than 0.75 are associated with abnormal stress tests (631). Unlike coronary flow velocity reserve (CVR), the FFR is relatively independent of microcirculatory disturbances. FFR does not use measurements in a reference vessel and is thought to be epicardial lesion-specific. FFR provides no information on

the microcirculation or on the absolute magnitude of the change in coronary flow.

On the other hand, CVR is the ratio of hyperemic to basal flow and reflects flow resistance through the epicardial artery and the microvascular bed. CVR less than 2.0 is positively correlated to abnormal stress perfusion imaging (632-634). In some cases, the uncertainty as to whether the impaired flow reserve is due to the target stenosis or to an abnormal microcirculation may be reduced by use of relative coronary flow reserve (rCVR, which is equal to CVR of the target vessel divided by CVR of the reference vessel). From preliminary studies, rCVR greater than 0.8 may have prognostic values similar to those of negative stress testing (635). There is a correlation between rCVR and pressure-derived FFR (629,635). An abnormal CVR indicates that the stenosis in the epicardial artery is significant when the microcirculation is normal. For coronary lesion assessment, the best measurement appears to be FFR.

CVR measurement of less than 2 after stent placement was an independent predictor of target-vessel revascularization. CVR after PCI in DEBATE-2 (Doppler Endpoints Balloon Angioplasty Trial Europe) also predicted early MACE due to microcirculatory disturbances (636). However, because of the complexity in the interpretation of CVR, pressure-derived FFR is the preferred measurement for lesion assessment and outcome of PCI. Coronary physiologic measurements associated with major clinical outcomes are supported by numerous studies (Table 23) (632,637).

Strong correlations exist between myocardial stress testing and FFR or CVR (633,638-649). An FFR of less than 0.75 identified physiologically significant stenoses associated with inducible myocardial ischemia with high sensitivity (88%), specificity (100%), positive predicted value (100%), and overall accuracy (93%). An abnormal CVR (less than 2.0) corresponded to reversible myocardial perfusion imaging defects with high sensitivity (86% to 92%), specificity (89% to 100%), predictive accuracy (89% to 96%), and positive and negative predictive values (84% to 100% and 77% to 95%, respectively).

The clinical outcomes of deferring coronary intervention for intermediate stenoses with normal physiology are remarkably consistent, with clinical event rates of less than 10% over a 2-year follow-up period (639,647-651). Bech *et al.* (649) studied 325 patients with intermediate coronary stenosis without documented myocardial ischemia and randomly assigned those with FFR greater than 0.75 to a deferral group of 91 patients or a performance group of 90 patients. PTCA was performed as planned in 144 patients with FFR less than 0.75. At clinical follow-up of 1, 3, 6, 12, and 24 months, event-free survival was similar between the deferral and performance groups (92% vs 89% at 12 months and 89% vs 83% at 24 months). However, these rates were significantly lower in the reference (PTCA) group (80% at 12 months and 78% at 24 months). The percentage of patients free from angina was similar between the deferral and the performance group at 12 and 24 months, but there was a significantly higher incidence of angina in the refer-

Table 23. Catheter-Based Anatomic and Physiological Criteria Associated With Clinical Outcomes

Application	IVUS	CVR	rCVR	FFR
Ischemia detection	Less than 3 to 4 mm ²	Less than 2.0	Less than 0.8	Less than 0.75
Deferred angioplasty	NA	Greater than 2.0	NA	Greater than 0.75
End point of stenting	Greater than 9 mm ² Greater than 80% reference area, full apposition (depending on vessel size and volume plus morphology of plaque in target-vessel segment)			Greater than 0.94 (depending on diffuse disease in persistent segment)

CVR indicates coronary flow velocity reserve; FFR, fractional flow reserve; IVUS, intravascular ultrasound; NA, not applicable; and rCVR, relative coronary flow velocity. Modified with permission from Kern. *Circulation* 2000;101:1344-51 (637).

ence group (67% vs 50% at 12 months and 80% vs 50% at 24 months). These data indicated that in patients with coronary stenosis without evidence of ischemia, coronary pressure-derived FFR identifies those patients who will benefit from PCI as well as those who will not.

FFR after stenting predicts adverse cardiac events at follow-up. Pijls *et al.* (648) examined 750 patients with postprocedural FFR and related these findings to MACE at 6 months. In 76 patients (10.2%), 1 adverse event occurred. Five patients died, 19 experienced MI, and 52 underwent at least 1 repeat target-vessel revascularization. Fractional flow reserve immediately after stenting was an independent variable related to all types of events. In 36% of patients, FFR normalized (greater than 0.95) with an event rate of 5%. In 32% of patients with poststenting FFR between 0.90 and 0.95, the event rate was 6%. In the remaining 32% with FFR less than 0.90, event rates were 20%. In 6% of patients with FFR less than 0.80, the event rate was 30% (Table 23) (637). FFR after stenting is a strong predictor of outcome at 6 months. These data suggest that both edge stent subnormalization and diffuse disease are associated with worse long-term outcome.

6. MANAGEMENT OF PATIENTS UNDERGOING PCI

6.1. Evolution of Technologies

The introduction of coronary stents and other devices has broadened the scope of patients who can be approached by PCI beyond those who could be safely treated by PTCA alone. Coronary stenting has become the dominant final therapy in patients undergoing PCI. The NHLBI registry, which collects sampling of unselected patients from 15 medium- to large-volume institutions, shows increasing use of stenting over the past 5 years. In the most recent wave of this registry, 83.6% of PCI patients received stents, and stents were placed in 79.4% of all lesions treated. Stenting has been more successful than balloon angioplasty in mid-sized coronary lesions, chronic total occlusions (652,653), and SVGs (562). Directional coronary atherectomy has been used successfully in proximal anterior descending lesions and bifurcation lesions (638). Rotational atherectomy successfully treats calcific and diffusely diseased coronary vessels (654) and ostial stenoses (655,656). Excimer laser has been used to treat diffuse disease (657). Vascular brachytherapy has been successful in treating restenosis occurring within stents (92,658,659). Other adjunctive therapies for ISR have shown mixed results. The cutting balloon has been used successfully; however, a recent trial did not show superiority for the cutting balloon compared with the normal balloon (95). Rotary ablation, excimer laser, and restenting have also been used for ISR; however, there are no data to indicate that these methods are better than balloon angioplasty.

Intracoronary brachytherapy with both gamma and beta radiation sources has been effective in treatment of ISR, and both radiation sources were approved by the FDA as therapy approved specifically for ISR (92,658-660).

Beta-radiation systems have been used most widely, resulting in an approximately 50% reduction in the need for reintervention over the 9 months after the procedure (92,659). In-stent restenosis is now significantly less than in prior years, but even with drug-eluting stenting, the problem still exists. Early observation of the use of DES to treat ISR has shown mixed results. Studies are currently under way comparing placement of DES to brachytherapy for ISR. Results of those trials are not available at this time.

6.1.1. Acute Results

Class I

It is recommended that distal embolic protection devices be used when technically feasible in patients undergoing PCI to saphenous vein grafts. (Level of Evidence: B)

Historically, one of the important limitations of balloon angioplasty has been its high rate of abrupt closure (4% to 7%) and less than optimal acute angiographic result (30% residual diameter stenosis, with frequent evidence of dissections). Significant reductions in acute complication rates for PTCA have resulted from the wide use of stenting, which has been shown to reduce abrupt closure and periprocedural emergency surgery rates. Improved acute outcomes in terms of reduced target-lesion residual diameter stenosis have also been seen with the use of coronary stents, directional coronary atherectomy, and other adjunctive therapies. The GuardWire distal protection device, as studied in the SAFER (Saphenous vein graft Angioplasty Free of Emboli Randomized) trial, has reduced the incidence of MI in patients treated for SVG lesions (255), and the FilterWire was shown not to be inferior to the GuardWire in the FIRE (FilterWire EX Randomized Evaluation) trial (254) (see Section 5.5.2.). However, “embolic” protection devices have not shown a similar benefit in the setting of primary PCI for STEMI, as noted in the EMERALD (Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris) trial (GuardWire), in which distal protection did not convey significant benefit (661). Thus, the use of distal embolic protection devices for STEMI patients undergoing PCI requires further evaluation (253,661).

6.1.2. Late-Term Results

PCI devices, especially coronary stents, offer the possibility of lower restenosis than with PTCA in the native coronary circulation. Lower restenosis rates have been demonstrated for balloon-expandable stents in large (3 mm) native coronary arteries (80,83) and in saphenous vein lesions (562).

The use of stents in smaller arteries has shown mixed results. Use of stenting in the treatment of chronic total occlusions has been superior to balloon angioplasty alone (652,653). The use of vascular brachytherapy has been shown to reduce restenosis rates and improve clinical outcomes in patients with ISR (92,658,660).

Directional coronary atherectomy, when applied aggressively, produces a larger lumen and has been associated with

a lower angiographic restenosis rate (85). Despite the improvement in acute results seen for rotational atherectomy and excimer laser, there is no evidence that these devices improve late outcomes in lesions that can be safely treated with balloon angioplasty or stenting alone (662-664).

6.2. Antiplatelet and Antithrombotic Adjunctive Therapies for PCI

6.2.1. Oral Antiplatelet Therapy

Class I

1. Patients already taking daily chronic aspirin therapy should take 75 to 325 mg of aspirin before the PCI procedure is performed. (*Level of Evidence: A*)
2. Patients not already taking daily chronic aspirin therapy should be given 300 to 325 mg of aspirin at least 2 hours and preferably 24 hours before the PCI procedure is performed. (*Level of Evidence: C*)
3. After the PCI procedure, in patients with neither aspirin resistance, allergy, nor increased risk of bleeding, aspirin 325 mg daily should be given for at least 1 month after bare-metal stent implantation, 3 months after sirolimus-eluting stent implantation, and 6 months after paclitaxel-eluting stent implantation, after which daily chronic aspirin use should be continued indefinitely at a dose of 75 to 162 mg. (*Level of Evidence: B*)
4. A loading dose of clopidogrel should be administered before PCI is performed. (*Level of Evidence: A*) An oral loading dose of 300 mg, administered at least 6 hours before the procedure, has the best established evidence of efficacy. (*Level of Evidence: B*)
5. In patients who have undergone PCI, clopidogrel 75 mg daily should be given for at least 1 month after bare-metal stent implantation (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 weeks), 3 months after sirolimus stent implantation, and 6 months after paclitaxel stent implantation, and ideally up to 12 months in patients who are not at high risk of bleeding. (*Level of Evidence: B*)

Class IIa

1. If clopidogrel is given at the time of procedure, supplementation with GP IIb/IIIa receptor antagonists can be beneficial to facilitate earlier platelet inhibition than with clopidogrel alone. (*Level of Evidence: B*)
2. For patients with an absolute contraindication to aspirin, it is reasonable to give a 300-mg loading dose of clopidogrel, administered at least 6 hours before PCI, and/or GP IIb/IIIa antagonists, administered at the time of PCI. (*Level of Evidence: C*)
3. When a loading dose of clopidogrel is administered, a regimen of greater than 300 mg is reasonable to achieve higher levels of antiplatelet activity more rapidly, but the efficacy and safety compared with a 300-mg loading dose are less established. (*Level of*

Evidence: C)

4. It is reasonable that patients undergoing brachytherapy be given daily clopidogrel 75 mg indefinitely and daily aspirin 75 to 325 mg indefinitely unless there is significant risk for bleeding. (*Level of Evidence: C*)

Class IIb

In patients in whom subacute thrombosis may be catastrophic or lethal (unprotected left main, bifurcating left main, or last patent coronary vessel), platelet aggregation studies may be considered and the dose of clopidogrel increased to 150 mg per day if less than 50% inhibition of platelet aggregation is demonstrated. (*Level of Evidence: C*)

Aspirin reduces the frequency of ischemic complications after PCI. Although the minimum effective aspirin dosage in the setting of PCI has not been established, for those patients not already taking chronic aspirin therapy (75 to 162 mg per day), an empiric dose of aspirin (300 to 325 mg) given at least 2 h and preferably 24 h before the PCI procedure is generally recommended (665-668). Although other antiplatelet agents have antiplatelet effects similar to aspirin (669), only the thienopyridine derivatives (670) ticlopidine and clopidogrel have been used routinely as alternative antiplatelet agents in aspirin-sensitive patients during coronary angioplasty. Glycoprotein IIb/IIIa antagonists might also be substituted for aspirin before PCI. However, aspirin desensitization can be performed safely in selected patients (671,672). A strategy of pretreatment with clopidogrel in patients who have not already had their coronary anatomy defined is controversial, because patients who undergo CABG within 5 to 7 days of clopidogrel treatment have an increased risk of bleeding (665,673).

Clopidogrel and ticlopidine have similar side effects, which include gastrointestinal distress (20%), cutaneous rashes (4.8% to 15%), and abnormal liver function tests (674). Severe neutropenia has been reported to occur in approximately 1% of patients taking ticlopidine (674,675). Rare (less than 1:1000) but fatal episodes of thrombotic thrombocytopenic purpura have also been reported (676-678). Patients receiving ticlopidine should be monitored for the occurrence of this untoward sequela. A shorter duration (10 to 14 days) of ticlopidine therapy may reduce untoward side effects of therapy while maintaining therapeutic efficacy (679). For these reasons, clopidogrel has become the preferred thienopyridine for patients undergoing PCI. Available data show that approximately 4% to 30% of patients treated with conventional doses of clopidogrel do not display adequate platelet response (680). Preliminary data suggests that clopidogrel "nonresponders" may be at higher risk for thrombotic events. Thus, in patients in whom stent thrombosis may be catastrophic or lethal (ULM, bifurcating left main, and last patent coronary vessel), platelet aggregation studies may be considered and the dose of clopidogrel increased to 150 mg per day if less than 50% inhibition of platelet aggregation is demonstrated.

Before the advent of potent combination antiplatelet therapy in recent years, enthusiasm for stenting during MI (with or without ST elevation) or UA was tempered by the sudden and often unpredictable occurrence of subacute stent thrombosis, which developed in 3.5% to 8.6% of stent-treated patients (80,83,681,682). Anatomic factors (e.g., underdilation of the stent, proximal and distal dissections, poor inflow or outflow obstruction, less than 3-mm vessel diameter) were believed to predispose some patients to the occurrence of subacute stent thrombosis (612,683,684). With the advancements in PCI technology and adjunctive antiplatelet therapy (aspirin plus thienopyridine) after PCI, the incidence of stent thrombosis is now approximately 1% (685,686). The potential risk of stent occlusion should be considered when discontinuation of antiplatelet therapy is contemplated in patients undergoing stent implantation (687,688).

The efficacy of combination antiplatelet therapy in patients undergoing urgent and elective stent implantation has been shown by the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial of 517 patients treated with BMS for MI, suboptimal angioplasty, or other high-risk clinical and anatomic features. Patients were randomly assigned to treatment with aspirin plus ticlopidine or aspirin, intravenous heparin, and phenprocoumon after successful stent placement (689). The primary end point of cardiac death, MI, coronary bypass surgery, or repeat angioplasty occurred in 1.5% of patients assigned to antiplatelet therapy and 6.2% of those assigned to anticoagulant therapy (relative risk 0.25; 95% CI 0.06 to 0.77) (689).

In the STARS trial (619), the efficacy of aspirin (325 mg daily), the combination of aspirin (325 mg daily) plus ticlopidine (500 mg daily for 1 month), and aspirin (325 mg daily) plus warfarin on ischemic end points at 30 days in 1653 in low-risk patients after optimal BMS placement demonstrated more adverse events in patients not receiving ticlopidine as part of the therapeutic regimen. The primary 30-day composite end point of death, target-lesion revascularization, subacute thrombosis, or MI was 3.6% in patients assigned to aspirin only, 2.7% in those assigned to aspirin plus warfarin, and 0.5% in those assigned to aspirin plus ticlopidine (aspirin plus ticlopidine vs aspirin alone, P less than 0.001; aspirin plus ticlopidine vs aspirin plus warfarin, P equals 0.014) (619). Pretreatment with ticlopidine without a loading dose for more than 72 h may allow more effective inhibition of platelet activation than shorter durations of therapy (691,692).

In the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) trial, the effects of clopidogrel in addition to aspirin were tested in 12 562 patients with non-ST-elevation acute coronary syndromes with either positive biomarkers of myocardial injury or new ECG changes (665). The patients were randomized to receive an immediate 300-mg loading dose of clopidogrel in the emergency room followed by 75 mg a day for 1 year or to a matching placebo.

The primary end points of MI, stroke, and cardiovascular death from randomization to 1 year were reported. There was a 20% RRR in the primary outcome of MI, stroke, or cardio-

vascular death, a highly significant result at 12 months in patients treated with clopidogrel. The most pronounced benefit was observed in the reduction of MIs, with the largest reductions of 40% in Q-wave or ST-elevation MI, also statistically significant. In parallel with the reduction in large MI was a 43% reduction in the use of fibrinolytic therapy after randomization and an 18% reduction in radiologically confirmed HF, both of which reached statistical significance. In PCI CLARITY, patients treated with fibrinolysis for STEMI who underwent PCI 2 to 8 days after receiving a 300 mg loading dose of clopidogrel, had reduced incidence of CV death or ischemic complications when compared to those receiving 300 mg clopidogrel immediately prior to PCI (665a). In another trial (ISAR-REACT [Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment]), a higher loading dose of clopidogrel (600 mg) was used before elective, low-risk stent procedures with favorable results compared with routine abciximab administration (693). However, the sample size was such that it may have been underpowered to show a benefit of abciximab administration in low-risk populations.

After PCI with BMS implantation, short term (at least 1 month) clopidogrel therapy in addition to aspirin leads to greater protection from thrombotic complications than aspirin alone. The benefits of long-term treatment with clopidogrel after PCI and the benefit of initiating pretreatment with clopidogrel with a preprocedural loading dose in addition to aspirin therapy were tested in CREDO (Clopidogrel for the Reduction of Events During Observation), a randomized, double-blind, controlled trial of early and sustained dual oral antiplatelet therapy after PCI (666). In this trial of 2116 patients undergoing PCI from 99 North American centers, the patients received either a 300-mg loading dose of clopidogrel (n equals 1053) or placebo (no loading dose; n equals 1063) 3 to 24 h before PCI. All patients thereafter received clopidogrel 75 mg daily through day 28. For the following 12 months, patients in the loading dose group received clopidogrel and those in the control group received placebo. All patients received aspirin (325 mg per day through day 28, 81 to 325 mg daily thereafter) throughout the study. At 1 year, long-term clopidogrel therapy was associated with a 27% RRR in the combined risk of death, MI, or stroke for an absolute reduction of 3% (P equals 0.02). Clopidogrel pretreatment did not significantly reduce MACE at 28 days. However, in a prespecified subgroup analysis, the patients who received clopidogrel at least 6 h before PCI had a RRR of 39% (P equals 0.051) for the combined end point compared with no reduction with treatment less than 6 h before PCI. Major bleeding risk at 1 year increased but not significantly (8.8% with clopidogrel vs 6.7% with placebo, P equals 0.07). These data suggest that after PCI, long-term clopidogrel therapy (1 year) significantly reduced the risk of adverse ischemic events. A 300-mg loading dose of clopidogrel given at least 3 h before the procedure did not reduce events at 28 days, but longer intervals between the loading dose and PCI appeared to be associated with a highly favorable trend toward reduced events.

Importantly, the CREDO trial did not have a control group that was given a loading dose at the time of the procedure.

The effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing PCI was also evaluated in the PCI CURE study (667). The PCI CURE study examined 2658 patients with non-ST-elevation acute coronary syndromes undergoing PCI assigned randomly to double-blind treatment with clopidogrel (n equals 1313) or placebo (n equals 1345). The patients were pretreated with aspirin and the study drug for 6 days before PCI during initial hospital admission and for 10 days overall. After PCI, 80% of patients in both groups received open-label clopidogrel for 4 weeks, after which the study drug was restarted for a mean of 8 months. Fifty-nine patients (4.5% in the clopidogrel group) experienced the primary end point of cardiovascular death, MI, or urgent target-lesion revascularization within 30 days compared with 6.4% in the placebo group (*P* equals 0.03). Long-term clopidogrel administration after PCI conferred a lower rate of cardiovascular death, MI, or any revascularization (*P* equals 0.03) and cardiovascular death or MI (*P* equals 0.047). Including events before and after PCI, there was an overall reduction of 31% in cardiovascular death and MI (*P* equals 0.002).

The use of clopidogrel in patients with diabetes had especially favorable results. The CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) trial showed a 9% RRR that favored clopidogrel versus aspirin for cardiovascular events. A subgroup analysis in patients who had prior cardiac surgery and who had been randomized to clopidogrel revealed a significant reduction in risk of MI, stroke, and cardiovascular death compared with those taking aspirin. In patients with diabetes in the CAPRIE substudy, the benefit of clopidogrel appeared larger compared with aspirin alone, especially in those who required insulin (694). Tabulation of the number of adverse events prevented per 1000 patients treated for 1 year with clopidogrel compared with aspirin revealed 9 events prevented in the patients without diabetes, with 21 events in all patients with diabetes and 38 in insulin-requiring patients with diabetes.

Further trials are needed to identify the optimum loading dose and timing of clopidogrel administration before PCI. A strategy of administering a 300-mg loading dose 6 h before PCI has the best established evidence of efficacy (666). Higher loading doses increase the magnitude and speed of inhibition of platelet aggregation; however, no large-scale randomized trials have been conducted to date comparing the efficacy and safety of different loading doses of clopidogrel. Furthermore, an important consideration in the decision for pretreatment is the increased risk of bleeding in patients managed with CABG. The ARMYDA-2 trial (Antiplatelet therapy for the Reduction of MYocardial Damage during Angioplasty) is a randomized, prospective, double-blind study of patients with stable angina or UA/NSTEMI and indications for coronary angiography. In this trial, 126 patients were randomized to a 600-mg loading dose and 129 patients to a 300-mg loading dose 4 to 8 h before PCI. The primary end point of death, MI (defined as CK-MB greater

than 3 times the upper limit of normal), or target-vessel revascularization up to 30 days after the procedure occurred in 4% of patients in the 600-mg loading dose group and 12% in the 300-mg loading dose group (*P* equals 0.041) owing to a reduction in periprocedural MI. This was a small study of relatively low-risk patients, with only a few patients receiving IIB/IIIa inhibitors. Thus, whether the results would also apply to higher-risk patients taking IIB/IIIa blockers is unknown (695). Some insights may be derived from the CLEAR PLATELETS study (Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets), which evaluated a 300-mg and 600-mg clopidogrel loading dose with or without eptifibatide in 120 patients undergoing elective stenting procedures. Clopidogrel was administered immediately after stenting. Aggregometry and flow cytometry were used to assess platelet reactivity. The authors concluded that a strategy of eptifibatide administration was associated with superior platelet inhibition and lower cardiac biomarker release than high-dose (600 mg) or standard-dose (300 mg) clopidogrel at the time of PCI (696). Further study is needed to determine the relationship of platelet reactivity to clinical outcomes such as bleeding, myocardial necrosis, and stent thrombosis, which could not be derived from this small, pharmacodynamic study.

Continuation of combination treatment with aspirin and clopidogrel after PCI appears to reduce rates of cardiovascular ischemic events (666,667,697,698). On the basis of randomized clinical trial protocols, aspirin 325 mg daily should be given for at least 1 month after BMS implantation (unless there is a risk of bleeding, in which case it should be given for 2 weeks), 3 months after SES implantation, and 6 months after paclitaxel-eluting stent (PES) implantation, after which daily chronic aspirin should be continued indefinitely at a dose of 75 to 162 mg. Likewise, clopidogrel 75 mg daily should be given for at least 1 month after BMS implantation, 3 months after SES implantation, and 6 months after PES implantation and ideally up to 12 months in patients who are not at high risk of bleeding. To reduce the incidence of bleeding complications associated with dual antiplatelet therapy, lower-dose aspirin (75 to 162 mg daily) is recommended for long-term therapy (665).

6.2.2. Glycoprotein IIB/IIIa Inhibitors

Class I

In patients with UA/NSTEMI undergoing PCI without clopidogrel administration, a GP IIB/IIIa inhibitor (abciximab, eptifibatide, or tirofiban) should be administered. (Level of Evidence: A)*

Class IIa

- 1. In patients with UA/NSTEMI undergoing PCI with clopidogrel administration, it is reasonable to administer a GP IIB/IIIa inhibitor (abciximab, eptifibatide, or tirofiban). (Level of Evidence: B)***
- 2. In patients with STEMI undergoing PCI, it is reasonable to administer abciximab as early as possible.**

(Level of Evidence: B)

- 3. In patients undergoing elective PCI with stent placement, it is reasonable to administer a GP IIb/IIIa inhibitor (abciximab, eptifibatide, or tirofiban). (Level of Evidence: B)**

Class IIb

In patients with STEMI undergoing PCI, treatment with eptifibatide or tirofiban may be considered. (Level of Evidence: C)

*It is acceptable to administer the GP IIb/IIIa inhibitor before performance of the diagnostic angiogram (“upstream treatment”) or just before PCI (“in-lab treatment”).

Aspirin is only a partial inhibitor of platelet aggregation (699,700), because it affects only cyclooxygenase, thereby preventing the formation of thromboxane A₂. Functionally active GP IIb/IIIa receptors aggregate platelets through fibrin bound at the receptor sites. These receptors are activated by a variety of agonists, including thromboxane A₂, serotonin, adenosine diphosphate, and collagen, among others. The binding of fibrinogen and other adhesive proteins to adjacent platelets by means of the GP IIb/IIIa receptor serves as the “final common pathway” of platelet-thrombus formation and can be effectively attenuated by GP IIb/IIIa antagonists. These agents have reduced the frequency of ischemic complications after coronary angioplasty. Individual studies evaluating the impact of intravenous GP IIb/IIIa receptor antagonists on survival for patients undergoing PCI have not had adequate power to examine a difference in mortality. Two meta-analyses of GP IIb/IIIa trials (abciximab, eptifibatide, and tirofiban) have been performed to examine this potential benefit. In 1 meta-analysis involving 12 trials of 20 186 patients, overall 30-day mortality was significantly reduced by GP IIb/IIIa inhibition, although no individual trial showed a mortality benefit. At 6 months, the survival benefit was not significant. The trials included in this analysis encompassed a range of patient characteristics (e.g., UA, NSTEMI, and STEMI), therapeutic regimens (e.g., elective PCI, primary PCI), and adjunctive drugs. In another meta-analysis, which involved 19 trials of 20 137 patients, 30-day and 6-month mortality were both significantly reduced for those receiving IIb/IIIa receptor antagonists (Tables 24a and 24b) (64,111,112,191,195,198,200,201,442,443,701-717). Thus, patients undergoing PCI can expect a lower 30-day mortality when GP IIb/IIIa therapy is utilized. The RRR appears to be similar in trials of patients with or without acute MI and for trials using stents or another PCI as the intended primary procedure. Similar reductions in nonfatal MI are seen in association with the use of GP IIb/IIIa receptor antagonists.

There is no consistent evidence that the GP IIb/IIIa inhibitors reduce the frequency of late restenosis in patients without diabetes. In EPISTENT, patients with diabetes who received abciximab therapy in conjunction with stent deployment had a 51% reduction in target-vessel revascularization at 6 months (230,718). This trial is the only one that has

shown a reduction in target-vessel revascularization in the diabetic group.

A long-term mortality benefit of abciximab in patients with diabetes undergoing PCI was demonstrated in a pooled analysis of 3 trials (EPIC, EPILOG, and EPISTENT; 4.5% vs 2.5%, *P* equals 0.03) (718). A meta-analysis showed that the 30-day mortality benefit in patients with diabetes in the setting of UA/NSTEMI was greater in patients undergoing PCI (719).

In a meta-analysis of invasive versus conservative therapy of patients with UA/NSTEMI, men demonstrated a clear survival advantage with routine invasive therapy with GP IIb/IIIa inhibitors and intracoronary stents; however, with similar therapy, the results for women were not improved significantly (205).

On the basis of the numerous trials to date, intravenous GP IIb/IIIa receptor inhibitors should be considered in patients undergoing PCI, particularly those with UA/NSTEMI or with other clinical characteristics of high risk (Table 25). Detailed discussion of the trials applicable to UA/NSTEMI and STEMI patients can be found in the respective ACC/AHA guidelines (332,493).

6.2.2.1. Abciximab

Trials of GP IIb/IIIa inhibitors have utilized different definitions for adjuncting end points. These should be considered when the results are evaluated.

The clinical safety and efficacy of abciximab have been evaluated extensively in many randomized trials of patients with acute coronary syndromes with and without high-risk clinical features. These studies include EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) (704), EPILOG (Evaluation of Percutaneous transluminal coronary angioplasty to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade) (705), and EPISTENT (Evaluation of Platelet IIb/IIIa Inhibition in STENTing) (111). Despite early problems with excessive bleeding when weight-adjusted heparin dosing was not employed, abciximab was superior to placebo in all settings for reducing MACE.

ISAR-REACT randomly compared abciximab (n equals 1079) versus placebo (n equals 1080) in low-risk PCI patients pretreated with high-dose clopidogrel (600 mg orally) 2 h before the procedure, then with 75 mg BID for 3 days followed by 75 mg per day for 3 months (693). At 30 days, there was no difference between the groups. Thus, in that trial of low-risk patients having elective PCI, there was no benefit to the use of abciximab in patients receiving high-dose pretreatment with clopidogrel. The sample size was such that it may have been underpowered to show a benefit in low-risk populations (693).

Heeschen *et al.* (192), for the CAPTURE (Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment) investigators, demonstrated that troponin T, but not C-reactive protein, was predictive of cardiac risk during the initial 72-h period in the treatment of UA patients with standard therapy or with abciximab. Hamm *et al.* (193),

Table 24a. Eligible Trials of Intravenous Glycoprotein IIb/IIIa Inhibitors Used in Evaluation of Mortality After PCI

Trial (Reference)	n	PCI	AMI, % (Time)	Post-PCI		Mean Age, y	Past Medical History, %				
				Heparin	Male, %		DM	HTN	MI	PCI	CABG
Abciximab											
RAPPORT (443)	483	PTCA or DCA	100 (less than 12 h)	Yes	72	22	48	19	14		
ADMIRAL (442)	300	Stenting	100 (less than 12 h)	Yes	82	18	38	11	14		12
CADILLAC (64)	2082	PTCA/stenting	100 (less than 12 h)	No	73	17	48	14	11		2
EPIC (702-704)	2099	PTCA or DCA	30 (less than 12 h)	Yes	72	24	55	38	22		15
EPILOG (705,706)	2792	PTCA or DCA	0	No	72	23	ND	27	ND		13
EPISTENT (111,112,191)	1603	Stenting	0	No	75	20	53	51	ND		9
CAPTURE (195)	1266	PTCA	0	Yes	73	14	42	40	13		3
ERASER (280)	225	Stenting	Negligible*	No	79	14	50	ND	14		ND
Petronio et al. (708)	89	PTCA	100 (less than 24 h)	No	65	18	ND	10	ND		1
Simoons et al. (710)	60	PTCA	0	No	73	ND	ND	42	15		4
Kini et al. (711)	100	HSRA	0	No	75	26	44	18	ND		15
Tamburino et al. (712)	107	Stenting	0	No	87	27	34	67	ND		ND
ISAR-2 (707)	401	Stenting	100	Yes	76	15	64	ND	7		4
Eptifibatid											
IMPACT (713)	150	PTCA or DCA	0	Yes	75	21	53	43	39		17
IMPACT-II (198)	4010	Various†	3 (less than 24 h)	No	75	23	54	41	30		16
ESPRIT (200,201)	2064	Stenting	0	No	73	20	59	32	23		10
Harrington et al. 73 (714)		Various†	0	No	75	29	68	45	ND		26
Tirofiban											
RESTORE (715,716)	2141	PTCA or DCA	32 (less than 72 h)	No	72	20	55	34	21		7
Kereiakis et al. (717)	93	PTCA	0	Yes	82	24	53	47	23		15

AMI indicates acute MI; CABG, coronary artery bypass graft surgery; DCA, directional coronary atherectomy; DM, diabetes mellitus; h, hour; HSRA, high-speed rotational atherectomy; HTN, hypertension; MI, myocardial infarction; n, number of patients; ND, no data; PCI, percutaneous coronary intervention (originally intended procedure[s] in each trial); PTCA, percutaneous transluminal coronary angioplasty; and y, year. For expansion of study names, see corresponding reference.

*14% of patients had unstable angina or AMI within less than 48 h.

†PTCA, DCA, and HSRA (also excimer laser in IMPACT-II).

Reprinted with permission from Karvouni et al. *J Am Coll Cardiol* 2003;41:26-32 (701).

Table 24b. Subgroup Analyses for Mortality After PCI in Trials of Glycoprotein IIb/IIIa Inhibitors (See Table 24a for eligible trials)

	30 Days		6 Months	
	No. of Studies 20 (20 137)*	RR (95% CI) 0.69 (0.53 to 0.90)*	No. of Studies 14 (15 651)*	RR (95% CI) 0.79 (0.64 to 0.97)*
Population				
AMI	6 (3355)	0.69 (0.45 to 1.05)	6 (3355)	0.76 (0.55 to 1.05)
Mixed	2 (4240)	0.95 (0.54 to 1.68)	2 (4240)	0.97 (0.65 to 1.44)
Non-AMI	12 (12 542)	0.59 (0.39 to 0.89)	6 (8056)	0.71 (0.49 to 1.03)
Procedure				
Stent	7 (5736)	0.69 (0.43 to 1.09)	7 (5736)	0.70 (0.49 to 1.01)
Other	13 (14 401)	0.70 (0.51 to 0.96)	7 (9915)	0.84 (0.65 to 1.09)
Postprocedure				
Heparin	7 (4791)	0.72 (0.47 to 1.09)	5 (4548)	0.83 (0.60 to 1.13)
No heparin	13 (15 346)	0.68 (0.49 to 0.95)	9 (11 103)	0.77 (0.58 to 1.01)
Agent				
Abciximab	14 (11 606)	0.69 (0.51 to 0.94)	12 (11 446)	0.77 (0.61 to 0.96)
Tirofiban	2 (2234)	1.05 (0.42 to 2.61)	1 (2141)	1.27 (0.65 to 2.48)
Eptifibatide	4 (6297)	0.60 (0.33 to 1.06)	1 (2064)	0.56 (0.24 to 1.34)

AMI indicates acute myocardial infarction; CI, confidence interval; No., number; and RR, risk ratio (fixed effects).

There was no statistically significant heterogeneity in any case, and random effects estimates were similar (data not shown).

*Refers to all patients.

Reprinted with permission from Karvouni *et al.* *J Am Coll Cardiol* 2003;41:6-32 (701).

for the CAPTURE investigators, also reported that among the 1265 patients with UA enrolled in the CAPTURE trial, troponin T and CK-MB from 890 patients correlated with subsequent 6-month adverse cardiac risk. In patients without elevated troponin T levels, there was no benefit of treatment with respect to the relative risk of death or MI at 6 months (OR 1.26, CI 95% 0.74 to 2.31; *P* equals 0.47). Serum troponin T level, which is considered to be a surrogate marker for thrombus formation, identified a high-risk subgroup of patients with refractory UA suitable for coronary intervention who would particularly benefit from antiplatelet treatment with abciximab (192).

One putative limitation of abciximab is the potential for immune-mediated hypersensitivity reactions after subsequent readministration. Thrombocytopenia after readministration occurs in 3.5% to 6.3% of patients, which is similar to the rate of occurrence in patients receiving abciximab for the first time. Therefore, the absence of thrombocytopenia after a first abciximab exposure does not guarantee protection against its occurrence upon re-exposure. Moreover, the prevalence of severe thrombocytopenia (2.8%) and profound thrombocytopenia (2.0%) is greater with readministration than the incidence observed after first-time administration (1.0% and 0.4% for severe and profound thrombocytopenia, respectively) (202). With the first administration, human antichimeric antibodies (HACA) form in approximately 6% of patients (702). The implications of HACA, however, are unclear. Among 500 patients enrolled in the ReoPro

Readministration Registry (R3), there were no cases of anaphylaxis or other allergic manifestations whether or not HACA was present, and HACA was not predictive of any other measure of complication or success. From the R3 study, HACA has been shown to be an IgG (not IgE) immunoglobulin that does not neutralize abciximab. The more worrisome clinical phenomenon associated with readministration is the potential for increased rates of thrombocytopenia. In the 500-patient R3, a 4.4% incidence in thrombocytopenia (to a platelet count of less than 100×10^9 per liter) was observed, with half of the patients developing acute profound thrombocytopenia (to a platelet count of less than 20×10^9 per liter). This potential complication should always be monitored when treating a patient with abciximab (194-197). Abciximab readministration poses greater risk within 2 weeks of original abciximab dose.

6.2.2.2. Eptifibatide

The clinical utility of eptifibatide, a short-acting cyclic heptapeptide that also inhibits the GP IIb/IIIa receptor, was evaluated in the Integrilin to Manage Platelet Aggregation to prevent Coronary Thrombosis-II (IMPACT-II) trial, a double-blind, randomized, placebo-controlled multicenter trial that enrolled 4010 patients undergoing coronary angioplasty (198). Patients were assigned to treatment with aspirin, heparin and placebo, aspirin, heparin, and eptifibatide bolus (135 mcg per kg) followed by a low-dose eptifibatide infu-

Table 25. Recommendations for Use of GP IIb/IIIa Inhibitors in Patients Undergoing PCI

UA/NSTEMI and Clopidogrel Used	UA/NSTEMI and Clopidogrel Not Used	STEMI	Elective PCI
Abciximab, eptifibatide, or tirofiban	Abciximab, eptifibatide, or tirofiban	Abciximab	Abciximab, eptifibatide, or tirofiban
<i>Class IIa; LOE: B</i>	<i>Class I; LOE: A</i>	<i>Class IIa; LOE: B</i>	<i>Class IIa; LOE: B</i>
		Eptifibatide or tirofiban	
		<i>Class IIb; LOE: C</i>	

LOE indicates level of evidence; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; and UA/NSTEMI, unstable angina/non-ST-elevation myocardial infarction.

sion (0.5 mcg per kg per min for 20 to 24 h), or aspirin, heparin, and eptifibatide bolus (135 mcg per kg) and higher-dose infusion (0.75 mcg per kg per min for 20 to 24 h) (198). The 30-day composite primary end point of death, MI, unplanned surgical or repeat percutaneous revascularization, or coronary stent implantation for abrupt closure occurred in 11.4% of placebo-treated patients compared with 9.2% in the 135/0.5-mcg eptifibatide group (*P* equals 0.063) and 9.9% in the 135/0.75-mcg eptifibatide group (*P* equals 0.22) (198). The frequency of major bleeding events and transfusions was similar among the 3 groups.

A higher bolus and infusion of eptifibatide was evaluated in 10 948 patients with UA/NSTEMI who were assigned to treatment with placebo or 1 of 2 doses of eptifibatide: 180 mcg per kg bolus plus 1.3 mcg per kg per min infusion (180/1.3) or 180 mcg per kg bolus plus 2.0 mcg per kg per min infusion (180/2.0) (199). Compared with placebo, patients receiving 180/2.0-mcg eptifibatide had a lower frequency of 30-day death or MI (15.7% vs 14.2%; *P* equals 0.042). In patients undergoing early (less than 72 h) coronary intervention, 30-day composite events occurred less often in patients receiving 180/2.0-mcg eptifibatide (11.6% and 16.7% in placebo-treated patients; *P* equals 0.01) (200, 201).

The ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy) trial evaluated the efficacy and safety of eptifibatide treatment as adjunctive therapy during nonemergency coronary stent implantation. A total of 2064 patients were enrolled from June 1999 to February 2000 in this multicenter, randomized, double-blind, parallel-group, placebo-controlled (crossover-permitted) clinical trial. A double-bolus regimen of eptifibatide (180 mcg per kg bolus followed by a 2.0 mcg per kg per min infusion, with a second 180 mcg per kg bolus given 10 min after the first bolus) was compared with placebo treatment. The 48-h primary composite end point of death, MI, urgent target-vessel revascularization, or bailout treatment with open-label GP IIb/IIIa inhibitor therapy was reduced 37% from 10.5% to 6.6% (*P* equals 0.0015). There was a consistent treatment benefit across all components of the end point and across all subgroups of patients. At 30 days, the key secondary composite end point of death, MI, and urgent target-vessel revascularization was also improved 35% from 10.4% to 6.8% (*P* equals 0.0034) (200,201).

6.2.2.3. Tirofiban

Tirofiban is a nonpeptidyl tyrosine derivative that produces a dose-dependent inhibition of GP IIb/IIIa-mediated platelet aggregation (720). The clinical effect of tirofiban during coronary angioplasty was evaluated in the Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trial, a double-blind, placebo-controlled trial of 2139 patients with UA or acute MI defined by CK measured at the end of 36 h or at the time of discharge (715). Patients were randomly assigned to aspirin, heparin, and a tirofiban bolus (10 mcg per kg over 3 min) plus infusion (0.15 mcg per kg per minute), or to aspirin, heparin, and a placebo bolus plus infusion for 36 h. The primary end point of the trial was the occurrence of major events at 30-day, including death due to any cause, MI, coronary bypass surgery due to angioplasty failure or recurrent ischemia, repeat target-vessel angioplasty for recurrent ischemia, or insertion of a stent due to threatened abrupt closure (715). The rate of primary 30-day end point was reduced from 12.2% in the placebo group to 10.3% in the tirofiban group (*P* equals 0.160). Patients treated with tirofiban had a 38% relative reduction in the composite end point at 48 h (*P* less than 0.005) and a 27% relative reduction at 7 days (*P* equals 0.022). The incidence of major bleeding was similar in the 2 groups with the TIMI criteria (2.4% in tirofiban-treated patients and 2.1% in placebo-treated patients; *P* equals 0.662) (715), although major bleeding tended to be higher in tirofiban-treated patients (5.3% vs 3.7% in placebo-treated patients; *P* equals 0.096). Thrombocytopenia was similar in both groups (0.9% for the placebo group vs 1.1% for the tirofiban group; *P* equals 0.709) (721). A larger clinical benefit with tirofiban was seen in patients with UA undergoing coronary angioplasty in the PRISM-PLUS study, a randomized trial of 1570 patients with UA or non-Q-wave MI assigned to 48- to 108-h treatment with heparin plus tirofiban or heparin alone (722). Coronary angioplasty was performed in 30.5% of patients between 49 to 96 h after randomization (722). The composite end point of death, MI, or refractory ischemia was reduced significantly in the heparin plus tirofiban group compared with the heparin alone group (10.0% vs 15.7%; *P* less than 0.01) (722).

6.2.3. Antithrombotic Therapy

6.2.3.1. Unfractionated Heparin, Low-Molecular-Weight Heparin, and Bivalirudin

Class I

1. **Unfractionated heparin should be administered to patients undergoing PCI. (Level of Evidence: C)**
2. **For patients with heparin-induced thrombocytopenia, it is recommended that bivalirudin or argatroban be used to replace heparin. (Level of Evidence: B)**

Class IIa

1. **It is reasonable to use bivalirudin as an alternative to unfractionated heparin and glycoprotein IIb/IIIa antagonists in low-risk patients undergoing elective PCI. (Level of Evidence: B)**
2. **Low-molecular-weight heparin is a reasonable alternative to unfractionated heparin in patients with UA/NSTEMI undergoing PCI. (Level of Evidence: B)**

Class IIb

Low-molecular-weight heparin may be considered as an alternative to unfractionated heparin in patients with STEMI undergoing PCI. (Level of Evidence: B)

Intravenous unfractionated heparin prevents clot formation at the site of arterial injury (723) and on coronary guidewires and catheters used for coronary angioplasty (724). Although the intensity of anticoagulation with unfractionated heparin is generally determined with activated partial thromboplastin times, these values are less useful for monitoring anticoagulation during coronary angioplasty, because higher levels of anticoagulation are needed than can be discriminated with the activated partial thromboplastin time alone. Instead, the activated clotting time (ACT) has been more useful to follow heparin therapy during coronary angioplasty (725). The Hemochron and HemoTec devices are commonly used to measure ACT values during coronary angioplasty (725-727). The Hemochron ACT generally exceeds the HemoTec ACT by 30 to 50 s, although considerable measurement variability exists.

Empiric recommendations regarding heparin dosage during coronary angioplasty have been proposed (728,729), but ACT levels after a fixed dose of unfractionated heparin may vary substantially due to differences in body size (730), concomitant use of other medications, including intravenous nitroglycerin (731,732), and in the presence of acute coronary syndromes that increase heparin resistance.

The relationship between the level of the ACT and development of ischemic complications during coronary angioplasty has been controversial. Whereas some studies have identified an inverse relationship between the initial ACT and the risk of ischemic events (733,734), others found either no relationship or a direct relationship between the degree of anticoagulation and occurrence of complications (735). It is generally believed that very high levels (ACTs greater than

400 to 600 s) of periprocedural anticoagulation are associated with an increased risk for bleeding complications (736).

The safety of low-dose heparin during coronary angioplasty has also been shown in a recent study. Fatal complications (0.3%), emergency bypass surgery (1.7%), MI (3.3%), or repeat angioplasty within 48 h (0.7%) were uncommon after an empiric bolus of heparin 5000 U at the beginning of the procedure (618). In a smaller randomized study of 400 patients assigned to fixed-dose heparin (15 000 international units [IU]) or weight-adjusted heparin (100 IU per kg), there were no differences in procedural success or bleeding complications between the 2 groups (737), although use of the weight-adjusted heparin resulted in earlier sheath removal and more rapid transfer to a step-down unit (737). Another advantage of weight-adjusted heparin dosing is that “over-shooting” of the ACT value can be avoided.

Two analyses of ACT and PCI-related complications have not detected any relationship between ACT level and ischemic complications, which suggests that the degree of anticoagulation during PCI may be less of a factor in determining complications than in the earlier era of balloon angioplasty (738,739). The results of these limited studies suggest that heparin is an intraprocedural component for PCI, despite dosing uncertainties and an unpredictable therapeutic response with the unfractionated preparation. It appears that weight-adjusted heparin dosing may provide a clinically superior anticoagulation method to fixed heparin dosing, although definitive studies are lacking.

Routine use of unfractionated heparin after an uncomplicated coronary angioplasty is no longer recommended (72,740-743) and may be associated with more frequent bleeding events (72,740), particularly when platelet GP IIb/IIIa inhibitors are used (72,740). Subcutaneous administration of unfractionated heparin (741) may provide a safer and less costly means of extending antithrombin therapy than intravenous unfractionated heparin if there are clinical reasons to continue anticoagulation, such as residual thrombus or significant residual dissections.

In the SYNERGY (Superior Yield of the New strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors) study, patients with NSTEMI were randomized to treatment with either unfractionated heparin or subcutaneously administered enoxaparin. In patients who underwent PCI within 8 h of the last subcutaneous dose, no additional anticoagulation was administered. In those patients who underwent PCI 8 to 12 h after the last subcutaneous dose, an additional intravenous dose of enoxaparin 0.3 mg per kg was administered at the time of PCI. The rates of major ischemic complications in those patients undergoing PCI were similar between those treated with unfractionated heparin and those treated with enoxaparin (744). Bleeding was observed to be higher in those patients who “crossed over” from one anticoagulant to the other. Some of these crossover patients were those who received a different anticoagulant than what they had been randomized to and had received before. On the basis of this observation, it appears prudent to not give an additional anticoagulant to patients who are receiving one

form of anticoagulant (e.g., not to give unfractionated heparin to those who have received subcutaneous enoxaparin within the last 12 h and not to give intravenous enoxaparin to those receiving intravenous heparin).

The safety and efficacy of low-molecular-weight heparin therapy in patients undergoing PCI has been evaluated. In all but 1 of these studies, the agent studied has been enoxaparin. These studies have found bleeding and ischemic complication rates to be low and comparable to those observed in PCI patients who had been treated with unfractionated heparin.

In those patients who have received subcutaneous enoxaparin for the treatment of NSTEMI and are to undergo PCI within 8 h of the last subcutaneous dose, no additional anticoagulant should be administered. In those who undergo PCI 8 to 12 h after the last subcutaneous dose, an additional intravenous dose of 0.3 mg per kg should be administered immediately before device activation.

Bivalirudin, a hirudin analog, is a direct thrombin inhibitor. It has been tested against heparin and a GP IIb/IIIa inhibitor in the REPLACE-2 trial of patients undergoing PCI without high-risk features. The primary end point at 30 days included major bleeding plus the usual end points of death, MI, and urgent revascularization. These events occurred in 9.2% of the bivalirudin group and 10% of the group given unfractionated heparin plus GP IIb/IIIa inhibitors (nonsignificant). The secondary end point was freedom from death, MI, and urgent revascularization and occurred in 7.6% of the bivalirudin group and 7.1% of the group given unfractionated heparin plus GP IIb/IIIa inhibitors (also nonsignificant), but bleeding (combined major and moderate bleeding) was significantly reduced in the bivalirudin group (from 7.1% to 2.4%, P less than 0.001). Although a small, nonsignificant increase in periprocedural NSTEMI was seen in the bivalirudin-treated patients, by 1 year mortality was not significantly increased in the bivalirudin group (1.89% vs 2.46%) (744a). These results established that bivalirudin is not superior to standard therapy, but it appears to be a reasonable alternative in non-high-risk patients (745). Bivalirudin is a good anticoagulant for use in patients with heparin-induced thrombocytopenia and those with renal failure (746). Argatroban is also an effective therapy for heparin-induced thrombocytopenia (747). More data are needed to establish its use for patients with STEMI, NSTEMI, and diabetes.

6.2.3.2. Heparin Dosing Guidelines

In those patients who do not receive GP IIb/IIIa inhibitors, sufficient unfractionated heparin should be given during coronary angioplasty to achieve an ACT of 250 to 300 s with the HemoTec device and 300 to 350 s (200,201) with the Hemochron device. A weight-adjusted bolus heparin (70 to 100 IU per kg) can be used to avoid excess anticoagulation. If the target values for ACT are not achieved after a bolus of heparin, additional heparin boluses (2000 to 5000 IU) can be given. Early sheath removal should be performed when the ACT falls to less than 150 to 180 s.

The unfractionated heparin bolus should be reduced to 50 to 70 IU per kg when GP IIb/IIIa inhibitors are given in order

to achieve a target ACT of 200 s with either the HemoTec or Hemochron device. The currently recommended target ACT for eptifibatid and tirofiban is less than 300 s during coronary angioplasty. Postprocedural heparin infusions are not recommended during GP IIb/IIIa therapy (748-750).

Transitioning of patients with acute coronary syndromes who have been treated with enoxaparin from the medical floor to the cardiac catheterization laboratory is based on pharmacokinetic data, clinical experience, and expert opinion. In patients who received the last subcutaneously administered dose of enoxaparin within 8 h, no additional anticoagulant therapy is needed before PCI is performed. In patients who received the last subcutaneously administered dose of enoxaparin between 8 and 12 h before PCI, an additional 0.3 mg per kg dose of enoxaparin should be administered intravenously before PCI (whether or not the patient is to be treated with a GP IIb/IIIa inhibitor). Alternatively, in the latter group of patients, supplemental anticoagulation with unfractionated heparin can be used. Unfractionated heparin 50 U per kg (with a target ACT of 200 to 250 s) may be administered in those patients to be treated with a GP IIb/IIIa inhibitor; 60 U per kg unfractionated heparin (with a target ACT of 250 to 300 s) may be administered in those patients who are not concomitantly treated with a GP IIb/IIIa inhibitor. A higher risk of bleeding may result if patients cross over between different anticoagulant therapies during the index admission.

Low-molecular-weight heparins have little effect on measurements of ACT. Therefore, the ACT should not be used as a guide to anticoagulation therapy in patients currently being treated with a low-molecular-weight heparin. Sheath removal when followed by manual groin compression may be performed 4 h after the last intravenous dose of enoxaparin or 6 to 8 h after the last subcutaneous dose of enoxaparin (751,752).

6.3. Post-PCI Management

After PCI, in-hospital care should focus on monitoring the patient for recurrent myocardial ischemia, achieving hemostasis at the catheter insertion site, detecting and preventing contrast-induced renal failure, and monitoring results of the vascular closure device, if used (753). Attention should also be directed toward implementing appropriate secondary atherosclerosis prevention programs. The patient should understand and adhere to recommended medical therapies and behavior modifications known to reduce subsequent morbidity and mortality from coronary heart disease.

Most patients can be safely discharged from the hospital within the next calendar day after an uncomplicated elective PCI. Special skilled nursing units have been developed by many institutions to facilitate post-PCI management. Specific protocols for sheath removal, continuation of anticoagulation or antiplatelet therapies, and observation for recurrent myocardial ischemia/infarction and contrast-induced renal failure are of particular assistance in ensuring appropriate outcomes during this period. Pilot studies suggest that selected patients may be discharged on the same day

after PCI (754,755) especially when the procedure is performed by the percutaneous radial or brachial approach (756). However, confirmation by larger studies is necessary before widespread endorsement of this strategy.

In the prior setting of aggressive systemic anticoagulation, vascular complications may occur in as many as 14% of patients after PCI, but those requiring surgical repair occur in 3.5% (736) of patients, although lower rates of vascular complications can now be expected with reduced anticoagulation and smaller sheath sizes (757-762). Major factors associated with vascular complications include use of fibrinolytic or platelet inhibitor therapy, coexisting peripheral vascular disease, female gender, prolonged heparin use with delayed sheath removal, and older age (736,758,760-764). Although most bleeding complications at the vascular access site are obvious and readily managed, physicians and nurses should remain alert for retroperitoneal hematoma, the signs and symptoms of which may include hypotension, marked suprainguinal tenderness, and severe back or lower-quadrant abdominal pain (765). Post-PCI hematocrit should be monitored for a decrease greater than absolute 5% to 6%. Computed tomography can confirm the diagnosis of retroperitoneal hematoma, and more than 80% of patients can be treated conservatively with transfusions without surgery (764). Pseudoaneurysms may be treated effectively with ultrasound-directed compression in the majority of patients who are not bleeding and do not require continued anticoagulation (763,766,767). Arteriovenous fistulas, generally occurring late after a procedure, are detected by a continuous murmur over the puncture site and, in rare cases, may be associated with high-output failure. In general, repeat use of the access site should be avoided because of the possibility of making the fistula larger, accessing the vein when attempting to access the artery, and increasing potential issues with hemostasis. Both pseudoaneurysm and arteriovenous fistula can occur secondary to cannulation of the superficial rather than the common femoral artery (768). Arterial compression systems and percutaneous vascular closure devices reduce the incidence of vascular complications (753,756). A meta-analysis involving 37 000 patients undergoing diagnostic coronary arteriography and PCI compared manual compression with 3 closure devices (VasoSeal™, AngioSeal™, and PerClose™). No difference was seen in access-related complications between manual compression, PerClose™, and AngioSeal™; however, there were more complications associated with VasoSeal™ than with manual compression. The complications evaluated included pseudoaneurysm requiring ultrasound-guided compression or surgical repair; arteriovenous fistula; retroperitoneal hematoma causing hemodynamic compromise and necessitating surgery, blood transfusion, prolonged hospitalization, and/or death; femoral artery thrombosis (vessel occlusion requiring surgery or thrombolysis); surgical vascular repair; access-site infection necessitating treatment with antibiotics or surgical drainage; and blood transfusion. The study was performed with early generations of devices. Potential benefits of newer adjunctive therapies are not well established (753,769). However, the

degree to which these technologies reduce length of hospital stay and cost remains to be determined (764,770-772).

Patients with pre-existing renal insufficiency, diabetes, and dehydration are at higher risk and should be monitored for contrast-induced nephropathy, generally defined as an increase of greater than 25% or greater than 0.5 mg per dL in serum creatinine that occurs within 48 h after PCI. In addition, those patients receiving higher contrast loads or a second contrast load within 72 h and those undergoing IABP placement should have renal function assessed. A risk score based on 8 variables (hypotension, IABP, HF, chronic renal insufficiency, diabetes, age more than 75 years, anemia, and contrast volume) has been developed to assist in the identification of patients at risk for contrast-induced nephropathy after PCI (773). Whenever possible, nephrotoxic drugs (certain antibiotics, nonsteroidal anti-inflammatory agents, and cyclosporine) and metformin (especially in those with pre-existing renal dysfunction) should be withheld for 24 h before PCI is performed, and consideration should be given to withholding angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the day of the procedure (774-776). Although data on the prevention of contrast-induced nephropathy are inconclusive, several measures including preprocedural and postprocedural hydration, use of low and iso-osmolar contrast agents, and pretreatment with acetylcysteine or sodium bicarbonate may be helpful in reducing the incidence of contrast-induced nephropathy among higher-risk patients (774,775,777).

6.3.1. Postprocedure Evaluation of Ischemia

After PCI, chest pain may occur in as many as 50% of patients. ECG evidence of ischemia identifies those with significant risk for acute vessel closure (6,118,119,778-780). When angina pectoris or ischemic ECG changes occur after PCI, the decision to proceed with further interventional procedures, CABG surgery, or medical therapy should be individualized on the basis of factors such as hemodynamic stability, amount of myocardium at risk, and the likelihood that the treatment will be successful.

A 12-lead ECG should be obtained before and soon after PCI and again if symptoms should occur. Angina-like symptoms with ECG changes will assist in determining the need for repeat angiography and for additional therapy.

As discussed in Section 6.2.2, coronary stents and platelet GP receptor inhibitors have reduced the incidence of acute closure significantly. Factors that correlate with a poor outcome after acute coronary closure include age greater than 70 years, large ischemic burden, presentation with acute coronary syndromes, and LV ejection fraction less than 30% (778-780).

Elevated levels of CK or the MB subfraction (CK-MB) or ECG abnormalities are reported to occur in 5% to 30% of patients after PCI (23). The mechanisms associated with CK release include side-branch occlusion, distal embolization, intimal dissection, and coronary spasm (781). A more frequent requirement for revascularization procedures and a

higher risk of death or subsequent MI are associated with elevated cardiac biomarkers, increasing as a continuous function with no obvious threshold effect. Both acute and chronic complications are more common among patients with elevated cardiac biomarkers. Even in patients with low-level elevations of CK-MB in whom the in-hospital risk is low, the intermediate- and long-term risks are also increased. Postprocedural increases in CK and CK-MB are not specific for a particular technique and have been reported after balloon angioplasty, directional and rotator atherectomy, excimer laser angioplasty, and stent placement. Kong *et al.* (782) found that increased levels of CK are a significant independent predictor of cardiac mortality and subsequent MI (56). Cardiac mortality after elective PCI was significantly higher for patients with high (more than 3.0 times normal) and intermediate (1.5 to 3.0 times normal) CK compared with those with low CK (more than 1.0 but less than 1.5 times normal) elevations and control patients (P equals 0.007). (See Section 3.2, Acute Outcome: Procedural Complications.)

CK and CK-MB measurements should be obtained in patients with suspected ischemia (prolonged chest pain, side-branch occlusion, recurrent ischemia, or hemodynamic instability) during PCI. Ideally, the European Society of Cardiology and the ACC recommend that small infarcts may and should be detected by serial blood sampling and analysis before and after the procedure (6 to 8 h before and 24 h after, respectively) (21). In patients in whom a clinically driven CK-MB determination is made, a CK-MB index increase of more than 5 times the upper limit of normal should be treated as signifying an MI, and the patient should be referred for further observation. The results of CK-MB should be considered for the discharge management strategies for these patients.

The troponin isoforms I and T have a high level of sensitivity and specificity for the diagnosis of acute MI. Troponin T or I elevation occurs frequently after PCI. The timing of the peak elevation after PCI is unclear (25). Minor elevations do not appear to have prognostic value, whereas marked (more than 5 times) elevations are associated with worsened 1-year outcome (26,27).

6.3.2. Risk Factor Modifications

All patients should be instructed about necessary behavior and risk factor modification, and the appropriate medical therapies should be initiated for the secondary prevention of atherosclerosis before the patient leaves the hospital. The interventional cardiologist should emphasize the importance of these measures directly to the patient, because failure to do so may suggest that secondary prevention therapies are not necessary. The interventional cardiologist should interact with the primary care physician to ensure that the necessary secondary prevention therapies initiated during hospitalization are maintained by patients after discharge from the hospital. Secondary prevention measures are an essential part of long-term therapy because they can reduce future morbidity and mortality associated with the atherosclerotic process.

Depending on the risk factors and contraindications present, advice should include antithrombotic therapy (aspirin and/or clopidogrel or ticlopidine), control of hypertension, diabetic management, aggressive control of serum lipids, maintenance of a low-density lipoprotein cholesterol level substantially below 100 mg per dL (optional therapeutic target less than 70 mg per dL in very-high-risk patients [611]), abstinence from tobacco use, weight control, regular exercise, beta-blocker use, and inhibition of the renin-angiotensin-aldosterone system as recommended in the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Table 26) (332,783). Given the natural history and pathophysiology of CAD among patients undergoing PCI, the clinically indicated secondary prevention measures (Table 26) (332,783), which usually include aspirin, statin therapy, beta-blockers, and inhibitors of the renin-angiotensin-aldosterone system, should be continued indefinitely except in those patients intolerant to these agents (242,783-792). Patients should receive instructions on participation in cardiac rehabilitation and the timing of return to full activities, be informed to contact their physician or seek immediate medical attention if symptoms recur, and have made plans for a follow-up visit to assess compliance with secondary prevention therapies.

6.3.3. Exercise Testing After PCI

The published ACC/AHA practice guidelines for exercise testing (793) provide an excellent summary of the available information on exercise testing after PTCA. Although restenosis remains the major limitation of PCI, symptom status is an unreliable index to development of restenosis, with 25% of asymptomatic patients documented as having ischemia on exercise testing (794). (See Section 5.1, Patients With Asymptomatic Ischemia or CCS Class I or II Angina for further information.)

To identify restenosis rather than predict the probability of its occurrence, patients may be tested later (3 to 6 months after PCI). Table 27 reviews the predictive value of exercise testing for restenosis (794-802). Variability is attributed predominantly to differences in the populations studied and criteria for restenosis.

Because myocardial ischemia, whether painful or silent, worsens prognosis (803), some authorities have advocated routine testing. However, the ACC/AHA practice guidelines for exercise testing favor selective evaluation in patients considered to be at particularly high risk (e.g., patients with decreased LV function, multivessel CAD, proximal LAD disease, previous sudden death, diabetes mellitus, left main disease, hazardous occupations, and suboptimal PCI results) (793). The exercise ECG is an insensitive predictor of restenosis, with sensitivities ranging from 40% to 55%, significantly less than those obtainable with single photon emission computed tomography (SPECT) (804,805) or exercise echocardiography (806-808). This lower sensitivity of the exercise ECG and its inability to localize disease limit its usefulness in patient management both before and after PCI (797,804,809). For these reasons, stress imaging is preferred

Table 26. Comprehensive Risk Reduction for Patients With Coronary and Other Vascular Disease After PCI

Goals	Intervention Recommendations				
<p>Smoking: <u>Goal</u> Complete cessation. No exposure to environmental tobacco smoke</p>	<p>Ask about tobacco status at every visit. Strongly encourage patient and family to stop smoking and to avoid environmental tobacco smoke. Assess the tobacco user's willingness to quit. Assist by counseling and developing a plan for quitting. Arrange follow-up, referral to special programs, or pharmacological therapy (including nicotine replacement and bupropion). Urge avoidance of exposure to environmental tobacco smoke at work and home.</p>				
<p>Blood pressure control: <u>Goal</u> Less than 140 over 90 mm Hg or less than 130 over 80 mm Hg if chronic kidney disease or diabetes is present</p>	<p><i>If blood pressure is 120 over 80 mm Hg or greater:</i></p> <ul style="list-style-type: none"> • Initiate or maintain lifestyle modification (weight control, increased physical activity, alcohol moderation, moderate sodium restriction, and emphasis on fruits, vegetables, and low-fat dairy products) in all patients. <p><i>If blood pressure is 140 over 90 mm Hg or greater (or 130 over 80 mm Hg or greater for individuals with chronic kidney disease or diabetes):</i></p> <ul style="list-style-type: none"> • Add blood pressure medication, emphasizing the use of beta-blockers and inhibitors of the renin-angiotensin-aldosterone system. 				
<p>Lipid management: (TG less than 200 mg per dL)</p>	<p>Start dietary therapy in all patients (less than 7% of total calories as saturated fat and less than 200 mg of cholesterol per day). Promote physical activity and weight management. Encourage increased consumption of omega-3 fatty acids in fish[#] or 1 g per day omega-3 fatty acids from supplements for risk reduction (for treatment of elevated TG, higher doses are usually necessary for risk reduction).</p>				
<p><u>Primary goal</u> LDL-C substantially less than 100 mg per dL (optional target less than 70 mg per dL for very-high-risk patients)[¶]</p>	<p>Assess fasting lipid profile in all patients, preferably within 24 h of an acute event. For patients hospitalized, initiate lipid-lowering medication as recommended below before discharge according to the following guide:</p> <table border="0" data-bbox="706 1050 1550 1302"> <tr> <td data-bbox="706 1050 1023 1102"> LDL-C less than 100 mg per dL (baseline or on-treatment): </td> <td data-bbox="1209 1050 1518 1123"> LDL-C greater than or equal to 100 mg per dL (baseline or on-treatment): </td> </tr> <tr> <td data-bbox="738 1123 1079 1155"> <ul style="list-style-type: none"> • Statins preferred to lower LDL-C. </td> <td data-bbox="1250 1123 1550 1302"> <ul style="list-style-type: none"> • Initiate or intensify LDL-C-lowering therapy with drug treatment. May require combination therapy with standard-dose ezetimide, bile acid sequestrant, or niacin[‡]. </td> </tr> </table>	LDL-C less than 100 mg per dL (baseline or on-treatment):	LDL-C greater than or equal to 100 mg per dL (baseline or on-treatment):	<ul style="list-style-type: none"> • Statins preferred to lower LDL-C. 	<ul style="list-style-type: none"> • Initiate or intensify LDL-C-lowering therapy with drug treatment. May require combination therapy with standard-dose ezetimide, bile acid sequestrant, or niacin[‡].
LDL-C less than 100 mg per dL (baseline or on-treatment):	LDL-C greater than or equal to 100 mg per dL (baseline or on-treatment):				
<ul style="list-style-type: none"> • Statins preferred to lower LDL-C. 	<ul style="list-style-type: none"> • Initiate or intensify LDL-C-lowering therapy with drug treatment. May require combination therapy with standard-dose ezetimide, bile acid sequestrant, or niacin[‡]. 				
<p>Lipid management: (TG 200 mg per dL or greater)</p>	<p>If TG is greater than or equal to 150 mg per dL or HDL-C is less than 40 mg per dL:</p> <ul style="list-style-type: none"> • Emphasize weight management and physical activity. Advise smoking cessation. 				
<p><u>Primary goal</u> Non-HDL-C* substantially less than 130 mg per dL</p>	<p>If TG is 200-499 mg per dL:</p> <ul style="list-style-type: none"> • After LDL-C-lowering therapy^{†**}, consider adding fibrate or niacin[‡]. 				
<p>Physical activity: <u>Minimum goal</u> 30 minutes 5 days per week; optimal daily</p>	<p>Assess risk, preferably with exercise test, to guide prescription. Encourage minimum of 30 to 60 minutes of activity, preferably daily or at least 5 times weekly (brisk walking, jogging, cycling, or other aerobic activity) supplemented by an increase in daily lifestyle activities (e.g., walking breaks at work, gardening, household work). Encourage resistance training 2 days per week. Cardiac rehabilitation programs are recommended, particularly for those patients with multiple modifiable risk factors and/or those moderate- to high-risk patients in whom supervised exercise training is warranted.</p>				

Continued on next page

Table 26. *Continued*

Goals	Intervention Recommendations
<p>Weight management: <u>Goal</u> BMI 18.5 to 24.9 kg per m²</p> <p>Waist circumference: Women: Less than 35 inches Men: Less than 40 inches</p>	<p>Calculate BMI and measure waist circumference as part of evaluation. Monitor response of BMI and waist circumference to therapy.</p> <p>Start weight management and physical activity as appropriate. Desirable BMI range: 18.5 to 24.9 kg per m².</p> <p>If waist circumference is 35 inches or greater in women or 40 inches or greater in men, initiate lifestyle changes and consider treatment strategies for metabolic syndrome.</p>
<p>Diabetes management: <u>Goal</u> HbA1c less than 7%</p>	<p>Appropriate glucose-lowering therapy to achieve near-normal fasting plasma glucose as indicated by HbA1c.</p> <p>Treatment of other risk factors (e.g., physical activity, weight management, blood pressure cholesterol management).</p>
<p>Antiplatelet agents/ anticoagulants:</p>	<p>For all post-PCI stented patients, aspirin 325 mg daily should be given for at least 1 month after bare metal stent implantation, 3 months after sirolimus stent, and 6 months after paclitaxel stent, after which daily chronic aspirin^{††} (75 to 162 mg per day) should be continued indefinitely in all patients if not contraindicated.</p> <p>For post-PCI stented patients, clopidogrel 75 mg per day should be given for at least 1 month after bare metal stent implantation, 3 months after sirolimus stent, and 6 months after paclitaxel stent, after which clopidogrel should ideally be continued up to 12 months in all stented patients who are not at high risk of bleeding. Use warfarin in combination with clopidogrel and low-dose aspirin with great caution and when INR is carefully regulated (2.0 to 3.0).</p> <p>Manage warfarin to INR 2.5 to 3.5 for post-MI patients when clinically indicated or for those not able to take aspirin or clopidogrel.</p>
<p>Renin-angiotensin-aldosterone system blockers:</p>	<p>Consider ACE inhibitors for all CHD patients indefinitely; start early after MI in stable high-risk patients (anterior MI, previous MI, Killip class greater than or equal to II [S₃ gallop, rales, radiographic HF]).</p> <p>Continue indefinitely in for all patients with LV dysfunction (ejection fraction less than or equal to 0.40) or symptoms of heart failure.</p> <p>Use as needed to manage blood pressure or consider for chronic therapy in all other patients.</p> <p>Use angiotensin receptor blockers in post-STEMI patients who are intolerant of ACE inhibitors and who have either clinical or radiological signs of heart failure or LVEF less than 0.40.</p> <p>Aldosterone blockade in post-STEMI patients without significant renal dysfunction[§] or hyperkalemia[‡] who are already receiving therapeutic doses of an ACE inhibitor, have an LVEF less than or equal to 0.40, and have either diabetes or heart failure.</p>
<p>Beta-blockers:</p>	<p>Start in all post-MI and acute patients (arrhythmia, LV dysfunction, inducible ischemia). Continue for a minimum of 6 months; continue indefinitely in patients with STEMI. Observe usual contraindications. Use as needed to manage angina, rhythm, or blood pressure in all other patients.</p>

ACE indicates angiotensin-converting enzyme; BMI, body mass index; HF, congestive heart failure; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; INR, international normalized ratio; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; and TG, triglyceride.

*Non-HDL-C equals total cholesterol minus HDL cholesterol.

[†]Treat to a goal of non-HDL-C substantially less than 130 mg per dL.

[‡]Dietary supplement niacin must not be used as a substitute for prescription niacin.

[§]Creatinine should be less than or equal to 2.5 mg per dL in men and less than or equal to 2.0 mg per dL in women.

[¶]Potassium should be less than or equal to 5.0 mEq per liter.

^{¶¶}Patients with acute coronary syndromes and other very-high-risk patients (e.g., established CHD plus multiple major risk factors [especially diabetes] or severe and poorly controlled risk factors [especially continued cigarette smoking and/or metabolic syndrome]) should be considered for optional LDL-C goal less than 70 mg per dL.

[#]Pregnant and lactating women should limit their intake of fish to minimize exposure to methylmercury.

**The use of resin is relatively contraindicated when TGs are greater than 200 mg per dL.

^{††}Some recommend avoiding regular use of ibuprofen, which may limit the cardioprotective effects of aspirin. Use of cyclo-oxygenase-2 inhibitors may be associated with increased incidence of cardiovascular events.

Modified with permission from Smith et al. *J Am Coll Cardiol* 2004;44:e211 (362). Downloaded from <http://online.lww.com/ahajournals> by Ted Feldman on March 19, 2006

Table 27. Predictive Value of Exercise ECG Testing for Identification of Restenosis After PCI

Author	Year	Ref	n	Clinical	Post-PCI, mo	Restenosis, %	Positive PV, %	Negative PV, %	Definition of Restenosis
Kidell	1989	(795)	398	Consecutive	Up to 6	33	66	75	Greater than 70% luminal diameter stenosis
Honan	1989	(796)	144	Post-MI	6	40	57	64	Greater than 75% luminal diameter stenosis
Schroeder	1989	(797)	111	Asymptomatic	6	12	53	63	Greater than 70% luminal diameter stenosis
Larman	1990	(798)	141	Asymptomatic	1 to 6	12	15	87	Greater than 50% luminal diameter stenosis
et Tamimi	1990	(799)	31	Consecutive	6	45	100	94	Loss of more than 50% initial gain of lumen diameter
Hengston	1990	(794)	200	Asymptomatic (n=127)	6	44	46	63	Greater than 75% luminal diameter stenosis
et			200	Symptomatic (n=66)	6	59	76	47	Greater than 75% luminal diameter stenosis
et	1994	(800)	78	1-vessel CAD	6	28	37	77	Greater than 50% luminal diameter stenosis
Desmet	1995	(801)	191	Asymptomatic	6	33	52	70	Greater than 50% luminal diameter stenosis

CAD indicates coronary artery disease; MI, myocardial infarction; mo, month; n, number of patients; PCI, percutaneous coronary intervention; PV, predictive value; and Ref, reference.

to evaluate symptomatic patients after PCI. If the patient's exertional capacity is significantly limited, coronary angiography may be more efficacious to evaluate symptoms of typical angina. Exercise testing after discharge is helpful for activity counseling and exercise training as part of cardiac rehabilitation. Neither exercise testing nor radionuclide imaging is indicated for the routine, periodic monitoring of asymptomatic patients after PCI without specific indications.

6.3.4. Left Main CAD

Class IIa

It is reasonable that patients undergoing PCI to unprotected left main coronary obstructions be followed up with coronary angiography between 2 and 6 months after PCI. (Level of Evidence: C)

Careful postprocedure surveillance with coronary angiography is needed to prevent fatal MI or sudden death that may be associated with ISR with a large area of myocardium in jeopardy; however, the frequency and best method of follow-up is unknown (162). Early experience in the ULTIMA registry using BMS for ULM lesions suggested a high early mortality (2% per month) after PCI, which led the study's authors to suggest routine surveillance angiography at 2 and 4 months after PCI (153). Others advocate routine stress testing or cardiac catheterization at 3 and 6 months even in asymptomatic patients (148,150). In view of these observations and suggestions, the Committee recommends routine

surveillance angiography at 2 to 3 months for all patients after ULM PCI. Studies from the DES era have reported the performance of routine angiography 4 to 8 months after PCI or earlier if clinically indicated by symptoms or documented myocardial ischemia (159,160).

7. SPECIAL CONSIDERATIONS

7.1. Ad Hoc Angioplasty—PCI at the Time of Initial Cardiac Catheterization

Ad hoc coronary intervention is defined as PCI performed at the same time as diagnostic cardiac catheterization. During the past several years, in an effort to reduce hospital length of stay and potentially reduce costs, PCI has increasingly been performed immediately after the diagnostic coronary angiographic procedure (811), with reported incidence ranging from 52% to 83% (812-814). The indications for diagnostic catheterization and coronary angiography in different catheterization laboratory settings are discussed in the ACC/SCAI Expert Consensus Document on Catheterization Laboratory Standards (Table 28) (309,815).

Ad hoc angioplasty has several inherent advantages. It expedites patient care, avoids a second invasive procedure with its associated risks and recognized morbidity, and reduces total X-ray exposure and therefore cost, but only in settings in which intrinsic risks are low (813). However, ad hoc intervention is associated with a higher procedural contrast use and should be avoided in situations where excessive

Table 28. Exclusion Criteria for Invasive Cardiac Procedures in Settings Without Full-Support Services

Location	Type of Patient	Diagnostic Procedures	Therapeutic Procedures
Hospitals	Adult	Age greater than 75 years NYHA class III or IV heart failure Acute, intermediate, or high-risk ischemic syndromes Recent MI with postinfarction ischemia Pulmonary edema thought to be caused by ischemia Markedly abnormal noninvasive test indicating a high likelihood of left main or severe multivessel coronary disease Known left main coronary artery disease Severe valvular dysfunction, especially in the setting of depressed LV performance	All valvuloplasty procedures, complex adult congenital heart disease diagnostic or therapeutic procedures Diagnostic pericardiocentesis when the effusion is small or moderate in size and there is no tamponade Elective coronary intervention
	Pediatric	No procedures approved	No procedures approved
Freestanding laboratories	Adult	All of the above plus high-risk patients by virtue of comorbid conditions, including need for anticoagulation, poorly controlled hypertension or diabetes, contrast allergy, or renal insufficiency	
	Pediatric	No procedures approved	No procedures approved

LV indicates left ventricular, MI, myocardial infarction; and NYHA, New York Heart Association.
 Modified from Bashore et al. *J Am Coll Cardiol* 2001;37:2170-214.

contrast has been used and when adequate pretreatment with aspirin or antiplatelet agents has not been achieved (814).

In contrast to ad hoc angioplasty, a staged approach also has several advantages. It allows ample time to review the angiogram and plan the procedural strategy; discuss the risks, benefits, and alternatives with the patient and family; and obtain consultation from cardiothoracic surgical colleagues. It is far more difficult to adequately inform the patient of risks, benefits, and alternatives without knowledge of the anatomy and the extent of coronary disease. A staged approach also allows for optimal hydration and pretreatment with oral antiplatelet agents. Explicit and clear informed consent, especially for ad hoc PCI, should be discussed by the interventional cardiologist with the patient and family.

Studies evaluating the outcome of patients undergoing ad hoc coronary intervention have reported that informed patients with suitable anatomy have a shorter hospital stay, less radiation exposure, and lower costs without an increase in procedural complications compared with patients undergoing a staged approach (812,813,816,817). In a multicenter cohort study of 35 700 patients undergoing elective coronary angioplasty between 1992 and 1995, the risk of a major complication (MI, emergency CABG, or death) from combined ("ad hoc") versus staged procedures was 2% and 1.6%, respectively. After adjustment for clinical and angiographic differences between groups, the risk from combined procedures was not significantly different. However, patients with multivessel disease, women, patients older than 65 years, and patients undergoing multilesion coronary angioplasty were at increased risk of an adverse outcome (818). In an analysis of patients in the New York State PCI Registry, in-hospital mortality was similar in patients undergoing ad hoc and staged procedures, although patients with HF had a significantly lower mortality when undergoing staged procedures. These studies suggest that it is safe to perform PCI after diagnostic catheterization in selected patients (819).

Ad hoc coronary intervention is particularly suitable for patients with clinical evidence of restenosis 6 to 12 months after the initial procedure (820), patients undergoing primary angioplasty for MI, and patients with refractory UA in need of urgent revascularization (821). Before the procedure, these patients should be treated with aspirin and clopidogrel (822) only when PCI with stent placement is highly likely, and they should give appropriate informed consent for anticipated PCI. Ad hoc PCI should be performed only in a well-informed patient, particularly in the setting of single-vessel disease without morphologic features predictive of an adverse outcome, when it is clear that this treatment strategy is the best alternative. However, ad hoc percutaneous revascularization should not be performed in patients in whom the angiographic findings are unanticipated or in whom the indication, suitability, or preference for percutaneous revascularization is unclear (823). Patient safety should be the paramount consideration when ad hoc intervention is being considered. This Committee endorses the recommendations from the SCAI that ad hoc PCI be individualized and not be a standard or required strategy for all patients (824). The

Writing Committee encourages future studies to further evaluate the outcomes associated with ad hoc angioplasty and its cost effectiveness.

7.2. PCI in Cardiac Transplant Patients

Allograft atherosclerosis and vasculopathy are the main cause of death in cardiac transplant recipients. Because no medical therapy is known to prevent graft atherosclerosis, and retransplantation is associated with decreased survival, palliative therapy with PCI has been proposed and performed (825). No single medical center has performed PCI in many patients, and thus, the responses and outcomes of a large cohort are unavailable for review. However, pooled information from 11 medical centers retrospectively analyzing results of coronary angioplasty in cardiac transplant patients has been reported (826). These investigators concluded that although high procedural success can be achieved and PCI may be applied in a selected cardiac transplant population with success and complication rates comparable to the routine patient population, it remains unknown whether PCI prolongs allograft survival.

Coronary stenting in cardiac allograft vascular disease has been performed in small numbers of patients with favorable results (827). Heublein *et al.* (828) compared angioplasty and stenting in 27 patients who received 48 stents, 5.7 plus or minus 2.9 years after heart transplantation. Coronary angioplasty resulted in a minimal increase in luminal dimensions compared with stenting (2.04 plus or minus 0.36 mm for angioplasty vs 2.53 plus or minus 0.38 mm for stenting). There were no stent thromboses or bleeding complications. At a mean follow-up period of 8 plus or minus 5 months (range 2 weeks to 23 months), all patients were clinically event-free. Six of 24 stented vessels in 16 patients had restenosis greater than 50% by ultrasound or angiography 6 months after the procedure. These somewhat disappointing results highlight the need for a better understanding of the mechanism of graft vasculopathy and the development of refined, specific PCI-related therapies with better outcomes. The largest reported experience of PCI in cardiac transplant recipients to date showed that PCI with stents is effective in relieving focal stenoses in patients with allograft coronary disease (829). Between 1990 and 2000, 62 patients (1.5 to 15 years after transplant) underwent 151 procedures that resulted in PCI of 219 lesions. Periprocedural mortality was low at 2% (4 of 151 procedures). Two-year freedom from allograft coronary disease death or graft loss was 74% for 1-vessel disease at first PCI, 75% for 2-vessel disease, and 27% for 3-vessel disease (P equals 0.009). There were no incidences of acute stent thrombosis. Freedom from repeat PCI of the same vessel ranged from 75% at 6 months to 57% at 4 years. Freedom from restenosis ranged from 95% at 1 month to 57% at 6 months. Multivariate predictors of freedom from restenosis were the use of stents, higher antiproliferative immunosuppressant dose, and an era effect (e.g., procedural advances and widespread use of periprocedural GP IIb/IIIa inhibitors and thienopyridines, among others). Long-term

survival effects remain under examination (Table 29) (826,830-833).

7.3. Clinical Restenosis: Background and Management

7.3.1. Background on Restenosis After PTCA

Angiographic restenosis after PTCA has been reported to occur in 32% to 40% of patients within 6 months after the procedure (80,85). Initial procedural success rates after PTCA of restenotic lesions appear similar to those after PTCA for de novo lesions. The risk for repeat angiographic restenosis after repeat PTCA for a single episode of restenosis also appears similar to the restenosis risk for de novo lesions (834,835). The risk of recurrent symptoms progressively increases with the number of restenosis episodes, approaching 50% to 53% for patients undergoing a fourth PTCA for a third episode of restenosis (836,837).

7.3.2. Clinical and Angiographic Factors for Restenosis After PTCA

A number of factors are associated with lesion recurrence among patients undergoing a second PTCA for restenosis. These factors include an interval less than 60 to 90 days between the initial angioplasty and the treatment of restenosis (834-838), LAD lesion location (837), multivessel versus single-vessel redilatations (838), the presence of diabetes mellitus (834,838), hypertension (834), UA (834), need for higher (7 atm) balloon inflation pressures (835), and multiple (3) balloon inflations (835,836). Of these, the most important factor is the time between the initial and subsequent PTCA (839). In a series of 423 patients, restenosis was more common in those having repeat angioplasty less than 3 months after a first angioplasty than in patients undergoing later redilatation (56% vs 37%, P equals 0.007) (839).

Some studies have suggested that lesions become longer and more severe after repeat PTCA of restenotic lesions (840,841). In a serial angiographic study, the mean stenosis length before the initial angioplasty was 7.0 mm but increased to 8.7 mm at the time of the repeat procedure (an increase of more than 1.7 mm, 95% CI 0.6 to 2.8 mm, P less than 0.01) (841). A history of restenosis may also predict the risk for subsequent restenosis after PTCA of a new lesion (104). Multivariate analysis identified that prior restenosis (P less than 0.02, OR equals 3.4), LAD location of stenosis (P less than 0.04, OR equals 3.0), and severity of stenosis before PTCA (P less than 0.02, OR equals 1.8) were independently associated with restenosis after PTCA (104).

7.3.3. Management Strategies for Restenosis After PTCA

Class IIa

It is reasonable to consider that patients who develop restenosis after PTCA or PTCA with atheroablative devices are candidates for repeat coronary intervention with intracoronary stents if anatomic factors are appropriate. (Level of Evidence: B)

Downloaded from content.onlinejacc.org by Ted Feldman on March 19, 2006

Long-term patency of the initial target lesion may be achieved with repeated balloon dilatations. In a series of 1455 de novo lesions treated with PTCA, angiographic restenosis requiring repeat PTCA developed in 32% (842). Late patency was achieved in 93% of lesions with up to 3 PTCA procedures. Only 23 lesions (1.6%) required 4 or more procedures (842).

Although atheroablation devices have been developed in an attempt to lower the second restenosis risk in patients, none has shown an incremental benefit over PTCA. In a study of 1569 patients who underwent excimer laser coronary angioplasty for restenotic (n equals 620 patients) or de novo (n equals 949) lesions (843), procedural success was higher in restenotic patients (92% vs 88% in de novo patients; P less than 0.001), although clinical recurrence was high in both groups (49% in restenotic patients and 44% in de novo patients, P equals NS) (843).

Stent placement is superior to PTCA for the treatment of restenotic lesions. In the REstenosis STent (REST) Study (844), a randomized clinical trial, late clinical and angiographic outcomes were compared in 351 patients undergoing either PTCA or Palmaz-Schatz stent placement for restenotic lesions. Stent-treated patients had lower rates of target-lesion revascularization (10% vs 32% in balloon-treated patients) and restenosis (18% vs 32% in balloon-treated patients; P equals 0.03) (844).

Given these findings, it is recommended that patients who develop restenosis after an initially successful PTCA be considered for repeat PCI with stent placement. Factors that may influence this decision include the technical difficulty of the initial procedure, the potential for the lesion to be treated successfully with a stent, and the severity and extent of the restenotic process. If restenosis presents as a much longer lesion than was originally present, additional procedures may aggravate rather than relieve coronary narrowing. If repeat intervention is performed, treatment with a stent appears to be preferred. Each time restenosis recurs, consideration should be given to alternate methods of revascularization, particularly CABG surgery, as well as continued medical therapy. Patients who have angiographic evidence of restenosis but no symptoms or evidence for ischemia may be able to continue with medical therapy alone. It is recommended that patients who develop restenosis after PTCA or atheroablative device therapy plus PTCA be candidates for repeat coronary intervention with intracoronary stents if anatomy is appropriate. Patients who have no signs or symptoms of ischemia and who have intermediate (50%) stenoses at the time of clinical follow-up may not require PCI and, especially where the anatomy is complex, may be followed up for evidence of ischemia rather than subjected to PCI.

7.3.4. Background on Restenosis After BMS Implantation

Although coronary stents have been shown to reduce the frequency of restenosis compared with conventional balloon angioplasty, lumen renarrowing due to intimal hyperplasia within the stent may develop in 17% to 32% of patients

Table 29. Coronary Angioplasty Studies in Heart Transplant Patients

First Author	Year	Ref.	n	Procedures	Lesions	Time After Tx, mo	Success Rate, %	Major Complex	Minor Complex	Restenosis Rate at More Than 6 mo, %	1-Year Event-Free Rate, %	Late Death or reTx at More Than 6 mo, n
Haase	1992	(826)	35	51	95	45 plus or minus 5	93	3	3	NA	60	7
Sapich	1992	(830)	8	11	13	43 plus or minus 19	85	NA	1	NA	38	4
Swain	1993	(831)	13	31	NA	NA	NA	NA	NA	100	NA	NA
Von Scheidt	1995	(832)	14	38	62	41 plus or minus 25	97	1	NA	61	60	5
Parise	1996	(833)	8	NA	11	NA	91	1	1	NA	50	3

mo indicates month; n, number of patients; NA, not applicable; Ref, reference; reTX, retreatment; and Tx, treatment.

(80,83,845). A number of factors have been associated with the propensity to develop stent restenosis, including small vessel size (846), smaller postprocedure minimum lumen diameter (847), higher residual percent diameter stenosis (848), lesions located in the LAD (83), stent length, and the presence of diabetes mellitus (721,841,842,844,846-848).

Stent restenosis may occur within the stent, due to intimal hyperplasia, or at the stent margins, due to both intimal hyperplasia and arterial remodeling (849). A serial IVUS study performed in 115 lesions treated with the Palmaz-Schatz stent demonstrated that tissue growth was uniformly distributed throughout the stent at follow-up study, with a slightly higher tendency for neointimal tissue accumulation at the central articulation (850). The stent lumen tended to be smallest at the articulation site, presumably owing to tissue prolapse between the stent struts. For multiple stents, there was no difference in the postintervention or follow-up lumen when overlapped stents were compared with nonoverlapped stents (850). In another series of patients treated with the Palmaz-Schatz stent, 77 (26%) of 301 stent margins were restenotic at follow-up (more than 50% late lumen loss) (849). The dominant periprocedural predictor of stent margin restenosis was the plaque burden of the contiguous reference segment (849).

Balloon angioplasty has been used frequently to treat patients with stent restenosis (851-853). The mechanism of lumen improvement after balloon angioplasty for stent restenosis relates to further stent expansion (851) and extrusion of the tissue through the stent struts (851-854). In an IVUS study of 64 restenotic Palmaz-Schatz stents, 56% plus or minus 28% of the lumen enlargement was the result of additional stent expansion and 44% plus or minus 28% was the result of a decrease in neointimal tissue (851). Despite the use of high-pressure balloon dilation, a relatively high residual stenosis (18% plus or minus 12%) remained after treatment with balloon angioplasty.

The outcome after balloon angioplasty has been variable, depending, in part, on the size of the stented segment and length of the stent restenosis (855). In a consecutive series of 124 patients presenting with stent restenosis successfully treated with repeat percutaneous intervention, clinical follow-up was obtained at 27.4 plus or minus 14.7 months (855). Recurrent clinical events occurred in 25 patients (20%), including death (2%), MI (1%), and target-vessel revascularization (11%) (855). Cumulative event-free survival at 12 and 24 months was 86.2% and 80.7%, respectively (855).

A number of factors have been related to the frequency of clinical recurrence after balloon angioplasty for stent restenosis (855), which include repeat intervention in SVGs, multivessel disease, low ejection fraction, and a 3-month interval between stent implantation and repeat intervention. One preliminary report has shown target-lesion revascularization was related to the length of the stent restenosis, ranging from 10% for focal stent stenosis to 25% for intrastent restenosis, 50% for diffuse stent restenosis, and 80% for stent total occlusions (856).

New coronary devices, including directional (857,858), rotational (859,860), extraction (861-865), and pullback (866) atherectomy, a cutting balloon, and excimer laser-assisted angioplasty, have also been used for stent restenosis before balloon dilation. Although some comparative registry series have suggested an improved angiographic outcome associated with the use of these ablative devices, no long-term studies demonstrating clinical advantage have been completed.

When a significant residual stenosis exists after conventional PTCA of stent restenosis fails to achieve an optimal lumen diameter, additional stents have been used to improve the initial angiographic result (867-869). Although preliminary results of clinical trials failed to demonstrate a benefit using routine BMS placement for the treatment of stent restenosis, favorable results have been shown with DES (see Section 7.3.5 for further discussion) (116,870,871).

Acute platelet inhibition with abciximab does not reduce ISR, as demonstrated in the ERASER (Evaluation of ReoPro And Stenting to Eliminate Restenosis) study (280). In a study of 225 patients randomly allocated to placebo or abciximab before intervention, 215 patients received a stent and the study drug. Of the 191 patients who returned for follow-up more than 4 months after evaluation, there was no difference between tissue volume as measured by IVUS between the placebo and treatment groups. Lack of abciximab benefit was confirmed by quantitative angiography. The investigators concluded that potent platelet inhibition with abciximab as administered in the ERASER study did not reduce ISR.

Since the last (2001) revision of the ACC/AHA PCI guideline, the proportional use of stents in percutaneous interventions has continued to increase. In part, this derives from randomized trial data suggesting that routine stenting is more effective than provisional stenting (636,872-874). In addition, stents are being used in a much wider spectrum of coronary and even graft anatomies (875). Accordingly, ISR has become increasingly important. Because stents prevent elastic recoil and late negative remodeling, the predominant mechanism of ISR is neointimal hyperplasia due to smooth muscle cell proliferation and extracellular matrix production. Two of the biggest changes since the 2001 revision have been the expanding databases of 1) brachytherapy to treat ISR and 2) DES to try to prevent ISR.

7.3.5. Drug-Eluting Stents

Class I

A drug-eluting stent (DES) should be considered as an alternative to the bare-metal stent in subsets of patients in whom trial data suggest efficacy. (Level of Evidence: A)

Class IIb

A DES may be considered for use in anatomic settings in which the usefulness, effectiveness, and safety have not been fully documented in published trials. (Level of Evidence: C)

All PCI creates injury to the vessel wall, specifically tears or dissection. Larger devices and higher pressures are associated with tears at deeper levels of the vessel wall (media or even adventitia, as opposed to intima and plaque boundary only). All injuries tend to heal; specifically, injury to the vessel wall is associated with re-establishment of an intact endothelial layer. Failure to re-establish an intact, functional endothelial layer is likely to be associated with continued risk of arterial thrombosis and an abnormal balance between vasoconstrictive and vasodilatory mechanisms. In general, deeper injury is associated with more proliferative healing (876-878). The demonstration, by quantitative angiography, that late lumen diameter after balloon angioplasty follows a "normal" or Gaussian distribution supports the concept that restenosis is an exaggerated healing response rather than a distinct biologic process, which occurs in a minority of individuals.

For balloon angioplasty, the healing response includes, on the macroscopic level, negative (narrowing) and positive (dilatation) remodeling, elastic recoil, and neointimal hyperplasia. Because stents block elastic recoil and negative remodeling, ISR is predominantly due to neointimal hyperplasia. Neointimal hyperplasia is the name given to a complex process of multifactorial causation, which leads to vessel lumen encroachment. The causes of neointimal hyperplasia appear to include, but are not limited to, the following inflammatory response involving cells and molecular mediators; growth factors and cytokines; release of mediators and upregulation of signaling systems that stimulate cellular migration and proliferation; activation, adherence, and aggregation of platelets; and thrombosis with release of clotting factors. Neointimal hyperplasia may be distinct from atherosclerosis and negative remodeling, but it shares many of the same causative factors. Accordingly, investigators and clinicians are inclined to try many of the same antithrombotic, antiplatelet, anti-inflammatory, and antiproliferative agents to try to modify atherosclerosis, neointimal hyperplasia, and negative remodeling. Additionally, many therapeutic agents affect multiple mechanisms.

To date, no systemically administered therapeutic agent has consistently reduced restenosis after balloon angioplasty or placement of BMS. Stents have reduced restenosis relative to balloon angioplasty (albeit with increased late loss due to increased neointimal proliferation), and locally delivered radiation (brachytherapy) has reduced ISR. Taken together, these observations and the early success of sirolimus- and paclitaxel-eluting stents have supported the paradigm of blocking elastic recoil and negative remodeling with a mechanical stent and inhibiting neointimal hyperplasia with a locally delivered (higher concentration than can be achieved systemically) antiproliferative and anti-inflammatory agent.

Local delivery of a therapeutic agent with stents has taken 2 forms: simple coating of the stent and adherence of the therapeutic agent to a polymer, which allows for sustained release over time. Diffusion of the therapeutic agent into the tissues and into blood is an additional complexity. For coat-

ed stents, the long-term outcome depends on the response to both stent and coating. For DES, the long-term healing response depends on the response to the polymer and the therapeutic agent, as well as the stent. As evidenced by the trials of gold coating and the preliminary experiences (registry) with the QuaDS stent, actinomycin, and batimastat, some combinations are potentially even more proliferative, inflammatory, or thrombogenic than BMS.

Peer-reviewed publications of human DES implantation, including consecutive case series and randomized trials, are available for 3 polymer-based, drug-eluting, balloon-expandable stent systems (Table 30) (236,441,624,628,697,698,879-888): the antiproliferative, antimigratory, anti-inflammatory macrolide antibiotic rapamycin (sirolimus) affixed to a stent (Bx Velocity); the 7-hexanoyltaxol (QP2)-eluting polymer stent system (QuaDS); and the microtubule inhibitor paclitaxel (TAXUS) affixed to a stent. Each of these systems had undergone rigorous testing in animal models that demonstrated an intact endothelial layer and significant reductions in neointimal hyperplasia and inflammation.

The first reported series of 45 patients who underwent SES implantation in either Sao Paulo, Brazil, or Rotterdam, Holland, demonstrated the virtual absence of intimal hyperplasia at 4 months (889). Subsequent studies of the same cohort at 1 and 2 years continued to document sustained suppression of neointimal hyperplasia as detected with both IVUS and quantitative angiography (628,879). In the Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, 238 patients were randomly allocated between BMS and SES (624). At 6 months the binary restenosis rate was 26% for the bare metal group versus 0% for the DES group, and there were no subacute stent thromboses with a 2-month dual antiplatelet regimen. In 1 year of follow-up, the bare metal group had a 29% rate of MACE versus 5.8% for the sirolimus-eluting group; this difference was driven entirely by target-vessel revascularization.

A 3-year follow-up of the RAVEL trial (890), involving 114 patients from the SES arm and 113 in the BMS arm, documented target-vessel revascularization in 11.4% of the SES group compared with 33.6% of the BMS group. These data support the long-term durability of SES in reducing repeat revascularization compared with BMS.

The SIRIUS (Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions) investigators reported 1058 patients randomly allocated at 1 of 53 centers between BMS and SES (93). This cohort included diabetic patients (26%) and somewhat longer lesions (mean 14.4 mm) and smaller-diameter vessels (mean 2.8 mm) than the RAVEL population. Again, the sirolimus-eluting group had lower MACE at 270 days than the BMS group (7.1% vs 18.9%), which was driven by lower rates of target-vessel revascularization (4.1% vs 16.6%). Both quantitative angiography and IVUS were used to document that the mechanism for this salutary effect was decreased neointimal hyperplasia. SIRIUS was the pivotal

Table 30. Published Randomized Trials and Selected Registry Experiences of Drug-Eluting Stents Compared With Bare Metal Stents

Eluting Drug	Trial (Ref.)	Year	n, Active/Control	Stent	Eluting Drug Dosage	Deaths Active/Control, %	MI, Active/Control, %	Restenosis, Active/Control, %	TLR, Active/Control, %
Sirolimus	FIM (628)	2001	30 in Sao Paulo; 15 in Rotterdam	BxVelocity	140 mcg/cm ²	NA	NA	0% at 1 year	Minimal neointimal proliferation at 1 year
	FIM (879)	2002	15 from Rotterdam	BxVelocity	140 mcg/cm ²	NA	NA	0% at 2 years	Minimal neointimal proliferation at 2 years
	RAVEL (624)	2002	120/118	BxVelocity	140 mcg/cm ²	1.7/1.7	3.3/4.2	0/26.6 at 6 months (P less than 0.001)	0/22.9 at 1 year (P equals 0.001)
	SIRIUS (698)	2004	533/525	BxVelocity	140 mcg/cm ²	0.9/0.6	2.8/3.2	8.9/36.3 at 8 months (P less than 0.001)	4.9/20 at 1 year (P less than 0.001)
	C-SIRIUS (880)	2004	50/50	BxVelocity	140 mcg/cm ²	0/0	2.0/4.0	2.3/51.1	4.0/18.0 at 9 months (P less than 0.001)
	E-SIRIUS (881)	2003	175/177	BxVelocity	140 mcg/cm ²	1.1/0.6	4.6/2.3	5.9/42.3	4.0/20.9 at 9 months (P less than 0.001)
	RESEARCH Registry Overall (236)	2004	508/450	BxVelocity	140 mcg/cm ²	1.6/2.0 at 30 days	0.8/1.6 at 30 days	NA	1.0/1.8 at 30 days
	RESEARCH Registry ACS (882)	2003	198/301	BxVelocity	140 mcg/cm ²	3.0/3.0 at 30 days	3.0/1.0 at 30 days	NA	1.0/2.7 at 30 days
	RESEARCH Registry STEMI (441)	2004	186/183	BxVelocity	140 mcg/cm ²	8.3/8.2 at 300 days	0.5/2.2 at 300 days	NA	1.1/8.2 at 300 days (P less than 0.01)
	RESEARCH Registry Chronic Totals (883)	2004	56/28	BxVelocity	140 mcg/cm ²	0/0 in hospital	NA	NA	12-month MACE: 5.6/17.2 (P less than 0.05)

Continued on next page

Table 30. Continued

Eluting Drug	Trial (Ref.)	Year	n, Active/Control	Stent	Eluting Drug Dosage	Deaths Active/Control, %	MI, Active/Control, %	Restenosis, Active/Control, %	TLR, Active/Control, %
Pacitaxel	QuaDS-QP2 (884)	2002	15	QuaDS-QP2	2400 to 3200 mcg total dose	NA	NA	13.3 at 6 months 61.5 at 1 year	20 at 6 months 60 at 1 year
	ASPECT (885)	2003	59 High dose 58 low dose/ 59 control	Supra-G	3.1 mcg/mm ² 1.3 mcg/mm ²	0.9/0	2.6/1.7	4/12/27 at 4 to 6 months (high dose vs control, <i>P</i> less than 0.001)	2/2/2 at 1 to 6 months
	TAXUS I (886)	2003	31/30	NIR	1.0 mcg/mm ²	0/0	0/0	0/10 at 6 months (<i>P</i> equals 0.012)	0/10 at 1 year (<i>P</i> equals 0.237)
	TAXUS II (887)	2003	266/279	NIR	1.0 mcg/mm ²	0/0.8	3.1/5.3	7.1/21.9 at 6 months	10.4/21.7 at 12 months
	TAXUS III (888)	2003	28 ISR	NIR	1.0 mcg/mm ²	NA	NA	NA	21.4 at 1 year
	TAXUS IV (697)	2004	662/652	EXPRESS	1.0 mcg/mm ²	1.4/1.1	3.5/3.7	7.9/26.6 at 9 months (<i>P</i> less than 0.0001)	4.4/15.1 at 1 year (<i>P</i> less than 0.0001)

AC indicates acute coronary syndromes; ASPECT, Asian Paclitaxel-Eluting Stent Clinical Trial; FIM, First in Man; ISR, in-stent restenosis; NA, not applicable; RESEARCH, Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital; SIRIUS, Sirius-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (C-SIRIUS indicates Canadian study; E-SIRIUS, European study); and TLR, target-lesion revascularization.

trial for FDA release of the rapamycin, polymer, Bx Velocity system.

Subsequent studies from the RESEARCH (Rapamycin-Eluting and TAXUS Stent Evaluated At Rotterdam Cardiology Hospital) registry experience at Thoraxcenter, Rotterdam, Netherlands, have documented the short-term safety of using these SES systems in patients with acute coronary syndromes, including STEMI (882,891). An additional small registry experience from the Rotterdam group suggests the potential applicability of the sirolimus DES system to ISR. A consecutive case series of 368 patients with 735 lesions for which 841 SES were implanted documented only 11 cases of restenosis (greater than 50% diameter), and all of those occurred in a focal pattern (892). The operators in that series, which included longer lesions (mean length of lesion 17.48 plus or minus 12.19 mm) and more complex anatomic subsets, learned from earlier studies of DES edge lesions to fully cover diseased segments (mean stent length 27.59 plus or minus 14.02 mm) (892).

TAXUS-I was the first feasibility and safety study of the paclitaxel, polymer, NIR stent system. There were 61 patients randomly allocated between a BMS and DES. At 12 months, the MACE rate was 3% (1 event) in the TAXUS group and 10% in the BMS group (4 events in 3 patients), and there were no subacute stent thromboses. Although these differences were not statistically significantly different, the continuous outcome of minimal lumen diameter was significantly better in the TAXUS group (886).

The ASPECT trial was a 3-center prospective, randomized trial of 177 patients with short (less than 15 mm), favorable (2.25 to 3.5 mm diameter) native vessel lesions who were randomly allocated between bare-metal Cook Supra-G stents and stents bonded with 1 of 2 doses of paclitaxel (885). Interpretation of this trial was complicated by the use of 3 different antiplatelet regimens. Binary restenosis was 4% in the high dose of paclitaxel, 12% in the low dose of paclitaxel, and 27% in the BMS arm. Subsequent mechanistic studies with IVUS documented that the paclitaxel-coated stents reduced neointimal hyperplasia (893).

TAXUS-IV was a prospective, randomized clinical trial of the slow-release; polymer-based paclitaxel-NIR stent system conducted at 73 US centers (94). A total of 1314 patients with native coronary lesions 10 to 28 mm in length and 2.5 to 3.75 mm in diameter were randomly allocated between BMS and the paclitaxel polymer system. At 9 months, angiographic restenosis was reduced from 26.6% to 7.9% with DES, albeit there were no differences in death, MI, or subacute stent thrombosis (0.6% and 0.8%, respectively). It is primarily on the basis of TAXUS-IV that the FDA released the paclitaxel, polymer NIR stent system. TAXUS-III was a registry study that demonstrated the potential efficacy of this DES system for ISR (888).

There is considerable promise and excitement surrounding the release of DES; nevertheless, important reservations remain, including the following:

- Most of the follow-up is still relatively short-term (1 year or less)
- Comparison of the 2 FDA-released systems is needed and should provide clinically useful information. One such trial that supplies information in this regard is ISAR-DESIRE (Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis), which is discussed in Section 7.3.6.2.
- Preliminary results from randomized trials (REALITY, SIRTAX) comparing SES and PES (CYPHER versus TAXUS) have not shown large differences in clinical outcomes [M.C. Morice, oral presentation, American College of Cardiology Scientific Session, Orlando, Fla, March 2005; S. Windecker, oral presentation, American College of Cardiology Scientific Session, Orlando, Fla, March 2005].
- Mandated angiographic follow-up applied in trials has increased the reintervention rate, and therefore, the difference between DES and BMS in clinical practice may be less.

The major trials of SES and PES, which were the basis for FDA approval, involved patients with stable or unstable ischemia with documented coronary artery narrowing of 51% to 99%, which stenoses were, for the most part, between 2.75 and 3.5 mm in diameter and 15 to 30 mm in length. Specific clinical exclusions from these landmark trials included the following: MI within 48 h; LV ejection fraction less than 0.25; previous or planned use of brachytherapy; previous PCI of the same lesion; coexisting medical conditions likely to limit life expectancy; contraindications to aspirin, thienopyridines, or stent substances; and severe renal or hematologic comorbidity. Specific angiographic exclusions from these landmark trials included the following: ostial lesions; bifurcation lesions; ULM lesion; SVG lesion; severe calcification; angiographic thrombus; severe tortuosity; and occluded vessel. Babapulle and coworkers have performed a Bayesian meta-analysis of randomized clinical trials of DES that incorporates the results of RAVEL, SIRIUS, C-SIRIUS, and E-SIRIUS regarding rapamycin-eluting stents and TAXUS, I, II, and IV regarding PES (234, 880, 881). These authors also included 4 trials of a nonpolymeric formulation of paclitaxel, which has not been shown to be effective in reducing restenosis or target-lesion or target-vessel revascularization and which has not been released for commercial use (234).

In an effort to extend the application of DES to most of the other clinical angiographic subsets, unstudied in these landmark trials, Serruys and coworkers at Thoraxcenter Rotterdam, the Netherlands, established the RESEARCH Registry (882). In this experience, the rapamycin-eluting stent has been used as the default strategy since it became available, and consecutive prospective cases of particular clinical and angiographic subsets have been compared with

the immediately prior experience at the same institution with the particular subset (882).

Patients with acute coronary syndromes were considered for SES in a RESEARCH registry comparison of 198 consecutive patients receiving the SES versus a prior consecutive case series of 301 patients with acute coronary syndromes treated with BMS (882). Major adverse cardiac events including death (3.0% vs 3.0%), nonfatal MI (3.0% vs 1.0%), and target-vessel revascularization (1.0% vs 2.7%) were comparable for SES and BMS (total 6.1% vs 6.6%). Lemos and colleagues reported a series of 186 consecutive STEMI patients treated with an SES and compared that group with 183 patients treated with a BMS in terms of both short- and long-term outcomes (441). MACE at 30 days (7.5% vs 10.4%) and stent thrombosis (0% vs 1.6%) were not significantly different for SES compared with BMS patients. By 300 days, both target-vessel revascularization (1.1% vs 8.2%) and MACE (9.4% vs 17.0%) were reduced with SES versus BMS (441). A quantitative study reported by Saia *et al* demonstrated a binary restenosis rate of 0% at 6 months in a subset of 96 STEMI patients, which documented reduced late loss to a degree comparable to what was seen in the landmark trials of more stable patients with less complex anatomy (891).

Hoye and coauthors compared the outcomes of a consecutive case cohort of 56 patients with chronic total occlusions treated with SES and compared them with a prior consecutive case series of 28 patients with chronic total occlusions treated with BMS (883). By 12 months, MACE was 96.4% with SES and 82.1% with BMS (*P* less than 0.05 by log-rank testing) (883). A consecutive case series of 19 patients with 21 lesions of old SVGs treated with SES had 0% early revascularization and a 1-year (average) MACE of 84% (894). Unlike the other RESEARCH Registry series, this report included no historic control group.

7.3.6. Management Strategies for ISR

Since the last (2001) revision of the ACC/AHA PCI guideline, the proportional use of stents in percutaneous interventions has continued to increase. In part, this derives from randomized trial data suggesting that routine stenting is more effective than provisional stenting (636,872-874). In addition, stents are being used in a much wider spectrum of coronary and even graft anatomies (875). Accordingly, ISR has become increasingly important. Because stents prevent elastic recoil and late negative remodeling, the predominant mechanism of ISR is neointimal hyperplasia due to smooth muscle cell proliferation and extracellular matrix production. Two of the biggest changes since the 2001 revision have been the expanding databases evaluating the use of 1) DES to prevent ISR and 2) brachytherapy to treat ISR (discussed in Sections 7.3.6.2 and 7.3.6.3, respectively).

7.3.6.1. PTCA

PTCA has been used to treat patients with ISR (851-853). The mechanism of lumen improvement after PTCA for ISR

relates to further stent expansion (851) and extrusion of the tissue through the stent struts (851-854). In an IVUS study of 64 restenotic Palmaz-Schatz stents, 56% plus or minus 28% of the lumen enlargement was the result of additional stent expansion, and 44% plus or minus 28% was the result of a decrease in neointimal tissue (851). Despite the use of high-pressure balloon dilation, a relatively high residual stenosis (18% plus or minus 12%) remained after treatment with PTCA.

The outcome after PTCA has been variable, depending in part on the size of the stented segment and length of the stent restenosis (855). In a consecutive series of 124 patients presenting with stent restenosis successfully treated with repeat PTCA, clinical follow-up was obtained at 27.4 plus or minus 14.7 months (855). Recurrent clinical events occurred in 25 patients (20%), including death (2%), MI (1%), and target-vessel revascularization (11%) (855). Cumulative event-free survival at 12 and 24 months was 86.2% and 80.7%, respectively (855).

A number of factors have been related to the frequency of clinical recurrence after PTCA for ISR (855), which include repeat intervention in SVGs, multivessel disease, low ejection fraction, and a 3-month interval between stent implantation and repeat intervention. One report involving 245 patients receiving BMS in the pre-DES era has categorized ISR into 4 classifications: focal, diffuse intrastent, diffuse proliferative, and total occlusion. Pattern I contains 4 types (A-D). Patterns II through IV are defined according to geographic position of ISR in relation to the previously implanted stent. Target-lesion revascularization was related to the length of the ISR, ranging from 10% for focal in-stent stenosis (class I) to 25% for intrastent restenosis (class II), 50% for diffuse proliferative ISR (class III), and 80% for ISR with total occlusion (class IV) (856).

A broad array of catheter-based technologies, including directional (857,858), rotational (859,860), extraction (861-865), and pullback (866) atherectomy, a cutting balloon, and excimer laser-assisted angioplasty, have been used to treat ISR in association with PTCA. Although some comparative registry series have suggested an improved angiographic outcome associated with the use of these ablative devices, no long-term studies demonstrating clinical advantage have been completed.

When a significant residual stenosis exists after conventional PTCA for ISR, PCI with stenting has been used to improve the initial angiographic result (867-869). Although preliminary results of clinical trials failed to demonstrate a benefit using routine BMS placement for the treatment of ISR, favorable results have been shown with DES, as summarized in the following section (116,870,871).

7.3.6.2. Drug-Eluting Stents

Class IIa

It is reasonable to perform repeat PCI for ISR with a DES or a new DES for patients who develop ISR if anatomic factors are appropriate. (Level of Evidence: B)

In-stent restenosis represents a clinical challenge of great interest for DES technology. Sousa and coworkers treated 25 consecutive cases of ISR with SES (870). They demonstrated minimal intimal hyperplasia and no delayed malapposition by intracoronary ultrasound (870). Clinically, they reported a remarkable 0 repeat revascularizations, stent thromboses, or deaths (870). Degertekin and colleagues reported a group of 26 consecutive ISR patients treated with SES (871). They also used 3-dimensional ultrasound to document minimal neointimal formation by 4 months (871). This more complex cohort included 1 patient with transplant vasculopathy and 4 with prior brachytherapy, which provided support not only for the effectiveness of SES but also of the need for prolonged antiplatelet therapy and risk factor modification in patients with diffuse coronary disease (871). Saia and coworkers reported a series of 12 patients with ISR refractory to brachytherapy who received SES; 4 of 10 patients who were followed up long-term developed restenosis (895).

The ISAR-DESIRE trial compared the use of balloon angioplasty SES and PES treatment of ISR in 300 patients (896). Angiography at 6 months in 92% of the patients (n equals 275) demonstrated angiographic restenosis in 44.6% (41 of 92) of the balloon-alone group; 14.3% (13 of 91) of the SES group; and 21.7% (20 of 92) of the PES group. Both DES were superior to balloon alone, reducing the incidence of target-vessel revascularization (33% for balloon alone vs 8% for SES and 19% for PES). There was a trend toward superiority of SES over PES in angiographic restenosis that was marginally significant (P equals 0.19) and significance for target-vessel revascularization (P equals 0.02). These data support the use of either approved DES for the treatment of ISR over a BMS. Additional data for DES and ISR have been reported in the Treatment Of Patients with an In-STENT REstenotic Coronary Artery Lesion (TROPICAL) Study, which assessed outcomes in 155 patients with ISR receiving an SES. In-lesion late loss of 0.08 plus or minus 0.49 and a binary restenosis rate of 9.7% was reported at 6-month follow-up, with a reintervention rate of 7.4% (897). Furthermore, preliminary data suggest that in patients receiving SES for ISR (TROPICAL group), late lesion loss and binary restenosis at 6 months were significantly reduced compared with a historical group receiving brachytherapy for ISR in the GAMMA I and II studies [F.J. Neumann, oral presentation, EuroPCR, Paris, France, May 2004]. The potential benefit of SES compared with brachytherapy remains to be delineated in ongoing randomized trials.

7.3.6.3. Radiation

Class IIa

Brachytherapy can be useful as a safe and effective treatment for ISR. (Level of Evidence: A)

Both gamma energy (photons), and beta energy (electrons) have been used in randomized clinical trials and prospective registries to reduce the neointimal proliferation associated

with ISR (898-900). In the 2001 revision of the guideline, the initial results of the SCRIPPS trial (Scripps Coronary Radiation to Inhibit Proliferation Post Stenting) were summarized (117). Since then, the 5-year results of the SCRIPPS cohort have been published (901). The Ir-192-treated patients continued to demonstrate improved event-free survival (freedom from death, MI, or target-lesion revascularization) compared with placebo (61.5% vs 34.5%; P equals 0.02) (900). As shown in Table 31, this composite end point derived from improvements in each of the 3 component end points (92,116,117,658-660,901-903).

A number of reports of the GAMMA-1 trial have been published since the 2001 revision (622,658,904,905). The initial report of 9 months of follow-up demonstrated a statistically significant reduction in target-lesion revascularization with Ir-192 (42% vs 24 %; P less than 0.01). Death and MI were insignificantly higher with radiation.

The WRIST (Washington Radiation for In-Stent Restenosis Trial) investigators randomized 130 patients (65/65) with ISR between placebo and 15 Gy Ir-192 (116). The SVG-WRIST investigators randomized 120 patients (60/60) between placebo and Ir-192 for the treatment of ISR in SVGs (902). Again, the brachytherapy-treated cohort had lower rates of binary restenosis (21% vs 44%; P equals 0.005) and target-lesion revascularization (17% vs 57%; P less than 0.001).

Among the specific limitations of gamma radiation are the need for long treatment times and the high radiation exposure, which necessitate special shielding and removal of staff from the treatment room during dwell times (906). Beta radiation, in the form of electrons or particulate energy, has also demonstrated effectiveness in randomized trials of ISR, despite its more limited tissue penetration (92,659,660). Taken together, these data support the effectiveness of radiation in reducing restenosis after treatment of ISR. Further investigation into the causes of late stent thrombosis (907) have led to recommendations that 1) new stents not be implanted at the time of brachytherapy unless necessary and 2) antiplatelet therapy with both aspirin and a thienopyridine be continued for at least 6 to 12 months after brachytherapy (898-900,906).

Brachytherapy dosing for ISR is prescribed so as to achieve adequate radiation in the vessel wall to block cellular proliferation. The manufacturer's recommended dosing for the beta radiation source is 18.4 Gy at 2 mm from the source center for vessels from 2.7 to 3.35 mm in diameter and 23 Gy for vessels 3.35 to 4.0 mm in diameter. It is also recommended that radiation be delivered over the entire segment injured by balloon dilation and that at least a 5-mm margin be allowed on each side of the injured segment (908).

To date, the following potential limitations have been observed with the use of brachytherapy to treat ISR: edge stenoses or geographic miss; acute thrombosis; late thrombosis and occlusion (up to 14%); persistent dissections; late stent malapposition; increased plaque burden outside the stent; IVUS echolucent areas or black holes (898-900,906);

Table 31. Randomized Clinical Trials of Brachytherapy for In-Stent Restenosis

Trial (Ref.)	Year	n XRT/Placebo	Follow-Up, Angiographic/ Clinical	Source	Restenosis, XRT/Placebo	TLR, % XRT/Placebo	MI, XRT/Placebo	Death, XRT/Placebo
SCRIPPS (117)	1997	26/29	6 mo 12 mo	Gamma IR-192	17%/54% (<i>P</i> equals 0.01)	12%/45% (<i>P</i> equals 0.01)	4%/0% (<i>P</i> equals NS)	0%/3% (<i>P</i> equals NS)
PREVENT (660)	2000	80/25	6 mo 12 mo	Beta P-32	22%/50% (<i>P</i> equals 0.018)	6%/24% (<i>P</i> less than 0.05)	10%/4% (<i>P</i> equals NS)	1%/0% (<i>P</i> equals NS)
WRIST (116)	2000	65/65	6 mo 12 mo	Gamma IR-192	22%/60% (<i>P</i> equals 0.0001)	3%/63% (<i>P</i> less than 0.001)	9%/9% (<i>P</i> equals NS)	6%/6% (<i>P</i> equals NS)
GAMMA-ONE (658)	2001	131/121	6 mo 9 mo	Gamma IR-192	32%/55% (<i>P</i> equals 0.01)	24%/42% (<i>P</i> less than 0.01)	9.9%/4.1% (<i>P</i> equals 0.09)	3.1%/0.8% (<i>P</i> equals 0.17)
INHIBIT (659)	2002	166/166	9 mo 290 d	Beta P-32	26%/52% (<i>P</i> less than 0.0001)	8%/26% (<i>P</i> less than 0.0001)	3%/3% (<i>P</i> equals NS)	3%/2% (<i>P</i> equals NS)
SCRIPPS (901)	2002	26/29	5 y	Gamma IR-192	NA	23%/48% (<i>P</i> equals 0.05)	4%/10% (<i>P</i> equals NS)	19%/31% (<i>P</i> equals NS)
START (92)	2002	244/232	8 mo	Beta Sr-90/Y-90	29%/45% (<i>P</i> equals 0.001)	14%/25% (<i>P</i> less than 0.001)	1.7%/3.3% (<i>P</i> equals 0.364)	1.3%/0.5% (<i>P</i> equals 0.625)
SVG-WRIST (902)	2002	60/60	6 mo 12 mo	Gamma IR-192	21%/44% (<i>P</i> equals 0.005)	17%/57% (<i>P</i> less than 0.001)	2%/3% (<i>P</i> equals NS)	7%/7% (<i>P</i> equals NS)
Long WRIST (903)	2003	60/60	6 mo 12 mo	Gamma IR-192	45%/73% (<i>P</i> less than 0.05)	39%/62% (<i>P</i> less than 0.05)	16.9%/18.3% (<i>P</i> equals NS)	6.8%/1.7% (<i>P</i> equals NS)

n indicates number of patients; NA, not applicable; NS, not significant; MI, myocardial infarction; TLR, target-lesion revascularization; and XRT, radiation therapy.

and very late catch-up phenomenon (in studies with more than 1 year of follow-up).

7.3.6.4. Medical Therapy

Acute platelet inhibition with abciximab does not reduce ISR, as demonstrated in the ERASER study (280). In a study of 225 patients randomly allocated to placebo or abciximab before intervention, 215 patients received a stent and the study drug. Of the 191 patients who returned for follow-up more than 4 months after evaluation, there was no difference between tissue volume, as measured by IVUS, between the placebo and treatment groups. Lack of abciximab benefit was confirmed by quantitative angiography. The investigators concluded that potent platelet inhibition with abciximab as administered in the ERASER study did not reduce ISR. In the Oral Sirolimus to Inhibit Recurrent In-Stent Restenosis (OSIRUS) trial, 300 patients were randomly assigned to receive a cumulative loading dose of either placebo (0 mg), usual-dose (8 mg) oral sirolimus, or high-dose (24 mg) oral sirolimus 2 days before and the day of repeat PCI, followed by maintenance therapy of 2 mg per day for 7 days (909). Restenosis was significantly reduced from 42.2% to 36.8% and 22.1% in the placebo, usual-dose, and high-dose groups, respectively (P equals 0.005). The need for target-vessel revascularization was reduced from 25.5% to 24.2% and 15.2%, respectively, although this was not statistically significant (P equals 0.08). Blood concentration of oral sirolimus was significantly correlated with late lumen loss at follow-up (P less than 0.001). The investigators concluded that oral adjunctive sirolimus treatment for treatment of ISR resulted in significant improvement in the angiographic parameters of restenosis. Further elucidation of optimal dosing, need for pretreatment, and duration of oral sirolimus, as well as long-term follow-up, are needed.

7.3.7. Subacute Stent Thrombosis

The issues of subacute stent thrombosis and technical issues with the PES balloon-delivery system were early causes for concern (910). After many more data have been accumulated, as exemplified by the above-cited registry data, there does not appear to be an increased incidence of early thrombosis with either SES or PES. As reported in the FDA editorial (910), Boston Scientific has recalled a number of TAXUS stent systems because of reports of balloon deflation or retrieval problems and is working closely with the FDA to monitor the situation.

7.3.8. Drug-Eluting Stents: Areas Requiring Further Investigation

Both small vessels (less than 2.75 mm) and long lesions (greater than 18 mm) have been included in the C-SIRIUS and E-SIRIUS trials (880,881). In addition, there are increasing numbers of patients entered into prospective registries and compared retrospectively with the following clinical and angiographic subsets, which were not included in random-

ized comparative trials of DES versus BMS: acute coronary syndromes; STEMI, chronic total occlusions; SVGs; and ISR. Most of the data currently available regarding the use of DES for ostial lesions, bifurcation lesions, ULM arteries, and extremely long segments are in the form of uncontrolled case reports or series. Nonetheless, given the promising results in reducing late target-lesion and target-vessel revascularization in nearly every group, it is to be expected that registry and randomized trial data will continue to accumulate at a rapid pace.

7.4. Cost-Effectiveness Analysis for PCI

Among all diseases worldwide, ischemic heart disease currently ranks fifth in disability burden and is projected to rank first by the year 2020 (911). As healthcare delivery systems in countries with established economic markets continue to incorporate new and expensive technologies, the costs of medical care have seemingly escalated beyond the revenue historically allotted to health care. Given limited healthcare resources, a cost-effectiveness analysis is appropriate to evaluate percutaneous coronary revascularization strategies (912). The results of cost-effectiveness analyses for any comparable treatment are reported in terms of the incremental cost per unit of health gained, such as 1 year of life adjusted to perfect health (quality-adjusted life year, QALY) compared with the standard of care (913). By modeling different treatments, different patient subsets, and different levels of disease, a series of cost-effectiveness ratios may be constructed to show the tradeoffs associated with choosing among competing interventions.

Although there is no established cost-effectiveness ratio threshold, cost-effectiveness ratios of less than \$20 000 per QALY (such as seen in the treatment of severe diastolic hypertension or with cholesterol lowering in patients with ischemic heart disease) are considered highly favorable and consistent with well-accepted therapies. Incremental cost-effectiveness ratios that range between \$20 000 and \$60 000 per QALY may be viewed as reasonably cost-effective and thus acceptable in most countries, whereas ratios greater than \$60 000 to \$80 000 may be considered too expensive for most healthcare systems. The Committee defines useful and efficacious treatments, in terms of cost-effectiveness, as treatments with acceptable or favorable cost-effectiveness ratios. Cost-effectiveness analysis is not by itself sufficient to incorporate all factors necessary for medical decision making on an individual patient basis, nor is it sufficient to dictate the broad allocation of societal resources for health care. Rather, cost-effectiveness analysis aims to serve mainly as an aid to medical decision making on the basis of comparison with other evaluated therapies.

The results of cost-effectiveness analysis in the field of percutaneous revascularization for ischemic heart disease have been derived from decision models that incorporate literature-based procedure-related morbidity and mortality, coronary disease-related mortality, and estimates of the benefit of selected revascularization procedures. When available,

results from randomized trials (levels of evidence A and B) are used to estimate the outcomes of each decision tree branch within the decision-analytical model, for example, using data estimating the restenosis rate after uncomplicated coronary stenting of a single, simple lesion. Cost-effectiveness analyses have been used to compare medical therapy with PTCA with CABG (914), balloon angioplasty with coronary stenting (915,916), and routine coronary angiography after acute MI with symptom-driven coronary angiography (917).

In patients with severe angina, normal LV function, and single-vessel disease of the LAD, the cost-effectiveness ratio for PTCA, directional coronary atherectomy, or coronary stenting that can be expected to provide a more than 90% success rate with a less than 3% major acute complication rate is very favorable (less than \$20 000 per QALY) compared with medical therapy (914). The rating also applies to patients with symptomatic angina or documented ischemia and 2-vessel coronary disease, in whom percutaneous coronary revascularization can be expected to provide a more than 90% success rate with a less than 3% major acute complication rate. In patients with 3-vessel coronary disease who have comorbidities that increase the operative risk for CABG surgery, PCI that is believed to be safe and feasible is reasonably acceptable (\$20 000 to \$60 000 per QALY). In patients in the post-MI setting, a strategy of routine, non-symptom-driven coronary angiography and PCI performed for critical (greater than 70% diameter stenosis) culprit coronary lesions amenable to balloon angioplasty or stenting has been proposed to be reasonably cost-effective in many subgroups (917).

In patients with symptomatic angina or documented ischemia and 3-vessel coronary disease, for which bypass surgery can be expected to provide full revascularization and an acute complication rate of less than 5%, the cost-effectiveness of PCI is not well established. Although PTCA for 2- and 3-vessel coronary disease appears to be as safe as but initially less expensive than CABG surgery, the costs of PTCA converge toward the higher costs of bypass surgery after 3 to 5 years (918,919). Thus, whereas PTCA or CABG surgery has been shown to be cost-effective compared with medical therapy, there is no evidence for incremental cost-effectiveness of PTCA over bypass surgery for 2- or 3-vessel coronary disease in patients who are considered good candidates for both procedures. For patients with 1- or 2-vessel coronary disease who are asymptomatic or have only mild angina, without documented left main disease, the estimated cost-effectiveness ratios for PCI are greater than \$80 000 per QALY compared with medical therapy and are thus considered less favorable.

The initial mean cost of angioplasty was 65% that of surgery, but the need for repeat interventions increased medical expenses so that after 5 years, the total medical cost of PTCA was 95% that of surgery (\$56 225 vs \$58 889), a significant difference of \$2664 (P equals 0.047). Compared with CABG, PTCA appeared less costly for patients with 2-vessel disease but not for patients with 3-vessel disease.

The use of DES is affecting the cost-effectiveness of PCI. In the SIRIUS trial (93), there were 21 fewer repeat revascularization procedures per 100 patients treated with the sirolimus stent. Although the DES group's hospital costs were \$2800 more, much of that was negated in follow-up by the high reintervention rate in the BMS group (920). However, the number of repeat procedures in such trials with routine angiographic follow-up is inflated compared with registries of BMS, which suggests only 6 to 7 repeat procedures are avoided by routinely using DES (882). The ultimate cost effectiveness of drug-eluting stenting will depend on the cost of the stents, how many are implanted per patient, and how many repeat procedures are avoided.

Because cost-effectiveness analysis research is new in the field of PCI, its results are limited. The Committee underscores the need for cost containment and careful decision making regarding the use of PCI strategies.

8. FUTURE DIRECTIONS

The field of coronary intervention has expanded dramatically over the past decade and will continue to evolve over the next several years. New directions will focus on strategies that will further improve procedural safety, reduce the recurrence rate after PCI, and expand the procedure to more complex anatomic subsets. Clinical acceptance of these technologies will be based on demonstration of safety and efficacy over conventional therapies in randomized clinical studies. Several novel strategies are summarized below.

Because the widespread use of stent implantation has lessened the risk of need for emergency bypass, future clinical research will focus on remaining obstacles that decrease procedural success or increase risk. Chronic total occlusion remains a stubborn problem. New devices such as the Frontrunner catheter and new ultrastiff guidewires show some promise in improving procedural success; however, new approaches are needed.

Degenerated vein graft disease remains a high-risk subset. The SAFER trial (255) has demonstrated that distal protection with a balloon occlusive device with intraprocedural aspiration decreases procedural risk. Similarly, a number of distal filter devices are undergoing active testing (254). The results of one such multicenter trial comparing a filter-based catheter with a balloon occlusive and aspiration device showed similar results for MACE at 30 days (254). In spite of these approaches, these procedures are still associated with MACE event rates of 8% to 10%. More research is still needed in this area. The use of distal protection devices in settings other than degenerative vein graft disease requires further study. For example, initial studies in primary PCI suggested a benefit with the FilterWire™; however, subsequent trials with the GuideWire have failed to show any benefit, instead showing poor outcomes in this setting. Thus, further research is needed before this technology is adopted for use beyond degenerative vein graft disease.

Dramatic advances have been made in the treatment of restenosis. Although the oral agents tranilast (921) and folic

acid have proven unsuccessful, other catheter-based strategies have dramatically decreased restenosis risk. Brachytherapy (for ISR), rapamycin-eluting stents, and PES have been extremely effective. Subgroups such as diffuse ISR and insulin-dependent diabetes mellitus will require further study. Other therapies, such as photodynamic therapy, cryotherapy, and therapeutic ultrasound, remain interesting but unproven approaches to treat restenosis.

In patients with refractory angina who have no vessels suited for revascularization, a number of new therapies are being tested. Enhanced external counterpulsation appears to decrease symptoms (922). Treatment with fibroblast growth factor by an intracoronary approach also shows promise (923). Percutaneous laser transmyocardial revascularization has shown mixed results. The PACIFIC trial (Potential Class Improvement From Intramyocardial Channels) putatively demonstrated some benefit of percutaneous laser transmyocardial revascularization, but the major limitation of that study was that it was not placebo-controlled; thus, after its failure to address potential concerns, general consensus attributes the results in PACIFIC to a placebo effect. Also, in PACIFIC, diverse outcomes tended to be higher with laser therapy (924). Although the randomized, double-blind BELIEF trial (Blinded Evaluation of Laser PMR Intervention Electively For angina pectoris) of 82 patients appeared to show some benefit of percutaneous laser transmyocardial revascularization versus sham procedure on angina class and quality-of-life measures, the results were inconclusive given the small size of the study (925). To date, data are insufficient for FDA approval of percutaneous laser therapy. A new frontier has been opened with the intra-arte-

rial infusion of marrow-derived stem cells (926) and direct injection of skeletal muscle-derived myoblasts (927) for myogenesis. Studies to date were performed in patients with severe angina; thus, it is uncertain how this technology might apply to other subsets of patients with coronary disease (e.g., acute coronary syndromes, ischemic cardiomyopathy), and rigorous, blinded evaluation of these approaches must occur.

STAFF

American College of Cardiology

Christine W. McEntee, Chief Executive Officer

Katherine D. Doermann, Senior Specialist, Practice Guidelines

Kristina N. Petrie, MS, Associate Director, Evidence-Based Medicine

Dawn R. Phoubandith, MSW, Associate Director, Practice Guidelines

Peg Christian, Librarian, Knowledge Management

American Heart Association

M. Cass Wheeler, Chief Executive Officer

Rose Marie Robertson, MD, FACC, FAHA, Chief Science Officer

Kathryn A. Taubert, PhD, FAHA, Senior Science Advisor

Society for Cardiovascular Angiography and Interventions

Norm Linsky, Executive Director

Wayne Powell, Senior Director, Advocacy and Guidelines

APPENDIX 1. ACC/AHA/SCAI Committee to Update 2002 Guidelines for Percutaneous Coronary Intervention—Relationships with Industry

Committee Member	Research Grant	Speakers Bureau/ Honoraria	Stock Ownership	Consultant
Dr. Ted E. Feldman	Abbot Boston Scientific Cardia EV3 Evalve Guidant	Boston Scientific	None	None
Dr. John W. Hirshfeld, Jr	None	None	None	None
Dr. Alice K. Jacobs	None	None	None	Wyeth
Dr. Morton J. Kern	None	None	None	None
Dr. Spencer B. King, III	Guidant	BMS-Sanofi Guidant	None	Medtronic Novoste
Dr. Douglass A. Morrison	None	None	None	None
Dr. William W. O'Neill	None	None	None	None
Dr. Hartzell V. Schaff	None	None	None	None
Dr. Sidney C. Smith, Jr	Merck	Bayer	Johnson & Johnson Medtronic	Bristol-Myers Squibb Eli Lilly Pfizer Sanofi-Aventis
Dr. Patrick L. Whitlow	Abbot Cordis, Inc Fox Hollow Technologies Lumend, Inc	None	Medtronic	None
Dr. David O. Williams	None	None	None	None

This table represents the relevant relationships of authors with industry that were reported orally at the initial writing committee meeting in July 2002 and updated in conjunction with all meetings and conference calls of the writing committee. It does not reflect any actual or potential relationships at the time of publication.

APPENDIX 2. External Peer Reviewers for the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention*

Peer Reviewer Name†	Representation	Research Grant	Speakers Bureau/Honoraria	Stock Ownership	Consultant/Advisory Board
Dr. Michael Cowley	Official Reviewer – SCAI	None	None	None	None
Dr. David Faxon	Official Reviewer – ACC/AHA Task Force on Practice Guidelines	None	None	None	None
Dr. Roxana Mehran	Official Reviewer – SCAI	None	The Medicines Co.	None	None
Dr. E. Magnus Ohman	Official Reviewer – AHA	Berlex Bristol-Myers Squibb Millennium Schering-Plough	None	Inovise Medical Medtronic Response Medical	None
Dr. Richard Pomerantz	Official Reviewer – ACCF Board of Governors		Aventis	Amgen Johnson & Johnson Pfizer Schering-Plough	Medacorp
Dr. Robert D. Safian	Official Reviewer – AHA	None	None	None	None
Dr. W. Douglas Weaver	Official Reviewer – ACCF Board of Trustees	None	None	None	None
Dr. Jeffrey L. Anderson	Content Reviewer – Individual Review	Sanofi/Bristol-Myers Squibb Novartis	Merck Sanofi/Bristol-Myers Squibb	None	Merck
Dr. Elliott M. Antman	Content Reviewer – Individual Review	Aventis Bayer Biosite Boehringer-Mannheim Bristol-Myers Squibb British Biotech Centor Cor/Millennium Corvas Dade Genentech Lilly Merck Pfizer Sunol	None	None	Aventis
Dr. Larry S. Dean	Content Reviewer – ACCF Cardiac Catheterization and Intervention Committee	None	None	None	None
Dr. Tommaso Gori	Content Reviewer – AHA Diagnostic and Interventional Cardiac Catheterization Committee	None	None	None	None
Dr. Sharon A. Hunt	Content Reviewer – Individual Review	None	None	None	None
Dr. Lloyd Klein	Content Reviewer – AHA Diagnostic and Interventional Cardiac Catheterization Committee	None	None	None	None
Dr. Glenn Levine	Content Reviewer AHA Diagnostic and Interventional Cardiac Catheterization Committee	None	Aventis	None	None
Dr. Joseph P. Ornato	Content Reviewer – Individual Review	Genentech	None	None	Bristol-Myers Squibb Genentech

This table represents the relevant relationships of peer reviewers with industry to this topic that were disclosed at the time of peer review of this guideline. It does not necessarily reflect relationships with industry at the time of publication.

*Participation in the peer review process does not imply endorsement of the document.

†Names are listed in alphabetical order within each category of review.

References

1. Smith SC, Jr., Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). *J Am Coll Cardiol* 2001;37:2215-39.
2. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. *N Engl J Med* 1979;301:61-8.
3. Kent KM, Bentivoglio LG, Block PC, et al. Percutaneous transluminal coronary angioplasty: report from the Registry of the National Heart, Lung, and Blood Institute. *Am J Cardiol* 1982;49:2011-20.
4. Williams DO, Riley RS, Singh AK, Most AS. Restoration of normal coronary hemodynamics and myocardial metabolism after percutaneous transluminal coronary angioplasty. *Circulation* 1980;62:653-6.
5. Miller DD, Verani MS. Current status of myocardial perfusion imaging after percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol* 1994;24:260-6.
6. Detre KM, Holmes DRJ, Holubkov R, et al. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. *Circulation* 1990;82:739-50.
7. Detre KM, Holubkov R, Kelsey S, et al. Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981: the National Heart, Lung, and Blood Institute Registry. *N Engl J Med* 1988;318:265-70.
8. O'Keefe JH Jr, Rutherford BD, McConahay DR, et al. Multivessel coronary angioplasty from 1980 to 1989: procedural results and long-term outcome. *J Am Coll Cardiol* 1990;16:1097-102.
9. American Heart Association. 2004 Heart and Stroke Statistical Update. 2003;
10. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. [published erratum appears in *N Engl J Med* 1997 Jan 9;336(2):147]. *N Engl J Med* 1996;335:217-25.
11. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. *Lancet* 1993;341:573-80.
12. Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease: German Angioplasty Bypass Surgery Investigation (GABI). *N Engl J Med* 1994;331:1037-43.
13. Rodriguez A, Bouillon F, Perez-Balino N, et al. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. *J Am Coll Cardiol* 1993;22:1060-7.
14. Pocock SJ, Henderson RA, Riococks AF, et al. Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. *Lancet* 1995;346:1184-9.
15. Laskey WK, Kimmel S, Krone RJ. Contemporary trends in coronary intervention: a report from the Registry of the Society for Cardiac Angiography and Interventions. *Catheter Cardiovasc Interv* 2000;49:19-22.
16. Kuntz RE, Baim DS, Cohen DJ, et al. A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]). *Am J Cardiol* 2002;89:326-30.
17. Liu F, Haude M, Ge J, Eick B, Baumgart D, Erbel R. Recanalization of totally occluded saphenous vein bypass grafts with rheolytic thrombectomy device AngioJet catheter. *J Intervent Cardiol* 1998;11:49-53.
18. American College of Cardiology-National Cardiovascular Data Registry Version 3.0. 2004;
19. Detre KM, Wright E, Murphy ML, Takaro T. Observer agreement in evaluating coronary angiograms. *Circulation* 1975;52:979-86.
20. Brown BG, Bolson EL, Dodge HT. Quantitative computer techniques for analyzing coronary arteriograms. *Prog Cardiovasc Dis* 1986;28:403-18.
21. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol* 2000;36:959-69.
- 21a. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. *Circulation* 2003;108:2543-9
22. Abdelmeguid AE, Topol EJ. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. *Circulation* 1996;94:3369-75.
23. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. *J Am Coll Cardiol* 1998;31:241-51.
24. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. *Circulation* 2002;106:1205-10.
25. Miller WL, Garratt KN, Burritt MF, Reeder GS, Jaffe AS. Timing of peak troponin T and creatine kinase-MB elevations after percutaneous coronary intervention. *Chest* 2004;125:275-80.
26. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. *J Am Coll Cardiol* 2002;39:1738-44.
27. Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. *Eur Heart J* 2003;24:1314-22.
28. Newby LK, Alpert JS, Ohman EM, Thygesen K, Califf RM. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. *Am Heart J* 2002;144:957-80.
29. Hunt AC, Chow SL, Shiu MF, Chilton DC, Cummins B, Cummins P. Release of creatine kinase-MB and cardiac specific troponin-I following percutaneous transluminal coronary angioplasty. *Eur Heart J* 1991;12:690-3.
30. Ravkilde J, Nissen H, Mickley H, Andersen PE, Thyssen P, Horder M. Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. *Am Heart J* 1994;127:13-20.
31. Karim MA, Shinn MS, Oskarsson H, Windle J, Deligonul U. Significance of cardiac troponin T release after percutaneous

- transluminal coronary angioplasty. *Am J Cardiol* 1995;76:521-3.
32. La VL, Bedogni F, Finocchi G, et al. Troponin T, troponin I and creatine kinase-MB mass after elective coronary stenting. *Coron Artery Dis* 1996;7:535-40.
 33. Johansen O, Brekke M, Stromme JH, et al. Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. *Eur Heart J* 1998;19:112-7.
 34. Shyu KG, Kuan PL, Cheng JJ, Hung CR. Cardiac troponin T, creatine kinase, and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting. *Am Heart J* 1998;135:862-7.
 35. Bertinchant JP, Polge A, Ledermann B, et al. Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. *Am J Cardiol* 1999;84:51-7.
 36. Garbarz E, Iung B, Lefevre G, et al. Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. *Am J Cardiol* 1999;84:515-8.
 37. Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. *Am J Cardiol* 2000;85:1077-82.
 38. Wu AH, Boden WE, McKay RG. Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. *Am J Cardiol* 2002;89:1300-2.
 39. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. *Am Heart J* 2003;145:522-8.
 40. Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. *Am J Cardiol* 2004;93:18-23.
 41. King SB, Yeh W, Holubkov R, et al. Balloon angioplasty versus new device intervention: clinical outcomes. A comparison of the NHLBI PTCA and NACI registries. *J Am Coll Cardiol* 1998;31:558-66.
 42. Feit F, Brooks MM, Sopko G, et al. Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators. *Circulation* 2000;101:2795-802.
 43. McGrath PD, Malenka DJ, Wennberg DE, et al. Changing outcomes in percutaneous coronary interventions: a study of 34,752 procedures in northern New England, 1990 to 1997. Northern New England Cardiovascular Disease Study Group. *J Am Coll Cardiol* 1999;34:674-80.
 44. Grassman ED, Johnson SA, Krone RJ. Predictors of success and major complications for primary percutaneous transluminal coronary angioplasty in acute myocardial infarction: an analysis of the 1990 to 1994 Society for Cardiac Angiography and Interventions registries. *J Am Coll Cardiol* 1997;30:201-8.
 45. Marks DS, Mensah GA, Kennard ED, Detre K, Holmes DRJ. Race, baseline characteristics, and clinical outcomes after coronary intervention: The New Approaches in Coronary Interventions (NACI) registry. *Am Heart J* 2000;140:162-9.
 46. Holmes DRJ, Berger PB, Garratt KN, et al. Application of the New York State PTCA mortality model in patients undergoing stent implantation. *Circulation* 2000;102:517-22.
 47. Hannan EL, Racz M, Ryan TJ, et al. Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. *JAMA* 1997;277:892-8.
 48. Peterson ED, Lansky AJ, Anstrom KJ, et al. Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network Database. *Am Heart J* 2000;139:198-207.
 49. Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. *Circulation* 2000;102:2945-51.
 50. Srinivas VS, Brooks MM, Detre KM, et al. Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study. *Circulation* 2002;106:1627-33.
 51. Anderson HV, Shaw RE, Brindis RG, et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR®). *J Am Coll Cardiol* 2002;39:1096-103.
 52. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. *N Engl J Med* 2005;352:2174-83.
 53. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet* 2003;361:13-20.
 54. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. *Circulation* 2001;103:2780-3.
 55. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. *Circulation* 2005;111:1027-32.
 56. Hong MK, Mehran R, Dangas G, et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. *Circulation* 1999;100:2400-5.
 57. Stone GW, Mehran R, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. *Circulation* 2001;104:642-7.
 58. Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). *J Am Coll Cardiol* 2002;40:662-8.
 59. Iakovou I, Mintz GS, Dangas G, et al. Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study. *J Am Coll Cardiol* 2003;42:1900-5.
 60. Williams DO. A twist in our understanding of enzyme elevation after coronary intervention. *J Am Coll Cardiol* 2003;42:1906-8.
 61. Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack--proposal for a new definition. *N Engl J Med* 2002;347:1713-6.
 62. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. *Circulation* 1999;99:2720-32.
 63. Noguchi T, Miyazaki MS, Morii I, Daikoku S, Goto Y, Nonogi H. Percutaneous transluminal coronary angioplasty of chronic total occlusions. Determinants of primary success and long-term clinical outcome. *Catheter Cardiovasc Interv* 2000;49:258-64.
 64. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *N Engl J Med* 2002;346:957-66.
 65. King SB, III. Ten-year completed follow-up of percutaneous transluminal coronary angioplasty: the early Zurich experience. *J*

- Am Coll Cardiol 1993;22:353-60.
66. Holmes DR, Jr., Kip KE, Kelsey SF, Detre KM, Rosen AD. Cause of death analysis in the NHLBI PTCA Registry: results and considerations for evaluating long-term survival after coronary interventions. *J Am Coll Cardiol* 1997;30:881-7.
 67. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation* 1997;96:1761-9.
 68. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation* 1999;99:633-40.
 69. Kelsey SF, James M, Holubkov AL, Holubkov R, Cowley MJ, Detre KM. Results of percutaneous transluminal coronary angioplasty in women: 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. *Circulation* 1993;87:720-7.
 70. Holmes DRJ, Detre KM, Williams DO, et al. Long-term outcome of patients with depressed left ventricular function undergoing percutaneous transluminal coronary angioplasty: the NHLBI PTCA Registry. *Circulation* 1993;87:21-9.
 71. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. *N Engl J Med* 1988;318:1714-9.
 72. Ellis SG, Roubin GS, Wilentz J, Douglas JSJ, King SB, III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. *Am Heart J* 1989;117:777-82.
 73. Pepine CJ, Hirshfeld JW, MacDonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty: M-HEART Group. *Circulation* 1990;81:1753-61.
 74. Serruys PW, Rutsch W, Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A₂-receptor blockade: a randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). *Circulation* 1991;84:1568-80.
 75. O'Keefe JH, Jr., McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. *J Am Coll Cardiol* 1992;19:1597-600.
 76. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. *Circulation* 1992;86:100-10.
 77. Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease: the CAVEAT Study Group. *N Engl J Med* 1993;329:221-7.
 78. Adelman AG, Cohen EA, Kimball BP, et al. A comparison of directional atherectomy with balloon angioplasty for lesions of the left anterior descending coronary artery. *N Engl J Med* 1993;329: 228-33.
 79. Serruys PW, Klein W, Tijssen JP, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: a multicenter randomized double-blind placebo-controlled trial. *Circulation* 1993;88:1588-601.
 80. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. *N Engl J Med* 1994;331:489-95.
 81. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparin Restenosis (ERA) Trial. *Circulation* 1994;90:908-14.
 82. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? *Circulation* 1994;90:2248-57.
 83. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. *N Engl J Med* 1994;331:496-501.
 84. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. *N Engl J Med* 1994;331:1331-7.
 85. Baim DS, Cutlip DE, Sharma SK, et al. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). *Circulation* 1998;97:322-31.
 86. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. *Am Heart J* 1996;132:23-9.
 87. Tardif JC, Cote G, Lesperance J, et al. Probuco and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probuco Study Group. *N Engl J Med* 1997;337:365-72.
 88. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) [published erratum appears in *Lancet* 1998 Oct 31;352(9138):1478]. *Lancet* 1998;352:673-81.
 89. Tamai H, Katoh O, Suzuki S, et al. Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). *Am Heart J* 1999;138:968-75.
 90. Holmes D, Fitzgerald P, Goldberg S, et al. The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial. *Am Heart J* 2000;139:23-31.
 91. vom DJ, Dietz U, Haager PK, et al. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). *Circulation* 2002;105:583-8.
 92. Popma JJ, Suntharalingam M, Lansky AJ, et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. *Circulation* 2002;106:1090-6.
 93. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003;349:1315-23.
 94. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med* 2004;350:221-31.
 95. Albiero R, Silber S, Di MC, et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). *J Am Coll Cardiol* 2004;43:943-9.
 96. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. *Circulation* 1991;84:1426-36.
 97. Haudenschild CC. Pathobiology of restenosis after angioplasty. *Am J Med* 1993;94:40S-4S.
 98. Currier JW, Haudenschild C, Faxon DP. Pathophysiology of restenosis: clinical implications. In: Ischinger T, Gohlke H, editors. *Strategies in Primary and Secondary Prevention of Coronary Artery Disease*. W. Zuckschwerdt Verlag, 1992:181-92.
 99. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after

- coronary angioplasty: a serial intravascular ultrasound study. *Circulation* 1996;94:35-43.
100. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? *J Am Coll Cardiol* 1995;25:516-20.
 101. Kuntz RE, Baim DS. Defining coronary restenosis: newer clinical and angiographic paradigms. *Circulation* 1993;88:1310-23.
 102. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. *J Am Coll Cardiol* 1993;21:15-25.
 103. Blackshear JL, O'Callaghan WG, Califf RM. Medical approaches to prevention of restenosis after coronary angioplasty. *J Am Coll Cardiol* 1987;9:834-48.
 104. Bresee SJ, Jacobs AK, Garber GR, et al. Prior restenosis predicts restenosis after coronary angioplasty of a new significant narrowing. *Am J Cardiol* 1991;68:1158-62.
 105. Hirshfeld JWJ, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. *J Am Coll Cardiol* 1991;18:647-56.
 106. Al SJ, Berger PB, Holmes DR, Jr. Coronary artery stents. *JAMA* 2000;284:1828-36.
 107. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. *J Am Coll Cardiol* 1996;27:255-61.
 108. Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PA. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. *N Engl J Med* 1997;336:817-22.
 109. George CJ, Baim DS, Brinker JA, et al. One-year follow-up of the Stent Restenosis (STRESS I) Study. *Am J Cardiol* 1998;81:860-5.
 110. Rodriguez A, Ayala F, Bernardi V, et al. Optimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS): immediate and long-term follow-up results. *J Am Coll Cardiol* 1998;32:1351-7.
 111. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. *Lancet* 1998;352:87-92.
 112. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. *N Engl J Med* 1999;341:319-27.
 113. Betriu A, Masotti M, Serra A, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. *J Am Coll Cardiol* 1999;34:1498-506.
 114. Weaver WD, Reisman MA, Griffin JJ, et al. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. *Lancet* 2000;355:2199-203.
 115. Deleted in press. See Ref 658.
 116. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. *Circulation* 2000 May 9;101 (18):2165 - 71 101:2165-71.
 117. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. *N Engl J Med* 1997;336:1697-703.
 118. Ellis SG, Roubin GS, King SB, III, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. *Circulation* 1988;77:372-9.
 119. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Multivessel Angioplasty Prognosis Study Group. *Circulation* 1990;82:1193-202.
 120. Hartzler GO, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV. "High-risk" percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1988;61:33G-7G.
 121. Gaul G, Hollman J, Simpfendorfer C, Franco I. Acute occlusion in multiple lesion coronary angioplasty: frequency and management. *J Am Coll Cardiol* 1989;13:283-8.
 122. Ellis SG, Roubin GS, King SB, III, et al. In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 procedures. *J Am Coll Cardiol* 1988;11: 211-6.
 123. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). *J Am Coll Cardiol* 1993;22:2033-54.
 124. de Feyter PJ, van den Brand M, Laarman GJ, et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up [published erratum appears in *Circulation* 1991 Jul;84(1):446]. *Circulation* 1991;83:927-36.
 125. Myler RK, Shaw RE, Stertz SH, et al. Lesion morphology and coronary angioplasty: current experience and analysis. *J Am Coll Cardiol* 1992;19:1641-52.
 126. Kastrati A, Schomig A, Elezi S, et al. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. *Circulation* 1999;100:1285-90.
 127. Budde T, Haude M, Hopp HW, et al. A prognostic computer model to individually predict post-procedural complications in interventional cardiology: the INTERVENT Project. *Eur Heart J* 1999;20:354-63.
 128. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. *Circulation* 2001;104:992-7.
 129. Harrell L, Schunkert H, Palacios IF. Risk predictors in patients scheduled for percutaneous coronary revascularization. *Catheter Cardiovasc Interv* 1999;48:253-60.
 130. Singh M, Lennon RJ, Holmes DR, Jr., Bell MR, Rihal CS. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. *J Am Coll Cardiol* 2002;40:387-93.
 131. Zaacks SM, Allen JE, Calvin JE, et al. Value of the American College of Cardiology/American Heart Association stenosis morphology classification for coronary interventions in the late 1990s. *Am J Cardiol* 1998;82:43-9.
 132. Krone RJ, Shaw RE, Klein LW, et al. Evaluation of the American College of Cardiology/American Heart Association and the Society for Coronary Angiography and Interventions lesion classification system in the current "stent era" of coronary interventions (from the ACC-National Cardiovascular Data Registry). *Am J Cardiol* 2003;92:389-94.
 133. Krone RJ, Laskey WK, Johnson C, et al. A simplified lesion classification for predicting success and complications of coronary angioplasty. Registry Committee of the Society for Cardiac Angiography and Intervention. *Am J Cardiol* 2000;85:1179-84.

134. Tan KH, Sulke N, Taub N, Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. *J Am Coll Cardiol* 1995;25:855-65.
135. Kimmel SE, Berlin JA, Strom BL, Laskey WK. Development and validation of simplified predictive index for major complications in contemporary percutaneous transluminal coronary angioplasty practice: the Registry Committee of the Society for Cardiac Angiography and Interventions. *J Am Coll Cardiol* 1995;26:931-8.
136. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. *J Am Coll Cardiol* 1999;34:1512-21.
137. Mueller C, Neumann FJ, Perruchoud AP, Buettner HJ. Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention. *Heart* 2004;90:902-7.
138. Taliercio CP, Vlietstra RE, Fisher LD, Burnett JC. Risks for renal dysfunction with cardiac angiography. *Ann Intern Med* 1986;104:501-4.
139. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation* 2002;105:2259-64.
140. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. *J Am Coll Cardiol* 2000;36:1542-8.
141. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. *J Am Coll Cardiol* 2002;39:1113-9.
142. Naidu SS, Selzer F, Jacobs A, et al. Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. *Am J Cardiol* 2003;92:1160-4.
143. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. *Circulation* 2003;108:2769-75.
144. Ellis SG, Myler RK, King SB, III, et al. Causes and correlates of death after unsupported coronary angioplasty: implications for use of angioplasty and advanced support techniques in high-risk settings. *Am J Cardiol* 1991;68:1447-51.
145. Block P, Peterson E, Krone R, et al. Identification of variables needed to risk adjust outcome of coronary interventions: evidence-based guidelines for efficient data collection. *J Am Coll Cardiol* 1998;32:275-82.
146. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). *J Am Coll Cardiol* 2004;44:1146-310.
147. Ellis SG, Tamai H, Nobuyoshi M, et al. Contemporary percutaneous treatment of unprotected left main coronary stenoses: initial results from a multicenter registry analysis 1994-1996. *Circulation* 1997;96:3867-72.
148. Silvestri M, Barragan P, Sainsous J, et al. Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. *J Am Coll Cardiol* 2000;35:1543-50.
149. Black A, Cortina R, Bossi I, Choussat R, Fajadet J, Marco J. Unprotected left main coronary artery stenting: correlates of midterm survival and impact of patient selection. *J Am Coll Cardiol* 2001;37:832-8.
150. Park SJ, Hong MK, Lee CW, et al. Elective stenting of unprotected left main coronary artery stenosis: effect of debulking before stenting and intravascular ultrasound guidance. *J Am Coll Cardiol* 2001;38:1054-60.
151. Kelley MP, Klugherz BD, Hashemi SM, et al. One-year clinical outcomes of protected and unprotected left main coronary artery stenting. *Eur Heart J* 2003;24:1554-9.
152. Park SJ, Park SW, Hong MK, et al. Long-term (three-year) outcomes after stenting of unprotected left main coronary artery stenosis in patients with normal left ventricular function. *Am J Cardiol* 2003;91:12-6.
153. Tan WA, Tamai H, Park SJ, et al. Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. *Circulation* 2001;104:1609-14.
154. Takagi T, Stankovic G, Finci L, et al. Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. *Circulation* 2002;106:698-702.
155. Sakai K, Nakagawa Y, Kimura T, et al. Primary angioplasty of unprotected left main coronary artery for acute anterolateral myocardial infarction. *J Invasive Cardiol* 2004;16:621-5.
156. de Lezo JS, Medina A, Pan M, et al. Rapamycin-eluting stents for the treatment of unprotected left main coronary disease. *Am Heart J* 2004;148:481-5.
157. Arampatzis CA, Lemos PA, Hoye A, et al. Elective sirolimus-eluting stent implantation for left main coronary artery disease: six-month angiographic follow-up and 1-year clinical outcome. *Catheter Cardiovasc Interv* 2004;62:292-6.
158. Agostoni P, Valgimigli M, Van Mieghem CA, et al. Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidance. *Am J Cardiol* 2005;95:644-7.
159. Chieffo A, Stankovic G, Bonizzoni E, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. *Circulation* 2005;111:791-5.
160. Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. *J Am Coll Cardiol* 2005;45:351-6.
161. Valgimigli M, Van Mieghem CA, Ong AT, et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). *Circulation* 2005;111:1383-9.
162. Sadeghi HM, O'Neill WW, Grines CL. Percutaneous intervention of unprotected left main coronary artery. *J Interv Cardiol* 2003;16:281-8.
163. Bergelson BA, Jacobs AK, Cupples LA, et al. Prediction of risk for hemodynamic compromise during percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1992;70:1540-5.
164. Califf RM, Phillips HR3, Hindman MC, et al. Prognostic value of a coronary artery jeopardy score. *J Am Coll Cardiol* 1985;5:1055-63.
165. Holmes DRJ, Holubkov R, Vlietstra RE, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. *J Am Coll Cardiol* 1988;12:1149-55.
166. Sinclair IN, McCabe CH, Sipperly ME, Baim DS. Predictors, therapeutic options and long-term outcome of abrupt reclosure. *Am J Cardiol* 1988;61:61G-6G.
167. Anderson RD, Ohman EM, Holmes DR, Jr, et al. Prognostic value

- of congestive heart failure history in patients undergoing percutaneous coronary interventions. *J Am Coll Cardiol* 1998;32:936-41.
168. Fuchs S, Stabile E, Kinnaird TD, et al. Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications. *Circulation* 2002;106:86-91.
169. Lansky AJ, Hochman JS, Ward PA, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. *Circulation* 2005;111:940-53.
170. Malenka DJ, Wennberg DE, Quinon HA, et al. Gender-related changes in the practice and outcomes of percutaneous coronary interventions in Northern New England from 1994 to 1999. *J Am Coll Cardiol* 2002;40:2092-101.
171. Bell MR, Holmes DRJ, Berger PB, Garratt KN, Bailey KR, Gersh BJ. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty. *JAMA* 1993;269:2091-5.
172. Cowley MJ, Mullin SM, Kelsey SF, et al. Sex differences in early and long-term results of coronary angioplasty in the NHLBI PTCA Registry. *Circulation* 1985;71:90-7.
173. McEniery PT, Hollman J, Knezinek V, et al. Comparative safety and efficacy of percutaneous transluminal coronary angioplasty in men and in women. *Cathet Cardiovasc Diagn* 1987;13:364-71.
174. Kahn JK, Rutherford BD, McConahay DR, et al. Comparison of procedural results and risks of coronary angioplasty in men and women for conditions other than acute myocardial infarction. *Am J Cardiol* 1992;69:1241-2.
175. Davis KB, Chaitman B, Ryan T, Bittner V, Kennedy JW. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. *Coronary Artery Surgery Study*. *J Am Coll Cardiol* 1995;25:1000-9.
176. Mendes LA, Davidoff R, Cupples LA, Ryan TJ, Jacobs AK. Congestive heart failure in patients with coronary artery disease: the gender paradox. *Am Heart J* 1997;134:207-12.
177. Welty FK, Lewis SM, Kowalker W, Shubrooks SJ, Jr. Reasons for higher in-hospital mortality >24 hours after percutaneous transluminal coronary angioplasty in women compared with men. *Am J Cardiol* 2001;88:473-7.
178. Malenka DJ, O'Connor GT, Quinon H, et al. Differences in outcomes between women and men associated with percutaneous transluminal coronary angioplasty. A regional prospective study of 13,061 procedures. Northern New England Cardiovascular Disease Study Group. *Circulation* 1996;94:II99-104.
179. Cantor WJ, Miller JM, Hellkamp AS, et al. Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women. *Am Heart J* 2002;144:297-302.
180. Kornowski R, Lansky AJ, Mintz GS, et al. Comparison of men versus women in cross-sectional area luminal narrowing, quantity of plaque, presence of calcium in plaque, and lumen location in coronary arteries by intravascular ultrasound in patients with stable angina pectoris. *Am J Cardiol* 1997;79:1601-5.
181. Greenberg MA, Mueller HS. Why the excess mortality in women after PTCA? *Circulation* 1993;87:1030-2.
182. Lansky AJ, Pietras C, Costa RA, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2005;111:1611-8.
183. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. *J Am Coll Cardiol* 2000;36:381-6.
184. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. *JAMA* 2003;289:853-63.
185. Jacobs AK, Johnston JM, Haviland A, et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. *J Am Coll Cardiol* 2002;39:1608-14.
186. Bell MR, Grill DE, Garratt KN, Berger PB, Gersh BJ, Holmes DR, Jr. Long-term outcome of women compared with men after successful coronary angioplasty. *Circulation* 1995;91:2876-81.
187. Weintraub WS, Wenger NK, Kosinski AS, et al. Percutaneous transluminal coronary angioplasty in women compared with men. *J Am Coll Cardiol* 1994;24:81-90.
188. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). *Circulation* 1998;98:1279-85.
189. Robertson T, Kennard ED, Mehta S, et al. Influence of gender on in-hospital clinical and angiographic outcomes and on one-year follow-up in the New Approaches to Coronary Intervention (NACI) registry. *Am J Cardiol* 1997;80:26K-39K.
190. Jacobs AK, Kelsey SF, Yeh W, et al. Documentation of decline in morbidity in women undergoing coronary angioplasty: a report from the 1993-94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry. National Heart, Lung, and Blood Institute. *Am J Cardiol* 1997;80:979-84.
191. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicenter randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. *Lancet* 1999;354:2019-24.
192. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. *J Am Coll Cardiol* 2000;35:1535-42.
193. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators [published erratum appears in *N Engl J Med* 1999 Aug 12;341(7):548]. *N Engl J Med* 1999;340:1623-9.
194. Madan M, Kereiakes DJ, Hermiller JB, et al. Efficacy of abciximab readministration in coronary intervention. *Am J Cardiol* 2000 Feb 15 ;85(4):435-40.
195. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study [see comments] [published erratum appears in *Lancet* 1997 Sep 6;350(9079):744]. *Lancet* 1997;349:1429-35.
196. Bhatt DL, Lincoff AM, Kereiakes DJ, et al. Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. *Am J Cardiol* 1998;82:1105-6, A6.

197. Tcheng JE, Kereiakes DJ, Braden GA, et al. Safety of abciximab retreatment: final clinical report of the ReoPro readministration registry (R3). *Circulation* 1998;98 (Suppl):I-17.
198. Randomised placebo-controlled trial of effect of eptifibatid on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. *Lancet* 1997;349:1422-8.
199. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatid in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. *N Engl J Med* 1998;339:436-43.
200. Novel dosing regimen of eptifibatid in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. *Lancet* 2000;356:2037-44.
201. O'shea JC, Madan M, Cantor WJ, et al. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen eptifibatid in percutaneous coronary intervention. *Am Heart J* 2000;140:834-9.
202. Dery JP, Braden GA, Lincoff AM, et al. Final results of the ReoPro readministration registry. *Am J Cardiol* 2004;93:979-84.
203. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. *JAMA* 2004;292:2727-34.
204. Watanabe CT, Maynard C, Ritchie JL. Comparison of short-term outcomes following coronary artery stenting in men versus women. *Am J Cardiol* 2001;88:848-52.
205. Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S, Antman EM. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature. *Am J Cardiol* 2004;93:830-5.
206. Wiviott SD, Cannon CP, Morrow DA, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. *Circulation* 2004;109:580-6.
207. Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. *Am Heart J* 2004;147:133-9.
208. Wong SC, Sleeper LA, Monrad ES, et al. Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK Trial Registry. *J Am Coll Cardiol* 2001;38:1395-401.
209. Movsowitz HD, Emmi RP, Manginas A, et al. Directional coronary atherectomy in women compared with men. *Clin Cardiol* 1994;17:597-602.
210. Ahmed JM, Dangas G, Lansky AJ, et al. Influence of gender on early and one-year clinical outcomes after saphenous vein graft stenting. *Am J Cardiol* 2001;87:401-5.
211. Thompson RC, Holmes DR Jr, Gersh BJ, Mock MB, Bailey KR. Percutaneous transluminal coronary angioplasty in the elderly: early and long-term results. *J Am Coll Cardiol* 1991;17:1245-50.
212. Wennberg DE, Makenka DJ, Sengupta A, et al. Percutaneous transluminal coronary angioplasty in the elderly: epidemiology, clinical risk factors, and in-hospital outcomes. The Northern New England Cardiovascular Disease Study Group. *Am Heart J* 1999;137:639-45.
213. Iakovou I, Dangas G, Mintz GS, et al. Comparison of frequency of hemorrhagic stroke in patients <75 years versus > or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. *Am J Cardiol* 2004;93:346-9.
214. Assali AR, Moustapha A, Sdringola S, et al. The dilemma of success: percutaneous coronary interventions in patients > or = 75 years of age-successful but associated with higher vascular complications and cardiac mortality. *Catheter Cardiovasc Interv* 2003;59:195-9.
215. Taddei CF, Weintraub WS, Douglas JS Jr, et al. Influence of age on outcome after percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1999;84:245-51.
216. Tsai TP, Chaux A, Kass RM, Gray RJ, Matloff JM. Aortocoronary bypass surgery in septuagenarians and octogenarians. *Cardiovasc Surg (Torino)* 1989;30:364-8.
217. Holt GW, Sugrue DD, Bresnahan JF, et al. Results of percutaneous transluminal coronary angioplasty for unstable angina pectoris in patients 70 years of age and older. *Am J Cardiol* 1988;61:994-7.
218. Cohen HA, Williams DO, Holmes DR, Jr, et al. Impact of age on procedural and 1-year outcome in percutaneous transluminal coronary angioplasty: a report from the NHLBI Dynamic Registry. *Am Heart J* 2003;146:513-9.
219. Simpfendorfer C, Raymond R, Schraider J, et al. Early- and long-term results of percutaneous transluminal coronary angioplasty in patients 70 years of age and older with angina pectoris. *Am J Cardiol* 1988;62:959-61.
220. Klein LW, Block P, Brindis RG, et al. Percutaneous coronary interventions in octogenarians in the American College of Cardiology-National Cardiovascular Data Registry: development of a nomogram predictive of in-hospital mortality. *J Am Coll Cardiol* 2002;40:394-402.
221. Chauhan MS, Kuntz RE, Ho KL, et al. Coronary artery stenting in the aged. *J Am Coll Cardiol* 2001;37:856-62.
222. Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. *Ann Intern Med* 2004;141:186-95.
223. Guagliumi G, Stone GW, Cox DA, et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2004;110:1598-604.
224. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. *Lancet* 2001;358:951-7.
225. Batchelor WB, Anstrom KJ, Muhlbaier LH, et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. *J Am Coll Cardiol* 2000;36:723-30.
226. Terrin ML, Williams DO, Kleiman NS, et al. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial. *J Am Coll Cardiol* 1993;22:1763-72.
227. Aguirre FV, Younis LT, Chaitman BR, et al. Early and 1-year clinical outcome of patients' evolving non-Q-wave versus Q-wave myocardial infarction after thrombolysis: results from the TIMI II Study. *Circulation* 1995;91:2541-8.
228. Laskey WK, Selzer F, Vlachos HA, et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). *Am*

- J Cardiol 2002;90:1062-7.
229. Gaxiola E, Vlietsra R, Browne KF, et al. Is the outcome of coronary stenting worse in elderly patients? *J Intervent Cardiol* 1998;11:37-40.
230. Marso SP, Lincoff AM, Ellis SG, et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. *Circulation* 1999;100:2477-84.
231. Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. *Circulation* 2002;105:2730-6.
232. Brooks RC, Detre KM. Clinical trials of revascularization therapy in diabetics. *Curr Opin Cardiol* 2000;15:287-92.
233. Detre KM, Lombardero MS, Brooks MM, et al. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. *Bypass Angioplasty Revascularization Investigation Investigators. N Engl J Med* 2000;342:989-97.
234. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. *Lancet* 2004;364:583-91.
235. Schofer J, Schluter M. Are drug-eluting stents a panacea for patients with coronary heart disease? *Lancet* 2004;364:558-9.
236. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. *Circulation* 2004;109:190-5.
237. Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease. National Library of Medicine. Available at <http://www.clinicaltrials.gov/ct/gui/show/NCT00086450>. Last update 6-30-2005.
238. Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. *J Am Coll Cardiol* 2004;43:8-14.
239. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). *Diabetes Care* 1997;20:614-20.
240. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med* 1998;339:1349-57.
241. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. *Circulation* 1998;98:2513-9.
242. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360:7-22.
243. Holmes DRJ, Topol EJ, Califf RM, et al. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions: CAVEAT-II Investigators. *Circulation* 1995;91:1966-74.
244. Pomerantz RM, Kuntz RE, Carozza JP, et al. Acute and long-term outcome of narrowed saphenous venous grafts treated by endoluminal stenting and directional atherectomy. *Am J Cardiol* 1992;70:161-7.
245. Wong SC, Baim DS, Schatz RA, et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group. *J Am Coll Cardiol* 1995;26:704-12.
246. Brener SJ, Ellis SG, Apperson-Hansen C, Leon MB, Topol EJ. Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years. *Am J Cardiol* 1997;79:13-8.
247. Gruberg L, Dangas G, Mehran R, et al. Percutaneous revascularization of the internal mammary artery graft: short- and long-term outcomes. *J Am Coll Cardiol* 2000;35:944-8.
248. Lopez JJ, Ho KK, Stoler RC, et al. Percutaneous treatment of protected and unprotected left main coronary stenoses with new devices: immediate angiographic results and intermediate-term follow-up. *J Am Coll Cardiol* 1997;29:345-52.
249. Dorros G, Lewin RF, Mathiak LM. Coronary angioplasty in patients with prior coronary artery bypass surgery: all prior coronary artery bypass surgery patients and patients more than 5 years after coronary bypass surgery. *Cardiol Clin* 1989;7:791-803.
250. Plokker HW, Meester BH, Serruys PW. The Dutch experience in percutaneous transluminal angioplasty of narrowed saphenous veins used for aortocoronary arterial bypass. *Am J Cardiol* 1991;67:361-6.
251. Webb JG, Myler RK, Shaw RE, et al. Coronary angioplasty after coronary bypass surgery: initial results and late outcome in 422 patients. *J Am Coll Cardiol* 1990;16:812-20.
252. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. *Circulation* 2002;106:3063-7.
253. Limbruno U, Micheli A, De CM, et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. *Circulation* 2003;108:171-6.
254. Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. *Circulation* 2003;108:548-53.
255. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. *Circulation* 2002;105:1285-90.
256. Mathew V, Clavell AL, Lennon RJ, Grill DE, Holmes DRJ. Percutaneous coronary interventions in patients with prior coronary artery bypass graft surgery: Changes in patient characteristics and outcome during two decades. *Am J Med* 2000;108:127.
257. Bhatt DL, Topol E. Percutaneous coronary intervention for patients with prior bypass surgery: Therapy in Evolution. *Am J Med* 2000;108:176.
258. Teirstein PS, Warth DC, Haq N, et al. High speed rotational coronary atherectomy for patients with diffuse coronary artery disease. *J Am Coll Cardiol* 1991;18:1694-701.
259. Sharma SK, Dangas G, Mehran R, et al. Risk factors for the development of slow flow during rotational coronary atherectomy. *Am J Cardiol* 1997;80:219-22.
260. Dehmer GJ, Nichols TC, Bode AP, et al. Assessment of platelet activation by coronary sinus blood sampling during balloon angioplasty and directional coronary atherectomy. *Am J Cardiol*

- 1997;80:871-7.
261. Koch KC, vom DJ, Kleinhans E, et al. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. *J Am Coll Cardiol* 1999;33:998-1004.
262. Bhatt DL, Lincoff AM, Califf RM, et al. The benefit of abciximab in percutaneous coronary revascularization is not device-specific. *Am J Cardiol* 2000;85:1060-4.
263. Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new device era: incidence, classification, management, and outcome. *Circulation* 1994;90:2725-30.
264. Ajluni SC, Glazier S, Blankenship L, O'Neill WW, Safian RD. Perforations after percutaneous coronary interventions: clinical, angiographic, and therapeutic observations. *Cathet Cardiovasc Diagn* 1994;32:206-12.
265. Vogel RA, Tommaso CL, Gundry SR. Initial experience with coronary angioplasty and aortic valvuloplasty using elective semipercutaneous cardiopulmonary support. *Am J Cardiol* 1988;62:811-3.
266. Shawl FA, Domanski MJ, Hernandez TJ, Punja S. Emergency percutaneous cardiopulmonary bypass support in cardiogenic shock from acute myocardial infarction. *Am J Cardiol* 1989;64:967-70.
267. Kreidieh I, Davies DW, Lim R, et al. High-risk coronary angioplasty with elective intra-aortic balloon pump support. *Int J Cardiol* 1992;35:147-52.
268. Anwar A, Mooney MR, Stertz SH, et al. Intra-aortic balloon counter pulsation support for elective coronary angioplasty in the setting of poor left ventricular function: a two center experience. *J Invas Cardiol* 1990;2:175-80.
269. Voudris V, Marco J, Morice MC, Fajadet J, Royer T. "High-risk" percutaneous transluminal coronary angioplasty with preventive intra-aortic balloon counterpulsation. *Cathet Cardiovasc Diagn* 1990;19:160-4.
270. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Hartzler GO. Supported "high risk" coronary angioplasty using intraaortic balloon pump counterpulsation. *J Am Coll Cardiol* 1990;15:1151-5.
271. Briguori C, Sarais C, Pagnotta P, et al. Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty. *Am Heart J* 2003;145:700-7.
272. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. *N Engl J Med* 1986;314:1-6.
273. Kshetry VR, Flavin TF, Emery RW, Nicoloff DM, Arom KV, Petersen RJ. Does multivessel, off-pump coronary artery bypass reduce postoperative morbidity? *Ann Thorac Surg* 2000;69:1725-30.
274. Alderman EL, Bourassa MG, Cohen LS, et al. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. *Circulation* 1990;82:1629-46.
275. Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina: the VA Coronary Artery Bypass Surgery Cooperative Study Group. *Circulation* 1992;86:121-30.
276. Danchin N, Brengard A, Ethevenot G, et al. Ten year follow-up of patients with single vessel coronary artery disease that was suitable for percutaneous transluminal coronary angioplasty. *Br Heart J* 1988;59:275-9.
277. Hueb WA, Bellotti G, de Oliveira SA, et al. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. *J Am Coll Cardiol* 1995;26:1600-5.
278. Goy JJ, Eeckhout E, Burnand B, et al. Coronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosis. *Lancet* 1994;343:1449-53.
279. Rodriguez A, Mele E, Peyregne E, et al. Three-year follow-up of the Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease (ERACI). *J Am Coll Cardiol* 1996;27:1178-84.
280. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. *Circulation* 99 A.D.;100:799-806.
281. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. *N Engl J Med* 2001;344:1117-24.
282. Legrand VM, Serruys PW, Unger F, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. *Circulation* 2004;109:1114-20.
283. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. *Lancet* 2002;360:965-70.
284. Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. *J Am Coll Cardiol* 2001;37:51-8.
285. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). *J Am Coll Cardiol* 2001;38:143-9.
286. King SB, III, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery: Emory Angioplasty versus Surgery Trial (EAST). *N Engl J Med* 1994;331:1044-50.
287. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation): CABRI Trial Participants. *Lancet* 1995;346:1179-84.
288. Carrie D, Elbaz M, Puel J, et al. Five-year outcome after coronary angioplasty versus bypass surgery in multivessel coronary artery disease: results from the French Monocentric Study. *Circulation* 1997;96:II-1-6.
289. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. *J Am Coll Cardiol* 2004;43:1743-51.
290. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. *J Am Coll Cardiol* 2000;35:1122-9.
291. Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. *J Am Coll Cardiol* 1998;31:10-9.
292. King SB, III, Kosinski AS, Guyton RA, Lembo NJ, Weintraub WS. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). *J Am Coll Cardiol* 2000;35:1116-21.
293. Rozenman Y, Sapoznikov D, Mosseri M, et al. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of

- the BARI study. Balloon Angioplasty Revascularization Investigation. *J Am Coll Cardiol* 1997;30:1420-5.
294. Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. *Circulation* 2001;104:533-8.
 295. Sedlis SP, Morrison DA, Lorin JD, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWE-SOME randomized trial and registry. *J Am Coll Cardiol* 2002;40:1555-66.
 296. Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. *N Engl J Med* 1992;326:10-6.
 297. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet* 1997;350:461-8.
 298. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med* 1999;341:70-6.
 299. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. *J Am Coll Cardiol* 2003;42:1161-70.
 300. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME Investigators. *J Am Coll Cardiol* 1997;29:1505-11.
 301. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. *Circulation* 1997;95:2037-43.
 302. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. *Lancet* 2002;360:743-51.
 303. Dakik HA, Kleiman NS, Farmer JA, et al. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. *Circulation* 1998;98:2017-23.
 304. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. *Lancet* 1999;354:708-15.
 305. Shaw RE, Anderson HV, Brindis RG, et al. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. *J Am Coll Cardiol* 2002;39:1104-12.
 306. Ellis SG, Weintraub W, Holmes D, Shaw R, Block PC, King SB, III. Relation of operator volume and experience to procedural outcome of percutaneous coronary revascularization at hospitals with high interventional volumes. *Circulation* 1997;95:2479-84.
 307. Moscucci M, Kline-Rogers E, Share D, et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. *Circulation* 2001;104:263-8.
 308. Holmes DR, Selzer F, Johnston JM, et al. Modeling and risk prediction in the current era of interventional cardiology: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. *Circulation* 2003;107:1871-6.
 309. Bashore TM, Bates ER, Berger PB, et al. American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 2001;37:2170-214.
 310. Hirshfeld JW, Jr., Ellis SG, Faxon DP, et al. ACC clinical competence statement: recommendations for the assessment and maintenance of proficiency in coronary interventional procedures. *J Am Coll Cardiol* 1998;31:722-43.
 311. Pepine CJ, Babb JD, Brinker JA, et al. Guidelines for training in adult cardiovascular medicine. Core Cardiology Training Symposium (COCATS): Task Force 3: training in cardiac catheterization and interventional cardiology. *J Am Coll Cardiol* 1995;25:14-6.
 312. Hirshfeld JW, Banas JS, Brundage BH, et al. American College of Cardiology training statement on recommendations for the structure of an optimal adult interventional cardiology training program: a report of the American College of Cardiology task force on clinical expert consensus documents. *J Am Coll Cardiol* 1999;34:2141-7.
 313. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). *J Am Coll Cardiol* 1988;12:529-45.
 314. Shook TL, Sun GW, Burstein S, Eisenhauer AC, Matthews RV. Comparison of percutaneous transluminal coronary angioplasty outcome and hospital costs for low-volume and high-volume operators. *Am J Cardiol* 1996;77:331-6.
 315. Kimmel SE, Berlin JA, Laskey WK. The relationship between coronary angioplasty procedure volume and major complications. *JAMA* 1995;274:1137-42.
 316. Jollis JG, Peterson ED, Nelson CL, et al. Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patients. *Circulation* 1997;95:2485-91.
 317. Ho V. Evolution of the volume-outcome relation for hospitals performing coronary angioplasty. *Circulation* 2000;101:1806-11.
 318. Hamad N, Pichard AD, Lyle HR, Lindsay J, Jr. Results of percutaneous transluminal coronary angioplasty by multiple, relatively low frequency operators: 1986-1987 experience. *Am J Cardiol* 1988;61:1229-31.
 319. O'Neill WW, Brodie BR, Ivanhoe R, et al. Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry). *Am J Cardiol* 1994;73:627-34.
 - 319a. Hannan EL, Wu C, Wallford G, et al. Volume-outcome relationships for percutaneous coronary interventions in the stent era. *Circulation* 2005;112:1171-79.
 320. Hannan EL, Kilburn HJ, Bernard H, O'Donnell JF, Lukacik G, Shields EP. Coronary artery bypass surgery: the relationship between inhospital mortality rate and surgical volume after controlling for clinical risk factors. *Med Care* 1991;29:1094-107.
 321. McGrath PD, Wennberg DE, Dickens JD, et al. Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent. *JAMA* 2000;284:3139-44.
 322. Ryan TJ. The critical question of procedure volume minimums

- for coronary angioplasty. *JAMA* 1995;274:1169-70.
323. Epstein AJ, Rathore SS, Volpp KG, Krumholz HM. Hospital percutaneous coronary intervention volume and patient mortality, 1998 to 2000: does the evidence support current procedure volume minimums? *J Am Coll Cardiol* 2004;43:1755-62.
324. Brown DL. Analysis of the institutional volume-outcome relations for balloon angioplasty and stenting in the stent era in California. *Am Heart J* 2003;146:1071-6.
325. Moscucci M, Share D, Smith D, et al. Relationship Between Operator Volume and Adverse Outcome in Contemporary Percutaneous Coronary Intervention Practice: An Analysis of a Quality-Controlled Multicenter Percutaneous Coronary Intervention Clinical Database. *J Am Coll Cardiol* 2005;46:625-32.
326. Every NR, Maynard C, Schulman K, Ritchie JL. The association between institutional primary angioplasty procedure volume and outcome in elderly Americans. *J Invasive Cardiol* 2000;12:303-8.
327. Magid DJ, Calonge BN, Rumsfeld JS, et al. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. *JAMA* 2000;284:3131-8.
328. Vakili BA, Kaplan R, Brown DL. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. *Circulation* 2001;104:2171-6.
329. Vakili BA, Brown DL. Relation of total annual coronary angioplasty volume of physicians and hospitals on outcomes of primary angioplasty for acute myocardial infarction (data from the 1995 Coronary Angioplasty Reporting System of the New York State Department of Health). *Am J Cardiol* 2003;91:726-8.
330. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. *JAMA* 2000;283:2941-7.
331. Canto JG, Every NR, Magid DJ, et al. The volume of primary angioplasty procedures and survival after acute myocardial infarction: National Registry of Myocardial Infarction 2 Investigators. *N Engl J Med* 2000;342:1573-80.
332. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). *J Am Coll Cardiol* 2004;44:E1-E211.
333. Klinke WP, Hui W. Percutaneous transluminal coronary angioplasty without on-site surgical facilities. *Am J Cardiol* 1992;70:1520-5.
334. Meier B, Urban P, Dorsaz PA, Favre J. Surgical standby for coronary balloon angioplasty. *JAMA* 1992;268:741-5.
335. Iiguez A, Macaya C, Hernandez R, et al. Comparison of results of percutaneous transluminal coronary angioplasty with and without selective requirement of surgical standby. *Am J Cardiol* 1992;69:1161-5.
336. Surgical cover for percutaneous transluminal coronary angioplasty: the Council of the British Cardiovascular Intervention Society. *Br Heart J* 1992;68:339-41.
337. Sowton E, de Bono D, Gribbin B, O'Keefe B, et al. Coronary angioplasty in the United Kingdom. *Br Heart J* 1991;66:325-31.
338. Hasdai D, Berger PB, Bell MR, Rihal CS, Garratt KN, Holmes DR Jr. The changing face of coronary interventional practice: the Mayo Clinic experience. *Arch Intern Med* 1997;157:677-82.
339. Altmann DB, Racz M, Battleman DS, et al. Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients. *Am Heart J* 1996;132:503-7.
340. Stauffer JC, Eeckhout E, Vogt P, Kappenberger L, Goy JJ. Stand-by versus stent-by during percutaneous transluminal coronary angioplasty. *Am Heart J* 1995;130:21-6.
341. Andreasen JJ, Mortensen PE, Andersen LI, et al. Emergency coronary artery bypass surgery after failed percutaneous transluminal coronary angioplasty. *Scand Cardiovasc J* 2000;34:242-6.
342. Shubrooks SJ Jr, Nesto RW, Leeman D, et al. Urgent coronary bypass surgery for failed percutaneous coronary intervention in the stent era: Is backup still necessary? *Am Heart J* 2001;142:190-6.
343. Berger PB, Stensrud PE, Daly RC, et al. Time to reperfusion and other procedural characteristics of emergency coronary artery bypass surgery after unsuccessful coronary angioplasty. *Am J Cardiol* 1995;76:565-9.
344. Beyersdorf F, Mitrev Z, Sarai K, et al. Changing patterns of patients undergoing emergency surgical revascularization for acute coronary occlusion: importance of myocardial protection techniques. *J Thorac Cardiovasc Surg* 1993;106:137-48.
345. Nollert G, Amend J, Detter C, Reichart B. Coronary artery bypass grafting after failed coronary angioplasty: risk factors and long-term results. *Thorac Cardiovasc Surg* 1995;43:35-9.
346. Lazar HL, Faxon DP, Paone G, et al. Changing profiles of failed coronary angioplasty patients: impact on surgical results. *Ann Thorac Surg* 1992;53:269-73.
347. Talley JD, Weintraub WS, Roubin GS, et al. Failed elective percutaneous transluminal coronary angioplasty requiring coronary artery bypass surgery: in-hospital and late clinical outcome at 5 years. *Circulation* 1990;82:1203-13.
348. Loubeyre C, Morice MC, Berzin B, et al. Emergency coronary artery bypass surgery following coronary angioplasty and stenting: results of a French multicenter registry. *Catheter Cardiovasc Interv* 1999;47:441-8.
349. Vogt A, Bonzel T, Harmjan D, et al. PTCA registry of German community hospitals. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) Study Group [see comments]. *Eur Heart J* 1997;18:1110-4.
350. Dellavalle A, Steffenino G, Ribichini F, Russo P, Uslenghi E. Elective coronary angioplasty with and without surgical standby: clinical and angiographic criteria for the selection of patients. *Coron Artery Dis* 1995;6:513-20.
351. Richardson SG, Morton P, Murtagh JG, O'Keefe DB, Murphy P, Scott ME. Management of acute coronary occlusion during percutaneous transluminal coronary angioplasty: experience of complications in a hospital without on site facilities for cardiac surgery. *BMJ* 1990;300:355-8.
352. Reifart N, Preusler W, Schwarz F, et al. A large center experience of coronary angioplasty without on-site surgical standby. In: Topol EJ, Serruys PW, editors. *Current Review of Interventional Cardiology*. Philadelphia: Current Medicine, 1995:296-303.
353. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. *JAMA* 1991;266:93-8.
354. Loop FD, Whitlow PL. "Beauty is in the eye" *Am J Cardiol* 1992;70:1608-9.
355. Kent KM. Interventional cardiology: 1990s. *Am J Cardiol* 1992;70:1607-8.
356. Wennberg DE, Lucas FL, Siewers AE, Kellett MA, Malenka DJ. Outcomes of percutaneous coronary interventions performed at centers without and with onsite coronary artery bypass graft surgery. *JAMA* 2004;292:1961-8.

357. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction: Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). *Lancet* 1986;1:397-402.
358. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. *Lancet* 1988;2:349-60.
359. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. *JAMA* 1993;270:1211-6.
360. Stone GW, Brodie BR, Griffin JJ, et al. Role of cardiac surgery in the hospital phase management of patients treated with primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2000 Jun 1 ;85(11):1292-6.
361. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group [see comments]. *N Engl J Med* 1993;328:673-9.
362. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction [see comments]. *N Engl J Med* 1993;328:680-4.
363. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfensperger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. *N Engl J Med* 1993;328:685-91.
364. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. *JAMA* 1997;278:2093-8.
365. Moosvi AR, Khaja F, Villanueva L, Gheorghide M, Douthat L, Goldstein S. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. *J Am Coll Cardiol* 1992;19:907-14.
366. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N Engl J Med* 1999;341:625-34.
367. Vogel JH. Changing trends for surgical standby in patients undergoing percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1992;69:25F-32F.
368. Wharton TPJ, McNamara NS, Fedele FA, Jacobs MI, Gladstone AR, Funk EJ. Primary angioplasty for the treatment of acute myocardial infarction: experience at two community hospitals without cardiac surgery. *J Am Coll Cardiol* 1999;33:1257-65.
369. Weaver WD, Litwin PE, Martin JS. Use of direct angioplasty for treatment of patients with acute myocardial infarction in hospitals with and without on-site cardiac surgery: the Myocardial Infarction, Triage, and Intervention Project Investigators. *Circulation* 1993;88:2067-75.
370. Iannone LA, Anderson SM, Phillips SJ. Coronary angioplasty for acute myocardial infarction in a hospital without cardiac surgery. *Tex Heart Inst J* 1993;20:99-104.
371. Brush JEJ, Thompson S, Ciuffo AA, et al. Retrospective Comparison of a Strategy of Primary Coronary Angioplasty versus Intravenous Thrombolytic Therapy for Acute Myocardial Infarction in a Community Hospital without Cardiac Surgical Backup. *J Invasive Cardiol* 1996;8:91-8.
372. Smyth DW, Richards AM, Elliott JM. Direct Angioplasty for Myocardial Infarction: One-Year Experience in a Center with Surgical Back-up 220 Miles Away. *J Invasive Cardiol* 1997;9:324-32.
373. Weaver WD, Parsons LS, Every NR. Primary coronary angioplasty in hospitals with and without surgery backup. *J Invas Cardiol* 1995;7:34F-9F.
374. Meier B. Surgical standby for percutaneous transluminal coronary angioplasty. In: Topol EJ, ed. *Textbook of Interventional Cardiology*. Philadelphia: W.B. Saunders Company, 1999:466-74.
375. Wharton TP Jr, Grines LL, Turco MA, et al. Primary angioplasty in acute myocardial infarction at hospitals with no surgery on-site (the PAMI-No SOS study) versus transfer to surgical centers for primary angioplasty. *J Am Coll Cardiol* 2004;43:1943-50.
376. Brodie BR. Primary percutaneous coronary intervention at hospitals without on-site cardiac surgery: expanding the use of mechanical reperfusion for acute myocardial infarction. *J Am Coll Cardiol* 2004;43:1951-3.
377. Vogel JH. Angioplasty in the patient with an evolving myocardial infarction: with and without surgical backup. *Clin Cardiol* 1992;15:880-2.
378. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med* 2003;349:733-42.
379. Lange RA, Hillis LD. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Thrombolysis—the preferred treatment. *N Engl J Med* 1996;335:1311-2; discussion 1316-7.
380. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. *JAMA* 2002;287:1943-51.
381. Grines CL, Westerhausen DR Jr, Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. *J Am Coll Cardiol* 2002;39:1713-9.
382. Caputo RP, Ho KK, Stoler RC, et al. Effect of continuous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 1997;79:1159-64.
383. Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1999;34:890-911.
384. Lotfi M, Mackie K, Dzavik V, Seidelin PH. Impact of delays to cardiac surgery after failed angioplasty and stenting. *J Am Coll Cardiol* 2004;43:337-42.
385. Campeau L. Letter: Grading of angina pectoris. *Circulation* 1976;54:522-3.
386. Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. *Circulation* 1983;68:951-60.
387. Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina: the Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. *N Engl J Med* 1984;311:1333-9.
388. Varnauskas E. Survival, myocardial infarction, and employment status in a prospective randomized study of coronary bypass sur-

- gery. *Circulation* 1985;72:V90-101.
389. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration [published erratum appears in *Lancet* 1994 Nov 19;344(8934):1446]. *Lancet* 1994;344:563-70.
390. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. *J Am Coll Cardiol* 1995;26:1643-50.
391. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators [published erratum appears in *N Engl J Med* 1998 Oct 8;339(15):1091]. *N Engl J Med* 1998;338:1785-92.
392. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. *Lancet* 1999;354:701-7.
393. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med* 2001;344:1879-87.
394. Cannon CP. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial. *J Am Coll Cardiol* 2003;41:43S-8S.
395. Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study. *Eur Heart J* 2002;23:230-8.
396. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. *Fast Revascularisation during Instability in Coronary artery disease.* *Lancet* 2000;356:9-16.
397. Michalis LK, Stroumbis CS, Pappas K, et al. Treatment of refractory unstable angina in geographically isolated areas without cardiac surgery. Invasive versus conservative strategy (TRUCS study). *Eur Heart J* 2000;21:1954-9.
398. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow-up and analysis of individual patient data from randomized trials. *Am Heart J* 2003;145:47-57.
399. Laster SB, O'Keefe JH Jr, Gibbons RJ. Incidence and importance of thrombolysis in myocardial infarction grade 3 flow after primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 1996;78:623-6.
400. Brodie BR, Grines CL, Ivanhoe R, et al. Six-month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Final results from the Primary Angioplasty Registry. *Circulation* 1994;90:156-62.
401. Brodie BR, Weintraub RA, Stuckey TD, et al. Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy. *Am J Cardiol* 1991;67:7-12.
402. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators [published erratum appears in *N Engl J Med* 1997 Jul 24;337(4):287]. *N Engl J Med* 1997;336: 1621-8.
403. Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. *J Am Coll Cardiol* 1993;22:376-80.
404. Grinfeld L, Berrocal D, Bellardi J. Fibrinolytics versus primary angioplasty in acute myocardial infarction (FAP): a randomized trial in a community hospital in Argentina. *J Am Coll Cardiol* 1996;27 (suppl):A222.
405. Akhras F, Ousa AA, Swan G et al. Primary coronary angioplasty or intravenous thrombolysis for patients with acute myocardial infarction? Acute and late follow-up results in a new cardiac unit. *J Am Coll Cardiol* 1997;29:A235-A236.
406. Zijlstra F, Beukema WP, van't Hof AW, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. *J Am Coll Cardiol* 1997;29:908-12.
407. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. *Eur Heart J* 2000;21:823-31.
408. de Boer MJ, Ottervanger JP, van't Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. *J Am Coll Cardiol* 2002;39:1723-8.
409. Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). *J Am Coll Cardiol* 2001;37:985-91.
410. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. *Lancet* 2002;360:825-9.
411. Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. *N Engl J Med* 2000;343:385-91.
412. Vermeer F, Oude Ophuis AJ, Van de Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. *Heart* 1999;82:426-31.
413. Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study. *J Am Coll Cardiol* 1998;32:1687-94.
414. Garcia E, Elizaga J, Perez-Castellano N, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. *J Am Coll Cardiol* 1999;33:605-11.
415. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. *Eur Heart J* 2003;24:94-104.
416. Grines CL, Serruys P, O'Neill WW. Fibrinolytic therapy: is it a

- treatment of the past? *Circulation* 2003;107:2538-42.
417. Melandri G. The obsession with primary angioplasty. *Circulation* 2003;108:e162.
 418. Berger PB, Ellis SG, Holmes DR, Jr., et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. *Circulation* 1999;100:14-20.
 419. Brodie BR, Stuckey TD, Hansen C, Muncy D. Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2000;85:13-8.
 420. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. *Circulation* 2001;104:636-41.
 421. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? *Am J Cardiol* 2003;92:824-6.
 422. Juliard JM, Feldman LJ, Golmard JL, et al. Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time. *Am J Cardiol* 2003;91:1401-5.
 423. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J* 2003;24:28-66.
 424. De LG, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. *Circulation* 2004;109:1223-5.
 425. Zijlstra F, van't Hof AW, Liem AL, Hoorntje JC, Suryapranata H, de Boer MJ. Transferring patients for primary angioplasty: a retrospective analysis of 104 selected high risk patients with acute myocardial infarction. *Heart* 1997;78:333-6.
 426. Zahn R, Schiele R, Seidl K, et al. Primary Angioplasty in Acute Myocardial Infarction: Differences Between Referred Patients and Those Treated in Hospitals with On-site Facilities? *J Invasive Cardiol* 1999;11:213-9.
 427. Straumann E, Yoon S, Naegeli B, et al. Hospital transfer for primary coronary angioplasty in high risk patients with acute myocardial infarction. *Heart* 1999;82:415-9.
 428. NRMI-4 Investigators. The National Registry of Myocardial Infarction-4 Quarterly Report. 2003;2.
 429. Nallamothu BK, Bates ER, Herrin J, Wang Y, Bradley EH, Krumholz HM. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. *Circulation* 2005;111:761-7.
 430. Kastrati A, Mehilli J, Dirschinger J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomized trial. *Lancet* 2002;359:920-5.
 431. Stone GW, Brodie BR, Griffin JJ, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators. *J Am Coll Cardiol* 1998;31:23-30.
 432. Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low-risk patients with acute myocardial infarction. PAM-II Investigators. Primary Angioplasty in Myocardial Infarction. *J Am Coll Cardiol* 1998;31:967-72.
 433. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 1999;341:1949-56.
 434. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. *J Am Coll Cardiol* 1998;31:1234-9.
 435. Maillard L, Hamon M, Khalife K, et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators. *J Am Coll Cardiol* 2000;35:1729-36.
 436. Saito S, Hosokawa G, Tanaka S, Nakamura S. Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the primary angioplasty versus stent implantation in acute myocardial infarction (PASTA) trial. PASTA Trial Investigators. *Catheter Cardiovasc Interv* 1999;48:262-8.
 437. Scheller B, Hennen B, Severin-Kneib S, Ozbek C, Schieffer H, Markwirth T. Long-term follow-up of a randomized study of primary stenting versus angioplasty in acute myocardial infarction. *Am J Med* 2001;110:1-6.
 438. Rodriguez A, Bernardi V, Fernandez M, et al. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction. *Am J Cardiol* 1998;81:1286-91.
 439. Suryapranata H, Ottervanger JP, Nibbering E, et al. Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction. *Heart* 2001;85:667-71.
 440. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. *Am J Cardiol* 2001;88:297-301.
 441. Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. *J Am Coll Cardiol* 2004;43:704-8.
 442. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. *N Engl J Med* 2001;344:1895-903.
 443. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. *Circulation* 1998;98:734-41.
 444. Montalescot G. Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams? *Eur Heart J* 2004;25:1562-4.
 445. Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anti-coagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. *Circulation* 2004;109:997-1003.
 446. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion

- strategy for acute myocardial infarction. *J Am Coll Cardiol* 2003;42:1886-9.
447. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). *J Am Coll Cardiol* 2002;40:1389-94.
448. Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. *J Am Coll Cardiol* 1992;20:1482-9.
449. Lee L, Erbel R, Brown TM, Laufer N, Meyer J, O'Neill WW. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. *J Am Coll Cardiol* 1991;17:599-603.
450. Stone GW, Grines CL, Browne KF, et al. Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy. *Am J Cardiol* 1996;78:19-25.
451. van't Hof AW, Henriques J, Ottervanger J-P. No mortality benefit of primary angioplasty over thrombolytic therapy in patients with nonanterior myocardial infarction at long-term follow-up: results of the Zwolle trial [abstr]. *J Am Coll Cardiol* 2003;41:369A.
452. Williams DO. Treatment delayed is treatment denied. *Circulation* 2004;109:1806-8.
453. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. *Ann Intern Med* 1991;115:173-7.
454. Himbert D, Juliard JM, Steg PG, et al. Primary coronary angioplasty for acute myocardial infarction with contraindication to thrombolysis. *Am J Cardiol* 1993;71:377-81.
455. Zahn R, Schuster S, Schiele R, et al. Comparison of primary angioplasty with conservative therapy in patients with acute myocardial infarction and contraindications for thrombolytic therapy. Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Study Group. *Catheter Cardiovasc Interv* 1999;46:127-33.
456. Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. *JAMA* 2003;290:1891-8.
457. Gibson CM. A union in reperfusion: the concept of facilitated percutaneous coronary intervention. *J Am Coll Cardiol* 2000;36:1497-9.
458. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. *J Am Coll Cardiol* 2000;36:1489-96.
459. Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2004;291:947-54.
460. Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). *J Am Coll Cardiol* 2005;46:417-24.
461. Neuhaus KL, von ER, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). *J Am Coll Cardiol* 1992;19:885-91.
462. Lange RA, Cigarroa RG, Wells PJ, Kremers MS, Hills LD. Influence of antegrade flow in the infarct artery on the incidence of late potentials after acute myocardial infarction. *Am J Cardiol* 1990;65:554-8.
463. Cigarroa RG, Lange RA, Hillis LD. Prognosis after acute myocardial infarction in patients with and without residual antegrade coronary blood flow. *Am J Cardiol* 1989;64:155-60.
464. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. *Circulation* 1994;90:1731-8.
465. Ross AM, Lundergan CF, Rohrbeck SC, et al. Rescue angioplasty after failed thrombolysis: technical and clinical outcomes in a large thrombolysis trial. GUSTO-1 Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries [see comments]. *J Am Coll Cardiol* 1998;31:1511-7.
466. Ellis SG, da Silva ER, Spaulding CM, Nobuyoshi M, Weiner B, Talley JD. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. *Am Heart J* 2000;139:1046-53.
467. Ellis SG, da Silva ER, Heyndrickx G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. *Circulation* 1994;90:2280-4.
468. Goldman LE, Eisenberg MJ. Identification and management of patients with failed thrombolysis after acute myocardial infarction. *Ann Intern Med* 2000;132:556-65.
469. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave-front phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. *Circulation* 1977;56:786-94.
470. Califf RM, Topol EJ, Stack RS, et al. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group. *Circulation* 1991;83:1543-56.
471. Califf RM, Topol EJ, George BS, et al. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. *Circulation* 1988;77:1090-9.
472. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O'Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. *Circulation* 1988;78:1345-51.
473. Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. *Am J Cardiol* 1994;74:1220-8.
474. Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. *J Am Coll Cardiol* 2003;42:7-16.
475. Jeremy RW, Hackworthy RA, Bautovich G, Hutton BF, Harris PJ. Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction. *J Am Coll Cardiol* 1987;9:989-95.
476. Kersschot IE, Brugada P, Ramentol M, et al. Effects of early reperfusion in acute myocardial infarction on arrhythmias induced by programmed stimulation: a prospective, randomized study. *J Am Coll Cardiol* 1986;7:1234-42.
477. Stadius ML, Davis K, Maynard C, Ritchie JL, Kennedy JW. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction: the Western

- Washington Intracoronary Streptokinase Trial. *Circulation* 1986;74:703-11.
478. Topol EJ, Califf RM, Vandormael M, et al. A randomized trial of late reperfusion therapy for acute myocardial infarction: Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. *Circulation* 1992;85:2090-9.
479. Dzavik V, Beanlands DS, Davies RF, et al. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (< 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMI-IS]—a pilot study). *Am J Cardiol* 1994;73:856-61.
480. Zeymer U, Uebis R, Vogt A, et al. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte. *Circulation* 2003;108:1324-8.
481. Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. *Circulation* 1998;98:2377-82.
482. Yousef ZR, Redwood SR, Bucknall CA, Sulke AN, Marber MS. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). *J Am Coll Cardiol* 2002;40:869-76.
483. Steg PG, Thuair C, Himbert D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. *Eur Heart J* 2004;25:2187-94.
484. Kaandorp TA, Bax JJ, Schuijf JD, et al. Head-to-head comparison between contrast-enhanced magnetic resonance imaging and dobutamine magnetic resonance imaging in men with ischemic cardiomyopathy. *Am J Cardiol* 2004;93:1461-4.
485. Beek AM, Kuhl HP, Bondarenko O, et al. Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. *J Am Coll Cardiol* 2003;42:895-901.
486. Lima JA. Myocardial viability assessment by contrast-enhanced magnetic resonance imaging. *J Am Coll Cardiol* 2003;42:902-4.
487. Sadanandan S, Buller C, Menon V, et al. The late open artery hypothesis—a decade later. *Am Heart J* 2001;142:411-21.
488. Barbash GI, Roth A, Hod H, et al. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. *Am J Cardiol* 1990;66:538-45.
489. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction: SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. *BMJ* 1991;302:555-60.
490. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. *N Engl J Med* 1989;320:618-27.
491. Duber C, Jungbluth A, Rumpelt HJ, Erbel R, Meyer J, Thoenes W. Morphology of the coronary arteries after combined thrombolysis and percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 1986;58:698-703.
492. Williams DO, Braunwald E, Knatterud G, et al. One-year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase II Trial. *Circulation* 1992;85:533-42.
493. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). *J Am Coll Cardiol* 2002;40:1366-74.
494. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. *Lancet* 2004;364:1045-53.
495. Stenestrand U, Wallentin L. Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. *Lancet* 2002;359:1805-11.
496. Alter DA, Tu JV, Austin PC, Naylor CD. Waiting times, revascularization modality, and outcomes after acute myocardial infarction at hospitals with and without on-site revascularization facilities in Canada. *J Am Coll Cardiol* 2003;42:410-9.
497. Gupta M, Chang WC, Van de WF, et al. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. *Eur Heart J* 2003;24:1640-50.
498. Danchin N, Blanchard D, Steg PG, et al. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. *Circulation* 2004;110:1909-15.
499. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. *Circulation* 1997;96:748-55.
500. Ellis SG, Mooney MR, George BS, et al. Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction. Treatment of Post-Thrombolytic Stenoses (TOPS) Study Group. *Circulation* 1992;86:1400-6.
501. Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. *Circulation* 1995;91:873-81.
502. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. *Eur Heart J* 1999;20:1030-8.
503. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. *JAMA* 2001;285:190-2.
504. Dzavik V, Sleeper LA, Picard MH, et al. Outcome of patients aged ≥ 75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? *Am Heart J* 2005;149:1128-34.
505. Dauerman HL, Goldberg RJ, Malinski M, Yarzebski J, Lessard D, Gore JM. Outcomes and early revascularization for patients ≥ 65 years of age with cardiogenic shock. *Am J Cardiol* 2001;87:844-8.
506. Dauerman HL, Ryan TJ, Jr., Piper WD, et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: a multicenter, decade-long experience. *J Invasive*

- Cardiol 2003;15:380-4.
507. Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. *Am J Cardiol* 2002;89:132-6.
508. Giri S, Mitchel J, Azar RR, et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. *Am J Cardiol* 2002;89:126-31.
509. Antoniucci D, Valenti R, Migliorini A, et al. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. *Am J Cardiol* 2002;90:353-7.
510. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. *Circulation* 2003;107:2998-3002.
511. Nicod P, Gilpin EA, Dittrich H, et al. Trends in use of coronary angiography in subacute phase of myocardial infarction. *Circulation* 1991;84:1004-15.
512. Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. *J Am Coll Cardiol* 2003;42:1739-46.
513. Berger AK, Radford MJ, Wang Y, Krumholz HM. Thrombolytic therapy in older patients. *J Am Coll Cardiol* 2000;36:366-74.
514. Holmes DR, Jr., White HD, Pieper KS, Ellis SG, Califf RM, Topol EJ. Effect of age on outcome with primary angioplasty versus thrombolysis. *J Am Coll Cardiol* 1999;33:412-9.
515. Aguirre FV, McMahon RP, Mueller H, et al. Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy: results from the TIMI II Study. TIMI II Investigators. *Circulation* 1994;90:78-86.
516. Schulman SP, Achuff SC, Griffith LS, et al. Prognostic cardiac catheterization variables in survivors of acute myocardial infarction: a five year prospective study. *J Am Coll Cardiol* 1988;11:1164-72.
517. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. *N Engl J Med* 1993;329:673-82.
518. Lincoff AM, Califf RM, Van de WF, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. *JAMA* 2002;288:2130-5.
519. Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. *Circulation* 2001;104:1229-35.
520. Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction: analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. *Circulation* 1992;85:1254-64.
521. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. *Arch Intern Med* 2003;163:2345-53.
522. Campeau L, Lesperance J, Bourassa MG. Natural history of saphenous vein aortacoronary bypass grafts. *Mod Concepts Cardiovasc Dis* 1984;54:59-63.
523. Bourassa MG. Fate of venous grafts: the past, the present and the future. *J Am Coll Cardiol* 1991;17:1081-3.
524. FitzGibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. *J Am Coll Cardiol* 1996;28:616-26.
525. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. *Prog Cardiovasc Dis* 1991;34:45-68.
526. Kahn JK, Rutherford BD, McConahay DR, et al. Early postoperative balloon coronary angioplasty for failed coronary artery bypass grafting. *Am J Cardiol* 1990;66:943-6.
527. Dimas AP, Arora RR, Whitlow PL, et al. Percutaneous transluminal angioplasty involving internal mammary artery grafts. *Am Heart J* 1991;122:423-9.
528. Dorogy ME, Highfill WT, Davis RC. Use of angioplasty in the management of complicated perioperative infarction following bypass surgery. *Cathet Cardiovasc Diagn* 1993;29:279-82.
529. Rentrop P, Blanke H, Karsch KR, Kosterling H, Oster H, Leitz H. Recanalization of an acutely occluded aortocoronary bypass by intragraft fibrinolysis. *Circulation* 1980;62:1123-6.
530. Holmes DRJ, Chesebro JH, Vlietstra RE, Orszulak TA. Streptokinase for vein graft thrombosis--a caveat. *Circulation* 1981;63:729.
531. Marx M, Armstrong WP, Wack JP, et al. Short-duration, high-dose urokinase infusion for recanalization of occluded saphenous aortocoronary bypass grafts. *AJR Am J Roentgenol* 1989;153:167-71.
532. Hartzler GO, Johnson WL, McConahay DR, et al. Dissolution of coronary artery bypass graft thrombi by streptokinase infusion. *Am J Cardiol* 1981;47:493.
533. van Ommen VG, van den Bos AA, Pieper M, et al. Removal of thrombus from aortocoronary bypass grafts and coronary arteries using the 6Fr Hydrolyser. *Am J Cardiol* 1997;79:1012-6.
534. Douglas JSJ, Gruentzig AR, King SB3, et al. Percutaneous transluminal coronary angioplasty in patients with prior coronary bypass surgery. *J Am Coll Cardiol* 1983;2:745-54.
535. Reeves F, Bonan R, Cote G, et al. Long-term angiographic follow-up after angioplasty of venous coronary bypass grafts. *Am Heart J* 1991;122:620-7.
536. Meester BJ, Samson M, Suryapranata H, et al. Long-term follow-up after attempted angioplasty of saphenous vein grafts: the Thoraxcenter experience 1981-1988. *Eur Heart J* 1991;12:648-53.
537. de Feyter PJ, van Suylen RJ, de Jaegere PP, Topol EJ, Serruys PW. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. *J Am Coll Cardiol* 1993;21:1539-49.
538. Gruberg L, Hong MK, Mehran R, et al. In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site. *Am J Cardiol* 1999;84:1381-4.
539. Strauss BH, Natarajan MK, Batchelor WB, et al. Early and late quantitative angiographic results of vein graft lesions treated by excimer laser with adjunctive balloon angioplasty. *Circulation* 1995;92:348-56.
540. Bittl JA, Sanborn TA, Yardley DE, et al. Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions: the Percutaneous Excimer Laser Coronary Angioplasty Registry. *Am J Cardiol* 1994;74:144-8.
541. Stullman WS, Hilliard GK. Unrecognized internal mammary artery stenosis treated by percutaneous angioplasty after coronary bypass surgery. *Am Heart J* 1987;113:393-5.
542. Vivekaphirat V, Yellen SF, Foschi A. Percutaneous transluminal

- angioplasty of a stenosis at the origin of the left internal mammary artery graft: a case report. *Cathet Cardiovasc Diagn* 1988;15:176-8.
543. Sketch MHJ, Quigley PJ, Perez JA, et al. Angiographic follow-up after internal mammary artery graft angioplasty. *Am J Cardiol* 1992;70:401-3.
544. Popma JJ, Cooke RH, Leon MB, et al. Immediate procedural and long-term clinical results of internal mammary artery angioplasty. *Am J Cardiol* 1992;69:1237-9.
545. Pijls NH, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. *Circulation* 1993;87:1354-67.
546. Breall JA, Grossman W, Stillman IE, Gianturco LE, Kim D. Atherectomy of the subclavian artery for patients with symptomatic coronary-subclavian steal syndrome. *J Am Coll Cardiol* 1993;21:1564-7.
547. Perrault LP, Carrier M, Hudon G, Lemarbre L, Hebert Y, Pelletier LC. Transluminal angioplasty of the subclavian artery in patients with internal mammary grafts. *Ann Thorac Surg* 1993;56:927-30.
548. Tan KH, Henderson RA, Sulke N, Cooke RA, Karani S, Sowton E. Percutaneous transluminal coronary angioplasty in patients with prior coronary artery bypass grafting: ten years' experience. *Cathet Cardiovasc Diagn* 1994;32:11-7.
549. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. *Am J Cardiol* 1995;75:778-82.
550. Liu MW, Douglas JSJ, Lembo NJ, King SB3. Angiographic predictors of a rise in serum creatine kinase (distal embolization) after balloon angioplasty of saphenous vein coronary artery bypass grafts. *Am J Cardiol* 1993;72:514-7.
551. Meany TB, Leon MB, Kramer BL, et al. Transluminal extraction catheter for the treatment of diseased saphenous vein grafts: a multicenter experience. *Cathet Cardiovasc Diagn* 1995;34:112-20.
552. Safian RD, Grines CL, May MA, et al. Clinical and angiographic results of transluminal extraction coronary atherectomy in saphenous vein bypass grafts. *Circulation* 1994;89:302-12.
553. Dooris M, Hoffmann M, Glazier S, et al. Comparative results of transluminal extraction coronary atherectomy in saphenous vein graft lesions with and without thrombus. *J Am Coll Cardiol* 1995;25:1700-5.
554. Kaplan BM, Safian RD, Grines CL, et al. Usefulness of adjunctive angioscopy and extraction atherectomy before stent implantation in high-risk aortocoronary saphenous vein grafts. *Am J Cardiol* 1995;76:822-4.
555. Hong MK, Popma JJ, Pichard AD, et al. Clinical significance of distal embolization after transluminal extraction atherectomy in diffusely diseased saphenous vein grafts. *Am Heart J* 1994;127:1496-503.
556. Barcin C, Denktas AE, Lennon RJ, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. *Catheter Cardiovasc Interv* 2004;61:484-91.
557. Parham WA, Bouhasin A, Ciaramita JP, Khoukaz S, Herrmann SC, Kern MJ. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. *Circulation* 2004;109:1236-43.
558. Hillegeass WB, Dean NA, Liao L, Rhinehart RG, Myers PR. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. *J Am Coll Cardiol* 2001;37:1335-43.
559. Weyrens FJ, Mooney J, Lesser J, Mooney MR. Intracoronary diltiazem for microvascular spasm after interventional therapy. *Am J Cardiol* 1995;75:849-50.
560. Stephan WJ, Bates ER, Garratt KN, Hinohara T, Muller DW. Directional atherectomy of coronary and saphenous vein graft ostial stenoses. *Am J Cardiol* 1995;75:1015-8.
561. Cowley MJ, Whitlow PL, Baim DS, Hinohara T, Hall K, Simpson JB. Directional coronary atherectomy of saphenous vein graft narrowings: multicenter investigational experience. *Am J Cardiol* 1993;72:30E-4E.
562. Savage MP, Douglas JSJ, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts: Saphenous Vein De Novo Trial Investigators. *N Engl J Med* 1997;337:740-7.
563. Abdelmeguid AE, Whitlow PL, Simpfendorfer C, et al. Percutaneous revascularization of ostial saphenous vein graft stenoses. *J Am Coll Cardiol* 1995;26:955-60.
564. Rechavia E, Litvack F, Macko G, Eigler NL. Stent implantation of saphenous vein graft aorto-ostial lesions in patients with unstable ischemic syndromes: immediate angiographic results and long-term clinical outcome. *J Am Coll Cardiol* 1995;25:866-70.
565. Wong SC, Popma JJ, Pichard AD, et al. Comparison of clinical and angiographic outcomes after saphenous vein graft angioplasty using coronary versus 'biliary' tubular slotted stents. *Circulation* 1995;91:339-50.
566. Eeckhout E, Goy JJ, Stauffer JC, Vogt P, Kappenberger L. Endoluminal stenting of narrowed saphenous vein grafts: long-term clinical and angiographic follow-up. *Cathet Cardiovasc Diagn* 1994;32:139-46.
567. Keane D, Buis B, Reifart N, et al. Clinical and angiographic outcome following implantation of the new Less Shortening Wallstent in aortocoronary vein grafts: introduction of a second generation stent in the clinical arena. *J Interv Cardiol* 1994;7:557-64.
568. Fenton SH, Fischman DL, Savage MP, et al. Long-term angiographic and clinical outcome after implantation of balloon-expandable stents in aortocoronary saphenous vein grafts. *Am J Cardiol* 1994;74:1187-91.
569. Piana RN, Moscucci M, Cohen DJ, et al. Palmaz-Schatz stenting for treatment of focal vein graft stenosis: immediate results and long-term outcome. *J Am Coll Cardiol* 1994;23:1296-304.
570. Ellis SG, Brener SJ, DeLuca S, et al. Late myocardial ischemic events after saphenous vein graft intervention--importance of initially "nonsignificant" vein graft lesions. *Am J Cardiol* 1997;79:1460-4.
571. de Jaegere P, van Domburg RT, Feyter PJ, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. *J Am Coll Cardiol* 1996;28:89-96.
572. Kahn JK, Rutherford BD, McConahay DR, et al. Initial and long-term outcome of 83 patients after balloon angioplasty of totally occluded bypass grafts. *J Am Coll Cardiol* 1994;23:1038-42.
573. Hartmann JR, McKeever LS, Stamato NJ, et al. Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts by extended infusion of urokinase: initial results and short-term clinical follow-up. *J Am Coll Cardiol* 1991;18:1517-23.
574. Hartmann JR, McKeever LS, O'Neill WW, et al. Recanalization of Chronically Occluded Aortocoronary Saphenous Vein Bypass Grafts With Long-Term, Low Dose Direct Infusion of Urokinase (ROBUST): a serial trial. *J Am Coll Cardiol* 1996;27:60-6.
575. Denardo SJ, Morris NB, Rocha-Singh KJ, Curtis GP, Rubenson DS, Teirstein PS. Safety and efficacy of extended urokinase infusion plus stent deployment for treatment of obstructed, older

- saphenous vein grafts. *Am J Cardiol* 1995;76:776-80.
576. McKeever LS, Hartmann JR, Bufalino VJ, et al. Acute myocardial infarction complicating recanalization of aortocoronary bypass grafts with urokinase therapy. *Am J Cardiol* 1989;64:683-5.
577. Blankenship JC, Modesto TA, Madigan NP. Acute myocardial infarction complicating urokinase infusion for total saphenous vein graft occlusion. *Cathet Cardiovasc Diagn* 1993;28:39-43.
578. Gurley JC, MacPhail BS. Acute myocardial infarction due to thrombolytic reperfusion of chronically occluded saphenous vein coronary bypass grafts. *Am J Cardiol* 1991;68:274-5.
579. Margolis JR, Mogensen L, Mehta S, Chen CY, Krauthamer D. Diffuse embolization following percutaneous transluminal coronary angioplasty of occluded vein grafts: the blush phenomenon. *Clin Cardiol* 1991;14:489-93.
580. Taylor MA, Santoian EC, Aji J, Eldredge WJ, Cha SD, Dennis CA. Intracerebral hemorrhage complicating urokinase infusion into an occluded aortocoronary bypass graft. *Cathet Cardiovasc Diagn* 1994;31:206-10.
581. Bedotto JB, Rutherford BD, Hartzler GO. Intramyocardial hemorrhage due to prolonged intracoronary infusion of urokinase into a totally occluded saphenous vein bypass graft. *Cathet Cardiovasc Diagn* 1992;25:52-6.
582. Chapekis AT, George BS, Candela RJ. Rapid thrombus dissolution by continuous infusion of urokinase through an intracoronary perfusion wire prior to and following PTCA: results in native coronaries and patent saphenous vein grafts. *Cathet Cardiovasc Diagn* 1991;23:89-92.
583. Sabri MN, Johnson D, Warner M, Cowley MJ. Intracoronary thrombolysis followed by directional atherectomy: a combined approach for thrombotic vein graft lesions considered unsuitable for angioplasty. *Cathet Cardiovasc Diagn* 1992;26:15-8.
584. Whisenant BK, Baim DS, Kuntz RE, Garcia LA, Ramee SR, Carrozza JP. Rheolytic Thrombectomy with the Possis AngioJet: Technical Considerations and Initial Clinical Experience. *J Invasive Cardiol* 1999;11:421-6.
585. El Gamal M, Bonnier H, Michels R, Heijman J, Stassen E. Percutaneous transluminal angioplasty of stenosed aortocoronary bypass grafts. *Br Heart J* 1984;52:617-20.
586. Block PC, Cowley MJ, Kaltenbach M, Kent KM, Simpson J. Percutaneous angioplasty of stenoses of bypass grafts or of bypass graft anastomotic sites. *Am J Cardiol* 1984;53:666-8.
587. Dorros G, Johnson WD, Tector AJ, Schmahl TM, Kalush SL, Janke L. Percutaneous transluminal coronary angioplasty in patients with prior coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 1984;87:17-26.
588. Corbelli J, Franco I, Hollman J, Simpfendorfer C, Galan K. Percutaneous transluminal coronary angioplasty after previous coronary artery bypass surgery. *Am J Cardiol* 1985;56:398-403.
589. Reeder GS, Bresnahan JF, Holmes DRJ, et al. Angioplasty for aortocoronary bypass graft stenosis. *Mayo Clin Proc* 1986;61:14-9.
590. Cote G, Myler RK, Stertzer SH, et al. Percutaneous transluminal angioplasty of stenotic coronary artery bypass grafts: 5 years' experience. *J Am Coll Cardiol* 1987;9:8-17.
591. Ernst SM, van der Feltz TA, Ascoop CA, et al. Percutaneous transluminal coronary angioplasty in patients with prior coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 1987;93:268-75.
592. Pinkerton CA, Slack JD, Orr CM, VanTassel JW, Smith ML. Percutaneous transluminal angioplasty in patients with prior myocardial revascularization surgery. *Am J Cardiol* 1988;61:15G-22G.
593. Dorros G, Lewin RF, Mathiak LM, et al. Percutaneous transluminal coronary angioplasty in patients with two or more previous coronary artery bypass grafting operations. *Am J Cardiol* 1988;61:1243-7.
594. Reed DC, Beller GA, Nygaard TW, Tedesco C, Watson DD, Burwell LR. The clinical efficacy and scintigraphic evaluation of post-coronary bypass patients undergoing percutaneous transluminal coronary angioplasty for recurrent angina pectoris. *Am Heart J* 1989;117:60-71.
595. Cooper I, Ineson N, Demirtas E, Coltart J, Jenkins S, Webb-Peploe M. Role of angioplasty in patients with previous coronary artery bypass surgery. *Cathet Cardiovasc Diagn* 1989;16:81-6.
596. Platko WP, Hollman J, Whitlow PL, Franco I. Percutaneous transluminal angioplasty of saphenous vein graft stenosis: long-term follow-up. *J Am Coll Cardiol* 1989;14:1645-50.
597. Kussmaul WG. Percutaneous angioplasty of coronary bypass grafts: an emerging consensus. *Cathet Cardiovasc Diagn* 1988;15: 1-4.
598. Hannan EL, Kilburn HJ, O'Donnell JF, Lukacik G, Shields EP. Adult open heart surgery in New York State: an analysis of risk factors and hospital mortality rates. *JAMA* 1990;264:2768-74.
599. Lytle BW, McElroy D, McCarthy P, et al. Influence of arterial coronary bypass grafts on the mortality in coronary reoperations. *J Thorac Cardiovasc Surg* 1994;107:675-82.
600. Mishra YK, Mehta Y, Juneja R, Kasliwal RR, Mittal S, Trehan N. Mammery-coronary artery anastomosis without cardiopulmonary bypass through a minithoracotomy. *Ann Thorac Surg* 1997;63: S114-S118.
601. Allen KB, Matheny RG, Robison RJ, Heimansohn DA, Shaar CJ. Minimally invasive versus conventional reoperative coronary artery bypass. *Ann Thorac Surg* 1997;64:616-22.
602. Calafiore AM, Giammarco GD, Teodori G, et al. Left anterior descending coronary artery grafting via left anterior small thoracotomy without cardiopulmonary bypass. *Ann Thorac Surg* 1996;61:1658-63.
603. Boonstra PW, Grandjean JG, Mariani MA. Reoperative coronary bypass grafting without cardiopulmonary bypass through a small thoracotomy. *Ann Thorac Surg* 1997;63:405-7.
604. Grossi EA, Groh MA, Lefrak EA, et al. Results of a prospective multicenter study on port-access coronary bypass grafting. *Ann Thorac Surg* 1999;68:1475-7.
605. Cohen HA, Zenati M. Integrated Coronary Revascularization. *J Invasive Cardiol* 1999;11:184-91.
606. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM. Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation [letter]. *Lancet* 1996;347:757-8.
607. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. CASS Investigators. *J Am Coll Cardiol* 1992;20:287-94.
608. Voors AA, van Brussel BL, Plokker HW, et al. Smoking and cardiac events after venous coronary bypass surgery: a 15-year follow-up study. *Circulation* 1996;93:42-7.
609. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996;335:1001-9.
610. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators [published erratum appears in *N Engl J Med* 1997 Dec 18;337(25): 1859]. *N Engl J Med* 1997;336:153-62.
611. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program

- Adult Treatment Panel III guidelines. *Circulation* 2004;110:227-39.
612. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 1995;91:1676-88.
 613. Kern MJ, Dupouy P, Drury JH, et al. Role of coronary artery lumen enlargement in improving coronary blood flow after balloon angioplasty and stenting: a combined intravascular ultrasound Doppler flow and imaging study. *J Am Coll Cardiol* 1997;29:1520-7.
 614. Tobis J, Colombo A. IVUS and coronary stenting. *Cathet Cardiovasc Diagn* 1996;39:346.
 615. Yock PG, Fitzgerald PJ, Linker DT, Angelsen BA. Intravascular ultrasound guidance for catheter-based coronary interventions. *J Am Coll Cardiol* 1991;17:39B-45B.
 616. Mudra H, Klaus V, Blasini R, et al. Ultrasound guidance of Palmaz-Schatz intracoronary stenting with a combined intravascular ultrasound balloon catheter. *Circulation* 1994;90:1252-61.
 617. Nakamura S, Colombo A, Gaglione A, et al. Intracoronary ultrasound observations during stent implantation. *Circulation* 1994;89:2026-34.
 618. Karrison GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy: 30-day clinical outcome of the French Multicenter Registry. *Circulation* 1996;94:1519-27.
 619. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. *N Engl J Med* 1998;339:1665-71.
 620. Moussa I, Moses J, Di Mario C, et al. Does the specific intravascular ultrasound criterion used to optimize stent expansion have an impact on the probability of stent restenosis? *Am J Cardiol* 1999;83:1012-7.
 621. Fitzgerald PJ, Oshima A, Hayase M, et al. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. *Circulation* 2000;102:523-30.
 622. Maehara A, Mintz GS, Bui AB, et al. Incidence, morphology, angiographic findings, and outcomes of intramural hematomas after percutaneous coronary interventions: an intravascular ultrasound study. *Circulation* 2002;105:2037-42.
 623. Gilutz H, Russo RJ, Tsameret I, Fitzgerald PJ, Yock PG. Comparison of coronary stent expansion by intravascular ultrasonic imaging in younger versus older patients with diabetes mellitus. *Am J Cardiol* 2000;85:559-62.
 624. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 2002;346:1773-80.
 625. Serruys PW, Foley DP, Pieper M, Kleijne JA, de Feyter PJ. The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. *Eur Heart J* 2001;22:1938-47.
 626. Wilensky RL, Tanguay JF, Ito S, et al. Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia. *Am Heart J* 2000;139:1061-70.
 627. Mintz GS, Weissman NJ, Teirstein PS, et al. Effect of intracoronary gamma-radiation therapy on in-stent restenosis: An intravascular ultrasound analysis from the gamma-1 study. *Circulation* 2000;102:2915-8.
 628. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. *Circulation* 2001;104:2007-11.
 629. Pijls NH, Van Gelder B, Van der Voort P, et al. Fractional flow reserve: a useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow. *Circulation* 1995;92:3183-93.
 630. De Bruyne B, Bartunek J, Sys SU, Heyndrickx GR. Relation between myocardial fractional flow reserve calculated from coronary pressure measurements and exercise-induced myocardial ischemia. *Circulation* 1995;92:39-46.
 631. Pijls NH, De Bruyne B, Peels K, et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. *N Engl J Med* 1996;334:1703-8.
 632. Donohue TJ, Kern MJ, Aguirre FV, et al. Assessing the hemodynamic significance of coronary artery stenoses: analysis of translesional pressure-flow velocity relations in patients. *J Am Coll Cardiol* 1993;22:449-58.
 633. Miller DD, Donohue TJ, Younis LT, et al. Correlation of pharmacological 99mTc-sestamibi myocardial perfusion imaging with poststenotic coronary flow reserve in patients with angiographically intermediate coronary artery stenoses. *Circulation* 1994;89:2150-60.
 634. Heller LI, Cates C, Popma J, et al. Intracoronary Doppler assessment of moderate coronary artery disease: comparison with 201Tl imaging and coronary angiography. FACTS Study Group. *Circulation* 1997;96:484-90.
 635. Baumgart D, Haude M, Goerge G, et al. Improved assessment of coronary stenosis severity using the relative flow velocity reserve. *Circulation* 1998;98:40-6.
 636. Serruys PW, De BB, Carlier S, et al. Randomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group. *Circulation* 2000;102:2930-7.
 637. Kern MJ. Coronary physiology revisited: practical insights from the cardiac catheterization laboratory. *Circulation* 2000;101:1344-51.
 638. Baim DS, Hinohara T, Holmes D, et al. Results of directional coronary atherectomy during multicenter preapproval testing: the US Directional Coronary Atherectomy Investigator Group. *Am J Cardiol* 1993;72:6E-11E.
 639. Kern MJ, Donohue TJ, Aguirre FV, et al. Clinical outcome of deferring angioplasty in patients with normal translesional pressure-flow velocity measurements. *J Am Coll Cardiol* 1995;25:178-87.
 640. Joye JD, Schulman DS, Lasorda D, Farah T, Donohue BC, Reichek N. Intracoronary Doppler guide wire versus stress single-photon emission computed tomographic thallium-201 imaging in assessment of intermediate coronary stenoses. *J Am Coll Cardiol* 1994;24:940-7.
 641. Zijlstra F, Fioretti P, Reiber JH, Serruys PW. Which cineangiographically assessed anatomic variable correlates best with functional measurements of stenosis severity? A comparison of quantitative analysis of the coronary cineangiogram with measured coronary flow reserve and exercise/redistribution thallium-201 scintigraphy. *J Am Coll Cardiol* 1988;12:686-91.
 642. Danzi GB, Pirelli S, Mauri L, et al. Which variable of stenosis severity best describes the significance of an isolated left anterior descending coronary artery lesion? Correlation between quantitative coronary angiography, intracoronary Doppler measurements and high dose dipyridamole echocardiography. *J Am Coll Cardiol* 1998;31:526-33.
 643. Bartunek J, Van SE, De BB. Comparison of exercise electrocar-

- diography and dobutamine echocardiography with invasively assessed myocardial fractional flow reserve in evaluation of severity of coronary arterial narrowing. *Am J Cardiol* 1997;79:478-81.
644. Chamuleau SA, Meuwissen M, van Eck-Smit BL, et al. Fractional flow reserve, absolute and relative coronary blood flow velocity reserve in relation to the results of technetium-99m sestamibi single-photon emission computed tomography in patients with two-vessel coronary artery disease. *J Am Coll Cardiol* 2001;37:1316-22.
645. Fearon WF, Takagi A, Jeremias A, et al. Use of fractional myocardial flow reserve to assess the functional significance of intermediate coronary stenoses. *Am J Cardiol* 2000;86:1013-4, A10.
646. El-Shafei A, Chiravuri R, Stikovac MM, et al. Comparison of relative coronary Doppler flow velocity reserve to stress myocardial perfusion imaging in patients with coronary artery disease. *Catheter Cardiovasc Interv* 2001;53:193-201.
647. Bech GJ, De BB, Bonnier HJ, et al. Long-term follow-up after deferral of percutaneous transluminal coronary angioplasty of intermediate stenosis on the basis of coronary pressure measurement. *J Am Coll Cardiol* 1998;31:841-7.
648. Pijls NH, Klauss V, Siebert U, et al. Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry. *Circulation* 2002;105:2950-4.
649. Bech GJ, De BB, Pijls NH, et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. *Circulation* 2001;103:2928-34.
650. Ferrari M, Schnell B, Werner GS, Figulla HR. Safety of deferring angioplasty in patients with normal coronary flow velocity reserve. *J Am Coll Cardiol* 1999;33:82-7.
651. Bech GJ, Pijls NH, De BB, et al. Usefulness of fractional flow reserve to predict clinical outcome after balloon angioplasty. *Circulation* 1999;99:883-8.
652. Sirnes PA, Golf S, Myreng Y, et al. Sustained benefit of stenting chronic coronary occlusion: long-term clinical follow-up of the Stenting in Chronic Coronary Occlusion (SICCO) study. *J Am Coll Cardiol* 1998;32:305-10.
653. Buller CE, Dzavik V, Carere RG, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). *Circulation* 1999;100:236-42.
654. Warth DC, Leon MB, O'Neill W, Zacca N, Polissar NL, Buchbinder M. Rotational atherectomy multicenter registry: acute results, complications and 6-month angiographic follow-up in 709 patients. *J Am Coll Cardiol* 1994;24:641-8.
655. Popma JJ, Brogan WC3, Pichard AD, et al. Rotational coronary atherectomy of ostial stenoses. *Am J Cardiol* 1993;71:436-8.
656. Jain SP, Liu MW, Dean LS, et al. Comparison of balloon angioplasty versus debulking devices versus stenting in right coronary ostial lesions. *Am J Cardiol* 1997;79:1334-8.
657. Ahmed WH, al-Anazi MM, Bittl JA. Excimer laser-facilitated angioplasty for undilatable coronary narrowings. *Am J Cardiol* 1996;78:1045-6.
658. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. *N Engl J Med* 2001;344:250-6.
659. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. *Lancet* 2002;359:551-7.
660. Raizner AE, Oesterle SN, Waksman R, et al. Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). *Circulation* 2000;102:951-8.
661. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. *JAMA* 2005;293:1063-72.
662. Reifart N, Vandormael M, Krajcar M, et al. Randomized comparison of angioplasty of complex coronary lesions at a single center: Excimer Laser, Rotational Atherectomy, and Balloon Angioplasty Comparison (ERBAC) Study. *Circulation* 1997;96:91-8.
663. Appelman YE, Piek JJ, Strikwerda S, et al. Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease. *Lancet* 1996;347:79-84.
664. Bittl JA. Excimer laser angioplasty: focus on total occlusions. *Am J Cardiol* 1996;78:823-4.
665. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494-502.
- 665a. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. *JAMA* 2005;294:1224-32.
666. Steinhubl SR, Berger PB, Mann JT, III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002;288:2411-20.
667. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001;358:527-33.
668. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126:576S-99S.
669. Timmermans C, Vrolix M, Vanhaecke J, et al. Ticlopidine in the setting of percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1991;68:463-6.
670. Knudtson ML, Flintoft VF, Roth DL, Hansen JL, Duff HJ. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol* 1990;15:691-7.
671. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. *Am J Cardiol* 2005;95:509-10.
672. Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. *JAMA* 2004;292:3017-23.
673. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. *J Am Coll Cardiol* 2002;40:231-7.
674. Hass WK, Easton JD, Adams HPJ, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. *N Engl J Med* 1989;321:501-7.
675. Rodriguez JN, Fernandez-Jurado A, Dieguez JC, Amian A, Prados D. Ticlopidine and severe aplastic anemia [letter; comment]. *Am J Hematol* 1994;47:332.
676. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura related to ticlopidine. *Lancet* 1991;337:774-6.
677. Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura [letter; comment]. *N Engl J Med* 1997;337:1245.

678. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. *Ann Intern Med* 1998;128:541-4.
679. Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DRJ. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. *Circulation* 1999;99:248-53.
680. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. *J Am Coll Cardiol* 2005;45:1157-64.
681. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. *Circulation* 1992;85:916-27.
682. Hearn JA, King SB, III, Douglas JSJ, Carlin SF, Lembo NJ, Ghazzal ZM. Clinical and angiographic outcomes after coronary artery stenting for acute or threatened closure after percutaneous transluminal coronary angioplasty: initial results with a balloon-expandable, stainless steel design. *Circulation* 1993;88:2086-96.
683. Goldberg SL, Colombo A, Nakamura S, Almagor Y, Maiello L, Tobis JM. Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents. *J Am Coll Cardiol* 1994;24:996-1003.
684. Hall P, Colombo A, Almagor Y, et al. Preliminary experience with intravascular ultrasound guided Palmaz-Schatz coronary stenting: the acute and short-term results on a consecutive series of patients. *J Interv Cardiol* 1994;7:141-59.
685. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. *Circulation* 2001;103:1967-71.
686. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. *J Am Coll Cardiol* 2005;45:947-53.
687. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. *Lancet* 2004;364:1519-21.
688. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. *J Am Coll Cardiol* 2005;45:456-9.
689. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. *N Engl J Med* 1996;334:1084-9.
690. Deleted in press.
691. Gregorini L, Marco J, Fajadet J, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. *J Am Coll Cardiol* 1997;29:13-20.
692. Steinhubl SR, Lauer MS, Mukerjee DP, Moliterno DJ, Ellis SG, Topol EJ. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. *J Am Coll Cardiol* 1998;32:1366-70.
693. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. *N Engl J Med* 2004;350:232-8.
694. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. *Am J Cardiol* 2002;90:625-8.
695. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di SG. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. *Circulation* 2005;111:2099-106.
696. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. *Circulation* 2005;111:1153-9.
697. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. *Circulation* 2004;109:1942-7.
698. Holmes DR Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. *Circulation* 2004;109:634-40.
699. Gasperetti CM, Goniais SL, Gimple LW, Powers ER. Platelet activation during coronary angioplasty in humans. *Circulation* 1993;88:2728-34.
700. Anderson HV, Kirkeeide RL, Krishnaswami A, et al. Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. *J Am Coll Cardiol* 1994;23:1031-7.
701. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. *J Am Coll Cardiol* 2003;41:26-32.
702. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: the EPIC Investigation. *N Engl J Med* 1994;330:956-61.
703. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. *Lancet* 1994;343:881-6.
704. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication [see comments]. *JAMA* 1997;278:479-84.
705. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: the EPILOG Investigators. *N Engl J Med* 1997;336:1689-96.
706. Lincoff AM, Tchong JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. *Circulation* 1999;99:1951-8.
707. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. *J Am Coll Cardiol* 2000;35:915-21.
708. Petronio AS, Musumeci G, Limbruno U, et al. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. *Am Heart J* 2002;143:334-41.
709. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. *Circulation* 1999;100:799-806.
710. Simoons ML, de Boer MJ, van den Brand MJ, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina: European Cooperative Study Group. *Circulation* 1994;89:596-603.
711. Kini A, Reich D, Marmur JD, Mitre CA, Sharma SK. Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial. *Am Heart J* 2001;142:965-9.
712. Tamburino C, Russo G, Nicosia A, et al. Prophylactic abciximab

- in elective coronary stenting: results of a randomized trial. *J Invasive Cardiol* 2002;14:72-9.
713. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. *Circulation* 1995;91:2151-7.
714. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. *Am J Cardiol* 1995;76:1222-7.
715. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: the RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. *Circulation* 1997;96:1445-53.
716. Gibson CM, Goel M, Cohen DJ, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. *J Am Coll Cardiol* 1998;32:28-34.
717. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. *J Am Coll Cardiol* 1996;27:536-42.
718. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. *J Am Coll Cardiol* 2000;35:922-8.
719. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. *Circulation* 2001;104:2767-71.
720. Peerlinck K, De Lepeleire I, Goldberg M, et al. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. *Circulation* 1993;88:1512-7.
721. Kereiakes DJ, Midei M, Hermiller J, et al. Procedural and late outcomes following MULTI-LINK DUET coronary stent deployment. *Am J Cardiol* 1999;84:1385-90.
722. Barr E, Snapinn SM, Sax FL, Theroux P. Improved Long-Term Clinical Outcomes in Unstable Angina Patients Undergoing Coronary Angioplasty Following Therapy With Tirofiban and Heparin (abstr). *J Am Coll Cardiol* 1998;31:55A.
723. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. *Circulation* 1993;87:1622-9.
724. Grayburn PA, Willard JE, Brickner ME, Eichhorn EJ. In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: evidence for inadequate heparinization. *Cathet Cardiovasc Diagn* 1991;23:141-3.
725. Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. *Cathet Cardiovasc Diagn* 1992;26:260-3.
726. Bowers J, Ferguson JJ. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. *Clin Cardiol* 1994;17:357-61.
727. Ferguson JJ. All ACTs are not created equal (editorial). *Texas Heart Inst J* 1992;19:1-3.
728. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. *J Thorac Cardiovasc Surg* 1975;69:674-84.
729. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. *Ann Thorac Surg* 1978;26:231-40.
730. Schiele F, Vuilleminot A, Kramarz P, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. *Am J Hematol* 1995;50:20-5.
731. Brack MJ, More RS, Hubner PJ, Gershlick AH. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times. *Blood Coagul Fibrinolysis* 1993;4:183-6.
732. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin: a word of caution when both drugs are used concomitantly. *Arch Intern Med* 1987;147:857-60.
733. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol* 1994;23:1061-5.
734. Narins CR, Hillegass WBJ, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. *Circulation* 1996;93:667-71.
735. Frierson JH, Dimas AP, Simpfendorfer CC, Pearce G, Miller M, Franco I. Is aggressive heparinization necessary for elective PTCA? *Cathet Cardiovasc Diagn* 1993;28:279-82.
736. Popma JJ, Satler LF, Pichard AD, et al. Vascular complications after balloon and new device angioplasty. *Circulation* 1993;88:1569-78.
737. Boccaro A, Benamer H, Juliard JM, et al. A randomized trial of a fixed high dose versus a weight-adjusted low dose of intravenous heparin during coronary angioplasty. *Eur Heart J* 1997;18:631-5.
738. Tolleson TR, O'shea JC, Bittl JA, et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. *J Am Coll Cardiol* 2003;41:386-93.
739. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. *Circulation* 2004;110:994-8.
740. Friedman HZ, Cragg DR, Glazier SM, et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. *J Am Coll Cardiol* 1994;24:1214-9.
741. Fail PS, Maniet AR, Banka VS. Subcutaneous heparin in postangioplasty management: comparative trial with intravenous heparin. *Am Heart J* 1993;126:1059-67.
742. Kong DF, Califf RM. Post-procedure heparin: boon or burden? *Am Heart J* 1998;136:183-5.
743. Garachemani AR, Kaufmann U, Fleisch M, Meier B. Prolonged heparin after uncomplicated coronary interventions: a prospective, randomized trial. *Am Heart J* 1998;136:352-6.
744. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA* 2004;292:45-54.
- 744a. Lincoff AM, Kleiman NS, Kereiakes D, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 Randomized Trial. *JAMA* 2004;292:696-703.
745. Maroo A, Lincoff AM. Bivalirudin in PCI: an overview of the

- REPLACE-2 trial. *Semin Thromb Hemost* 2004;30:329-36.
746. Angiomax (bivalirudin) for injection. Package Insert. The Medicine Company, Parsippany, NJ. Available at http://www.themedicinecompany.com/~products_content/PN16019gt2.pdf. Accessed May 27, 2005.
747. Argatroban Injection. Prescribing Information. GlaxoSmithKline, Research Triangle, NC. Available at: http://us.gsk.com/products/assets/us_argatroban.pdf. Accessed May 27, 2005.
748. Mandak JS, Blankenship JC, Gardner LH, et al. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. *J Am Coll Cardiol* 1998;31:1518-24.
749. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. *Circulation* 1995;91:2882-90.
750. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. *Am J Cardiol* 1998;81:36-40.
751. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. *Am Heart J* 2002;144:615-24.
752. Fox KA, Antman EM, Cohen M, Bigonzi F. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. *Am J Cardiol* 2002;90:477-82.
753. Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. *JAMA* 2004;291:350-7.
754. Laarman GJ, Kiemeneij F, van der Wieken LR, Tijssen JG, Suwarganda JS, Slagboom T. A pilot study of coronary angioplasty in outpatients. *Br Heart J* 1994;72:12-5.
755. Cragg DR, Friedman HA, Almany SL, et al. Early hospital discharge after percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1989;64:1270-4.
756. Mann T, Cowper PA, Peterson ED, et al. Transradial coronary stenting: comparison with femoral access closed with an arterial suture device. *Catheter Cardiovasc Interv* 2000;49:150-6.
757. Johnson LW, Esente P, Giambartolomei A, et al. Peripheral vascular complications of coronary angioplasty by the femoral and brachial techniques. *Cathet Cardiovasc Diagn* 1994;31:165-72.
758. Skillman JJ, Kim D, Baim DS. Vascular complications of percutaneous femoral cardiac interventions: incidence and operative repair. *Arch Surg* 1988;123:1207-12.
759. Khoury M, Batra S, Berg R, Rama K, Kozul V. Influence of arterial access sites and interventional procedures on vascular complications after cardiac catheterizations. *Am J Surg* 1992;164:205-9.
760. Kresowik TF, Khoury MD, Miller BV, et al. A prospective study of the incidence and natural history of femoral vascular complications after percutaneous transluminal coronary angioplasty. *J Vasc Surg* 1991;13:328-33; discussion 333-5.
761. Lumsden AB, Miller JM, Kosinski AS, et al. A prospective evaluation of surgically treated groin complications following percutaneous cardiac procedures. *Am Surg* 1994;60:132-7.
762. Muller DW, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. *Am J Cardiol* 1992;69:63-8.
763. Agrawal SK, Pinheiro L, Roubin GS, et al. Nonsurgical closure of femoral pseudoaneurysms complicating cardiac catheterization and percutaneous transluminal coronary angioplasty. *J Am Coll Cardiol* 1992;20:610-5.
764. Bogart DB, Bogart MA, Miller JT, Farrar MW, Barr WK, Montgomery MA. Femoral artery catheterization complications: a study of 503 consecutive patients. *Cathet Cardiovasc Diagn* 1995;34:8-13.
765. Kent KC, Moscucci M, Mansour KA, et al. Retroperitoneal hematoma after cardiac catheterization: prevalence, risk factors, and optimal management. *J Vasc Surg* 1994;20:905-10; discussion 910-3.
766. Feld R, Patton GM, Carabasi RA, Alexander A, Merton D, Needleman L. Treatment of iatrogenic femoral artery injuries with ultrasound-guided compression. *J Vasc Surg* 1992;16:832-40.
767. Schaub F, Theiss W, Heinz M, Zagal M, Schomig A. New aspects in ultrasound-guided compression repair of postcatheterization femoral artery injuries. *Circulation* 1994;90:1861-5.
768. Kim D, Orron DE, Skillman JJ, et al. Role of superficial femoral artery puncture in the development of pseudoaneurysm and arteriovenous fistula complicating percutaneous transfemoral cardiac catheterization. *Cathet Cardiovasc Diagn* 1992;25:91-7.
769. Nikolsky E, Mehran R, Halkin A, et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. *J Am Coll Cardiol* 2004;44:1200-9.
770. Sanborn TA, Gibbs HH, Brinker JA, Knopf WD, Kosinski EJ, Roubin GS. A multicenter randomized trial comparing a percutaneous collagen hemostasis device with conventional manual compression after diagnostic angiography and angioplasty. *J Am Coll Cardiol* 1993;22:1273-9.
771. Silber S. Hemostasis success rates and local complications with collagen after femoral access for cardiac catheterization: analysis of 6007 published patients. *Am Heart J* 1998;135:152-6.
772. Kussmaul WG, Buchbinder M, Whitlow PL, et al. Femoral artery hemostasis using an implantable device (Angio-Seal) after coronary angioplasty. *Cathet Cardiovasc Diagn* 1996;37:362-5.
773. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol* 2004;44:1393-9.
774. Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. *J Am Coll Cardiol* 2004;44:1763-71.
775. Levine GN, Kern MJ, Berger PB, et al. Management of patients undergoing percutaneous coronary revascularization. *Ann Intern Med* 2003;139:123-36.
776. Aguilar C, Reza A, Garcia JE, Rull JA. Biguanide related lactic acidosis: incidence and risk factors. *Arch Med Res* 1992;23:19-24.
777. Agrawal M, Stouffer GA. Cardiology Grand Rounds from The University of North Carolina at Chapel Hill. Contrast induced nephropathy after angiography. *Am J Med Sci* 2002;323:252-8.
778. Kuntz RE, Piana R, Pomerantz RM, et al. Changing incidence and management of abrupt closure following coronary intervention in the new device era. *Cathet Cardiovasc Diagn* 1992;27:183-90.
779. Simpfendorfer C, Belardi J, Bellamy G, Galan K, Franco I, Hollman J. Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1987;59:267-9.
780. de Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. *Am Heart J* 1994;127:643-51.

781. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q-wave myocardial infarction associated with coronary angioplasty. *J Am Coll Cardiol* 1991;17:621-6.
782. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. *JAMA* 1997;277:461-6.
783. Smith SC, Jr., Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. *J Am Coll Cardiol* 2001;38:1581-3.
784. Yusuf S, Sleight P, Pogue J, Bosch JDR, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342:145-53.
785. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators [see comments]. *N Engl J Med* 1992;327:669-77.
786. Fung AY, Lorch G, Cambier PA, et al. Efgatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators. *Am Heart J* 1999;138:696-704.
787. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. *Hypertension* 2003;41:1178-9.
788. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2981-97.
789. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;324:71-86.
790. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;350:1495-504.
791. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet* 2003;362:782-8.
792. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003;362:772-6.
793. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *Circulation* 2002;106:1883-92.
794. Bengtson JR, Mark DB, Honan MB, et al. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. *Am J Cardiol* 1990;65:28-34.
795. Kadel C, Strecker T, Kaltenbach M, Kober G. Recognition of restenosis: can patients be defined in whom the exercise-ECG result makes angiographic restudy unnecessary? *Eur Heart J* 1989;10(Suppl G):22-6.
796. Honan MB, Bengtson JR, Pryor DB, et al. Exercise treadmill testing is a poor predictor of anatomic restenosis after angioplasty for acute myocardial infarction. *Circulation* 1989;80:1585-94.
797. Schroeder E, Marchandise B, De Coster P, et al. Detection of restenosis after coronary angioplasty for single-vessel disease: how reliable are exercise electrocardiography and scintigraphy in asymptomatic patients? *Eur Heart J* 1989;10(Suppl G):18-21.
798. Laarman GJ, Luijten HE, van Zeyl LG, et al. Assessment of “silent” restenosis and long-term follow-up after successful angioplasty in single vessel coronary artery disease: the value of quantitative exercise electrocardiography and quantitative coronary angiography. *J Am Coll Cardiol* 1990;16:578-85.
799. el-Tamimi H, Davies GJ, Hackett D, Fragasso G, Crea F, Maseri A. Very early prediction of restenosis after successful coronary angioplasty: anatomic and functional assessment. *J Am Coll Cardiol* 1990;15:259-64.
800. Roth A, Miller HI, Keren G, et al. Detection of restenosis following percutaneous coronary angioplasty in single-vessel coronary disease: the value of clinical assessment and exercise tolerance testing. *Cardiology* 1994;84:106-13.
801. Desmet W, De Scheerder I, Piessens J. Limited value of exercise testing in the detection of silent restenosis after successful coronary angioplasty. *Am Heart J* 1995;129:452-9.
802. Vlay SC, Charnilas J, Lawson WE, Dervan JP. Restenosis after angioplasty: don't rely on the exercise test. *Am Heart J* 1989;117:980-6.
803. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the Atenolol Silent Ischemia Study. *Circulation* 1994;90:762-8.
804. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). *J Am Coll Cardiol* 2003;42:1318-33.
805. Hecht HS, Shaw RE, Chin HL, Ryan C, Stertz SH, Myler RK. Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. *J Am Coll Cardiol* 1991;17:670-7.
806. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). *J Am Coll Cardiol* 2003;42:954-70.
807. Hecht HS, DeBord L, Shaw R, et al. Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1993;71:293-6.
808. Fioretti PM, Pozzoli MM, Ilmer B, et al. Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA. *Eur Heart J* 1992;13:213-9.
809. Pirelli S, Danzi GB, Alberti A, et al. Comparison of usefulness of high-dose dipyridamole echocardiography and exercise electrocardiography for detection of asymptomatic restenosis after angioplasty. *Am J Cardiol* 1991;67:1335-8.
810. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001

- update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation* 2001;104:1577-9.
811. Clark VL, Dolce J. Unplanned admissions after outpatient cardiac catheterization. *Clin Cardiol* 1993;16:823-6.
812. Rozenman Y, Gilon D, Zelingher J, et al. One-stage coronary angiography and angioplasty. *Am J Cardiol* 1995;75:30-3.
813. Adele C, Vaitkus PT, Wells SK, Zehnacker JB. Cost advantages of an ad hoc angioplasty strategy. *J Am Coll Cardiol* 1998;31:321-5.
814. Breisblatt WM, Ruffner RJ, Uretsky BF, Reddy PS. Same-day angioplasty and diagnostic catheterization: safe and effective but riskier in unstable angina. *Angiology* 1991;42:607-13.
815. Deleted in press.
816. O'Keefe JHJ, Gernon C, McCallister BD, Ligon RW, Hartzler GO. Safety and cost effectiveness of combined coronary angiography and angioplasty. *Am Heart J* 1991;122:50-4.
817. O'Keefe JHJ, Reeder GS, Miller GA, Bailey KR, Holmes DR Jr. Safety and efficacy of percutaneous transluminal coronary angioplasty performed at time of diagnostic catheterization compared with that performed at other times. *Am J Cardiol* 1989;63:27-9.
818. Kimmel SE, Berlin JA, Hennessy S, Strom BL, Krone RJ, Laskey WK. Risk of major complications from coronary angioplasty performed immediately after diagnostic coronary angiography: results from the Registry of the Society for Cardiac Angiography and Interventions. *J Am Coll Cardiol* 1997;30:193-200.
819. Goldstein CL, Racz M, Hannan EL. Impact of cardiac catheterization-percutaneous coronary intervention timing on in-hospital mortality. *Am Heart J* 2002;144:561-7.
820. Alfonso F, Macaya C, Iniguez A, Zarco P. Repeat coronary angioplasty during the same angiographic diagnosis of coronary restenosis. *Am Heart J* 1990;119:237-41.
821. Myler RK, Stertzer SH, Clark DA, Shaw RE, Fishman-Rosen J, Murphy MC. Coronary angioplasty at the time of initial cardiac catheterization: "ad hoc" angioplasty possibilities and challenges. *Cathet Cardiovasc Diagn* 1986;12:213-4.
822. Barnathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. *Circulation* 1987;76:125-34.
823. Blankenship JC, Mishkel GJ, Chambers CE, et al. Ad Hoc Coronary Intervention. *Cathet Cardiovasc Intervent* 2000;49:130-4.
824. Blankenship JC, Islam MA, Wood GC, Iliadis EA. Angiographic adverse events during percutaneous coronary intervention fail to predict creatine kinase-MB elevation. *Catheter Cardiovasc Interv* 2004;63:31-41.
825. Pamboukian SV, Costanzo MR. Transplant Coronary Vasculopathy. *Curr Treat Options Cardiovasc Med* 2001;3:55-63.
826. Halle AA3, Wilson RF, Massin EK, et al. Coronary angioplasty in cardiac transplant patients: results of a multicenter study. *Circulation* 1992;86:458-62.
827. Redonnet M, Tron C, Koning R, et al. Coronary angioplasty and stenting in cardiac allograft vasculopathy following heart transplantation. *Transplant Proc* 2000;32:463-5.
828. Heublein B, Pethig K, Maass C, Wahlers T, Haverich A. Coronary artery stenting in cardiac allograft vascular disease. *Am Heart J* 1997;134:930-8.
829. Benza RL, Zoghbi GJ, Tallaj J, et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. *J Am Coll Cardiol* 2004;43:1973-81.
830. Sandhu JS, Uretsky BF, Reddy PS, et al. Potential limitations of percutaneous transluminal coronary angioplasty in heart transplant recipients. *Am J Cardiol* 1992;69:1234-7.
831. Swan JW, Norell M, Yacoub M, Mitchell AG, Ilsley C. Coronary angioplasty in cardiac transplant recipients. *Eur Heart J* 1993;14:65-70.
832. von Scheidt W, Uberfuhr P, Reichart B, Steinbeck G. The role of PTCA in the management of focal critical lesions in transplant coronary artery disease. *Transplant Proc* 1995;27:1936-8.
833. Pande AK, Gosselin G, Rashdan I, Carrier M, Leung TK, Bonan R. Coronary angioplasty in the treatment of post-cardiac transplant coronary artery disease. *J Invas Cardiol* 1996;8:252-6.
834. Quigley PJ, Hlatky MA, Hinohara T, et al. Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. *Am J Cardiol* 1989;63:409-13.
835. Bauters C, LaBlanche JM, Leroy F, Bertrand ME. Treatment of first restenosis by recurrent angioplasty: immediate results and angiographic follow-up after 6 months. *Arch Mal Coeur Vaiss* 1992;85:1515-20.
836. Glazier JJ, Varricchione TR, Ryan TJ, Ruocco NA, Jacobs AK, Faxon DP. Factors predicting recurrent restenosis after percutaneous transluminal coronary balloon angioplasty. *Am J Cardiol* 1989;63:902-5.
837. Teirstein PS, Hoover CA, Ligon RW, et al. Repeat coronary angioplasty: efficacy of a third angioplasty for a second restenosis. *J Am Coll Cardiol* 1989;13:291-6.
838. Deligonul U, Vandormael M, Kern MJ, Galan K. Repeat coronary angioplasty for restenosis: results and predictors of follow-up clinical events. *Am Heart J* 1989;117:997-1002.
839. Bauters C, LaBlanche JM, McFadden EP, Leroy F, Bertrand ME. Clinical characteristics and angiographic follow-up of patients undergoing early or late repeat dilation for a first restenosis. *J Am Coll Cardiol* 1992;20:845-8.
840. Bauters C, LaBlanche JM, Leroy F, Bertrand ME. Morphological changes of coronary stenosis after repeated balloon angioplasties: a quantitative angiographic study. *Cathet Cardiovasc Diagn* 1991;24:158-60.
841. Henderson RA, Pipilis A, Cooke R, Timmis AD, Sowton E. Angiographic morphology of recurrent stenoses after percutaneous transluminal coronary angioplasty: are lesions longer at restenosis? *Int J Card Imaging* 1990;6:77-84.
842. Kitazume H, Ichiro K, Iwama T, Ageishi Y. Repeat coronary angioplasty as the treatment of choice for restenosis. *Am Heart J* 1996;132:711-5.
843. Reeder GS, Bresnahan JF, Holmes DR Jr, Litvack F. Excimer laser coronary angioplasty: results in restenosis versus de novo coronary lesions. Excimer Laser Coronary Angioplasty Investigators. *Cathet Cardiovasc Diagn* 1992;25:195-9.
844. Erbel R, Haude M, Hopp HW, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group [see comments]. *N Engl J Med* 1998;339:1672-8.
845. Serruys PW, Emanuelsson H, van der Giessen W, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent-II Pilot Study. *Circulation* 1996;93:412-22.
846. Dussaillant GR, Mintz GS, Pichard AD, et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. *J Am Coll Cardiol* 1995;26:720-4.
847. Serruys PW, Kay IP, Disco C, Deshpande NV, de Feyter PJ. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the Belgian Netherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. *J Am Coll Cardiol* 1999;34:1067-74.

848. Ellis SG, Savage M, Fischman D, et al. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries: initial results of a multicenter experience. *Circulation* 1992;86:1836-44.
849. Hoffmann R, Mintz GS, Kent KM, et al. Serial intravascular ultrasound predictors of restenosis at the margins of Palmaz-Schatz stents. *Am J Cardiol* 1997;79:951-3.
850. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. *Circulation* 1996;94:1247-54.
851. Mehran R, Mintz GS, Popma JJ, et al. Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. *Am J Cardiol* 1996;78:618-22.
852. Baim DS, Levine MJ, Leon MB, Levine S, Ellis SG, Schatz RA. Management of restenosis within the Palmaz-Schatz coronary stent (the U.S. multicenter experience). The U.S. Palmaz-Schatz Stent Investigators. *Am J Cardiol* 1993;71:364-6.
853. Macander PJ, Roubin GS, Agrawal SK, Cannon AD, Dean LS, Baxley WA. Balloon angioplasty for treatment of in-stent restenosis: feasibility, safety, and efficacy. *Cathet Cardiovasc Diagn* 1994;32:125-31.
854. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within coronary stents—quantitative angiographic assessment. *J Am Coll Cardiol* 1993;21:1166-74.
855. Reimers B, Moussa I, Akiyama T, et al. Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis. *J Am Coll Cardiol* 1997;30:186-92.
856. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. *Circulation* 1999;100:1872-8.
857. Meyer T, Schmidt T, Buchwald A, Wiegand V. Stent wire cutting during coronary directional atherectomy. *Clin Cardiol* 1993;16:450-2.
858. Strauss BH, Umans VA, van Suylen RJ, et al. Directional atherectomy for treatment of restenosis within coronary stents: clinical, angiographic and histologic results. *J Am Coll Cardiol* 1992;20:1465-73.
859. Bottner RK, Hardigan KR. High-speed rotational ablation for in-stent restenosis. *Cathet Cardiovasc Diagn* 1997;40:144-9.
860. Stone GW. Rotational atherectomy for treatment of in-stent restenosis: role of intracoronary ultrasound guidance. *Cathet Cardiovasc Diagn* 1996;Suppl 3:73-7.
861. Hara K, Ikari Y, Tamura T, Yamaguchi T. Transluminal extraction atherectomy for restenosis following Palmaz-Schatz stent implantation. *Am J Cardiol* 1997;79:801-2.
862. Patel JJ, Meadaa R, Cohen M, Adiraju R, Kussmaul WG3. Transluminal extraction atherectomy for aortosaphenous vein graft stent restenosis. *Cathet Cardiovasc Diagn* 1996;38:320-4.
863. Goods CM, Jain SP, Liu MW, Babu RB, Roubin GS. Intravascular ultrasound-guided transluminal extraction atherectomy for restenosis after Gianturco-Roubin coronary stent implantation. *Cathet Cardiovasc Diagn* 1996;37:317-9.
864. Virk SJ, Bellamy CM, Perry RA. Transluminal extraction atherectomy for stent restenosis in a saphenous vein bypass graft [letter]. *Eur Heart J* 1997;18:350-1.
865. Ikari Y, Yamaguchi T, Tamura T, Isshiki T, Saeki F, Hara K. Transluminal extraction atherectomy and adjunctive balloon angioplasty for restenosis after Palmaz-Schatz coronary stent implantation. *Cathet Cardiovasc Diagn* 1993;30:127-30.
866. Chow WH, Chan TF. Pullback atherectomy for the treatment of intrastent restenosis [letter]. *Cathet Cardiovasc Diagn* 1997;41:94-5.
867. Cecena FA. Stenting the stent: alternative strategy for treating in-stent restenosis. *Cathet Cardiovasc Diagn* 1996;39:377-82.
868. Debbas N, Stauffer JC, Eeckhout E, Vogt P, Kappenberger L, Goy JJ. Stenting within a stent: treatment for repeat in-stent restenosis in a venous graft. *Am Heart J* 1997;133:460-3.
869. Moris C, Alfonso F, Lambert JL, et al. Stenting for coronary dissection after balloon dilation of in-stent restenosis: stenting a previously stented site. *Am Heart J* 1996;131:834-6.
870. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. *Circulation* 2003;107:24-7.
871. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. *J Am Coll Cardiol* 2003;41:184-9.
872. Di MC, Moses JW, Anderson TJ, et al. Randomized comparison of elective stent implantation and coronary balloon angioplasty guided by online quantitative angiography and intracoronary Doppler. DESTINI Study Group (Doppler Endpoint STenting International Investigation). *Circulation* 2000;102:2938-44.
873. Lafont A, Dubois-Rande JL, Steg PG, et al. The French Randomized Optimal Stenting Trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. F.R.O.S.T. Study Group. *J Am Coll Cardiol* 2000;36:404-9.
874. Anderson HV, Carabello BA. Provisional versus routine stenting: routine stenting is here to stay. *Circulation* 2000;102:2910-4.
875. Colombo A, Stankovic G, Moses JW. Selection of coronary stents. *J Am Coll Cardiol* 2002;40:1021-33.
876. Oberhoff M, Herdeg C, Baumbach A, Karsch KR. Stent-based antirestenotic coatings (sirolimus/paclitaxel). *Catheter Cardiovasc Interv* 2002;55:404-8.
877. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part I. *Circulation* 2002;106:2734-40.
878. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. *Circulation* 2002;106:2859-66.
879. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. *Circulation* 2002;106:1610-3.
880. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). *J Am Coll Cardiol* 2004;43:1110-5.
881. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). *Lancet* 2003;362:1093-9.
882. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. *J Am Coll Cardiol* 2003;41:2093-9.
883. Hoye A, Tanabe K, Lemos PA, et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. *J Am Coll Cardiol* 2004;43:1954-8.
884. Liistro F, Stankovic G, Di MC, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. *Circulation* 2002;105:1883-6.
885. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. *N Engl J Med* 2003;348:1537-45.

886. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. *Circulation* 2003;107:38-42.
887. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. *Circulation* 2003;108:788-94.
888. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. *Circulation* 2003;107:559-64.
889. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. *Circulation* 2001;103:192-5.
890. Fajadet J, Morice MC, Bode C, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. *Circulation* 2005;111:1040-4.
891. Saia F, Lemos PA, Lee CH, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study. *Circulation* 2003;108:1927-9.
892. Colombo A, Orlic D, Stankovic G, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. *Circulation* 2003;107:2178-80.
893. Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). *Circulation* 2003;107:517-20.
894. Hoyer A, Lemos PA, Arampatzis CA, et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. *J Invasive Cardiol* 2004;16:230-3.
895. Saia F, Lemos PA, Sianos G, et al. Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy. *Am J Cardiol* 2003;92:200-3.
896. Kastrati A, Mehilli J, von BN, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. *JAMA* 2005;293:165-71.
897. Neumann FJ, Desmet W, Grube E, et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. *Circulation* 2005;111:2107-11.
898. Sapirstein W, Zuckerman B, Dillard J. FDA approval of coronary-artery brachytherapy. *N Engl J Med* 2001;344:297-9.
899. Sheppard R, Eisenberg MJ. Intracoronary radiotherapy for restenosis. *N Engl J Med* 2001;344:295-7.
900. Teirstein PS, Kuntz RE. New frontiers in interventional cardiology: intravascular radiation to prevent restenosis. *Circulation* 2001;104:2620-6.
901. Grise MA, Massullo V, Jani S, et al. Five-year clinical follow-up after intracoronary radiation: results of a randomized clinical trial. *Circulation* 2002;105:2737-40.
902. Waksman R, Ajani AE, White RL, et al. Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. *N Engl J Med* 2002;346:1194-9.
903. Waksman R, Cheneau E, Ajani AE, et al. Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies. *Circulation* 2003;107:1744-9.
904. Cohen DJ, Cosgrove RS, Berezin RH, Teirstein PS, Leon MB, Kuntz RE. Cost-effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial. *Circulation* 2002;106:691-7.
905. Moses JW, Moussa I, Leon MB, et al. Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial). *Am J Cardiol* 2002;90:243-7.
906. Waksman R. Vascular brachytherapy: applications in the era of drug-eluting stents. *Rev Cardiovasc Med* 2002;3(Suppl 5):S23-S30.
907. Costa MA, Sabat M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. *Circulation* 1999;100:789-92.
908. User's Manual. Beta-Cath System. Atlanta, GA: Novoste Corporation; 2002.
909. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. *Circulation* 2004;110:790-5.
910. Muni NI, Gross TP. Problems with drug-eluting coronary stents--the FDA perspective. *N Engl J Med* 2004;351:1593-5.
911. Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. *Bull World Health Organ* 1994;72:495-509.
912. Cohen DJ, Sukin CA. Cost-effectiveness of coronary interventions. *Heart* 1997;78(Suppl 2):7-10.
913. Gold MR, Siegel JE, Russell LB, Weinstein MC. *Cost-Effectiveness in Health and Medicine*. NY: Oxford University Press, 1996.
914. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina: analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. *Ann Intern Med* 1990;113:852-71.
915. Cohen DJ, Breall JA, Ho KK, et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: use of a decision-analytic model. *Circulation* 1994;89:1859-74.
916. Cohen DJ, Krumholz HM, Sukin CA, et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty: results from a randomized clinical trial. Stent Restenosis Study Investigators. *Circulation* 1995;92:2480-7.
917. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. *Circulation* 1996;94:957-65.
918. Sim I, Gupta M, McDonald K, Bourassa MG, Hlatky MA. A meta-analysis of randomized trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty in multivessel coronary artery disease. *Am J Cardiol* 1995;76:1025-9.
919. Weintraub WS, Mauldin PD, Becker E, Kosinski AS, King SB, III. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease: results from the Emory Angioplasty Versus Surgery Trial (EAST). *Circulation* 1995;92:2831-40.
920. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. *Circulation* 2004;110:508-14.
921. Holmes DR, Jr., Savage M, LaBlanche JM, et al. Results of

- Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. *Circulation* 2002;106:1243-50.
922. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. *J Am Coll Cardiol* 1999;33:1833-40.
923. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. *Circulation* 2002;105:1291-7.
924. Oesterle SN, Sanborn TA, Ali N, et al. Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Potential Class Improvement From Intramyocardial Channels. *Lancet* 2000;356:1705-10.
925. Salem M, Rotevatn S, Stavnes S, Brekke M, Vollset SE, Nordrehaug JE. Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris. *Am J Cardiol* 2004;93:1086-91.
926. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). *Circulation* 2002;106:3009-17.
927. Menasche P, Hagege AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. *J Am Coll Cardiol* 2003;41:1078-83.

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)

Sidney C. Smith, Jr, Ted E. Feldman, John W. Hirshfeld, Jr, Alice K. Jacobs, Morton J. Kern, Spencer B. King, III, Douglass A. Morrison, William W. O'Neill, Hartzell V. Schaff, Patrick L. Whitlow, David O. Williams, Elliott M. Antman, Sidney C. Smith, Jr, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page and Barbara Riegel

J. Am. Coll. Cardiol. 2006;47;1-121
doi:10.1016/j.jacc.2005.12.001

This information is current as of March 19, 2006

Updated Information & Services	including high-resolution figures, can be found at: http://content.onlinejacc.org/cgi/content/full/47/1/e1
Rights & Permissions	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://content.onlinejacc.org/misc/permissions.dtl
Reprints	Information about ordering reprints can be found online: http://content.onlinejacc.org/misc/reprints.dtl

